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ABBREVIATIONS AND ACRONYMS 
Throughout this manuscript, abbreviations and acronyms recommended by the 
American Chemical Society in the Organic Chemistry and Medicinal Chemistry areas 
have been employed (revised in the Journal of Organic Chemistry and Journal of 
Medicinal Chemistry on January 2017; 
http://pubs.acs.org/paragonplus/submission/joceah/joceah_authguide.pdf and 
http://pubs.acs.org/paragonplus/submission/jmcmar/jmcmar_authguide.pdf). In 
addition, those indicated below have also been used. 
ATX Autotaxin 
BSI Back-scattering interferometry 
Caps Capsaicin 
DAPI 4',6-Diamidino-2-phenylindole 
DMEM Dulbecco’s modified Eagle medium 
DRG Dorsal root ganglion 
EDC N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
Edg Endothelial differentiation gene 
EGFP Enhanced green fluorescent protein 
Emax Maximal receptor activation 
FACS Fluorescence-activated cell sorting 
FAF BSA Fatty acid free bovin serum albumin 
FBS Fetal bovine serum 
Glu Glutamate 
HOBt 1-Hydroxybenzotriazole 
KD Dissociation constant 
LP Lysophospholipid 
LPA Lysophosphatidic acid 
LPC Lysophosphatidylcholine 
 MAG Myelin associated glycoprotein 
MBP Myelin basic protein 
MPZ Myelin protein zero 
MW Microwave 
N.E. No effect 
NP Neuropathic pain 
PG Protecting group 
PLA Phospholipase A 
PMP22 Peripheral myelin protein 22 
PS Polystyrene supported 
RI Refractive index 
ROCK Rho kinase 
S1P Sphingosine 1-phosphate 
s.e.m. Standard error of the mean 
SC Schwann cell 
SCI Spinal cord injury 
SP Substance P 
TBAI Tetrabutylammonium iodide 
TRPV1 Transient receptor potential of type 1 vanilloid channel 
VS Virtual screening 
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 INTRODUCTION AND OBJECTIVES 
Lysophospholipids (LPs) are cell membrane lipid derivatives that also act as 
extracellular signals and play important roles in humans and other animals. Analyses 
of LPs in human body fluids from subjects with different pathophysiological conditions 
reveal not only the relevance of LPs in human diseases, but also their potential 
application as biomarkers and/or therapeutic targets. In recent years, the identification 
and characterization of the receptors for LPs and enzymes regulating their 
metabolism have facilitated the understanding of their role and signaling properties. 
Moreover, genetic depletion of LP receptors in mice has provided and will continue to 
provide critical information on their biological roles. In this manner, specific agonists 
and antagonists for each LP receptor will be powerful tools not only for basic research, 
but also for potential therapeutic usages. Among the LPs, lysophosphatidic acid (LPA) 
stands out as a molecule that elicits a plethora of biological effects, notably within the 
developing and adult nervous system.1,2  
Structurally, LPA (1-acyl-sn-glycerol-3-phosphate) presents a phosphate head 
group and a single fatty acyl chain attached to a glycerol backbone. It is found in 
various body fluids, but it is highly present in plasma, where the most abundant forms 
are the 16:0, 18:1 and 18:2 (Figure 1).3 The 18:1 form is the most commonly used as 
research tool for activation of LPA receptors, and is the one we will refer as LPA along 
this work. 
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Figure 1. General structure of LPA (A) and different fatty acid hydrocarbon chains: palmitoyl 
(B), oleoyl (C) and linoleoyl (D). 
LPA is produced through several enzymatic pathways. Lysophospholipase D 
(known as autotaxin, ATX) is the primary enzyme responsible for LPA production in 
blood, where liberates a choline group from lysophosphatidylcholine (LPC). In 
addition, phospholipases A1 (PLA1) and A2 (PLA2) deacylate phosphatidic acid to 
produce 2-acyl and 1-acyl LPA, respectively (Figure 2). Importantly, LPA is also de 
novo synthesized from glycerol-3-phosphate by the action of acyltransferases.4,5  
LPA regulates a wide variety of biological activities, including cellular proliferation, 
survival and migration, cytoskeletal changes, and cytokine and chemokine mediated 
cell to cell interaction by binding to specific G protein-coupled receptors (GPCRs).6,7 
Currently there are six LPA (LPA1–6) receptors that can be classified into two 
subgroups: the endothelial differentiation gene (Edg) family and the non-Edg family 
(Figure 2).8 The first comprises LPA1/Edg2,9,10 LPA2/Edg411 and LPA3/Edg712 
receptors that share about 47-51% identities at the amino acid level. By using 
knockout mice, several important roles have been revealed for Edg family of LPA 
receptors in the nervous system, cancer, cardiovascular function and reproduction.13 
The non-Edg family includes LPA4/p2y9/GPR23,14,15 LPA5/GPR92/9316 and 
LPA6/p2y5,17 phylogenetically related to the P2Y purinergic receptor family. They are 
associated to distinct functions of LPA, including vasculature development, platelet 
activation and hair growth.13 In addition, LPA can also bind to the intracellular 
peroxisome proliferator activated receptor γ (PPARγ)18 and the transient receptor 
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potential of the type 1 vanilloid channel (TRPV1),19 thus playing important roles in 
gene regulation and nociception, respectively. 
 
Figure 2. Schematic representation of the major routes of LPA synthesis and the activated 
signaling pathways via the six cognate LPA receptors. (Source: J. Lipid Res. 2014, 55, 1192-
1214). 
To date, a wide range of LPA effects have been identified in the nervous 
system.20,21 In fact, in the developing nervous system, LPA plays a critical role during 
neurogenesis in establishing the cerebral cortex. Furthermore, LPA signaling is 
involved in neural progenitor cell physiology, astrocyte and microglia activation, 
neuronal cell death, axonal retraction and development of neuropathic pain.22 
Considering the pleiotropic effects of LPA on many key nervous system cell types, 
together with data showing localized up-regulation of LPA receptors after injury in 
mice and humans, it is likely that LPA regulates essential aspects of the cellular 
reorganization after neural trauma.  
Among all neuropathologies where LPA plays an important role, neuropathic pain 
(NP) and spinal cord injury (SCI) are high incidence and seriously disabling conditions 
which currently lack specific pharmacological therapies. LPA1 and LPA2 receptor 
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subtypes have been functionally linked to many neural processes associated to these 
pathologies, but the lack of potent and selective agonists and antagonists has 
impaired the delineation of their specific role. Hence, we have focused our efforts on 
the development of such agents to clarify the biological role of LPA1 and LPA2 
receptors in NP and SCI. 
1.1. Neuropathic Pain  
NP is a form of chronic pain affecting millions of people worldwide and it is 
associated with very significant loss in terms of life quality, including the ability to work 
and to work efficiently. It is not caused through stimulation of sensory neurons by 
“physiological” pain stimuli but rather by dysfunction or injury of the fibers. This 
dysfunction commonly occurs as a secondary symptom in diseases such as diabetes, 
cancer, and multiple sclerosis or as a side effect of chemotherapeutic treatments. 
Characteristic symptoms include unpleasant abnormal sensations (dysaesthesia), an 
enhanced perception of pain in response to noxious stimuli (hyperalgesia), as well as 
abnormal painful responses to innocuous or tactile stimuli that do not usually cause 
pain (allodynia). There are multiple molecular mechanisms underlying the 
pathophysiology of NP, thus increasing the complexity of developing effective 
targeted therapeutics. Currently approved treatments are focused on the inhibition of 
pain trasmission.23 The medication includes the antidepressants duloxetine and 
desipramine,24 as well as the anticonvulsivants gabapentin and pregabalin.25 The first 
two drugs produce their analgesic effects by preventing presynaptic reuptake of 
serotonin and noradrenaline, both of which inhibit the descending pain pathways in 
the central nervous system (CNS). On the other hand, gabapentin and pregabalin 
decrease the release of the excitatory neurotransmitters noradrenaline, glutamate 
(Glu), and substance P (SP). However, current therapeutics usually need to be taken 
chronically and many patients do not achieve a satisfactory response or observe 
intolerable side effects.26  
Among many processes that have been described to play a role in NP, an 
extensive body of work points to a role for LPA signaling.27-29  In the last decade, it 
was demonstrated that, after peripheral nerve damage, LPA produced in post-
synaptic neurons is able to activate macrophage cell types through LPA3 receptor, 
initiating de novo production of LPA via the enzymatic activity of c/iPLA2 and ATX 
(Figure 3).30-34 In this manner, the high concentration of LPA is responsible for 
demyelination and central sensitization, through LPA1 receptor, and TRPV1 
activation, considered the three key mechanisms for the initiation and maintenance of 
NP.35-40 
Introduction and objectives 
- 7 - 
 
Figure 3. Schematic representation of LPA production via LPA3 receptor activation following 
intense stimulation of primary afferent neurons. (Source: Neuropharmacology 2016, 113, 608-
617). 
a) Demyelination 
Myelinating Schwann cells (SC) form the myelin sheath around axons of motor 
and sensory neurons. They are essential for the proper functioning of nervous system, 
such as the conduction of nervous impulses along axons, nerve development and 
regeneration. During NP, the high level of LPA provokes a damage to the myelin 
sheath via LPA1 receptor, which occurs through two pathways; a rapid-acting non 
genomic pathway, that involves calpain-mediated myelin associated glycoprotein 
(MAG) degradation,41 and a late phase that involves transcriptional repression of 
myelin-related genes.42-46 The loss of MAG results in disinhibition of sprouting, while 
the downregulation of compact myelin proteins leads to a loosening of the myelin 
sheath (Figure 4). It seems that the demyelination may underlie the mechanisms for 
allodynia. 
LPAR3
LPAR1
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Figure 4. Schematic representation of LPA1 receptor-mediated demyelination and sprouting. 
Myelin basic protein (MBP), myelin protein zero (MPZ) and peripheral myelin protein 22 
(PMP22) have a role in the architecture of compact myelin, while MAG is restricted to the 
innermost membrane facing the neuronal axon through NgR complex. 
b) Central sensitization 
The dorsal root ganglion (DRG) contains the cell bodies of sensory neurons that 
help transmit the sensory messages of pain and touch from the periphery to the spinal 
cord. During NP, the high level of LPA alters this impulse transmission via LPA1, 
leading to hyperalgesia (Figure 5).47,48  
 
Figure 5. Schematic representation of LPAR1-mediated upregulation of Caα2δ1 and EphrinB1 in 
DRG and PKCγ in dorsal horn, leading to hyperalgesia. (Source: Biochim Biophys Acta 2013, 
1831, 61-73). 
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c) Involvement of TRPV1 in NP 
TRPV1 is activated by a variety of stimuli such as high temperature, low pH and 
pungent compounds. Also, multiple signals that originate from inflammatory 
processes converge on TRPV1, whose activation in sensory neurons has the final 
consequence of pain perception.49 In 2000, it was reported that TRPV1 knockout mice 
showed a significant blockade of the thermal hyperalgesia,50 and recently, it was 
demonstrated direct interaction of TRPV1 with LPA,19 suggesting a role for this 
channel in the development of NP, but the mechanisms of actions are still to be 
clarified. 
In summary, several signaling pathways are responsible of the NP development. 
Although many efforts have been made in order to interfere in these pathways, none 
of the synthesized compounds has progressed to a marketed drug, but they remain 
as valuable research agents. Among them, the most important are the Rho kinase 
(ROCK) inhibitors, H-115251 and Y-27632,52 involved in the downstream of LPA 
signaling (see Figure 2), and the ATX inhibitor, PF-8380 (Table 1).53 
Table 1. Research agents for the study of NP. 
Name Structure Mechanism of action Drawback 
H-1152 
 
ROCK inhibitor 
Excessive doses are 
required for sustained 
analgesic effect.51 
Y-27632 
 
ROCK inhibitor Lack of ROCK selectivity.54 
PF-8380 
 
ATX inhibitor 
Lack of improvement of the 
anti-inflammatory potential 
with respect to naproxen.53 
 
Given the implication of LPA1 receptor in NP, a strategy could be targeting this 
receptor with antagonists to block the signaling pathway. However, the efficacy of 
antagonists is usually limited, since they are only effective for the first 2-4 hours after 
administration. Hence, one alternative could be targeting LPA1 receptor with a 
selective agonist, which should promote receptor internalization and desensitization, 
and accordingly, could produce long-lasting antinociceptive effects. Although several 
structure-activity relationship (SAR) studies had been carried out, no potent ligands 
for the LPA1 receptor had been described, especially in the agonist field. Towards this 
end, in this work we will address the development of potent and selective LPA1 
receptor agonists, as antinociceptive agents.  
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1.2. Spinal Cord Injury 
Millions of people worldwide suffer from SCI, which is considered as one of the 
most physically disabling and psychologically devastating conditions known to 
humans. Moreover, the majority of victims are young and otherwise healthy 
individuals. 
Functionally, the spinal cord is the part of the CNS that controls the transmission 
of neural signals between the brain and the rest of the body. Although the spinal cord 
is well protected by the bone of the spinal column, it can be damaged by mechanical 
trauma or, less frequently, injured by infection, insufficient blood flow, or diseases that 
alter its nerve function. Any of these spinal cord injuries result in a disruption of the 
pathways that carry information between brain and body, leading to possible serious 
disability, as well as of neuronal networks related to many physiological functions, 
including the respiratory, gastrointestinal, urinary, and autonomic nervous system. 
The pathophysiology of SCI is widely described as biphasic. The primary phase 
involves the initial mechanical trauma and the subsequent neurological deficits, while 
the secondary phase results in a prolonged period of tissue destruction, contributing 
to permanent functional disabilities.55 Primary injury cannot be avoided, therefore 
comprehension of secondary injury mechanisms in SCI are invaluable requisite for 
planned therapeutic strategies, in order to improve neural regeneration and promote 
functional recovery. To date, only limited effective treatments are available. 
Pharmacological inhibition of Rho/ROCK pathway and PLA2 enzyme were 
studied in order to prevent cell death and promote axon regeneration after SCI. Many 
efforts have been made in this sense, but only a compound seems to be a promising 
drug; BA-210 (trademarked as Cethrin®) blocks activation of Rho and is in phase-II/III 
clinical trials to treat SCI.56  
 
Also, the pan-PLA2 inhibitor, AX-11557-60 is likely to be excellent candidate for 
drug development for the treatment of SCI, while the sPLA2 inhibitor, GK115,58-60 and 
the ROCK inhibitor, Y-27632,61 are used mainly as research agents for the study of 
SCI (Table 2). 
The inflammatory response that occurs after SCI strongly contributes to 
secondary injury. In this context, LPA is considered as an important mediator of 
inflammation.62 In fact, a recent study suggests that the increased level of LPA in the 
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injured spinal cord is implicated in demyelination and loss of function by signaling via 
LPA1 and LPA2 receptors, contributing to secondary damage.63-65 Moreover, two 
recent works confirmed this evidence, showing a reduced tissue damage after spinal 
cord hemisection injury in mice66 and brain trauma67 using the anti-LPA monoclonal 
antibody, LT3114, that blocks LPA interaction with its receptors. This antibody is 
currently under investigation as therapeutic agent, given that it recognizes all relevant 
LPA species, including the unusual 18:0 and 16:0 LPAs that are abundant in the 
cerebrospinal fluid of injured mice and humans (Table 2).66,67  
Table 2. Research agents for the study of SCI. 
Name Structure Mechanism of action Drawback 
GK115 
 
sPLA2 inhibitor Selective only for sPLA2.58 
Y-27632 
 
ROCK inhibitor 
Inhibition ability is not selective 
for ROCK, but for different 
protein kinases.54 
LT3114 Antibody LPA antibody 
Competition with LPA 
receptors for LPA.67 
 
Hence, the contribution of LPA signaling in the secondary damage after SCI is 
recognized and, among the LPA receptors, LPA1 and LPA2 seem to be implicated.68 
Currently, there are a number of LPA1 receptor antagonists in early pre-clinical phase 
studies for the treatment of cancer (Ki1642569 and ONO-730024370), fibrosis 
(AM96671 and AM095,72 the R stereoisomer of AM966) and systemic sclerosis 
(SAR100842,73 structure undisclosed). However, only two compounds are specifically 
indicated for treating CNS injury; BMS-986202, in phase I, and BMS-986020, in phase 
II clinical trials, whose structures have not been disclosed yet.74 
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Given that little is known about the specific involvement of LPA1 and, especially, 
LPA2 receptors in the pathophysiology of SCI, there is a need to elucidate the role of 
these receptors. Towards this end, in this work we have considered the 
complementary action of LPA1 and LPA2 receptors, focusing our investigation on 
targeting both receptors with antagonists.  
 
 
In summary, the objective of this work is the design and synthesis of new potent 
and selective LPA1 agonists that allow the validation of this approach to ameliorate 
NP, and the development of new LPA1 and LPA2 selective antagonists to study the 
role of these receptors in decreasing the damage associated to SCI. This overall 
objective involves the following steps:  
1. Design and synthesis of new ligands with agonist or antagonist activity at 
LPA1 and LPA2 receptors. 
2. Determination of the activity and selectivity at LPA receptors.  
3. Biological validation of the selected compounds. 
 
  
RESULTS AND DISCUSSION 
  
  
2. RESULTS AND DISCUSSION 
2.1. Design and synthesis of new agonists for the LPA1 receptor  
Binding of an agonist to a GPCR leads to the activation of heterotrimeric G 
proteins, which in turn stimulates or inhibits effector proteins. In the case of prolonged 
or repeated stimulation, GPCRs are phosphorylated by GPCR kinases and recruit -
arrestins, events responsible for fast signal desensitization. Subsequently, GPCRs 
are often internalized into endosomes, where they are either degraded or 
dephosphorylated and recycled back to the cell surface to sustain a new cycle of 
activation (Figure 6). This regulatory mechanism allows for the interruption of 
prolonged GPCR activation and the excessive amplification of the respective 
signaling pathways engaged in the response.75-77 The desensitization process can be 
the result of the own downregulation of the activated receptor (homologous 
desensitization), or it can be related to modulation of a pathway common to other 
receptors (heterologous desensitization). Currently it is known that many GPCRs can 
be phosphorylated, desensitized, and internalized by both agonist stimulation and in 
a heterologous manner. Generally, GPCR desensitization can limit the therapeutic 
usefulness of many receptor agonists, but there are cases where this reduced 
sensitivity is the aim of the research. One example is the sphingosine 1-phosphate 
(S1P) receptor modulator FTY720, marketed as Fingolimod® for the treatment of 
multiple sclerosis.78  It binds with high affinity to S1P receptor and mediates its cellular 
effects through agonist activation, followed by internalization of the receptors as a 
result of its potent stimulation.  
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Figure 6. Representation of GPCR desensitization and internalization processes (Source: 
Trends Pharmacol. Sci. 2010, 31, 221-228). 
In 2003, a study using human LPA1 receptor-transfected HeLa cells showed that 
treatment with LPA induced rapid endocytosis of approximately 40% of surface LPA1 
receptors within fifteen minutes.79 After that, several groups have elucidated the 
desensitization and internalization mechanisms of LPA1 receptor after stimulation with 
an agonist.80,81 Hence, it is possible that activation of LPA1 receptor with an agonist 
could lead to the desensitization of the receptor and accordingly block the signal 
transduction, which could translate into a blockade of neuropathic pain, one of the 
objective of this work. Therefore, in this context, we focused our efforts on finding new 
molecular entities with agonist activity at LPA1 and able to induce receptor 
desensitization. 
At the moment of starting this project, the 3D structure of the LPA1 receptor had 
not been elucidated and no potent and selective ligands for the LPA1 receptor had 
been described, especially in the agonist field. Hence, the structure of the 
endogenous ligand, LPA, was used as starting point. Initially, two series of 
compounds were designed: series I, which comprised changes in the acid group 
attached to the glycerol backbone of LPA, and series II, which included modifications 
in the hydrophobic chain (Figure 7). 
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Figure 7. Design of new LPA1 ligands. 
2.1.1. Design and synthesis of series I  
Several SAR studies82 suggest that changes in the polar head of LPA are poorly 
tolerated. In particular, it has been shown that an important requirement for activity is 
the presence of free acid groups retaining their negative charge under physiological 
conditions.83 In fact, when the phosphate group has been modified in LPA-like 
structures, it has usually led to a decrease in LPA1 activity of agonists. This is 
confirmed by the few potent agonists described for this receptor despite the variety of 
phosphate modifications tried.  
Accordingly, phosphorous-free isosters, specifically carboxylic and boronic acids, 
and tetrazole (Figure 8) were chosen as acidic subunits in compounds of series I, as 
they have been described as phosphoryl replacements.84,85 The synthesis of the 
designed compounds implied the preparation of the corresponding glycerol 
derivatives for their subsequent regioselective coupling with the oleate moiety (Figure 
8). It must be noted that in all cases the stereochemistry was conserved identical to 
LPA.  
 
Figure 8. Acid groups proposed for series I. 
The synthesis of the glycerol derivatives functionalized with a carboxylic acid 
started by choosing the adequate and compatible protecting groups for the diol and 
the carboxylic acid moieties present in these compounds (Figure 9). The two groups 
had to be orthogonal, this is, it was required that the deprotection of the diol did not 
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affect the protecting group of the carboxylic acid. Additionally, ultimate deprotection 
of the carboxylic acid had to be compatible with the presence of the oleate ester group 
in the final compounds. Therefore, tert-butyl (tBu) ester was chosen as protecting 
group of the carboxylic acid, due to its easy cleavage in acid media which should not 
affect the base-labile oleate ester. Regarding the glycerol, the benzyl group (Bn) was 
chosen as protecting group of the diol since its removal by hydrogenation would not 
affect the tBu ester. 
 
Figure 9. Retrosynthetic analysis for the carboxylic acid glycerol derivatives. 
In the case of the glycerol derivative bearing a boronic acid, the need of two 
orthogonal protecting groups was solved by protecting the diol as an isopropylidene 
acetal, whereas the boronic acid was introduced as a pinacol ester, whose 
deprotection conditions should be compatible with the presence of the oleate moiety 
(Figure 10).  
 
Figure 10. Retrosynthetic analysis for the boronic acid glycerol derivative. 
Regarding the tetrazole derivative, the diol was also protected as an acetal, and 
the primary hydroxyl group was transformed into a cyano group for its later conversion 
to the corresponding tetrazole (Figure 11).  
 
Figure 11. Retrosynthetic analysis for the cyano glycerol derivative. 
Starting with the carboxylic acid derivatives, alkylation of commercially available 
(S)-(-)-2,3-bis(benzyloxy)propan-1-ol with tert-butyl bromoacetate in the presence of 
sodium hydride (NaH) and tetrabutylammonium iodide (TBAI) led to compound 1, 
Results and discussion 
- 19 - 
which was deprotected by catalytic hydrogenation to afford the glycerol intermediate 
2 (Scheme 1).  
 
Scheme 1. Reagents and conditions: (a) tert-Butyl bromoacetate, NaH, 
TBAI, THF, 0ºC to 50ºC, 16 h, 22%; (b) H2, 10% Pd(C), EtOH, 60ºC, 95%. 
Next, glycerol derivatives functionalized with malonic and α-fluoromalonic acid 
were prepared, where the fluorine atom was introduced in order to increase the acidity 
of the carboxylic acids. Thus, (S)-(-)-2,3-bis(benzyloxy)propan-1-ol was transformed 
into the corresponding mesylate 3, which was then alkylated with di-tert-butyl 
malonate using NaH as base to yield intermediate 4. For the preparation of the α-
fluoromalonic derivative, intermediate 4 was treated with Selectfluor® under basic 
conditions. Catalytic hydrogenation of intermediates 4 and 6 afforded the glycerol 
derivatives 5 and 7 (Scheme 2). 
 
Scheme 2. Reagents and conditions: (a) Mesyl chloride, Et3N, DCM, 0ºC to rt, 1 h, 
80%; (b) di-tert-butyl malonate, NaH, NaI, DMF:THF, 0ºC to 80ºC, 17 h, 76%; (c) H2, 
10% Pd(C), EtOH, 60ºC, 89-95%; (d) Selectfluor®, NaH, DMF:THF, 0ºC to rt, 48 h, 
99%. 
For the glycerol derivative bearing a boronic acid moiety (10), the synthesis 
started with the tosylation of commercially available (S)-(+)-1,2-
isopropylydeneglycerol [(S)-solketal] to obtain intermediate 8, which was further 
reacted with 4-hydroxyphenylboronic acid pinacol ester to yield derivative 9. Diol 10 
was obtained by deprotection of the acetal using polystyrene-supported p-
toluensulfonic acid (PS-pTsOH) (Scheme 3). 
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Scheme 3. Reagents and conditions: (a) Tosyl chloride, pyridine, DCM, 0ºC to rt, 16 
h, 86%; (b) 4-hydroxyphenylboronic acid pinacol ester, Cs2CO3, DMF, 90ºC, 16 h, 
84%; (c) PS-pTsOH, CH3OH, rt, 18 h, 88%. 
The glycerol intermediate funcionalized with a cyano group was synthesized by 
transformation of (S)-solketal into the corresponding triflate, followed by treatment 
with potassium cyanide to afford nitrile 11. Diol 12 was obtained by cleavage of the 
acetal using trifluoroacetic acid (TFA) (Scheme 4). 
 
Scheme 4. Reagents and conditions: (a) i) Pyridine, triflic 
anhydride, DCM, -20ºC, 30 min; ii) KCN, CH3CN:H2O, rt, 
12 h, 99%; (b) TFA, CH3OH, rt, 1.5 h, 61%. 
Once the functionalized glycerol derivatives 2, 5, 7, 10, and 12 were synthesized, 
their regioselective condensation with oleic acid was carried out. Following reaction 
conditions previously employed by our group, 2 was coupled with oleoyl chloride in 
the presence of 2,4,6-collidine at low temperature to afford ester 13. The reaction was 
completely regioselective, and only the acylation at sn-1 position of the glycerol moiety 
was observed. The tert-butyl group of intermediate 13 was removed by treatment with 
TFA, yielding the final compound 1a without detection of the hydrolysis of the oleate 
ester (Scheme 5). 
  
Scheme 5. Reagents and conditions: (a) Oleoyl chloride, 2,4,6-collidine, DCM, -78ºC to rt, 24 
h, 36%; (b) TFA, DCM, rt, 17 h, 52%. 
The esterification conditions were then applied to the reaction of the oleoyl 
chloride with the malonate derivatives 5 and 7 to yield the intermediate esters 14 and 
15 which were then subjected to acidic conditions to remove the tert-butyl group. In 
this case, the treatment of derivatives 14 and 15 with TFA led to the formation of 
lactones 1b and 1c instead of the expected malonic acids (Scheme 6). These 
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products, obtained as a 1:1 mixture of diastereoisomers, are the consequence of the 
intramolecular cyclization of the carboxylic acid with the hydroxy group in γ position.  
 
Scheme 6. Reagents and conditions: (a) Oleoyl chloride, 2,4,6-collidine, DCM, -78ºC 
to rt, 24 h, 60-99%; (b) TFA, DCM, rt, 17-18 h, 88-99%. 
The esterification conditions were also used to carry out the reaction of glycerol 
derivative 10 with oleoyl chloride. The pinacolyl boronate ester 16 was transformed 
into the corresponding trifluoroborate salt 17, followed by hydrolysis with trimethylsilyl 
chloride (TMSCl) to yield final compound 1d (Scheme 7).  
 
Scheme 7. Reagents and conditions: (a) Oleoyl chloride, 2,4,6-collidine, DCM, 
-78ºC to rt, 24 h, 40%; (b) KHF2, CH3OH:H2O, rt, 30 min, 99%; (c) TMSCl, 
CH3CN:H2O, rt, 1 h, 60%. 
Finally, diol 12 was coupled with oleoyl chloride to obtain ester 18, which led to 
tetrazole derivative 1e by cycloaddition reaction with sodium azide, under microwave 
(MW) irradiation (Scheme 8). 
 
Scheme 8. Reagents and conditions: (a) Oleoyl chloride, 2,4,6-collidine, DCM, 
-78ºC to rt, 12 h, 88%; (b) NaN3, NH4Cl, DMF, MW, 160ºC, 45 min, 5%. 
Once the compounds 1a-e were synthesized, they were tested in a LPA1-
overexpressing cell line, to determine if any of the phosphate replacements carried 
out had allowed to obtain compounds with activity at this receptor. 
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2.1.2. Determination of the agonist activity at LPA1 receptor 
In order to test the synthesized compounds as LPA1 receptor agonists, the 
corresponding biological assay was set up in our laboratory. The ability of the 
compounds to activate the receptor was determined by the measurement of calcium 
mobilization in RH7777 cells stably transfected with the receptor, as the binding of an 
LPA1 agonist causes an increase in intracellular calcium levels,86 which can be 
quantified using a fluorescence-based assay.  
After some experimental optimizations, Fluo 4-NW (no-wash) was chosen as the 
most appropriate calcium sensor. To determine the agonist activity of the compounds, 
cells were preloaded with Fluo 4-NW and then incubated in the presence of the 
compounds under study. Fluorescence intensity was measured (excitation 
wavelength of 494 nm and emission wavelength of 516 nm) in a 96-well microplate 
reader. Ionomycin (10 µM) and LPA were employed as positive controls, with 10 µM 
LPA response being 30% of ionomycin response.87 In order to rule out non-LPA1 
receptor mediated calcium mobilization, parallel experiments using non-transfected 
RH7777 cells were carried out.  
The compounds were initially tested at a fixed dose of 10 µM and the maximal 
receptor activation (Emax) for each of them was expressed as a percentage, referring 
their response to that induced by 10 µM LPA. In order to obtain the half maximal 
effective concentration (EC50) value for those compounds that presented Emax over 
30%, the complete dose-response curve, at six or seven different concentrations of 
the ligand, was determined. Data are expressed as the average and standard error 
(s.e.m.) obtained from two to four independent experiments carried out in triplicate. 
The obtained results for compounds 1a-e are shown in Table 3. 
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Table 3. Agonist activities of compounds 1a-e at LPA1 receptor 
 
Compound 
 
Emax (%)a EC50 (µM)b pKac 
1a 
 
N.E.d - 3.4 ± 0.1 
1b 
 
N.E. - 2.7 ± 0.4 
1c 
 
33 ± 5 1.7 ± 0.2 0.5 ± 0.4 
1d 
 
N.E. - 8.7 ± 0.2 
1e 
 
N.E. - 5.0 ± 0.1 
LPA 
 
100 0.83 ± 0.02 1.8 ± 0.1 
aEmax = maximal efficacy of the drug/maximal efficacy of LPA, expressed as the percentage.
 bFor Emax > 30%, 
EC50 values are expressed as mean ± s.e.m, from a minimum of two independent experiments, performed in 
triplicate. cValues estimated with ACDLabs program. dNo effect was observed at the highest concentration of 
compound tested (10 µM). 
 
In this initial set of compounds, the influence of pKa seems to be important for 
activity, as only compound 1c, with a pKa value lower than LPA, activates the receptor 
(Table 3). Accordingly, it was necessary to confirm if the non-cyclic α-fluoromalonic 
derivative originally proposed, with two free carboxylic acids, would exhibit better 
activity at LPA1 receptor. In order to avoid the intramolecular cyclization, the most 
straightforward structural modifications were either the removal of the hydroxy group 
(compound 1f) or its masking with a methyl group, as in derivative 1g (Figure 12). 
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Figure 12. α-Fluoromalonic derivatives. 
Hence, the commercially available 3-(benzyloxy)propan-1-ol was transformed 
into the corresponding mesylate 19, which was further alkylated with di-tert-butyl 
malonate to obtain intermediate 20. Treatment of this compound with Selectfluor® to 
yield fluorinated derivative 21, and subsequent catalytic hydrogenation to remove the 
benzyl group afforded the desired alcohol 22 (Scheme 9). 
 
Scheme 9. Reagents and conditions: (a) Mesyl chloride, Et3N, DCM, 0ºC to rt, 1 h, 
99%; (b) di-tert-butyl malonate, NaH, NaI, DMF:THF, 0ºC to 80ºC, 17 h, 66%; (c) 
Selectfluor®, NaH, DMF:THF, 0ºC to rt, 48 h, 99%; (d) H2, 10% Pd(C), EtOH, 60ºC, 
95%. 
Once malonate intermediate 22 was synthesized, acylation with oleoyl chloride 
followed by hydrolysis with TFA allowed to obtain final compound 1f in good yield 
(Scheme 10). 
 
Scheme 10. Reagents and conditions: (a) Oleoyl chloride, 2,4,6-collidine, DCM, 
-78ºC to rt, 24 h, 70%; (b) TFA, DCM, rt, 16 h, 90%. 
Synthesis of final compound 1g started from derivative 15, which by reaction with 
trimethylsilyldiazomethane and subsequent hydrolysis of the tert-butyl ester groups 
led to the desired malonic derivative (Scheme 11).  
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Scheme 11. Reagents and conditions: (a) Trimethylsilyldiazomethane, HBF4, DCM, 0ºC, 90 
min, 38%; (b) TFA, DCM, rt, 17 h, 95%. 
The capacity of compounds 1f,g to activate LPA1 receptor was determined and 
the results are shown in Table 4. Taking together all the data obtained for series I, the 
necessity of an acidic polar group seems clear. However, it is not the only 
requirement, as 1f, with a pKa value similar to compound 1g, is completely inactive. 
This suggests the importance of the oxygen atom at the sn-2 position of the spacer 
that separates the fatty acid chain and the polar head group.  
Table 4. Agonist activities of compounds 1f,g at LPA1 receptor 
 
Compound 
 
Emax (%)a EC50 (µM)b pKac 
1f 
 
N.E.d - 1.1 ± 0.4 
1g 
 
74 ± 14 6 ± 1 0.9 ± 0.4 
LPA 
 
100 0.83 ± 0.02 1.8 ± 0.1 
aEmax = maximal efficacy of the drug/maximal efficacy of LPA, expressed as the percentage.
 bFor Emax > 30%, 
EC50 values are expressed as mean ± s.e.m, from a minimum of two independent experiments, performed in 
triplicate. cValues estimated with ACDLabs program. dNo effect was observed at the highest concentration of 
compound tested (10 µM). 
 
In conclusion, this initial series of compounds allowed to identify two LPA1 
receptor agonists, 1c (Emax = 33%; EC50 = 1.7 µM) and 1g (Emax = 74%; EC50 = 6 
µM), which confirms that it is possible to mimic the phosphate group of LPA with 
other polar moieties. However, these two agonists are still less potent than LPA so, 
in order to optimize the structure, the study of the influence of the hydrophobic chain 
of LPA was addressed.  
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2.1.3. Design and synthesis of series II 
During the last years, several studies have been carried out trying to establish 
the structural requirements needed for the hydrophobic moiety. Although no definitive 
conclusions have been reached yet, it seems clear that modifications on this part of 
the molecule are less critical for activity at LPA1 receptor, probably because its flexible 
disposition facilitates its fitting into the receptor pocket.  
Thus, for series II, a comprehensive study of the influence of the hydrophobic 
moiety was carried out, including modifications on the overall length of the fatty acid 
chain as well as the incorporation of aromatic rings (Figure 13). The designed 
compounds were prepared by regioselective acylation of the properly protected (PG) 
phosphorylated glycerol backbone with the appropriate hydrophobic subunit.  
 
Figure 13. Design of compounds of series II. 
2.1.3.1. Derivatives of series II containing aliphatic chains  
Modifications of the length of the fatty acid chain implied the synthesis of the 
corresponding alkynyl derivatives, followed by their partial hydrogenation to obtain the 
Z-alkenes. Regarding the protecting groups of the phosphorylated glycerol fragment, 
the compatibility between the deprotection conditions of the phosphate group and the 
existence of double bonds in the molecule had to be considered, and so, tBu group 
was chosen, as its hydrolysis takes place in acid media, which should not affect the 
double bond. Furthermore, the deprotection conditions of the diol should be 
orthogonal with the tBu phosphate ester, and benzyl group was selected as the most 
appropriate option (Figure 14).  
 
Figure 14. Retrosynthetic analysis for aliphatic derivatives of series II. 
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Alkynyl derivatives 26-28 were achieved by a Sonogashira reaction of methyl 8-
bromooctanoate (25) and the corresponding commercially available alkyne using a 
carbene-based palladium catalyst suitable for cross-coupling of unactivated alkyl 
bromides (Scheme 12).88 The subsequent stereoselective cis-hydrogenation of the 
alkynes 26-28 was carried out by Brown reaction89 under conditions previously 
optimized in the laboratory. Thus, the desired alkenes 29-31 were obtained with total 
conversion employing nickel acetate and sodium borohydride as the catalytic system, 
in the presence of ethylendiamine and under a hydrogen atmosphere. Then, the 
alkenes were hydrolyzed to their corresponding carboxylic acids 32-34 (Scheme 12).  
 
Scheme 12. Reagents and conditions: (a) pTsOH, CH3OH, reflux, 18 h, 95%; (b) 
[(π-allyl)PdCl]2, 1,3-bis(1-adamantyl)imidazolium chloride, CuI, Cs2CO3, DMF:Et2O, 
55ºC, 16 h, 36-44%; (c) Ni(OAc)2·4H2O, NaBH4, ethylenediamine, H2 (1 atm), EtOH, 
rt, 2 h, 89-92%; (d) LiOH·H2O, THF:H2O, rt, 16-18 h, 99%. 
Next, the glycerol-phosphate moiety was prepared following a synthetic 
methodology previously set up in the laboratory, consisting on the formation of an 
intermediate phosphite and its subsequent oxidation.90 Thus, one-pot reaction of (S)-
(-)-2,3-bis(benzyloxy)propan-1-ol with di-tert-butyl-N,N-diisopropylphosphoramidite 
and oxidation with m-chloroperbenzoic acid (mCPBA) led to phosphate 35. Removal 
of the benzyl groups by catalytic hydrogenation yielded diol 36 (Scheme 13).  
 
Scheme 13. Reagents and conditions: (a) i) iPr2NP(OtBu)2, 1H-
tetrazole, DCM, rt, 2 h; ii) mCPBA, DCM, -30ºC, 90 min, 38%; (b) H2, 
10% Pd(C), EtOH, 60ºC, 99%. 
Finally, regioselective esterification reaction between myristoleic or palmitoleic 
acid or the non-commercial carboxylic acids 32-34 and phosphorylated diol 36, using 
N,N'-dicyclohexylcarbodiimide (DCC) as coupling reagent at low temperature, led to 
intermediates 37-41, which were then deprotected to obtain the final products 2a-e 
with good yields (Scheme 14).  
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Scheme 14. Reagents and conditions: (a) 36, DCC, DMAP, DCM, -20ºC to rt, 16 
h, 12-49%; (b) TFA, DCM, rt, 4-5 h, 90-99%. 
Synthesized compounds 2a-e were tested for their activity at the LPA1 receptor 
(Table 5). The most remarkable conclusion that can be drawn from the data obtained 
is the great influence on activity exerted by the length of the hydrophobic chain. As 
shown in Table 5, variations in just one methylene unit can turn a compound inactive 
(for example derivative 2d shows an activity comparable to LPA whereas 2e is 
inactive) or increase its activity almost two-fold, as shown by compounds 2d (Emax = 
88%; EC50 = 3.6 µM) and 2c (Emax = 202%; EC50 = 2.1 µM). These data suggest that 
the optimal chain is the corresponding to (9Z)-hexadec-9-enoic acid (palmitoleic 
acid), present in compound 2b (Emax = 205%; EC50 = 0.45 µM), the most potent 
derivative within the series and better than the endogenous ligand LPA (Emax = 
100%; EC50 = 0.83 µM).  
Table 5. Agonist activities of compounds 2a-e at LPA1 receptor 
 
Compound 
 
Emax (%)a EC50 (µM)b 
2a 
 
127± 1 2.8 ± 0.1 
2b 
 
205 ± 9 0.45 ± 0.01 
2c 
 
202 ± 1 2.1 ± 0.3 
2d 
 
88 ± 2 3.6 ± 0.2 
2e 
 
N.E.c - 
LPA 
 
100 0.83 ± 0.02 
aEmax = maximal efficacy of the drug/maximal efficacy of LPA, expressed as the percentage.
 bFor Emax > 30%, 
EC50 values are expressed as mean ± s.e.m, from a minimum of two independent experiments, performed 
in triplicate. cNo effect was observed at the highest concentration of compound tested (10 µM). 
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2.1.3.2. Derivatives of series II containing aromatic rings 
Previous results from our group indicate that phenyl group can mimic unsaturated 
fatty acid chains.91 In addition, and considering the importance of the length of the 
chain for activity, the influence of the distance between the aromatic rings and the 
ester group of the molecule (n) was screened in detail (Figure 15).  
In this case, the synthesis involved the preparation of the non-commercial ω-
phenylalkanoic acids as well as the conveniently protected phosphorylated glycerol 
(Figure 15). Regarding the glycerol moiety and searching for synthetic simplicity and 
high yields, an ethyl group was used for phosphate protection, whose removal 
conditions should not interfere with the presence of an ester. As for the diol protecting 
group, an isopropylidene acetal was initially selected. 
 
Figure 15. Retrosynthetic analysis for aromatic ring derivatives of series II. 
Non-commercially available carboxylic acids (n = 7-9) were synthesized as 
depicted in Scheme 15, either by Wittig reaction between the appropriate bromoacid 
and benzaldehyde, followed by catalytic hydrogenation, in the case of acids 44 and 
45; or by oxidation of the corresponding alcohol, in the case of acid 46. 11-
Phenylundecanoic acid (n = 10) and 15-phenylpentadecanoic acid (n = 14) were 
commercially available. 
 
Scheme 15. Reagents and conditions: (a) PPh3, toluene, 
reflux, 18 h, 99%; (b) benzaldehyde, lithium 
bis(trimethylsilyl)amide, THF, -20ºC to rt, 18 h, 61-70%; (c) 
H2, 10% Pd(C), EtOH, rt, 81-97%; (d) PDC, DMF, rt, 16 h, 
52%. 
 
Results and discussion 
- 30 - 
For the preparation of the phosphorylated glycerol backbone, (S)-solketal was 
treated with diethyl chlorophosphate in the presence of potassium tert-butoxide to 
yield intermediate 47 in very high yield, which after cleavage of the acetal group 
afforded diol 48 (Scheme 16).  
 
Scheme 16. Reagents and conditions: (a) ClP(O)(OEt)2, 
KOtBu, DCM, rt, 48 h, 92%; (b) PS-pTsOH, CH3OH, rt, 16 h, 
50%. 
Once carboxylic acids 44-46 and phosphorylated glycerol 48 were prepared, 
intermediate 46 was used, as first example, to carry out the next step of the proposed 
synthetic route. Thus, the reaction between 48 and 46 using DCC as coupling reagent 
led to ester 49, which was treated with TMSBr as generally described92 to remove the 
ethyl groups from the phosphate. However, instead of the expected product, the 
bromo derivative 3a was obtained (Scheme 17), which structure was confirmed by 
nuclear magnetic resonance (NMR) and high pressure liquid chromatography coupled 
to mass spectrometry (HPLC-MS). The reaction mechanism proposed for the 
formation of compound 3a and the determination of its absolute configuration will be 
discussed later. 
 
Scheme 17. Reagents and conditions: (a) 48, DCC, DMAP, -20ºC to rt, 18 h, 
30%; (b) i) TMSBr, DCM, rt, 4 h; ii) MeOH/H2O, rt, 1h, 90%. 
Although different deprotection conditions using TMSBr were assayed for 
compound 49, it was not possible to isolate the desired product. Starting material was 
used thoroughly dried, N,O-bis(trimethylsilyl)trifluoroacetamide was employed as 
additive, and the reaction times were reduced, but mixtures of starting material, 
desired product and brominated product, which could not be separated by 
chromatography, were obtained in all cases. 
A benzyl group was then considered as an alternative phosphate protecting group 
in order to avoid the formation of compound 3a. Hence, dibenzyl phosphate glycerol 
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derivative 51 was obtained from (S)-solketal using the appropriate phosphoramidite 
reagent according to the methodology previously used, followed by deprotection of 
the diol (Scheme 18). 
 
Scheme 18. Reagents and conditions: (a) i) iPr2NP(OBn)2, 1H-
tetrazole, DCM, rt, 2 h; ii) mCPBA, DCM, -30ºC, 90 min, 76%; 
(b) PS-pTsOH, CH3OH, rt, 16 h, 65%. 
The regioselective esterification reaction between diol 51 and the corresponding 
ω-phenylalkanoic acids (n = 7-10, 14) allowed to obtain the esters 52-56, which after 
elimination of the benzyl groups by catalytic hydrogenation afforded the desired final 
compounds 2f-j (Scheme 19). 
 
Scheme 19. Reagents and conditions: (a) 51, DCC, DMAP, DCM, -20ºC to rt, 
16 h, 18-58%; (b) H2, 10% Pd(C), EtOH, rt, 80-99%. 
Synthesized compounds 2f-j were tested for activity at LPA1 receptor and the 
results are shown in Table 6. Although compound 3a bears a different glycerol 
phosphate scaffold, it was also tested, taken also into account that compounds 
containing a bromine in the polar head have been described as good agonists or 
antagonists for LPA receptors.93  
Again, the obtained data (Table 6) point out the importance of the length of the 
hydrophobic chain of the compound in the activity at LPA1 receptor, as small changes 
in the number of methylene units dramatically affects Emax and EC50 values. For 
example, compound 2f, with n = 7, is inactive, whereas derivative 2g, with n = 8, is 
almost as active as LPA. In addition, it must be highlighted that compound 3a, with a 
different polar head group, exhibits a very good activity at LPA1 receptor. Among these 
derivatives, compounds 2h and 3a, with Emax > 100% and EC50 values of 0.5 and 0.24 
µM, respectively, stand out.  
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Table 6. Agonist activities of compounds 2f-j and 3a at LPA1 receptor 
 
Compound 
 
Emax (%)a EC50 (µM)b 
2f 
 
N. E.c - 
2g 
 
74 ± 4 2.1 ± 0.3 
2h 
 
112 ± 3 0.5 ± 0.1 
2i 
 
135 ± 31 3.2 ± 0.5 
2j 
 
N. E. - 
3a 
 
118 ± 24 0.24 ± 0.09 
LPA 
 
100 0.83 ± 0.02 
aEmax = maximal efficacy of the drug/maximal efficacy of LPA, expressed as the percentage.
 bFor Emax > 30%, 
EC50 values are expressed as mean ± s.e.m, from a minimum of two independent experiments, performed in 
triplicate. cNo effect was observed at the highest concentration of compound tested (10 µM). 
Taking into account that the best agonist identified up to this moment was 
unexpected product 3a, and in order to establish the configuration of its chiral center, 
we decided to synthesize both enantiomers of this molecule using a chiral pool 
strategy. Thus, compounds (S)- and (R)-3a were obtained from the corresponding S 
or R form of oxiran-2-ylmethanol (glycidol), respectively, which was phosphorylated 
following the usual conditions. Then, opening of the oxirane ring of intermediates 
(R)- and (S)-57 with tetrabutylammonium bromide (TBABr) in the presence of TFA 
yielded derivatives (S)- and (R)-58, which were coupled with acid 46. Subsequent 
catalytic hydrogenation of the benzyl groups gave the desired final compounds (S)- 
and (R)-3a (Scheme 20).  
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Scheme 20. Reagents and conditions: (a) i) iPr2NP(OBn)2, 1H-tetrazole, DCM, rt, 2 h; 
ii) mCPBA, DCM, -30ºC, 90 min, 76-95%; (b) TBABr, TFA, CHCl3, rt, 10 min, 89-99%; 
(c) 46, DCC, DMAP, DCM, rt, 18 h, 68-73%; (d) H2, 10% Pd(C), EtOH, rt, 97-99%. 
The determination of the specific optical rotation of both enantiomers of 3a ([α]D20 
(S)-3a = +4.8, [α]D20 (R)-3a = -4.6, c = 0.50 methanol) confirmed that the compound 
obtained during the phosphate deprotection reaction (see Scheme 17), which had a 
positive optical rotation value, was the enantiomer S ([α]D20 3a = +4.9, c = 0.50 
methanol). The formation of (S)-3a in this reaction could be explained by migration of 
the acyl chain to the secondary hydroxy group, and subquent substitution of the 
primary hydroxy group by the bromide present in the reaction media (Figure 16). 
Intramolecular acyl chain migration, facilitated by both acidic and basic conditions, is 
a well known phenomenon of LPs, specially in the case of 2-acyl-sn-glycerol-3-
phosphate species, which are very labile under physiological conditions and easily 
isomerize to 1-acyl derivatives.94 
 
Figure 16. Proposed mechanism for the formation of compound (S)-3a. 
At this point, the effect of the stereocenter in the ligand activity was considered, 
and the assessment of the agonist activity of the R enantiomer of 3a revealed an 
enantiomer preference, as R isomer is much less active than the S one, showing an 
increase of two orders of magnitude in the EC50 value (Table 7). 
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Table 7. Agonist activitity of compounds (R)- and (S)-3a at LPA1 receptor 
Compound Structure Emax (%)a EC50 (µM)b 
(R)-3a 
 
32 ± 3 26 ± 5 
(S)-3a 
 
118 ± 24 0.24 ± 0.09 
LPA 
 
100 0.83 ± 0.02 
aEmax = maximal efficacy of the drug/maximal efficacy of LPA, expressed as the percentage.
 bFor Emax > 30%, 
EC50 values are expressed as mean ± s.e.m, from a minimum of two independent experiments, performed in 
triplicate.  
2.1.3.3. Synthesis of analogues of (S)-3a 
Considering the excellent activity of compound (S)-3a, which turned out to be the 
best LPA1 receptor agonist among all the synthesized compounds so far (Emax = 
118%, EC50 = 0.24 µM), additional structural exploration was extended around this 
new scaffold. In particular, it was analysed whether changes in the length of the 
methylenic chain would affect its activity in the same degree observed for compounds 
2f-2j of series II. In addition, the replacement of the hydrophobic unit by the oleoyl 
chain was studied, in order to see if it would involved an increase in activity. Hence, 
compounds 3b-d (Figure 17) were synthesized.  
 
Figure 17. Designed derivatives of (S)-3a. 
Phenyl-containing derivatives 3b and 3c were obtained from (S)-58, which was 
coupled with the corresponding ω-phenylalkanoic acids. Subsequent catalytic 
hydrogenation of the benzyl groups gave the desired final compounds 3b, c (Scheme 
21). 
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Scheme 21. Reagents and conditions: (a) 45 or 11-phenylundecanoic acid, DCC, 
DMAP, DCM, rt, 5 h, 55-96%; (b) H2, 10% Pd(C), EtOH, rt, 72-80%. 
A similar synthetic route, but employing tert-butyl instead of benzyl as protecting 
group for the phosphate, due to the presence of the double bond in the oleate moiety, 
allowed to obtain compound 3d starting from (S)-glycidol (Scheme 22).  
 
Scheme 22. Reagents and conditions: (a) i) iPr2NP(tBu)2, 1H-tetrazole, DCM, rt, 2 h; ii) 
mCPBA, DCM, -30ºC, 90 min, 52%; (b) TBABr, TFA, CHCl3, rt, 10 min, 95%; (c) oleoyl 
chloride, pyridine, rt, 18 h, 15%; (d) TFA, DCM, rt, 5 h, 81%. 
Activity of these new compounds at the LPA1 receptor was determined (Table 8). 
The obtained results showed that only oleoyl derivative 3d was able to activate the 
receptor, although it did not reach neither LPA nor (S)-3a values.  
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Table 8. Agonist activities of compounds (S)-3a and 3b-d at LPA1 receptor 
 
Compound 
 
Emax (%)a EC50 (µM)b 
(S)-3a 
 
118 ± 24 0.24 ± 0.09  
3b 
 
N. E.c  - 
3c 
 
N. E.  - 
3d 
 
39 ± 3 3.2 ± 0.4 
LPA 
 
100 0.83 ± 0.02 
aEmax = maximal efficacy of the drug/maximal efficacy of LPA, expressed as the percentage.
 bFor Emax > 30%, 
EC50 values are expressed as mean ± s.e.m, from a minimum of two independent experiments, performed 
in triplicate. cNo effect was observed at the highest concentration of compound tested (10 µM). 
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2.1.4. Selectivity of the identified LPA1 agonists over LPA2 and LPA3 receptors 
The purpose of present work is the development of potent and selective LPA1 
receptor agonists. Taking into account the high sequence homology among the LPA 
receptors, especially LPA1-3, the next step is to determine the selectivity of the 
identified agonists towards LPA2 and LPA3 receptors. 
Hence, cell lines stably overexpressing LPA2 and LPA3 receptor subtypes were 
generated. A B103 neuroblastoma cell line, which does not express LPA receptors 
intrinsically,95 was chosen for its transfection with the corresponding plasmid 
containing LPA2 and LPA3 receptors fused with the enhanced green fluorescent 
protein (EGFP). B103 cells expressing high levels of EGFP, and thus of the desired 
receptor, were isolated by fluorescence-activated cell sorting (FACS). 
The best agonist of each series (1c, 1g, 2b, 2h and (S)-3a, see Tables 3-6) was 
selected and screened for activity at these cell lines. The obtained results (Table 9) 
showed that compounds 1c, 1g and (S)-3a are selective for LPA1 versus LPA2 and 
LPA3 receptors. Compound 2b can also be considered selective, given that it is 50-
fold less active at LPA3 receptor than at LPA1 receptor. Lack of activity at LPA3 
receptor is especially important, given that the activation of this receptor is implicated 
in the production of high LPA levels after peripheral nerve damage, responsible for 
initiation and maintenance of NP (see Introduction pag. 6).  
Table 9. Agonist activity of compounds at LPA1-3 receptor 
  EC50 (µM)a 
Compound LPA1 receptor LPA2 receptor LPA3 receptor 
1c 
 
1.7 ± 0.2 N. E. b N. E.  
1g 
 
6 ± 1 N. E. N. E.  
2b 
 
0.45 ± 0.01 N. E. 21.6 ± 5 
2h 
 
0.5 ± 0.1 5.3 ± 0.6 N. E. 
(S)-3a 
 
0.24 ± 0.09 N. E. N. E. 
LPA 
 
0.83 ± 0.02 1.3 ± 0.5 3.4 ± 0.8 
aFor Emax > 30%, EC50 values are expressed as mean ± s.e.m, from a minimum of two independent experiments, 
performed in triplicate. bNo effect was observed at the highest concentration of compound tested (10 µM). 
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2.1.5. Combination of the acid and hydrophobic subunits 
Among all the synthesized compounds, derivatives 1c, 1g, 2b and (S)-3a were 
selected as the most active and selective agonists at the LPA1 receptor (Figure 18). 
They present EC50 values between 0.24 and 6 µM, comparable or even better than 
the endogenous ligand LPA (EC50 = 0.83 µM). This suggests that the phosphate 
glycerol backbone of LPA can be mimicked by other acid moieties such as (5S)-3-
fluoro-5-(hydroxymethyl)-2-oxotetrahydrofuran-3-carboxylic acid (present in 1c), 
fluoro[(2S)-3-hydroxy-2-methoxypropyl]malonic acid (present in 1g) and (2S)-3-
bromo-2-hydroxypropyl dihydrogen phosphate (present in (S)-3a). In addition to the 
oleoyl chain of LPA, the LPA1 receptor recognizes shorter chains such as those 
derived from palmitoleic acid (present in 2b) and 10-phenyldecanoic acid (present in 
(S)-3a) (Figure 18).  
 
Figure 18. Compounds with activity and selectivity at the LPA1 receptor. 
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With these results in hand, we combined the hydrophobic chains present in these 
compounds with the polar heads that seemed to be able to mimic the LPA phosphate 
group. Hence, the fluorinated lactone and malonic acid, and the bromo-phosphate 
moieties present in derivatives 1c, 1g and (S)-3a were selected as polar heads. 
Regarding the hydrophobic subunit, oleoyl (present in 1c and 1g), palmitoleoyl 
(present in 2b) and 10-phenyldecanoyl chains [present in (S)-3a] were chosen. The 
combination of these fragments led to products 1c, 1g, (S)-3a, and 3d (which were 
previously synthesized) and new derivatives 4a-e which were synthesized and tested 
as agonists of the LPA1 receptor (Figure 19).  
 
Figure 19. Combination of the acid and hydrophobic subunits. 
The synthesis of lactones 4a,b started with benzylation of (R)-glycidol, followed 
by oxirane opening reaction with di-tert-butyl malonate in basic media with 
concomitant intramolecular cyclization to give lactone 66, as a mixture of 
diastereoisomers. Fluorination reaction under usual conditions led to derivative 67, 
whose catalytic hydrogenation yielded alcohol 68. The esterification reaction between 
68 and palmitoleic acid afforded intermediate 69, which chromatographic purification 
allowed the separation of the two diastereoisomers. Final deprotection of both 
diastereoisomers led to compounds (3R,5S)- and (3S,5S)-4a (Scheme 23). The 
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absolute configuration of the chiral carbon bonded to the fluorine atom was 
determined on the basis of NOE experiments and the values of the (H,H) and (H,F) 
coupling constants in 1H- and 19F-NMR spectra. In the case of esterification with 10-
phenyldecanoic acid 46, derivative 4b was obtained after treatment with TFA as 1:1 
mixture of diastereoisomers (Scheme 23). 
 
Scheme 23. Reagents and conditions: (a) BnBr, NaH, DMF, 0ºC to rt, 18 h, 99%; 
(b) di-tert-butyl malonate, NaH, DMF:THF, 0ºC to 80ºC, 6 h, 62%; (c) Selectfluor®, 
NaH, DMF:THF, 0ºC to rt, 48 h, 99%; (d) H2, 10% Pd(C), 60ºC, 87%; (e) palmitoleic 
acid or 46, DCC, DMAP, rt, 18 h, 25-35%; (f) TFA, DCM, rt, 17 h, 69-90%. 
Malonic acid derivatives 4c,d were prepared by regioselective coupling of the 
corresponding carboxylic acid and diol 7. Methylation of the hydroxy group present in 
the resulting esters 71 and 73 with trimethylsilyldiazomethane followed by removal of 
the tert-butyl groups yielded the desired compounds 4c,d (Scheme 24).  
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Scheme 24. Reagents and conditions: (a) Palmitoleic acid or 46, DCC, DMAP, DCM, -20ºC 
to rt, 17 h, 44-75%; (b) trimethylsilyldiazomethane, HBF4, DCM, 0ºC, 90 min, 27-30%; (c) TFA, 
DCM, rt, 18 h, 68-93%. 
Final product 4e was prepared by esterification reaction between palmitoleic acid 
and bromo alcohol 63, followed by phosphate group deprotection using TFA (Scheme 
25).  
 
Scheme 25. Reagents and conditions: (a) Palmitoleic acid, DCC, DMAP, DCM, rt, 24 h, 
55%; (b) TFA, DCM, rt, 5 h, 93%. 
Compounds 4a-e were assayed for their activity at LPA1 receptor and the results 
are shown in Figure 20, where previously tested compounds 1c, 1g, (S)-3a and 3d 
have been included of comparison (Figure 20). The combination process has 
highlighted that replacement of the phosphate moiety is tolerated only in the presence 
of oleoyl chain as hydrophobic subunit (compounds 1c, 1g and 3d). 
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Figure 20. Agonist activity of compounds 1c, 1g, (S)-3a, 3d and 4a-e at LPA1 receptor. 
In summary, the two series proposed for mimicking the hydrophobic chain and 
the polar head of the endogenous ligand LPA, together with the combination process, 
have yielded new scaffolds capable to activate the receptor. Among them, derivatives 
(S)-3a and 4c stand out as agonists structurally different from the endogenous ligand 
LPA with excellent activity values. Besides, the screening at LPA2 and LPA3 receptors 
showed that compound 4c is also selective for LPA1 receptor. Hence, these two 
compounds were selected for further optimization process. 
2.1.6. Structural modifications of compounds (S)-3a and 4c 
The presence of an amide group in a drug molecule is usually associated to better 
chemical and metabolic stability. Thus, the synthesis of amides 5a and 5b, derived 
from compounds 4c and (S)-3a, respectively, were proposed in order to obtain LPA 
agonists with improved stability properties (Figure 21). 
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Figure 21. Amides 5a and 5b. 
The synthesis of compound 5a started with the ring-opening reaction of the 
oxirane present in (R)-(−)-N-(2,3-epoxypropyl)phthalimide with hydrobromic acid 
followed by methylation of the resulting hydroxy group with trimethylsilyldiazomethane 
to obtain intermediate 77, which was alkylated with di-tert-butyl malonate to afford 
derivative 78. This compound was treated with Selectfluor® to yield the fluorinated 
analogue 79. Next, deprotection reaction with hydrazine led to amine 80, which was 
coupled with palmitoleic acid to obtain final compound 5a after treatment with TFA 
(Scheme 26).  
Scheme 26. Reagents and conditions: (a) HBr, CHCl3, 0°C, 30 min, 96%; (b) HBF4, 
TMSCHN2, DCM, 0°C, 2 h, 62%; (c) di-tert-butyl malonate, NaH, NaI, DMF, rt, 12 h, 54%; (d) 
Selectfluor®, NaH, DMF:THF, 0ºC to rt, 48 h, 96%; (e) N2H4, EtOH, rt, 12 h, 66%; (f) palmitoleic 
acid, EDC, HOBt, DMF, rt, 12 h, 37%; (g) TFA, DCM, rt, 12 h, 99%. 
In the case of compound 5b, the synthesis started with the amino protection of 
the methyl ester of D-serine with the tert-butyloxycarbonyl group (Boc), followed by 
transformation of the hydroxy group into the corresponding tosylate to obtain 
derivative 83. Reduction of the methyl ester with NaBH4 yielded alcohol 84, which was 
phosphorylated under usual conditions. Next, nucleophilic substitution using lithium 
bromide led to intermediate 86. At this point, the Boc group was removed by treatment 
with TFA, and condensation of the free amine with the N-hydroxysuccinimyl ester of 
10-phenyldecanoic acid (46) was carried out in order to obtain intermediate amide 88, 
precursor of final compound 5b. However, the coupling reaction did not provide the 
desired compound and aziridine 87 was formed, as a consequence of an 
intramolecular cyclization (Scheme 27).  
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Scheme 27. Reagents and conditions: (a) Boc2O, Et3N, THF, MW, 100°C, 8 min, 
99%; (b) pTSCl, pyridine, DCM, 0°C to rt, 24 h, 49%; (c) NaBH4, EtOH, -5°C, 1 
h, 96%; (d) i) iPr2NP(OBn)2, 1H-tetrazole, DCM, rt, 2 h; ii) mCPBA, DCM, -30ºC, 
90 min, 38%; (e) LiBr, acetone, reflux, 12 h, 79%; (f) TFA, DCM, rt, 1 h, 99%; (g) 
N-hydroxysuccinimyl ester of 46, Et3N, DCM, rt, 12 h, 48%. 
In view of this result, a ring opening reaction of aziridine 87 with bromide was 
considered as an alternative route to obtain the -bromoamide 88.96 Thus, 87 was 
treated with magnesium bromide at room temperature, yielding compound 89, in 
which, besides the opening of the aziridine, the removal of one of the benzyl protecting 
groups was observed. This new intermediate was directly subjected to catalytic 
hydrogenation for complete deprotection of the phosphate (Scheme 28). 
Unfortunately, compound 5b could not be isolated, and a complex mixture of 
unidentified products was obtained instead, which could be explained by a low 
intrinsic stability of target compound.  
 
Scheme 28. Reagents and conditions: (a) MgBr2·OEt2, Et2O, rt, 4 h, 81%; (b) H2, 10% 
Pd(C), EtOH, rt. 
Compound 5a was tested for its activity at LPA1, but it was not able to activate 
the receptor, showing that the replacement of the ester group by an amide is 
detrimental for the activity. 
In summary, considering that potent activation of the LPA1 receptor is needed in 
order to induce its desensitization and internalization, compound (S)-3a, with an 
excellent agonist activity and selectivity versus LPA2 and LPA3 receptors, was 
selected as the best candidate to move forward in our study of the therapeutic 
potential of LPA1 agonists for the treatment of NP. 
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2.2. Biological characterization of compound (S)-3a 
To further characterize the biological potential of (S)-3a, we carried out a set of 
additional experiments aimed at confirming that (S)-3a bound directly LPA1 receptor 
and studying whether, after receptor binding and activation, it induced internalization 
and desensitization.  
2.2.1. LPA1 receptor binding affinity of compound (S)-3a 
The biological response produced by a drug is related to both the efficacy and 
the binding affinity for its molecular target. Therefore, the affinity of agonist (S)-3a for 
LPA1 receptor was determined in order to complete the pharmacological 
characterization of the compound. In the case of LPA receptors, the use of radioligand 
is not straightforward due to the high non-specific binding, that leads to low signal to 
noise ratio. Hence, this experiment was carried out using a technique named back-
scattering interferometry (BSI),97,98 during a predoctoral stay at Prof. Jerold Chun Lab 
at The Scripps Research Institute (La Jolla, California). BSI monitors changes in 
refractive index (RI) to detect molecular interactions in a label-free, free-solution 
manner. This shift in RI is a result of changes in molecular structure, dipole moment, 
polarizability, conformation, and solvation that occur during the interaction of the 
proteins with their ligands.  
Thus, BSI can be used to quantify binding affinities by detecting changes in the 
RI of mixtures of protein and ligand that have been incubated to achieve equilibrium. 
In this case, ligand binding to membrane homogenates containing LPA1 receptor was 
accomplished by incubating a solution of a fixed protein concentration with varying 
concentrations of compound (S)-3a. The difference between the signals of protein-
ligand complex and free protein solutions was plotted versus ligand concentration to 
obtain a saturation binding isotherm (Figure 22), which was fitted to a square 
hyperbolic function using GraphPad Prism software to determine the dissociation 
constant (KD) value (Table 10). Binding affinity of LPA to LPA1 receptor was 
determined as positive control, whereas the plasmid control without any receptor 
(VEC) was used as negative control (Figure 22). 
The obtained KD value indicated a high binding affinity of (S)-3a for LPA1 receptor 
(KD = 19.9 nM), comparable to that obtained of the endogenous ligand LPA (KD = 5.6 
nM) (Table 10). 
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Figure 22. Representative plots of BSI signal versus ligand concentration for the determination 
of affinity constant. Each data point represents the average of at least four independent 
measurements. Membranes from cells transfected with the empty plasmid -without any 
receptor (VEC)- were used as negative control. 
Table 10. Affinity constants (KD) determined by BSI at LPA1 receptor 
Compound KD (nM)a R2 (%)b 
(S)-3a 19.9 93 
LPA 5.6 92 
aKD values are the means from two or three independent experiments 
performed in triplicate. The s.e.m. is in all cases within a 10% of the mean 
value.bA goodness of fit (R2) greater than 90% is considered adequate. 
2.2.2. Receptor internalization 
B103 neuroblastoma cells overexpressing LPA1 receptor fused to EGFP were 
exposed to compound (S)-3a at concentrations ranging from 0.1 µM to 10 µM. LPA 
was employed as positive control and 0.1% fatty acid free bovin serum albumin (FAF 
BSA) as negative control. After fixing and staining the cells, images were acquired 
with a confocal microscope. Compound (S)-3a was able to induce internalization of 
the receptor at all the concentrations assayed in a similar manner to LPA. 
Representative image at 1 µM concentration of (S)-3a is shown in Figure 23.  
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Figure 23. Receptor internalization of LPA1 receptor by agonist stimulation. Cells were treated 
with compound (S)-3a (1 µM) (A) or with LPA, 1 µM (B). Cells were stained with 4',6-diamidino-
2-phenylindole (DAPI) and phalloydin for cell morphology. Samples were imaged under the 
same conditions by using a Zeiss fluorescence confocal microscope (bars 10 µm).  
2.2.3. Receptor desensitization 
Next, we determined the capacity of compound (S)-3a to induce desensitization 
in DRG neurons and accordingly block the signal trasduction involved in the pain 
transmission. Thus, calcium influx and action potential in sensory neurons were 
measured in order to evaluate the capacity of (S)-3a to induce desensitization. These 
experiments were done in collaboration with Prof. Antonio Vicente Ferrer Montiel, at 
Universidad Miguel Hernández de Elche (Alicante, Spain). Our data show that after a 
first administration, compound (S)-3a activates the LPA1 receptor in DRG sensory 
neurons in primary culture in a similar manner to LPA (Figure 24). However, a second 
administration of the agonist at 4 minutes is not able to trigger activation, reflecting 
the desensitization of the receptor (Figure 24A). A similar behavior was observed for 
(S)-3a under the same conditions (Figure 24B). Neurons were exposed to 500 nM of 
the agonist capsaicin (Caps) at the end of the recording to measure TRPV1 receptor 
sensitivity of the neurons exposed to LPA or (S)-3a. 
Furthermore, action potential of DRG neurons was affected when treated either 
with 10 µM LPA or (S)-3a (Figure 25), confirming the action of this agonist in sensory 
neurons in primary culture. 
B A 
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Figure 24. Measurement of calcium-influx peak intensity upon two repetitive applications of 
10 μM LPA (A) or (S)-3a (B) and one of 500 nM capsaicin (Caps) in DRG neurons. Data 
represent fluorescence expressed as mean ± s.e.m. First pulse (1st) was compared to the 
second (2nd) by t-test paired values, ***p<0.001. Number above columns represent 
percentage of responding cells to that stimulus, n = total registered neurons. 
 
Figure 25. Effect of 10 μM LPA (A) or (S)-3a (B) on the neuronal firing activity on DRG 
neurons. LPA and (S)-3a were applied in two consecutive pulses (1st and 2nd pulse). Data 
represent mean spike frequency (Hz) and are expressed as mean ± s.e.m. Number of cultures 
≥ 2. Comparison of 1st and 2nd pulse was performed by t-test paired values. *p<0.05; 
***p<0.001 
All in sum, the data obtained up to this moment confirm the capacity of (S)-3a to 
promote the internalization of LPA1 receptor and its desensitization in sensory 
neurons, which are involved in pain transmission. Hence, all these results have 
prompted us to consider (S)-3a a promising candidate for the treatment of NP and to 
study its in vivo efficacy in a mouse model of NP, experiments that are currently 
ongoing in collaboration with Prof. Fernando Rodríguez de Fonseca, at Instituto de 
Investigación Biomédica de Málaga (Spain). 
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2.3. Design and synthesis of new antagonists for the LPA1 and LPA2 receptors  
The discovery that LPA1 and LPA2 receptors contribute to the etiology of different 
disorders has prompted the development of selective antagonists for these receptors 
for pharmacological evaluation. The disclosed antagonists include lipid-like molecules 
that share structural similarity to LPA, and non-lipid chemical entities.99-101 The LPA 
analogues that antagonize LPA1 or LPA2 are generally not selective and lack the 
appropriate pharmacokinetic profiles to be useful for evaluation in clinical studies. For 
these reasons, broad emphasis has been placed during recent years on the design 
and discovery of non-lipid LPA receptor antagonists. 
Among the different potential therapeutic indications, SCI is currently receiving 
much interest. It has been recently described that activation of LPA1 and LPA2 
receptors is detrimental for secondary damage after SCI, suggesting that LPA1 and 
LPA2 antagonists might be useful tools not only to elucidate the specific mechanisms 
implicated in this pathology, but also for its therapeutic treatment. In order to discover 
new antagonists of these receptors we performed a virtual screening (VS) of the ZINC 
library of compounds against the LPA1 receptor, which 3D structure has just been 
described in complex with the selective antagonist ONO-9780307 (Figure 26).102 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Crystallographic structure of LPA1 receptor in complex with ONO-9780307. ICL, 
intracellular loop; ECL, extracellular loop; TM, transmembrane helix (Source: Cell 2015, 161, 
1633-1643). 
 
This VS yielded 18 potential hits, which were purchased and screened for 
antagonist activity at LPA1, LPA2 and LPA3 receptors given their sequence similarity 
(51.3% between LPA1 and LPA2 receptors, and 47.3% between LPA1 and LPA3 
receptors).  
Results and discussion 
- 50 - 
To experimentally confirm the antagonist activity of the compounds, RH7777 cells 
stably transfected with LPA1 receptor or B103 cells stably transfected with LPA2 or 
LPA3 receptors were preloaded with Fluo 4-NW, incubated with the compound under 
study at a fixed dose of 10 μM, and stimulated with LPA (10 μM). The antagonism 
was measured as the capacity of the compound to decrease the intensity of LPA 
response. Under these conditions six compounds were able to antagonize at least the 
30% of the LPA stimulation, and they were selected to perform complete dose-
response curves to obtain half-maximum inhibitory concentration (IC50) values (data 
not shown). Among the analyzed compounds, we were able to identify one compound 
selective for each receptor of interest, VS6 as LPA1 receptor antagonist and VS11 as 
LPA2 receptor antagonist. It is remarkable that they showed Emax and IC50 values close 
to Ki16425,69 the most potent but non-selective antagonist of the LPA receptors 
described so far (Table 11). 
Table 11. Antagonist activity of compounds at LPA1-3 receptors 
Compound Structure 
IC50 (µM)a (Emax (%)b) 
LPA1 LPA2 LPA3 
VS6 
 
10.1 ± 0.9 
(50 ± 5) 
N. E.c N. E. 
VS11 
 
N. E. 
1.9 ± 0.6 
(88 ± 4) 
N. E. 
Ki16425 
 
0.8 ± 0.2 
(97 ± 4) 
1.2 ± 0.6 
(92 ± 3) 
1.6 ± 0.5 
(99 ± 3) 
aFor Emax > 30%, IC50 values are expressed as mean ± s.e.m, from a minimum of two independent 
experiments, performed in triplicate.bEmax = maximal efficacy of the drug/maximal efficacy of Ki16425, 
expressed as the percentage.cNo effect was observed at the highest concentration of compound tested 
(10 µM). 
 
In order to confirm the structure of the supplied compounds VS6 and VS11, NMR 
and HPLC-MS analyses were performed. Once their structures were assessed, the 
next step was to set up synthetic routes that allow to obtain both antagonists, in order 
to confirm their activity at LPA1 and LPA2 receptors with independently synthesized 
compounds, and to start the optimization process. 
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2.3.1. Synthesis of antagonist VS6 
The synthetic route to obtain thiophene VS6 (Figure 27) could start by Gewald 
reaction between commercially available 1-(3,4-dimethylphenyl)propan-1-one and 
ethyl 2-cyanoacetate to build the heterocyclic central core. Next, the transformation 
of the ester group in primary amide, followed by coupling reaction with glutaric 
anhydride would afford the desired compound VS6.  
 
Figure 27. Retrosynthetic analysis for compound VS6 
Thus, 2-aminothiophene 90 was prepared in a two-step Gewald reaction 
(Scheme 29),103 in which the Knoevenagel condensation product was reacted with 
elemental sulfur to afford thiophene 90. 
 
Scheme 29. Reagents and conditions: (a) Ethyl 2-cyanoacetate, 
TiCl4, Et3N, THF, 0ºC to rt, 12 h; (b) S8, Et2NH, THF, rt, 12 h, 
32%. 
Intermediate 90 was then treated with a methanolic solution of ammonia, using 
calcium chloride as Lewis acid, to obtain the amide derivative 91.104 However, neither 
termal conditions nor MW radiation yielded the expected amide 91, recovering only 
starting material (Table 12). 
Table 12. Experimental conditions to obtain amide 91 
 
Conditions T (ºC) t 
Thermal 60 24 h 
MW 160 5 min 
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In view of these results, the possibility of obtaining 91 by hydrolysis of ester 90 
followed by transformation into the amide was considered. However, none of the 
tested reaction conditions (Table 13) afforded the desired product. 
Table 13. Experimental conditions for hydrolysis of ester 90 
 
Conditions Base Solvent T (°C) t Results 
Thermal LiOH THF/H2O (3:1) 80 24 h 90 
MW NaOH Dioxane 160 4 min 90 
MW NaOH Dioxane 160 7 min Byproducts 
 
The lack of reactivity of the ester group of compound 90 could be due to the 
presence of the primary amine in position 2 of the thiophene ring, which may exert an 
electron-donor effect, making difficult the amidation or the hydrolysis of the ester. For 
this reason, the amine was protected with a Boc group, previous to its treatment with 
potassium hydroxide in a mixture of ethanol/water at 60°C for 12 h, conditions that 
allowed to obtain acid 93 with high yield (Scheme 30). 
 
Scheme 30. Reagents and conditions: (a) Boc2O, DMAP, THF, rt, 12 h, 
28%; (b) KOH, EtOH:H2O, 60°C, 12 h, 89%. 
Next, the formation of the primary amide 94 was accomplished using a 
methanolic solution of ammonia, in the presence of N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide (EDC) and 1-hydroxybenzotriazole (HOBt) as coupling reagents 
(Scheme 31). The removal of the Boc group provided 2-aminothiophene 91, which 
was treated with glutaric anhydride and subsequently opened in basic media (Scheme 
31) to afford final compound 96 (VS6). 
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Scheme 31. Reagents and conditions: (a) 0.5 M NH3 in dioxane, EDC, HOBt, 
DIPEA, DCM, rt, 13 h, 70%; (b) TFA, DCM, rt, 12 h, 99%; (c) glutaric anhydride, 
Et3N, DMAP, DCM, reflux, 12 h, 33%; (d) Et3N, H2O, reflux, 15 min, 72%. 
2.3.2. Synthesis of antagonist VS11 
Obtention of compound VS11 was planned in four steps (Figure 28), starting with 
a Friedel-Crafts acylation of resorcinol with 2-(2,4-dichlorophenoxy)acetyl chloride. 
After attempting different conditions for this reaction (Table 14), only the use of the 
complex boron trifluoride diethyl etherate at reflux and in DCM, in order to improve 
the solubility of the materials, afforded the desired compound 97 with a moderate yield 
(21%) after 24 h of reaction. A reduction of the reaction time with the objective to 
decrease the formation of byproducts, led to similar results (Table 14). 
 
Figure 28. Retrosynthetic analysis for compound VS11. 
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Table 14. Experimental conditions to obtain intermediate 97 
 
Lewis Acid Solvent T t (h) Result 
AlCl3 DCM Reflux 12 Complex reaction mixture 
AlCl3 DCM r.t. 24 Complex reaction mixture 
BF3·Et2O - Reflux 24 97 (<5%) + Byproducts 
BF3·Et2O - r.t. 24 Starting materials 
BF3·Et2O DCM Reflux 24 97 (21%)a + Byproducts 
BF3·Et2O DCM Reflux 4 97 (20%)a + Byproducts 
a Yield of isolated product 97 after chromatography purification. 
Next, Allan−Robinson reaction between compound 97 and acetic anhydride 
afforded chromone 98 in quantitative yield, which was, after hydrolysis of acetyl group 
in acid media, alkylated with methyl 2-bromoacetate to yield intermediate 100 with 
good yield. Finally, opening of the pyrone ring with subsequent cyclization into the 
corresponding pyrazole and simultaneous hydrolysis of the methyl ester gave desired 
compound 101 (VS11) (Scheme 32).  
 
Scheme 32. Reagents and conditions: (a) Acetic anhydride, Et3N, NaOAc, 140°C, 2.5 h, 99%; 
(b) HCl, EtOH, reflux, 2 h, 99%; (c) methyl 2-bromoacetate, K2CO3, acetone, reflux, 3 h, 51%; 
(d) 65% N2H4.H2O, EtOH, reflux, 30 min, 99%. 
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2.3.3. Antagonist activity of compounds 96 (VS6) and 101 (VS11) 
Once established the independent synthesis of the antagonists identified in the 
VS, we determined their antagonist activity at LPA1-3 receptors. The obtained results 
confirmed the IC50 values showed by commercially supplied compounds VS6 and 
VS11 (Table 15). 
Table 15. Antagonist activity of compound 96, 101, VS6, VS11 and Ki16425 at LPA1-3 
receptors 
Compound 
IC50 (µM)a [Emax (%)]b 
LPA1 receptor LPA2 receptor LPA3 receptor 
96 45 ± 3 [33 ± 2] N. E.c N. E. 
VS6 10.1 ± 0.9 [50 ± 5] N. E N. E. 
101 N. E.c 5.5 ± 0.7 [84 ± 3] N. E. 
VS11 N. E. 1.9 ± 0.6 [88 ± 4] N. E. 
Ki16425 0.8 ± 0.2 [97 ± 4] 1.2 ± 0.6 [92 ± 3] 1.6 ± 0.5 [99 ± 3] 
aFor Emax > 30%, IC50 values are expressed as mean ± s.e.m, from a minimum of two independent experiments, 
performed in triplicate. bEmax = maximal efficacy of the drug/maximal efficacy of Ki16425, expressed as the 
percentage. cNo effect was observed at the highest concentration of compound tested (10 µM). 
Considering the limited knowledge about the role of LPA2 receptor in SCI, the 
selective antagonist 101 (VS11) has been selected in order to establish which 
structural characteristics are important for the antagonist activity, and to elucidate the 
specific involvement of LPA2 receptor in this pathology. 
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2.3.4. Structural modifications of compound 101 
We started studying whether the 2,4-dichlorophenoxy system, the 3-
hydroxyphenoxyacetic fragment or the methyl group in position 5 of the pyrazole ring 
are essential for the antagonism (Figure 29). 
  
Figure 29. Study of the influence of the 2,4-dichlorophenoxy system, the 3-hydroxy 
phenoxyacetic fragment or the methyl group in the antagonist activity of compound 101. 
2.3.4.1. Modifications in the 2,4-dichlorophenoxy system 
Regarding the importance of the 2,4-dichlorophenoxy system, the pyrazole 104 
was synthesized. The hydroxychromone 102 was prepared from the commercially 
available 1-(2,4-dihydroxyphenyl)ethanone by treatment with triethyl orthoformate 
and perchloric acid. Then, alkylation with methyl bromoacetate and treatment with an 
excess of hydrazine led to pyrazole 104 (Scheme 33). 
  
Scheme 33. Reagents and conditions: (a) CH(OEt)3, 70% HClO4, H2O, rt, 13 h, 
47%; (b) methyl bromoacetate, K2CO3, acetone, reflux, 3 h, 24%; (f) 65% 
N2H4·H2O, EtOH, reflux, 30 min, 98%. 
Biological assay revealed that compound 104 was inactive at LPA2 receptor, 
highlighting the importance of 2,4-dichlorophenoxy system for the antagonist activity. 
Therefore, the effect of the chlorine atoms was studied with the synthesis of 
compounds 105-107 (Figure 30). 
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Figure 30. Study of the influence of chlorine atoms in the antagonist activity of compound 101. 
Thus, Friedel-Craft reaction between the corresponding 2-phenoxyacetyl chloride 
and resorcinol, followed by Allan-Robinson reaction, hydrolysis of acetyl group, 
alkylation with methyl bromoacetate and, finally, pyrazole ring formation, allowed to 
obtain compounds 105-107 (Scheme 34).  
  
Scheme 34. Reagents and conditions: (a) i) SOCl2, toluene, 110°C, 12 h, 99%; ii) resorcinol, 
BF3.Et2O, DCM, reflux, 4 h, 10-20%; (b) acetic anhydride, Et3N, NaOAc, 140°C, 2.5 h, 81-99%; 
(c) HCl, EtOH, reflux, 2 h, 75-99%; (d) methyl bromoacetate, K2CO3, acetone, reflux, 3 h, 50-
62%; (f) 65% N2H4·H2O, EtOH, reflux, 30 min, 99%. 
Determination of the antagonist character of compounds 105-107 revealed their 
lack of activity at LPA2 receptor. Hence, the 2,4-dichlorophenoxy system was kept 
costant in the next modifications.  
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2.3.4.2. Modifications in the 3-hydroxyphenoxyacetic fragment 
Regarding the variations in the 3-hydroxyphenoxyacetic fragment, first we 
studied the need of the carboxylic acid chain and the hydroxy group with the synthesis 
of compound 120 (Figure 31). 
 
Figure 31. Study of the influence of carboxylic acid chain and hydroxy group in the antagonist 
activity of compound 101. 
Phenylpyrazole 120 was prepared by Williamson reaction between 2-bromo-1-
phenylethanone and 2,4-dichlorophenol, followed by enaminone formation to obtain 
intermediate 122, whose treatment with an excess of hydrazine led to the desired 
target compound (Scheme 35). 
Scheme 35. Reagents and conditions: (a) 2,4-Dichlorophenol, DBU, DMF, MW, 140°C, 30 
min, 70%; (b) 1,1-dimethoxy-N,N-dimethylethanamine, 90°C, 4 h, 55%; (c) 65% N2H4·H2O, 
EtOH, reflux, 1 h, 48%. 
The biological assay revealed that compound 120 was inactive, highlighting the 
importance of the substituents in the 3-hydroxyphenoxyacetic fragment for the 
antagonist activity. Therefore, we studied the influence of these substituents with the 
synthesis of compounds 123-125 (Figure 32). 
 
Figure 32. Study of the influence of the substituents in the 3-hydroxyphenoxyacetic fragment 
for the antagonist activity of compound 101. 
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Compounds 123 and 124 were obtained from chromone 99, which by reaction 
with an excess of hydrazine, followed by methylation led to desired compounds 
(Scheme 36). 
 
Scheme 36. Reagents and conditions: (a) 65% N2H4·H2O, EtOH, reflux, 30 min, 
65%; (b) CH3I, K2CO3, acetone, 65°C, 6 h, 19%. 
In the case of compound 125, Williamson reaction between 2-bromo-1-(4-
methoxyphenyl)ethanone and 2,4-dichlorophenol, using 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) as base under MW irradiation, led to 
intermediate 126. Then, treatment with 1,1-dimethoxy-N,N-dimethylethanamine 
yielded enaminone 127, which was reacted with hydrazine and then with BBr3 to 
obtain pyrazole 129. Finally, alkylation with methyl bromoacetate and hydrolysis led 
to compound 125 (Scheme 37). 
 
Scheme 37. Reagents and conditions: (a) 2,4-Dichlorophenol, DBU, DMF, MW, 
140°C, 30 min, 80%; (b) 1,1-dimethoxy-N,N-dimethylethanamine, 90°C, 4 h, 52%; 
(c) 65% N2H4·H2O, EtOH, reflux, 1 h, 44%; (d) BBr3, DCM, -78°C to rt, 21 h, 70%; 
(e) methyl bromoacetate, K2CO3, DMF, -20°C to rt, 24 h, 32%; (f) 1 M NaOH, 1,4-
dioxane, 60°C, 2 h, 99%. 
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Determination of the antagonist character of compounds 123-125 revealed their 
lack of activity, showing that modifications in the 3-hydroxyphenoxyacetic fragment 
are detrimental for antagonism at LPA2 receptor. 
2.3.4.3. Modification in pyrazole ring 
Up to this moment, the modifications done in the 2,4-dichlorophenoxy system and 
in the 3-hydroxyphenoxyacetic fragment showed that both fragments are essential for 
antagonist activity. Hence, compound 133 was prepared in order to study the 
influence of the methyl group in position 5 of the pyrazole ring. Its synthesis started 
from derivative 97, which by reaction with BF3.Et2O and methanesulfonyl chloride, 
alkylation with ethyl bromoacetate of the resulting hydroxychromone 131, and 
reaction with hydrazine, afforded desired pyrazole 133 (Scheme 38).  
 
Scheme 38. Reagents and conditions: (a) BF3.Et2O, CH3SO2Cl, DMF, 100°C, 1.5 h, 97%; (b) 
ethyl bromoacetate, K2CO3, acetone, reflux, 3 h, 91%; (f) 65% N2H4·H2O, EtOH, reflux, 30 min, 
58%. 
Once compound 133 was synthesized, it was tested for its antagonist activity at 
LPA2 receptor, presenting only a weak antagonist character (Emax = 35 ± 8%, IC50 = 
33.6 ± 0.3 µM). 
In summary, the results obtained up to this moment suggest that the 2,4-
dichlorophenoxy system and the 3-hydroxyphenoxyacetic fragment are essential for 
the antagonist activity. However, it is important at this point to establish, at least as 
proof of concept, whether an LPA2 selective antagonist is able to induce a beneficial 
effect in SCI. Towards this aim, we have started the first experiments needed to 
assess the suitability of antagonist 101 for these in vivo studies. In this context, we 
have determined whether the antagonism observed at LPA2 receptor is due to a direct 
binding to the receptor and the ability of the compound to cross biological membranes, 
important feature for subsequent in vivo administration. 
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2.3.5. Binding affinity of compound 101 for LPA2 receptor 
Binding affinity was determined with the BSI technique, following a similar 
procedure to the one employed for compound (S)-3a, but, in this case, using 
membrane homogenates containing LPA2 receptor. The obtained KD value indicated 
a high binding affinity of compound 101 for the LPA2 receptor (KD = 19.8 nM), 
comparable to the one obtained for the endogenous ligand LPA (KD = 6.7 nM) (Figure 
33, Table 16). 
 
Figure 33. Representative plots of BSI signal versus ligand concentration for the determination 
of binding constant. Each data point represents the average of at least four independent 
measurements. Membranes from cells transfected with the empty plasmid -without any 
receptor (VEC)- were used as negative control. 
Table 16. Binding constants determined by BSI at LPA2 receptor 
Compound KD (nM)a R2 (%)b 
101 19.8 95 
LPA 6.7 96 
aKD values are the means from two or three independent experiments 
performed in triplicate. The s.e.m. is in all cases within a 10% of the mean 
value. bA goodness of fit (R2) greater than 90% is considered adequate. 
2.3.6. Cell permeability of compound 101 
Determination of cell permeability is an important aspect of the drug development 
process and it can be estimated with the parallel artificial membrane permeability 
assay (PAMPA), which determines the permeability of substances from a donor 
compartment, through a lipid-infused artificial membrane, into an acceptor 
compartment. Using this technique, compound 101 showed a moderate permeability 
value (P) of 1.2×10−6 cm/s, considering as reference values P < 10−7 cm/s for low 
permeable compounds and P > 10−5 cm/s for highly permeable molecules. 
Overall, the obtained results point out that compound 101 can be used in an in 
vivo model of SCI, as proof of concept of the relevance of the LPA2 receptor in this 
[LPA] (µM) [101] (µM)
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pathology, experiments currently ongoing in collaboration with Prof. Rubèn Lopez 
Valés, at Universitat Autònoma de Barcelona (Spain). Hence, if these experiments 
confirm the suitability of LPA2 receptor antagonists in SCI, a medicinal chemistry 
program around compound 101 will be carried out in order to obtain most potent 
antagonists. The synthesis of these second generation compounds will include the 
replacement of the chlorine atoms with other substituents, the modification of the 
length of carboxylic chain, and the substitution of pyrazole ring for other heterocycles. 
 
Figure 34. Medicinal chemistry program around compound 101. 
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3. CONCLUSIONS 
In the present work we have addressed the development of new potent and 
selective LPA1 receptor agonists, as antinociceptive agents, and of new selective 
antagonists of LPA1 and LPA2 receptors, as research tools to elucidate the specific 
involvement of these receptors in the pathophysiology of SCI. 
With respect to the first goal, an exhaustive SAR study of several series of 
compounds, initially based on the endogenous ligand LPA, was performed and 
compound (S)-3a stood out for its high activity (EC50 = 0.24 ± 0.09 µM) and affinity 
(KD = 19.9 nM) for the LPA1 receptor, and selectivity towards LPA2 and LPA3 
receptors. In addition, this derivative promotes the internalization of LPA1 receptor and 
its desensitization in sensory neurons, which should lead to the blockade of the signal 
trasduction involved in pain transmission. Hence, we are currently validating this 
approach as a possible therapeutic alternative to treat chronic pain in an in vivo model. 
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Regarding the second part of this work, a VS has allowed us to identify two potent 
and selective antagonists of LPA1 and LPA2 receptors. Once their synthetic routes 
were set up and their antagonist activities were confirmed, structural modifications of 
the LPA2 receptor antagonist 101 (VS11) were carried out to determine which parts 
of the molecule are essential for its antagonist activity. Then, derivative 101 was 
selected in order to establish if an LPA2 selective antagonist is able to induce a 
beneficial effect in SCI, as proof of concept. This compound shows high binding 
affinity for LPA2 receptor (KD = 19.8 nM) and an acceptable cell permeability value (P 
= 1.2x10-6 cm/s), important features for subsequent in vivo studies, which are currently 
ongoing in our laboratory. 
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4. EXPERIMENTAL SECTION 
4.1. Synthesis 
Unless otherwise stated, the starting materials, reagents, and solvents were 
purchased as high-grade commercial products from Sigma-Aldrich, ABCR, Acros, 
Biotage, Fluka, Lancaster, Scharlab, or Panreac. Dichloromethane, diethyl ether and 
tetrahydrofuran (THF) were dried using a Pure SolvTM Micro 100 Liter solvent 
purification system. Triethylamine and pyridine were dried over CaH2 and distilled 
prior to its use. Alcohol-free chloroform was obtained by washing with water, drying 
over MgSO4, filtration and distillation over P2O5. Ethylenediamine was dried over 4Å 
molecular sieves, distilled and used immediately. All non-aqueous reactions were 
performed under an argon atmosphere in oven-dried glassware. Reactions under MW 
irradiation were performed in a Biotage Initiatior 2.5 reactor. 
Analytical thin-layer chromatography (TLC) was run on Merck silica gel plates 
(Kieselgel 60 F-254), with detection by UV light ( = 254 nm), ninhydrin solution, or 
10% phosphomolybdic acid solution in ethanol. Flash chromatography was performed 
on glass column using silica gel type 60 (particle size 230-400 mesh, Merck), or on a 
Varian 971-FP flash purification system, using silica gel cartridges (Varian, particle 
size 50 µm).  
All compounds were obtained as oils, except for those whose melting points 
(m.p.) are indicated, which were solids. M.p. were determined on a Stuart Scientific 
electrothermal apparatus. Infrared (IR) spectra were measured on a Bruker Tensor 
27 instrument equipped with a Specac ATR accessory of 5200-650 cm-1 transmission 
range; frequencies () are expressed in cm-1. Optical rotation [α] was measured on a 
Anton Paar MCP 100 modular circular polarimeter using a sodium lamp ( = 589 nm) 
with a 1 dm path length; concentrations are given as g/100 mL. 1H-, 13C-, and 31P-
NMR spectra were recorded on a Bruker Avance III 700MHz (1H, 700 MHz; 13C, 175 
MHz), Bruker Avance 500MHz (1H, 500 MHz; 13C, 125 MHz; 31P, 202 MHz) or Bruker 
DPX 300MHz (1H, 300 MHz; 13C, 75 MHz; 31P, 121 MHz) instrument at room 
temperature at the Universidad Complutense de Madrid’s NMR core facility. Proton-
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coupled 19F-NMR spectra were recorded on a Bruker DPX 300MHz. Chemical shifts 
(δ) are expressed in parts per million relative to the residual solvent peak for 1H and 
13C nucleus (acetone-d6: δH = 2.05, δC = 29.84; CDCl3: δH = 7.26, δC = 77.16; DMSO-
d6: δH = 2.50, δC = 39.52; methanol-d4: δH = 3.31, δC = 49.00), to internal phosphoric 
acid for 31P nucleus and to internal (trifluoromethyl)benzene for 19F nucleus; coupling 
constants (J) are in hertz (Hz). The following abbreviations are used to describe peak 
patterns when appropriate: s (singlet), d (doublet), t (triplet), q (quartet), qt (quintuplet), 
m (multiplet), app (apparent) and br (broad). 2D NMR experiments (COSY, HMQC 
and HMBC) of representative compounds were carried out to assign protons and 
carbons of the new structures. High resolution mass spectrometry (HRMS) was 
carried out on a FTMS Bruker APEX Q IV spectrometer in electrospray ionization 
(ESI) or matrix-assisted laser desorption/ionization (MALDI) mode at Universidad 
Complutense de Madrid’s mass spectrometry core facility. For all final compounds, 
purity was determined by HPLC-MS, and satisfactory chromatograms confirmed a 
purity of at least 95% for all tested compounds. HPLC-MS analysis was performed 
using an Agilent 1200LC-MSD VL instrument. LC separation was achieved with a 
Zorbax Eclipse XDB-C18 column (5 µm, 4.6 mm x 150 mm) or Zorbax SB-C3 (5 µm, 
2.1 mm x 50 mm) together with a guard column (5 µm, 4.6 mm x 12.5 mm). The 
gradient mobile phases consisted of A (95:5 water/methanol) and B (5:95 
water/methanol) with 0.1% ammonium hydroxide and 0.1% formic acid as the solvent 
modifiers, and the gradients are indicated in Table 17. MS analysis was performed 
with an ESI source. The capillary voltage was set to 3.0 kV and the fragmentor voltage 
was set at 25 eV. The drying gas temperature was 350 ºC, the drying gas flow was 
10 L/min, and the nebulizer pressure was 20 psi. 
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Table 17. HPLC gradients 
Method A Method B Method C 
Column SB-C3 
Buffers water/methanol 
Column XDB-C18 
Buffers water/methanol 
Column XDB-C18 
Buffers water/methanol 
t (min) % B t (min) % B t (min) % B 
0 0 0 0 0 0 
2 0 2 0 2 0 
8 60 10 50 8 60 
20 100 20 100 20 100 
25 100 50 100 25 100 
30 0 60 0 30 0 
 
4.2. Synthesis of new agonists for the LPA1 receptor 
4.2.1. General procedures 
4.2.1.1. Hydrogenation of alkenes and deprotection of dibenzyl phosphates and 
benzyl ethers 
The corresponding alkene or benzylated derivative was dissolved in absolute 
ethanol (0.2 mL/mg) and the solution was pumped through a H-Cube® continuous-
flow hydrogenation reactor using a 10% Pd/C CatCart® cartridge, under full-H2 mode 
at a flow-rate of 1 mL/min at room temperature (for alkenes and dibenzyl phosphates) 
or 60°C (for benzyl ethers). Solvent was then removed under reduced pressure to 
afford the corresponding compound in quantitative yield, which was used without 
further purification. 
4.2.1.2. Mesylation of alcohols 
To a cooled (0°C) stirred solution of the corresponding alcohol (1 equiv) and 
triethylamine (3 equiv) in anhydrous dichloromethane (3.5 mL/mmol), 
methanesulfonyl chloride (1.5 equiv) was added dropwise. The reaction mixture was 
stirred at 0°C for 10 min and then at room temperature for 1 h. Afterward, the mixture 
was partitioned between ethyl acetate and brine. The organic layer was separated, 
washed with a saturated aqueous solution of NaHCO3 and with brine, dried over 
Na2SO4, filtered and concentrated under reduced pressure to yield the corresponding 
mesylate, which was used in the next step without further purification. 
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4.2.1.3. Tosylation of alcohols 
To a cooled (0°C) stirred solution of the corresponding alcohol (1 equiv) and 
pyridine (3 equiv) in anhydrous dichloromethane (1.2 mL/mmol), p-toluenesulfonyl 
chloride (1.5 equiv) was added portionwise. The reaction mixture was stirred at 0°C 
for 10 min and then at room temperature for 16 h. Afterward, the mixture was washed 
with water and with brine, dried over Na2SO4, filtered and concentrated under reduced 
pressure. The residue was purified by flash chromatography to afford the 
corresponding tosylated derivative. 
4.2.1.4. Di-tert-butyl malonate alkylation 
Di-tert-butyl malonate (1.5 equiv) was added dropwise to a stirred suspension of 
NaH (1.5 equiv, 60% dispersion in oil) in a 2:1 mixture of anhydrous N,N-
dimethylformamide (DMF)/THF (6 mL/mmol) at 0ºC, and the mixture was stirred at 
room temperature for 15 min. A solution of the corresponding mesylate (1 equiv) in 
anhydrous THF (3 mL/mmol) was added, followed by sodium iodide (1.1 equiv), and 
the resulting mixture was heated at 80ºC overnight. Afterward, the reaction was 
cooled to room temperature and quenched by addition of a saturated aqueous 
solution of NH4Cl. The mixture was then diluted with water, and extracted with ethyl 
acetate. The organic phase was washed with brine, dried over Na2SO4, filtered and 
evaporated under reduced pressure. The residue was purified by flash 
chromatography to afford the corresponding alkylated product. 
4.2.1.5. α-Fluorination of malonate derivatives  
The corresponding malonate derivative (1 equiv) was added to a suspension of 
NaH (2 equiv, 60% dispersion in oil) in anhydrous THF (4 mL/mmol) at 0ºC, and the 
reaction mixture was warmed up to room temperature and then stirred at 70°C for 12 
h. The solution was cooled to room temperature and diluted with anhydrous THF (8 
mL/mmol) and DMF (8 mL/mmol). Afterward, Selectfluor® was added (2 equiv) at 0ºC 
and the solution was stirred at this temperature for 4 h and at room temperature 
overnight. The reaction mixture was quenched by addition of water and extracted with 
diethyl ether. The organic layer was dried over Na2SO4, filtered and concentrated 
under reduced pressure. The residue was purified by flash chromatography to afford 
the corresponding fluorinated derivative. 
4.2.1.6. Deprotection of acetals using polystyrene-supported pTsOH 
The corresponding acetal (1 equiv) was dissolved in methanol (3 mL/g resin) and 
polystyrene-supported pTsOH (PS-pTsOH) was added (0.3 equiv, 4.56 mmol 
pTsOH/g resin). The reaction was stirred at room temperature overnight. Afterward, 
the mixture was filtered and the solvent was evaporated under reduced pressure. The 
crude was purified by flash chromatography to afford the corresponding diol.  
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4.2.1.7. Regioselective esterification of oleoyl chloride with diols 
To a stirred solution of the corresponding diol (1.5 equiv) in anhydrous 
dichloromethane (12 mL/mmol) at -78°C, 2,4,6-collidine (2 equiv) and oleoyl chloride 
(1 equiv) were added. The mixture was stirred for 24 h while gradually warming to 
room temperature. After this time, solvent was evaporated under reduced pressure 
and the residue was treated with ethyl acetate, removing the 2,4,6-collidine 
hydrochloride by filtration. The filtrate was concentrated and the crude was purified 
by flash chromatography to yield the corresponding ester.  
4.2.1.8. Deprotection of tert-butyl esters and alkyl di-tert-butyl phosphates 
TFA (25 or 75 equiv) was added to a solution of the corresponding tert-butyl 
derivative (1 equiv) in anhydrous dichloromethane (20 mL/mmol) and the reaction was 
stirred at room temperature until disappearance of the starting material. The mixture 
was then treated with brine and the aqueous phase was extracted with 
dichloromethane. The combined organic layers were washed with water and brine, 
dried over Na2SO4 and filtered. The solvent was evaporated under reduced pressure 
to afford the corresponding phosphate or carboxylic acid.  
4.2.1.9. Methylation of alcohols with trimethylsilyldiazomethane 
To a vigorously stirred mixture of the corresponding alcohol (1 equiv) and 
tetrafluoroboric acid (1 equiv, 35% aqueous solution) in anhydrous dichloromethane 
(4 mL/mmol) at 0ºC, trimethylsilyldiazomethane (1 equiv, 2 M in diethyl ether) was 
added dropwise, waiting for the yellow colour to disappear before each addition. The 
stirring was continued at 0ºC and three further portions of trimethylsilyldiazomethane 
(0.5 equiv, 0.25 equiv and 0.25 equiv) were added dropwise at intervals of 20 min. 
Afterward, the mixture was stirred at 0ºC for further 30 min, poured into water and 
extracted with dichloromethane. The organic layer was washed with water, dried over 
MgSO4, filtered and concentrated under reduced pressure. The residue was purified 
by flash chromatography to afford the pure compound.  
4.2.1.10. Sonogashira coupling reaction of alkynes with methyl-8-bromooctanoate 
1,3-Bis(1-adamantyl)imidazolium chloride (0.15 equiv), CuI (0.225 equiv), [(π-
allyl)PdCl]2 (0.075 equiv), and Cs2CO3 (1.4 equiv) were added in turn to a thoroughly 
dried vial. A 2:1 mixture of anhydrous diethyl ether and DMF (1.5 mL/mmol ester) was 
added, followed by the corresponding alkyne (1.3 equiv) and methyl-8-
bromooctanoate (1 equiv). The vial was sealed with a Teflon-lined cap and the 
heterogeneous reaction mixture was stirred vigorously at 55ºC for 16 h. The solvents 
were then evaporated under reduced pressure and the residue was purified by flash 
chromatography to yield the desired coupled product.  
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4.2.1.11. Stereoselective cis-hydrogenation of alkynes with P-2 Ni catalyst 
Ni(OAc)2·4H2O (0.2 equiv) was suspended in absolute ethanol (3 mL/mmol 
alkyne) at room temperature. NaBH4 (0.2 equiv) was added and the mixture was 
stirred for 15 min. Then, argon atmosphere was replaced by hydrogen (balloon). 
Freshly distilled ethylenediamine was added (1.5 equiv) and the reaction was stirred 
for 15 min. A solution of the corresponding alkyne (1 equiv) in absolute ethanol (3 
mL/mmol) was then added, and the reaction was stirred under hydrogen atmosphere 
at room temperature for 2 h. After this time, the reaction mixture was filtered through 
a pad of Celite, and the solvent was removed under reduced pressure. The residue 
was dissolved in ethyl acetate and washed with water and brine. The organic layer 
was dried over Na2SO4, filtered and concentrated to afford the corresponding Z-
alkene, which was used in the next step without further purification. 
4.2.1.12. Hydrolysis of methyl esters 
The corresponding methyl ester (1 equiv) was dissolved in THF (10 mL/mmol) 
and a solution of lithium hydroxide (2 equiv) in water (1.5 mL/mmol) was added. The 
reaction was stirred at room temperature overnight. Then, the mixture was acidified 
with a 20% aqueous solution of HCl and extracted with dichloromethane. The organic 
phase was dried over Na2SO4, filtered, and concentrated, affording the corresponding 
carboxylic acid in quantitative yield.  
4.2.1.13. Phosphorylation of alcohols using phosphoramidites 
To a solution of the corresponding alcohol (1 equiv) in anhydrous 
dichloromethane (12 mL/mmol), 1H-tetrazole (3 equiv, 0.45 M in acetonitrile) and the 
corresponding phosphoramidite (2 equiv) were added at room temperature and the 
reaction mixture was stirred until total consumption of the alcohol. Then it was cooled 
to -30ºC, mCPBA (2 equiv) was added and the mixture was stirred at -30ºC for 90 
min. The reaction was quenched by addition of a 10% aqueous solution of Na2S2O3 
(12 mL/mmol alcohol) and allowed to warm to room temperature. Then, the mixture 
was extracted with dichloromethane and the extracts were successively washed with 
a 20% aqueous solution of K2CO3 and brine, dried over MgSO4, filtered and 
concentrated under reduced pressure. The residue was purified by flash 
chromatography to afford the corresponding pure phosphate derivative. 
4.2.1.14. Regioselective esterification of carboxylic acids with diols 
To a solution of the corresponding carboxylic acid (1 equiv), DCC (1.1 equiv) and 
DMAP (0.2 equiv) in anhydrous dichloromethane (10 mL/mmol acid) at -20ºC, a 
solution of the corresponding diol (2 equiv) in anhydrous dichloromethane (2 
mL/mmol) was added and the reaction was stirred overnight while warming up to room 
temperature. Afterward, the mixture was concentrated under reduced pressure, and 
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the residue was dissolved in carbon tetrachloride and filtered to remove 
dicyclohexylurea. The filtrate was evaporated and purified by flash chromatography 
to afford the corresponding pure ester.  
4.2.1.15. Wittig reaction of ω-bromoacids and aromatic aldehydes 
A mixture of the corresponding ω-bromoacid (1.2 equiv) and triphenylphosphine 
(6 equiv) in anhydrous toluene (2.4 mL/mmol) was refluxed for 24 h. Then, the mixture 
was allowed to cool to room temperature, the solvent was evaporated and the residue 
was washed with hexane to remove excess of triphenylphosphine, and dried. The 
obtained phosphonium salt (1.2 equiv) was dissolved in anhydrous THF (4.2 
mL/mmol), and lithium hexamethyldisilazane (2.7 equiv, 1 M in toluene) was added 
dropwise at -20ºC, turning the solution orange. The mixture was stirred for 30 min 
followed by addition of the corresponding aldehyde (1 equiv) at -20ºC and the stirring 
was continued overnight at room temperature. The reaction mixture was acidified with 
1 M HCl and extracted with ethyl acetate. The organic layer was dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude was purified by flash 
chromatography to yield the corresponding alkene.  
4.2.1.16. Ring-opening reaction of epoxides with TBABr 
To a solution of the corresponding oxirane (1 equiv) and TBABr (3 equiv) in 
freshly distilled alcohol-free chloroform (10 mL/mmol), TFA (1.5 equiv) was added and 
the reaction was stirred for 10 min at room temperature. Then, the reaction mixture 
was passed through a silica gel column (5 g/mmol) prepared in chloroform and it was 
washed with the same solvent (100 mL/mmol). The solvent was evaporated under 
reduced pressure to give the corresponding bromoalcohol, which was used in the next 
step without further purification.  
4.2.1.17. Esterification of carboxylic acids with bromoalcohols and primary alcohols 
To a stirred solution of the corresponding carboxylic acid (1 equiv), DCC (1.1 
equiv) and DMAP (0.2 equiv) in anhydrous dichloromethane (10 mL/mmol), a solution 
of the corresponding alcohol (1 equiv) in anhydrous dichloromethane (2 mL/mmol) 
was added at room temperature and the reaction was stirred until consumption of the 
starting material. Afterward, the mixture was concentrated under reduced pressure, 
and the residue was dissolved in carbon tetrachloride and filtered to remove 
dicyclohexylurea. The filtrate was concentrated and it was purified by flash 
chromatography to yield the corresponding ester.  
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4.2.2. Synthesis of final compounds 1a-f 
4.2.2.1. Synthesis of diol 2 
tert-Butyl {[(2R)-2,3-bis(benzyloxy)propyl]oxy}acetate, 1 
 (S)-(-)-2,3-Bis(benzyloxy)propan-1-ol (0.56 mL, 2.20 mmol, 1 equiv) was added 
dropwise to a stirred suspension of NaH (176 mg, 4.40 mmol, 2 equiv, 60% dispersion 
in oil) in anhydrous THF (10 mL) at 0°C. After stirring the mixture at room temperature 
for 30 min, tert-butyl bromoacetate (0.49 mL, 3.31 mmol, 1.5 equiv) and TBAI (41 mg, 
0.11 mmol, 0.05 equiv) were added, and the resulting mixture was heated at 50°C 
overnight. After cooling to room temperature, the reaction was quenched by addition 
of water and concentrated under reduced pressure. The residue was dissolved with 
dichloromethane, washed with brine, dried over Na2SO4, filtered and concentrated 
under reduced pressure. The residue was purified by flash chromatography 
(hexane/ethyl acetate, 9:1 to 8:2) to afford pure compound 1 in 22% yield.  
 
Rf: 0.52 (hexane/ethyl acetate, 8:2) 
IR (ATR): 1738 (C=O) 
1H-NMR (CDCl3, 300 MHz):  1.36 (s, 9H, 3CH3); 3.47-3.65 (m, 4H, 2CH2); 3.72 (qt, 
J = 4.7, 1H, CH); 3.88 (s, 2H, CH2CO2tBu); 4.44 (s, 2H, PhCH2); 4.61 (s, 2H, PhCH2); 
7.11-7.29 (m, 10H, 10CHAr) 
13C-NMR (CDCl3, 75 MHz):  28.1 (3CH3); 69.4, 70.4, 71.7 (3CH2); 72.3, 73.4 
(2PhCH2); 77.4 (CH); 81.5 (C); 127.5, 127.6 (2CHAr); 127.7 (2CHAr); 127.8 (2CHAr); 
128.3 (2CHAr); 128.4 (2CHAr); 138.4, 138.8 (2CAr); 169.6 (CO) 
MS (ESI, m/z): 387.7 [M+H]+ 
tert-Butyl {[(2R)-2,3-dihydroxypropyl]oxy}acetate, 2 
Following the general procedure 4.2.1.1., diol 2 was obtained from 1 (190 mg, 
0.49 mmol) at 60ºC in quantitative yield.  
 
Rf: 0.11 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3376 (O-H); 1738 (C=O) 
1H-NMR (methanol-d4, 300 MHz):  1.49 (s, 9H, 3CH3); 3.50-3.64 (m, 4H, 2CH2); 3.78 
(qt, J = 5.3, 1H, CH); 4.87 (s, 2H, CH2CO2tBu) 
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13C-NMR (CDCl3, 75 MHz):  28.1 (3CH3); 63.7 (CH2OH); 68.8 (CH2CO2tBu); 70.5 
(CH); 73.4 (CH2O); 82.5 (C); 170.6 (CO) 
MS (ESI, m/z): 229.1 [M+Na]+ 
4.2.2.2. Synthesis of diols 5 and 7 
(2R)-2,3-Bis(benzyloxy)propyl methanesulfonate, 3 
Following the general procedure 4.2.1.2., mesylate 3 was obtained from (S)-(-)-
2,3-bis(benzyloxy)propan-1-ol (0.35 mL, 1.39 mmol) in 80% yield.  
 
Rf: 0.51 (hexane/ethyl acetate, 7:3) 
IR (ATR): 1354 (SO2) 
1H-NMR (CDCl3, 300 MHz):  2.95 (s, 3H, CH3); 3.60 (dd, J = 4.8, 1.5, 2H, CH2OBn); 
3.86 (m, 1H, CH); 4.31 (dd, J = 11.0, 5.6, 1H, ½CH2OMs); 4.43 (dd, J  = 11.0, 3.7, 1H, 
½CH2OMs); 4.54 (s, 2H, PhCH2); 4.66 (s, 2H, PhCH2); 7.27-7.39 (m, 10H, 10CHAr) 
13C-NMR (CDCl3, 75 MHz):  37.5 (CH3); 68.5, 69.4 (2CH2); 72.5, 73.6 (2PhCH2); 75.7 
(CH); 127.8 (2CHAr); 127.9 (2CHAr); 127.91 (2CHAr); 128.0 (2CHAr); 128.5 (2CHAr); 
137.7 (2CAr) 
MS (ESI, m/z): 368.2 [M+NH4]+ 
Di-tert-butyl [(2S)-2,3-bis(benzyloxy)propyl]propanedioate, 4 
Following the general procedure 4.2.1.4., compound 4 was obtained from 
mesylate 3 (391 mg, 1.12 mmol) in 76% yield. Chromatography: hexane to 
hexane/ethyl acetate, 9:1. 
 
Rf: 0.65 (hexane/ethyl acetate, 9:1) 
IR (ATR): 1727 (C=O) 
1H-NMR (CDCl3, 300 MHz):  1.42 (s, 9H, 3CH3); 1.45 (s, 9H, 3CH3); 2.04-2.10 (m, 
2H, CH2CH(CO2tBu)2); 3.46 (dd, J = 8.9, 6.0, 1H, CH(CO2tBu)2); 3.55 (dd, J = 4.8, 0.8, 
2H, CH2OBn); 3.62-3.68 (m, 1H, CHOBn); 4.53 (d, J = 11.5, 1H, ½PhCH2); 4.54 (s, 
2H, PhCH2); 4.69 (d, J = 11.5, 1H, ½PhCH2); 7.31-7.38 (m, 10H, 10CHAr) 
13C-NMR (CDCl3, 75 MHz):  27.9 (3CH3); 28.0 (3CH3); 31.3 (CH2CH(CO2tBu)2); 50.4 
(CH(CO2tBu)2); 72.4, 72.8 (2PhCH2); 73.4 (CH2OBn); 76.0 (CHOBn); 81.4 (2C); 
127.55, 127.58 (2CHAr); 127.6 (2CHAr); 127.9 (2CHAr); 128.3 (2CHAr); 128.4 (2CHAr); 
138.6 (2CAr); 169.0 (2CO) 
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MS (ESI, m/z): 471.2 [M+H]+ 
Di-tert-butyl [(2S)-2,3-dihydroxypropyl]propanedioate, 5 
Following the general procedure 4.2.1.1., diol 5 was obtained from 4 (327 mg, 
0.74 mmol) at 60ºC in quantitative yield.  
 
Rf: 0.37 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3408 (O-H); 1726 (C=O) 
1H-NMR (methanol-d4, 300 MHz):  1.46 (s, 9H, 3CH3); 1.47 (s, 9H, 3CH3); 1.76 (ddd, 
J = 14.8, 9.6, 5.3, 1H, ½CH2CH(CO2tBu)2); 2.02 (ddd, J = 14.8, 9.5, 3.3, 1H, 
½CH2CH(CO2tBu)2); 3.39-3.48 (m, 3H, CH2OH, CH(CO2tBu)2); 3.52-3.63 (m, 1H, 
CHOH) 
13C-NMR (methanol-d4, 75 MHz):  28.2 (3CH3); 28.23 (3CH3); 33.7 
(CH2CH(CO2tBu)2); 52.0 (CH(CO2tBu)2); 67.4 (CH2OH); 70.9 (CHOH); 82.7 (2C); 
170.4, 170.8 (2CO) 
MS (ESI, m/z): 289.1 [M-H]- 
Di-tert-butyl [(2S)-2,3-bis(benzyloxy)propyl](fluoro)propanedioate, 6 
Following the general procedure 4.2.1.5., compound 6 was obtained from 4 (400 
mg, 0.85 mmol) in quantitative yield. Chromatography: hexane to hexane/ethyl 
acetate, 8:2.  
 
Rf: 0.53 (hexane/ethyl acetate, 8:2) 
IR (ATR): 1736 (C=O); 1148 (C-F) 
1H-NMR (CDCl3, 300 MHz):  1.35 (s, 9H, 3CH3); 1.45 (s, 9H, 3CH3); 2.24-2.38 (m, 
2H, CH2CF); 3.53 (d, J = 4.8, 2H, CH2OBn); 3.85-3.93 (m, 1H, CH); 4.51 (d, J = 11.3, 
1H, ½PhCH2); 4.51 (s, 2H, PhCH2); 4.60 (d, J = 11.3, 1H, ½PhCH2); 7.28-7.33 (m, 
10H, 10CHAr) 
13C-NMR (CDCl3, 75 MHz):  27.7 (3CH3); 27.8 (3CH3); 36.6 (CH2CF); 72.6, 73.0 
(2PhCH2); 73.3 (CH2OBn); 74.7 (CH); 82.4, 82.8 (2C(CH3)3); 127.5 (2CHAr); 127.6 
(2CHAr); 128.1 (2CHAr); 128.32 (2CHAr); 128.33 (2CHAr); 138.35, 138.7 (2CAr); 169.4, 
170.1 (2CO); CF not observed 
MS (ESI, m/z): 506.3 [M+NH4]+ 
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Di-tert-butyl [(2S)-2,3-dihydroxypropyl](fluoro)propanedioate, 7 
Following the general procedure 4.2.1.1., diol 7 was obtained from 6 (211 mg, 
0.43 mmol) at 60ºC in quantitative yield.  
 
Rf: 0.14 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3407 (O-H); 1743 (C=O); 1154 (C-F) 
1H-NMR (CDCl3, 300 MHz):  1.51 (s, 18H, 6CH3); 2.18 (dt, J = 15.3, 3.0, 1H, 
½CH2CF); 2.34 (ddd, J = 15.3, 9.2, 9.0, 1H, ½CH2CF); 2.91-3.20 (br s, 2H, 2OH); 
3.50 (dd, J = 11.3, 6.8, 1H, ½CH2OH); 3.65 (dd, J = 11.3, 3.3, 1H, ½CH2OH); 3.96-
4.06 (m, 1H, CH) 
13C-NMR (CDCl3, 75 MHz):  27.7 (3CH3); 27.75 (3CH3); 37.2 (d, J = 20.8, CH2CF); 
66.5 (CH2OH); 67.3 (d, J = 2.8, CH); 83.9 (2C(CH3)3); 93.4 (d, J = 196.0, CF); 165.3 
(d, J = 25.0, CO); 165.8 (d, J = 26.1, CO) 
4.2.2.3. Synthesis of diol 10 
[(4R)-2,2-Dimethyl-1,3-dioxolan-4-yl]methyl 4-methylbenzenesulfonate, 8 
Following the general procedure 4.2.1.3., tosylate 8 was obtained from (S)-(2,2-
dimethyl-1,3-dioxolan-4-yl)methanol (0.5 mL, 4.05 mmol) in 86% yield. 
Chromatography: hexane to hexane/ethyl acetate, 1:1. 
 
Rf: 0.28 (hexane/ethyl acetate, 5:1) 
IR (ATR): 1364 (SO2); 1179 (SO2) 
1H-NMR (CDCl3, 300 MHz):  1.31 (s, 3H, CH3); 1.34 (s, 3H, CH3); 2.45 (s, 3H, 
CH3CAr); 3.77 (dd, J = 8.8, 5.1, 1H, ½CH2O); 3.94-4.06 (m, 3H, CH2OS, ½CH2O); 
4.24-4.31 (m, 1H, CH); 7.35 (d, J = 8.1, 2H, 2CHAr); 7.80 (d, J = 8.3, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  21.8 (CH3CAr); 25.3, 26.8 (2CH3); 66.4 (CH2O); 69.6 
(CH2OS); 73.1 (CH); 110.2 (C); 128.2 (2CHAr); 130.1 (2CHAr); 132.8, 145.2 (2CAr) 
[α]D20: -4.2 (c = 1.41, methanol) 
MS (ESI, m/z): 287.1 [M+H]+ 
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2-(4-{[(4S)-2,2-Dimethyl-1,3-dioxolan-4-yl]methoxy}phenyl)-4,4,5,5-tetramethyl-
1,3,2-dioxaborolane, 9 
To a solution of tosylate 8 (343 mg, 1.2 mmol, 1.2 equiv) and 4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (220 mg, 1.0 mmol, 1 equiv) in anhydrous 
DMF (5 mL), Cs2CO3 (652 mg, 2.0 mmol, 2 equiv) was added. The mixture was heated 
at 90ºC for 16 h. Afterward, the mixture was partitioned between ethyl acetate and 
water and the aqueous layer was extracted with ethyl acetate. The organic phase was 
washed with brine, dried over Na2SO4, filtered and concentrated under reduced 
pressure. The residue was purified by flash chromatography (hexane to hexane/ethyl 
acetate, 7:3) to afford pure compound 9 in 84% yield.  
 
Rf: 0.63 (hexane/ethyl acetate, 8:2) 
IR (ATR): 1362 (B-O) 
1H-NMR (CDCl3, 300 MHz):  1.33 (s, 12H, 4CH3 boronate); 1.40 (s, 3H, CH3 acetal); 1.46 
(s, 3H, CH3 acetal); 3.90 (dd, J = 8.5, 5.8, 1H, ½CH2O); 3.96 (dd, J = 9.6, 6.0, 1H, 
½CH2O); 4.08 (dd, J = 9.5, 5.4, 1H, ½CH2O); 4.17 (dd, J = 8.5, 6.4, 1H, ½CH2O); 4.48 
(qt, J = 5.9, 1H, CH); 6.90 (d, J = 8.7, 2H, 2CHAr); 7.74 (d, J = 8.6, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  25.0 (4CH3 boronate); 25.5, 26.9 (2CH3 acetal); 67.0, 68.7 
(2CH2); 74.1 (CH); 83.7 (2Cboronate); 109.9 (Cacetal); 114.0 (2CHAr); 136.7 (2CHAr); 161.2 
(CAr); CB not observed 
[α]D20: +9.2 (c = 0.6, CHCl3) 
MS (ESI, m/z): 335.2 [M+H]+ 
(2R)-3-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]propane-1,2-
diol, 10 
Following the general procedure 4.2.1.6., diol 10 was obtained from 9 (425 mg, 
1.27 mmol) in 88% yield. Chromatography: hexane/ethyl acetate, 1:1 to 2:8.  
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Rf: 0.05 (hexane/ethyl acetate, 7:3) 
IR (ATR): 3372 (O-H); 1361 (B-O) 
1H-NMR (CDCl3, 300 MHz):  1.33 (s, 12H, 4CH3); 2.76 (br s, 2H, OH); 3.72 (dd, J = 
11.5, 5.5, 1H, ½CH2OAr); 3.82 (dd, J = 11.5, 3.7, 1H, ½CH2OAr); 4.02-4.04 (m, 2H, 
CH2OH); 4.06-4.13 (m, 1H, CH); 6.88 (d, J = 8.7, 2H, 2CHAr); 7.74 (d, J = 8.7, 2H, 
2CHAr)  
13C-NMR (CDCl3, 75 MHz):  25.0 (4CH3); 63.7 (CH2OH); 69.0 (CH2OAr); 70.5 (CH); 
83.8 (2C); 114.0 (2CHAr); 136.7 (2CHAr); 161.1 (CAr); CB not observed 
[α]D20: +14.2 (c = 1.70, methanol) 
MS (ESI, m/z): 295.1 [M+H]+; 312.2 [M+NH4]+ 
4.2.2.4. Synthesis of diol 12 
[(4S)-2,2-Dimethyl-1,3-dioxolan-4-yl]acetonitrile, 11 
To a solution of (S)-(+)-1,2-isopropylideneglycerol (0.37 mL, 3.0 mmol, 1 equiv) 
in anhydrous dichloromethane (13.6 mL), pyridine (0.98 mL, 12.1 mmol, 4 equiv) and 
triflic anhydride (1.0 mL, 6.1 mmol, 2 equiv) were added at -20ºC. The reaction mixture 
was stirred at this temperature for 30 min. Afterward, the mixture was poured into cold 
1M HCl (5 mL) and extracted with dichloromethane. The organic layer was washed 
with brine, dried over Na2SO4, filtered and concentrated under reduced pressure to 
yield the corresponding triflate derivative, which was used in the next step without 
further purification. 
To a solution of triflate derivative (793 mg, 3.0 mmol, 1 equiv) in a 7.5:1 mixture 
of acetonitrile:water (2.8 mL), KCN (234 mg, 3.6 mmol, 1.2 equiv) was added, and the 
mixture was stirred at room temperature overnight. Then it was concentrated under 
reduced pressure and the residue was dissolved in ethyl acetate and washed with 
water. The organic layer was dried over Na2SO4, filtered and concentrated under 
reduced pressure to afford nitrile derivative 11 in quantitative yield, without needing 
further purification. 
 
Rf: 0.44 (hexane/ethyl acetate, 8:2) 
IR (ATR): 2251 (CN); 1070 (C-O) 
1H-NMR (CDCl3, 300 MHz):  1.34 (s, 3H, CH3); 1.45 (s, 3H, CH3); 2.54-2.68 (dd, J = 
5.7, 3.1, 2H, CH2CN); 3.78 (dd, J = 8.7, 5.5, 1H, ½CH2O); 4.14 (dd, J = 8.7, 6.0, 1H, 
½CH2O); 4.33 (qt, J = 5.7, 1H, CH) 
13C-NMR (CDCl3, 75 MHz):  22.8 (CH2CN); 25.4, 26.9 (2CH3); 68.3 (CH2O); 71.1 
(CH); 110.6 (C); 116.7 (CN) 
[α]D20: +0.55 (c = 0.84, methanol) 
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(3S)-3,4-Dihydroxybutanenitrile, 12 
Nitrile 11 (207 mg, 1.47 mmol, 1 equiv) was treated with a 9:1 mixture of 
TFA:MeOH (6.6 mL) at room temperature for 90 min. Afterward, the reaction was 
concentrated under reduced pressure and the residue was purified by flash 
chromatography (hexane to hexane/ethyl acetate, 6:4) to afford pure 12 in 61% yield. 
 
Rf: 0.47 (hexane/ethyl acetate, 1:4) 
IR (ATR): 3354 (O-H); 2250 (CN); 1026 (C-O) 
1H-NMR (CDCl3, 300 MHz):  2.63 (ABX system, J = 16.9, 6.8, 4.7, 2H, CH2CN); 3.53 
(ABX system, J = 11.2, 5.9, 5.3, 2H, CH2OH); 3.87 (qt, J = 5.7, 1H, CH)  
13C-NMR (CDCl3, 75 MHz):  21.8 (CH2CN); 64.7 (CH2OH); 68.1 (CH); 118.2 (CN) 
[α]D20: +0.22 (c = 1.56, methanol) 
4.2.2.5. Synthesis of alcohol 22 
3-(Benzyloxy)propyl methanesulfonate, 19 
Following the general procedure 4.1.1.2., mesylate 19 was obtained from 
benzyloxypropan-1-ol (0.19 mL, 1.20 mmol) in quantitative yield.  
 
Rf: 0.4 (hexane/ethyl acetate, 5:1) 
1H-NMR (DMSO-d6, 300 MHz):  2.04 (qt, J = 6.1, 2H, CH2CH2OMs); 2.96 (s, 3H, 
CH3); 3.59 (t, J = 5.9, 2H, CH2OBn); 4.36 (t, J = 6.2, 2H, CH2OMs); 4.51 (s, 2H, 
PhCH2); 7.27-7.39 (m, 5H, 5CHAr) 
13C-NMR (DMSO-d6, 75 MHz):  29.6 (CH2CH2OMs); 37.2 (CH3); 65.5 (CH2OMs); 
67.4 (CH2OBn); 73.2 (PhCH2); 127.7 (2CHAr); 127.8 (CHAr); 128.5 (2CHAr); 138.1 (CAr) 
MS (ESI, m/z): 245.1 [M+H]+; 267.0 [M+Na]+ 
Di-tert-butyl [3-(benzyloxy)propyl]propanedioate, 20 
Following the general procedure 4.2.1.4., compound 20 was obtained from 
mesylate 19 (270 mg, 1.11 mmol) in 66% yield. Chromatography: hexane to 
hexane/ethyl acetate, 7:3.  
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Rf: 0.49 (hexane/ethyl acetate, 8:2) 
1H-NMR (DMSO-d6, 300 MHz):  1.45 (s, 18H, 6CH3); 1.60-1.70 (m, 2H, CH2CH2CH); 
1.86-1.94 (m, 2H, CH2CH); 3.14 (t, J = 7.5, 1H, CH); 3.49 (t, J = 6.4, 2H, CH2OBn); 
4.50 (s, 2H, PhCH2); 7.24-7.37 (m, 5H, 5CHAr) 
13C-NMR (DMSO-d6, 75 MHz):  25.4 (CH2CH); 27.4 (CH2CH2CH); 28.0 (6CH3); 53.7 
(CH); 69.8 (CH2OBn); 72.9 (PhCH2); 81.3 (2C); 127.5 (CHAr); 127.6 (2CHAr); 128.4 
(2CHAr); 138.5 (CAr); 168.9 (2CO) 
MS (ESI, m/z): 365.3 [M+H]+; 387.1 [M+Na]+ 
Di-tert-butyl [3-(benzyloxy)propyl](fluoro)propanedioate, 21 
Following the general procedure 4.1.1.5., compound 21 was obtained from 20 
(250 mg, 0.71 mmol) in quantitative yield, which was used in next step without further 
purification. 
 
Rf: 0.82 (hexane/ethyl acetate, 8:2) 
1H-NMR (DMSO-d6, 300 MHz):  1.49 (s, 18H, 6CH3); 1.59-1.77 (m, 2H, CH2CH2CF); 
2.00-2.24 (m, 2H, CH2CF); 3.46-3.52 (m, 2H, CH2OBn); 4.49 (s, 2H, PhCH2); 7.28-
7.37 (m, 5H, 5CHAr) 
13C-NMR (DMSO-d6, 75 MHz):  23.6 (d, J = 2.9, CH2CH2CF); 28.2 (6CH3); 31.2 (d, J 
= 21.8, CH2CF); 70.0 (CH2OBn); 73.1 (PhCH2); 83.8 (2C(CH3)3); 100.9 (d, J = 165.6, 
CF); 127.9 (CHAr); 128.0 (2CHAr); 128.8 (2CHAr); 138.9 (CAr); 165.7 (d, J = 25.7, 2CO) 
MS (ESI, m/z): 400.2 [M+NH4]+; 405.2 [M+Na]+ 
Di-tert-butyl fluoro(3-hydroxypropyl)propanedioate, 22 
Following the general procedure 4.2.1.1., alcohol 22 was obtained from 21 (329 
mg, 0.86 mmol) at 60ºC in quantitative yield.  
 
Rf: 0.31 (hexane/ethyl acetate, 4:1) 
1H-NMR (DMSO-d6, 300 MHz):  1.50 (s, 18H, 6CH3); 1.54-1.71 (m, 2H, CH2CH2CF); 
1.91-2.20 (m, 2H, CH2CF); 3.45-3.64 (m, 2H, CH2OH) 
13C-NMR (DMSO-d6, 75 MHz):  26.1 (d, J = 2.5, CH2CH2CF); 27.8 (6CH3); 30.2 (d, J 
= 21.8, CH2CF); 62.1 (CH2OH); 83.5 (2C(CH3)3); 96.0 (d, J = 196.0, CF); 165.6 (d, J 
= 25.8, 2CO) 
MS (ESI, m/z): 293.1 [M+H]+ 
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4.2.2.6. Synthesis of esters 13-15, 17-18 and 23 
(2S)-3-(2-tert-Butoxy-2-oxoethoxy)-2-hydroxypropyl (9Z)-octadec-9-enoate, 13 
Following the general procedure 4.2.1.7., ester 13 was obtained from diol 2 (82 
mg, 0.49 mmol) in 36% yield. Chromatography: dichloromethane/ethyl acetate, 100:1 
to 5:1. 
 
Rf: 0.52 (dichloromethane/ethyl acetate, 8:2) 
IR (ATR): 3460 (O-H); 1739 (C=O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.23-1.36 (m, 20H, 10CH2); 
1.48 (s, 9H, 3CH3); 1.57-1.69 (m, 2H, CH2CH2CO); 1.95-2.06 (m, 4H, 2CH2CHalkene); 
2.34 (t, J = 7.6, 2H, CH2CO); 3.56 (dd, J = 10.0, 6.4, 1H, ½CHCH2O); 3.66 (dd, J = 
10.0, 3.6, 1H, ½CHCH2O); 3.95-4.07 (m, 3H, CH2CO2tBu, CH); 4.11-4.21 (m, 2H, 
CO2CH2); 5.29-5.40 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.2 (CH3); 22.8, 25.1 (2CH2); 27.3, 27.4 (2CH2CHalkene); 
28.3 (3CH3); 29.3 (2CH2); 29.32 (CH2); 29.5 (2CH2); 29.7, 29.8, 29.9, 32.1 (4CH2); 
34.3 (CH2CO); 65.2 (CO2CH2); 69.0 (CH); 69.2 (CH2CO2tBu); 73.4 (CHCH2O); 82.4 
(C); 129.9, 130.2 (2CHalkene); 170.4 (CO2tBu); 174.0 (CO) 
MS (ESI, m/z): 493.1 [M+Na]+ 
Di-tert-butyl {(2S)-2-hydroxy-3-[(9Z)-octadec-9-enoyloxy]propyl}propanedioate, 
14 
Following the general procedure 4.2.1.7., ester 14 was obtained from diol 5 (190 
mg, 0.72 mmol) in 99% yield. Chromatography: dichloromethane/ethyl acetate, 100:1 
to 5:1. 
 
Rf: 0.60 (dichloromethane/ethyl acetate, 9:1) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.18-1.37 (m, 20H, 10CH2); 
1.45 (s, 9H, 3CH3); 1.46 (s, 9H, 3CH3); 1.56-1.69 (m, 3H, CH2CH2CO, 
½CH2CH(CO2tBu)2); 1.89-2.08 (m, 5H, 2CH2CHalkene, ½CH2CH(CO2tBu)2); 2.34 (t, J 
= 7.5, 2H, CH2CO); 3.44 (dd, J = 8.1, 6.2, 1H, CH(CO2tBu)2); 3.84-3.95 (m, 1H, 
CHOH); 4.01 (dd, J = 11.3, 6.7, 1H, ½CO2CH2); 4.12 (dd, J = 11.3, 3.7, 1H, 
½CO2CH2); 5.31-5.36 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.2 (CH3); 22.8, 25.1 (2CH2); 27.3, 27.4 (2CH2CHalkene); 
28.0 (3CH3); 28.1 (3CH3); 29.2 (2CH2); 29.3, 29.5, 29.7 (3CH2); 29.8 (2CH2); 29.9, 
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32.1, 32.4 (3CH2); 34.3 (CH2CO); 50.9 (CH(CO2tBu)2); 68.2 (CHOH); 68.3 (CO2CH2); 
82.0 (2C); 129.9, 130.2 (2CHalkene); 168.9, 169.2 (2CO2tBu); 174.0 (CO) 
MS (ESI, m/z): 555.2 [M+H]+ 
Di-tert-butyl fluoro{(2S)-2-hydroxy-3-[(9Z)-octadec-9-enoyloxy]propyl} 
propanedioate, 15 
Following the general procedure 4.2.1.7., ester 15 was obtained from diol 7 (116 
mg, 0.38 mmol) in 60% yield. Chromatography: dichloromethane to 
dichloromethane/ethyl acetate, 9:1. 
 
Rf: 0.56 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3513 (O-H); 1743 (C=O); 1164 (C-F) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.6, 3H, CH3); 1.22-1.37 (m, 20H, 10CH2); 
1.50 (s, 18H, 6CH3); 1.60-1.65 (m, 2H, CH2CH2CO); 1.97-2.03 (m, 4H, 2CH2CHalkene); 
2.23-2.44 (m, 4H, CH2CO, CH2CF); 3.99-4.21 (m, 3H, CO2CH2, CH); 5.32-5.36 (m, 
2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.1 (CH3); 22.7, 24.9 (2CH2); 27.2, 27.24 
(2CH2CHalkene); 27.7 (3CH3); 27.78 (3CH3); 29.1, 29.2 (2CH2); 29.3 (2CH2); 29.33, 
29.5, 29.7, 29.8, 31.9 (5CH2); 34.1 (CH2CO); 37.4 (d, J = 20.4, CH2CF); 65.3 (CH); 
67.9 (CO2CH2); 83.8, 83.9 (2C(CH3)3); 129.8, 130.0 (2CHalkene); 165.5 (d, J = 24.8, 
CO2tBu); 166.0 (d, J = 25.7, CO2tBu); 174.4 (CO); CF not observed 
MS (ESI, m/z): 590.5 [M+NH4]+ 
(2S)-2-Hydroxy-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy] 
propyl (9Z)-octadec-9-enoate, 16 
Following the general procedure 4.2.1.7., ester 16 was obtained from diol 10 (130 
mg, 0.44 mmol) in 40% yield. Chromatography: dichloromethane to 
dichloromethane/ethanol, 100:1. 
 
Rf: 0.46 (dichloromethane/ethanol, 20:1) 
IR (ATR): 3459 (O-H); 1737 (C=O); 1362 (B-O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.26-1.33 (m, 32H, 10CH2, 
4CH3 boronate); 1.56-1.68 (m, 2H, CH2CH2CO); 1.97-2.01 (m, 4H, 2CH2CHalkene); 2.35 (t, 
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J = 7.5, 2H, CH2CO); 2.57 (br s, 1H, OH); 4.00-4.09 (m, 2H, CH2OAr); 4.22-4.32 (m, 
3H, CH, CO2CH2); 5.28-5.40 (m, 2H, 2CHalkene); 6.90 (d, J = 8.7, 2H, 2CHAr); 7.75 (d, 
J = 8.6, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8 (CH2); 25.0 (4CH3); 25.04 (CH2); 27.3, 
27.4 (2CH2CHalkene); 29.2 (2CH2); 29.3 (CH2); 29.5 (2CH2); 29.7, 29.8, 29.9, 32.0 
(4CH2); 34.3 (CH2CO); 65.3 (CO2CH2); 68.6 (CH2OAr); 68.8 (CH); 83.8 (2C); 114.0 
(2CHAr); 129.9, 130.2 (2CHalkene); 136.7 (2CHAr); 161.0 (CAr); 174.1 (CO); CB not 
observed 
[α]D20: +1.5 (c = 1, CHCl3)  
MS (ESI, m/z): 557.8 [M-H]- 
Potassium [4-({(2S)-2-hydroxy-3-[(9Z)-octadec-9-enoyloxy]propyl}oxy)phenyl] 
trifluoroborate, 17 
To a solution of boronate ester 16 (50 mg, 0.09 mmol, 1 equiv) in methanol (2 
mL), potassium hydrogen fluoride was added (111 µL, 0.50 mmol, 5.6 equiv, 4.5 M in 
water) and the reaction was stirred at room temperature for 30 min. Then, solvent was 
evaporated under reduced pressure and the crude was dissolved in hot acetone and 
filtrated. The filtrate was concentrated under reduced pressure to afford intermediate 
17 as a syrup in quantitative yield.  
 
IR (ATR): 3500 (O-H); 1737 (C=O); 1237 (B-F); 1176 (B-C) 
1H-NMR (methanol-d4, 300 MHz):  0.90 (t, J = 6.6, 3H, CH3); 1.30-1.37 (m, 20H, 
10CH2); 1.60-1.64 (m, 2H, CH2CH2CO); 2.02-2.04 (m, 4H, 2CH2CHalkene); 2.36 (t, J = 
7.4, 2H, CH2CO); 3.94-4.02 (m, 2H, CH2OAr); 4.09-4.28 (m, 3H, CH, CO2CH2); 5.29-
5.40 (m, 2H, 2CHalkene); 6.79 (d, J = 8.0, 2H, 2CHAr); 7.42 (d, J = 8.3, 2H, 2CHAr) 
13C-NMR (methanol-d4, 75 MHz):  14.5 (CH3); 23.7, 26.0 (2CH2); 28.1 (2CH2CHalkene); 
30.2 (2CH2); 30.3, 30.34, 30.5, 30.6, 30.8, 30.84, 33.1 (7CH2); 34.9 (CH2CO); 66.5 
(CO2CH2); 69.2 (CH); 69.9 (CH2OAr); 114.1 (2CHAr); 130.8, 130.9 (2CHalkene); 133.6 
(2CHAr); 158.8 (CAr); 175.4 (CO); CB not observed 
[α]D20: +2.4 (c = 0.9, methanol) 
MS (ESI, m/z): 521.3 [M-OH]- 
(2S)-3-Cyano-2-hydroxypropyl (9Z)-octadec-9-enoate, 18 
Following the general procedure 4.2.1.7., ester 18 was obtained from diol 12 (61 
mg, 0.60 mmol) in 88% yield. Chromatography: hexane to hexane/ethyl acetate, 6:4. 
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Rf: 0.27 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3380 (O-H); 2250 (CN); 1740 (C=O); 1115 (C-O); 1093 (C-O) 
1H-NMR (methanol-d4, 300 MHz):  0.90 (t, J = 6.6, 3H, CH3); 1.29-1.33 (m, 20H, 
10CH2); 1.57-1.65 (m, 2H, CH2CH2CO); 2.00-2.06 (m, 4H, 2CH2CHalkene); 2.36 (t, J = 
7.6, 2H, CH2CO); 2.57-2.74 (m, 2H, CH2CN); 4.04-4.14 (m, 3H, CH, CO2CH2); 5.29-
5.39 (m, 2H, 2CHalkene) 
13C-NMR (methanol-d4, 75 MHz):  13.5 (CH3); 20.9 (CH2CN); 22.8, 24.9 (2CH2); 27.2 
(2CH2CHalkene); 29.22, 29.24, 29.3, 29.4, 29.5, 29.7, 29.8, 29.9, 32.1 (9CH2); 33.8 
(CH2CO); 65.3 (CH); 66.5 (CO2CH2); 118.7 (CN); 129.8, 129.9 (2CHAlkene); 173.9 (CO) 
[α]D20: +0.53 (c = 1.00, methanol) 
MS (ESI, m/z): 383.4 [M+NH4]+; 388.3 [M+Na]+ 
Di-tert-butyl fluoro{3-[(9Z)-octadec-9-enoyloxy]propyl}propanedioate, 23 
Following the general procedure 4.2.1.7., ester 23 was obtained from alcohol 22 
(199 mg, 0.68 mmol) in 70% yield. Chromatography: dichloromethane. 
 
Rf: 0.69 (hexane/ethyl acetate, 1:1) 
1H-NMR (DMSO-d6, 300 MHz):  0.88 (t, J = 6.8, 3H, CH3); 1.23-1.37 (m, 20H, 10CH2); 
1.46 (s, 3H, CH3); 1.50 (s, 15H, 5CH3); 1.56-1.64 (m, 2H, CH2CH2CO); 1.69-1.79 (m, 
2H, CH2CH2CF); 1.97-2.04 (m, 4H, 2CH2CHalkene); 2.07-2.20 (m, 2H, CH2CF); 2.29 (t, 
J = 7.6, 2H, CH2CO); 4.08 (t, J = 6.3, 2H, CO2CH2); 5.29-5.40 (m, 2H, 2CHalkene) 
13C-NMR (DMSO-d6, 75 MHz):  14.5 (CH3); 22.7 (d, J = 3.2, CH2CH2CF); 23.1, 25.3 
(2CH2); 27.6, 27.61 (2CH2CHalkene); 28.2 (6CH3); 28.3, 29.5, 29.54, 29.6, 29.7, 29.9, 
30.1, 30.2 (8CH2); 30.9 (d, J = 21.9, CH2CF); 32.3 (CH2); 34.7 (CH2CO); 63.9 
(CO2CH2); 84.0 (2C(CH3)3); 94.8 (d, J = 196.5, CF); 130.2, 130.4 (2CHalkene); 165.7 
(d, J = 25.4, 2CO2tBu); 174.2 (CO) 
MS (ESI, m/z): 557.5 [M+H]+ 
4.2.2.7. Synthesis of final compounds 1a-f 
({(2S)-2-Hydroxy-3-[(9Z)-octadec-9-enoyloxy]propyl}oxy)acetic acid, 1a 
Following the general procedure 4.2.1.8., compound 1a was obtained from tert-
butyl ester 13 (48 mg, 84 µmol) and TFA (0.16 mL, 2.10 mmol) in 52% yield. 
Chromatography: ethyl acetate/ethanol, 20:1 to 1:5. 
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Rf: 0.11 (ethyl acetate/ethanol, 8:2) 
IR (ATR): 3301 (O-H); 1737 (C=O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.6, 3H, CH3); 1.26-1.29 (m, 20H, 10CH2); 
1.52-1.65 (m, 2H, CH2CH2CO); 1.93-2.05 (m, 4H, 2CH2CHalkene); 2.30 (t, J = 7.5, 2H, 
CH2CO); 3.32-3.60 (m, 2H, CHCH2O); 3.76-3.92 (br s, 2H, CH2CO2H); 3.95-4.19 (m, 
3H, CO2CH2, CH); 5.26-5.35 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.9, 25.0 (2CH2); 27.3, 27.4 (2CH2CHalkene); 
29.2, 29.3, 29.4, 29.47, 29.48, 29.7, 29.8, 29.9, 32.1 (9CH2); 34.2 (CH2CO); 64.8 
(CO2CH2); 65.8 (CH); 70.5 (CH2CO2H); 72.1 (CHCH2O); 130.0, 130.2 (2CHalkene); 
173.4, 173.8 (2CO) 
[α]D20: -1.6 (c = 1.00, CHCl3) 
HRMS (ESI, m/z): calculated for C23H41O6 ([M-H]-): 413.2909, found: 413.2890 
(5S)-5-{[(9Z)-Octadec-9-enoyloxy]methyl}-2-oxotetrahydrofuran-3-carboxylic 
acid, 1b 
Following the general procedure 4.2.1.8., compound 1b was obtained from di-
tert-butyl ester 14 (169 mg, 0.30 mmol) and TFA (0.58 mL, 7.53 mmol) in 88% yield. 
Chromatography: ethyl acetate/ethanol, 20:1 to 1:5.  
 
Rf: 0.13 (ethyl acetate/ethanol, 8:2) 
1H-NMR (CDCl3, 300 MHz): Mixture of diastereoisomers A:B (1:1):  0.88 (t, J = 7.2, 
3H, CH3); 1.27-1.30 (m, 20H, 10CH2); 1.61-1.64 (m, 2H, CH2CH2CO); 1.97-2.03 (m, 
4H, 2CH2CHalkene); 2.35 (dt, J = 7.7, 1.8, 2H, CH2CO); 2.37-2.41 (m, 1H, 
½CH2CHCO2H A); 2.47-2.54 (m, 1H, ½CH2CHCO2H B); 2.62-2.68 (m, 1H, 
½CH2CHCO2H B); 2.78-2.84 (m, 1H, ½CH2CHCO2H A); 3.71-3.76 (m, 1H, CHCO2H); 
4.19 (dd, J = 12.6, 4.6, 1H, ½CO2CH2 A); 4.23 (dd, J = 12.5, 5.8, 1H, ½CO2CH2 B); 
4.35-4.40 (m, 1H, ½CO2CH2); 4.74-4.79 (m, 1H, CO2CH2CH A); 4.89-4.94 (m, 1H, 
CO2CH2CH B); 5.30-5.38 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz): Mixture of diastereoisomers A:B (1:1):  14.3 (CH3); 22.8 
(CH2); 24.9 and 24.94 (CH2); 27.3, 27.37 (2CH2CHalkene); 27.9, 29.2, 29.22, 29.3, 29.5, 
29.7, 29.8, 29.9, 31.1 (9CH2); 32.1 (CH2CHCO2H); 34.0 and 34.1 (CH2CO); 46.0 and 
46.2 (CHCO2H); 64.4 and 64.9 (CO2CH2); 76.7 and 76.8 (CO2CH2CH); 129.85 and 
129.8 (CHalkene); 130.17 and 130.19 (CHalkene); 171.9, 172.1 (CO2H, COlactone); 173.4 
and 173.6 (CO) 
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HRMS (ESI, m/z): calculated for C23H39O4 ([M-CO2H]-): 379.2854, found: 379.2861 
HPLC (method A, tR, min): 14.37 
(5S)-3-Fluoro-5-{[(9Z)-octadec-9-enoyloxy]methyl}-2-oxotetrahydrofuran-3-
carboxylic acid, 1c 
Following the general procedure 4.2.1.8., compound 1c was obtained from di-
tert-butyl ester 15 (80 mg, 0.14 mmol) and TFA (0.27 mL, 3.50 mmol) without further 
purification in quantitative yield. 
 
IR (ATR): 3466 (O-H); 1795 (C=O); 1742 (C=O); 1163 (C-F) 
1H-NMR (CDCl3, 500 MHz): Mixture of diastereoisomers A:B (1:1):  0.88 (t, J = 6.8, 
3H, CH3); 1.21-1.37 (m, 20H, 10CH2); 1.59-1.66 (m, 2H, CH2CH2CO); 1.99-2.02 (m, 
4H, 2CH2CHalkene); 2.37 (t, J = 7.5, CH2CO); 2.46-2.55 (m, 1H, ½CH2CF A); 2.76 (app 
dd, J = 26.1, 7.2, 2H, CH2CF B); 2.97-3.03 (m, 1H, ½CH2CF A); 4.24 (dd, J = 12.6, 4.8, 
1H, ½CO2CH2 A); 4.29 (dd, J = 12.5, 6.0, 1H, ½CO2CH2 B); 4.42-4.46 (m, 1H, 
½CO2CH2); 4.90-4.99 (m, 1H, CH); 5.31-5.38 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 125 MHz): Mixture of diastereoisomers A:B (1:1):  14.2 (CH3); 22.8, 
24.9 (2CH2); 27.3, 27.4 (2CH2CHalkene); 29.2, 29.22, 29.3, 29.5, 29.7, 29.81, 29.84, 
29.9, 32.0 (9CH2); 34.0 and 34.08 (CH2CO); 34.9 (d, J = 22.4) and 35.0 (d, J = 21.7, 
CH2CF); 63.6 and 63.9 (CO2CH2); 75.7 (d, J = 2.9) and 76.5 (CH); 91.7 (d, J = 197.8) 
and 92.1 (d, J = 200.9, CF); 129.9 (CHalkene); 130.16 and 130.18 (CHalkene); 167.5 (d, 
J = 23.3, CO); 167.8 (d, J = 24.7, CO); 173.8 and 173.84 (CO) 
HRMS (ESI, m/z): calculated for C24H38FO6 ([M-H]-): 441.2658, found 441.2667 
HPLC (method A, tR, min): 21.16 
[4-({(2S)-2-Hydroxy-3-[(9Z)-octadec-9-enoyloxy]propyl}oxy)phenyl]boronic 
acid, 1d 
To a solution of compound 17 (30 mg, 54 µmol, 1 equiv) in acetonitrile (0.5 mL), 
water (3 µL, 0.16 mmol, 3 equiv) and trimethylsilyl chloride (20 µL, 0.16 mmol, 3 equiv) 
were added and the mixture was stirred for 1 h at room temperature. Then, a saturated 
aqueous solution of NaHCO3 was added, and the reaction mixture was extracted with 
dichloromethane. The organic layer was washed with brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. Flash chromatography of the 
residue (hexane/ethyl acetate, 10:1 to 1:1, followed by ethyl acetate/ethanol, 10:1 to 
5:1) afforded compound 1d in 60% yield.  
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Rf: 0.30 (hexane/ethyl acetate, 1:1) 
IR (ATR): 1740 (C=O); 1368 (B-O); 1242 (B-C) 
1H-NMR (CDCl3, 300 MHz):  0.87 (t, J = 6.5, 3H, CH3); 1.26-1.30 (m, 20H, 10CH2); 
1.63-1.67 (m, 2H, CH2CH2CO); 1.99-2.01 (m, 4H, 2CH2CHalkene); 2.38 (t, J = 7.5, 2H, 
CH2CO); 4.03-4.12 (m, 2H, CH2OAr); 4.24-4.37 (m, 3H, CH, CO2CH2); 5.27-5.40 (m, 
2H, 2CHalkene); 7.02 (d, J = 8.5, 2H, 2CHAr); 8.16 (d, J = 8.4, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8, 25.1 (2CH2); 27.3, 27.4 (2CH2CHalkene); 
29.2 (2CH2); 29.3 (CH2); 29.5 (2CH2); 29.7, 29.8, 29.9, 32.1 (4CH2); 34.3 (CH2CO); 
65.4 (CO2CH2); 68.6 (CH2OAr); 68.8 (CH); 114.2 (2CHAr); 129.9, 130.2 (2CHalkene); 
137.6 (2CHAr); 141.1 (CAr); 174.2 (CO); CB not observed 
[α]D20: limited solubility 
HRMS (ESI, m/z): calculated for C27H46BO6 ([M+H]+): 477.3387, found 477.3395  
HPLC (method A, tR, min): 22.85 
(2S)-2-Hydroxy-3-(1H-tetrazol-5-yl)propyl (9Z)-octadec-9-enoate, 1e 
To a solution of compound 18 (64 mg, 0.18 mmol, 1 equiv) in dry DMF (0.3 mL), 
sodium azide (13 mg, 0.19 mmol, 1.1 equiv) and NH4Cl (12 mg, 0.23 mmol, 1.3 equiv) 
were added. The mixture was heated at 160°C under MW irradiation for 45 min. Then, 
the solvent was removed under reduced pressure. The crude was purified by flash 
chromatography (hexane to hexane/ethyl acetate, 6:4) afforded compound 1e in 5% 
yield.  
 
IR (ATR): 3390 (O-H, N-H); 1738 (C=O)  
1H-NMR (methanol-d4, 500 MHz):  0.90 (t, J = 6.9, 3H, CH3); 1.29-1.33 (m, 20H, 
10CH2); 1.58-1.64 (m, 2H, CH2CH2CO); 2.01-2.05 (m, 4H, 2CH2CHalkene); 2.34 (t, J = 
7.4, 2H, CH2CO); 3.07 (dd, J = 14.9, 8.2, 1H, ½CH2CN); 3.18 (dd, J = 14.9, 4.6, 1H, 
½CH2CN); 4.06-4.12 (m, 2H, CO2CH2); 4.17-4.22 (m, 1H, CH); 5.31-5.37 (m, 2H, 
2CHalkene) 
13C-NMR (methanol-d4, 125 MHz):  14.4 (CH3); 23.7, 25.9 (2CH2); 28.1 
(2CH2CHalkene); 29.3 (CH2CN); 30.18, 30.19, 30.3, 30.33, 30.4, 30.6, 30.8, 30.84, 33.1 
(9CH2); 34.8 (CH2CO); 68.2 (CO2CH2); 68.3 (CH); 130.8, 130.9 (2CHalkene); 155.5 
(CN); 175.2 (CO) 
[α]D20: +31.7 (c = 0.09, methanol) 
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HRMS (MALDI, m/z): calculated for C22H40N4NaO3 ([M+Na]+): 431.2998, found: 
431.1931 
HPLC (method A, tR, min): 19.45 
Fluoro{3-[(9Z)-octadec-9-enoyloxy]propyl}propanedioic acid, 1f 
Following the general procedure 4.2.1.8., compound 1f was obtained from di-tert-
butyl ester 24 (61 mg, 0.11 mmol) and TFA (0.21 mL, 2.75 mmol) without further 
purification in 90% yield. 
 
IR (ATR): 1738 (C=O); 1166 (C-F) 
1H-NMR (DMSO-d6, 300 MHz):  0.88 (t, J = 6.6, 3H, CH3); 1.18-1.39 (m, 20H, 10CH2); 
1.54-1.67 (m, 2H, CH2CH2CO); 1.70-1.85 (m, 2H, CH2CH2CF); 1.93-2.04 (m, 4H, 
2CH2CHalkene); 2.20-2.45 (m, 2H, CH2CF); 2.41 (t, J = 7.6, 2H, CH2CO); 4.02-4.18 (m, 
2H, CO2CH2); 5.27-5.41 (m, 2H, 2CHalkene) 
13C-NMR (DMSO-d6, 75 MHz):  14.1 (CH3); 22.7, 24.9 (2CH2); 24.93 (d, J = 2.8, 
CH2CH2CF); 27.2, 27.23 (2CH2CHalkene); 29.1, 29.2 (2CH2); 29.3 (2CH2); 29.5, 29.7, 
29.74, 29.8 (4CH2); 31.1 (d, J = 21.6, CH2CF); 31.9 (CH2); 34.3 (CH2CO); 63.29 
(CO2CH2); 129.7, 130.0 (2CHalkene); 174.7 (CO); 2CO2H and CF not observed 
HRMS (ESI, m/z): calculated for C24H40FO6 ([M-H]-): 443.2814, found: 443.2824 
HPLC (method A, tR, min): 16.75 
4.2.3. Synthesis of final compound 1g 
Di-tert-butyl fluoro{(2S)-2-methoxy-3-[(9Z)-octadec-9-enoyloxy]propyl} 
propanedioate, 24 
Following the general procedure 4.2.1.9., compound 24 was obtained from 15 
(90 mg, 0.16 mmol) in 38% yield. Chromatography: hexane/ethyl acetate, 30:1 to 5:1. 
 
Rf: 0.41 (hexane/ethyl acetate, 8:2) 
IR (ATR): 1769 (C=O); 1165 (C-F) 
1H-NMR (CDCl3, 300 MHz):  0.87 (t, J = 6.5, 3H, CH3); 1.26-1.29 (m, 20H, 10CH2); 
1.48 (s, 9H, 3CH3); 1.49 (s, 9H, 3CH3); 1.59-1.64 (m, 2H, CH2CH2CO); 1.99-2.01 (m, 
4H, 2CH2CHalkene); 2.16-2.48 (m, 2H, CH2CF); 2.32 (t, J = 7.5, 2H, CH2CO); 3.29 (s, 
3H, OCH3); 3.57-3.64 (m, 1H, CH); 4.10 (ABX system, J = 11.6, 4.8, 4.6, 2H, CO2CH2); 
5.28-5.39 (m, 2H, 2CHalkene) 
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13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8, 25.0 (2CH2); 27.3, 27.34 
(2CH2CHalkene); 27.8 (3CH3); 27.9 (3CH3); 29.2 (2CH2); 29.3 (CH2); 29.5 (2CH2); 29.7, 
29.8, 29.9, 32.0 (4CH2); 34.3 (CH2CO); 36.7 (d, J = 21.4, CH2CF); 57.9 (OCH3); 64.9 
(CO2CH2); 73.9 (d, J = 3.3, CH); 83.2, 83.6 (2C(CH3)3); 92.5 (d, J = 195.3, CF); 129.9, 
130.1 (2CHalkene); 165.1 (d, J = 27.4, CO2tBu); 165.2 (d, J = 23.8, CO2tBu); 173.7 (CO) 
[α]D20: +4.1 (c = 0.75, CHCl3) 
MS (ESI, m/z): 609.4 [M+Na]+ 
Fluoro{(2S)-2-methoxy-3-[(9Z)-octadec-9-enoyloxy]propyl}propanedioic acid, 
1g 
Following the general procedure 4.2.1.8., compound 1g was obtained from di-
tert-butyl ester 24 (10 mg, 17 µmol) and TFA (98 µL, 1.28 mmol) without further 
purification in 95% yield.  
 
IR (ATR): 3525 (O-H); 1742 (C=O); 1260 (C-F) 
1H-NMR (methanol-d4, 700 MHz):  0.90 (t, J = 7.1, 3H, CH3); 1.29-1.33 (m, 20H, 
10CH2); 1.61-1.63 (m, 2H, CH2CH2CO); 2.02-2.05 (m, 4H, 2CH2CHalkene), 2.24-2.30 
(m, 1H, ½CH2CF); 2.35 (t, J = 7.4, 2H, CH2CO); 2.45-2.52 (m, 1H, ½CH2CF); 3.33 (s, 
3H, OCH3); 3.63-3.65 (m, 1H, CH); 4.04 (dd, J = 11.7, 4.9, 1H, ½CO2CH2); 4.25 (dd, 
J = 11.7, 3.9, 1H, ½CO2CH2); 5.32-5.37 (m, 2H, 2CHalkene) 
13C-NMR (methanol-d4, 175 MHz):  14.5 (CH3); 23.8, 26.0 (2CH2); 28.1 
(2CH2CHalkene); 30.2 (2CH2); 30.3, 30.4, 30.5, 30.6, 30.8, 30.9, 33.1 (7CH2); 34.9 
(CH2CO); 38.4 (d, J = 20.1, CH2CF); 58.1 (OCH3); 65.9 (CO2CH2); 76.0 (CH); 94.4 (d, 
J = 192.5, CF); 130.8, 130.9 (2CHalkene); 170.9 (br s, 2CO2H); 175.2 (CO) 
[α]D20: +29.5 (c = 0.20, methanol) 
HRMS (ESI, m/z): calculated for C25H42FO7 ([M-H]-): 473.2915, found: 473.2922 
HPLC (method A, tR, min): 14.51  
4.2.4. Synthesis of final compounds 2a-e 
4.2.4.1. Synthesis of non-commercial fatty acids 32-34 
Methyl 8-bromooctanoate, 25 
To a solution of 8-bromooctanoic acid (2.0 g, 8.96 mmol, 1 equiv) in methanol (10 
mL), concentrated H2SO4 (0.2 mL) was added and the reaction mixture was refluxed 
overnight. Afterward, the solvent was evaporated and the residue was dissolved in 
ethyl acetate and washed with a saturated aqueous solution of NaHCO3 and brine. 
The organic phase was dried over Na2SO4, filtered and concentrated under reduced 
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pressure to yield ester 25 in quantitative yield, which was used in the next step without 
further purification. The spectroscopic data correspond with those previously 
reported.105  
 
Rf: 0.23 (hexane/ethyl acetate, 20:1) 
1H-NMR (CDCl3, 300 MHz):  1.30 (m, 4H, 2CH2); 1.40-1.45 (m, 2H, CH2); 1.57-1.67 
(m, 2H, CH2); 1.84 (qt, J = 7.5, 2H, CH2CH2CO); 2.30 (t, J = 7.5, 2H, CH2CO); 3.39 (t, 
J = 6.8, 2H, CH2Br); 3.66 (s, 3H, CH3) 
Methyl heptadec-9-ynoate, 26 
Following the general procedure 4.2.1.10., alkyne 26 was obtained from 1-
nonyne (0.27 mL, 1.64 mmol) and methyl 8-bromooctanoate 25 (300 mg, 1.26 mmol) 
in 36% yield. Chromatography: hexane. 
 
Rf: 0.32 (hexane/ethyl acetate, 20:1) 
IR (ATR): 1740 (C=O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.5, 3H, CH3); 1.28-1.38 (m, 14H, 7CH2); 
1.42-1.49 (m, 4H, 2CH2); 1.58-1.65 (m, 2H, CH2CH2CO); 2.13 (t, J = 6.9, 4H, 
2CH2Calkyne); 2.30 (t, J = 7.5, 2H; CH2CO); 3.66 (s, 3H, OCH3) 
13C-NMR (CDCl3, 75 MHz):  14.2 (CH3); 18.87, 18.9 (2CH2Calkyne); 22.8, 25.1, 28.8, 
29.9 (4CH2); 29.0 (2CH2); 29.2, 29.22, 29.3, 31.9 (4CH2); 34.2 (CH2CO); 51.6 (OCH3); 
80.2, 80.5 (2Calkyne); 174.4 (CO) 
Methyl nonadec-9-ynoate, 27 
Following the general procedure 4.2.1.10., alkyne 27 was obtained from 1-
undecyne (0.33 mL, 1.64 mmol) and methyl 8-bromooctanoate 25 (300 mg, 1.26 
mmol) in 38% yield. Chromatography: hexane.  
 
Rf: 0.36 (hexane/ethyl acetate, 20:1) 
IR (ATR): 1742 (C=O) 
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1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.27-1.51 (m, 22H, 11CH2); 
1.57-1.67 (m, 2H, CH2CH2CO); 2.11-2.16 (m, 4H, 2CH2Calkyne); 2.30 (t, J = 7.5, 2H, 
CH2CO), 3.66 (s, 3H, OCH3) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 18.88, 18.9 (2CH2Calkyne); 22.8, 25.1, 28.8, 
28.9, 29.0, 29.2, 29.22 (7CH2); 29.3 (2CH2); 29.5, 29.7, 32.1 (3CH2); 34.2 (CH2CO); 
51.6 (OCH3); 80.2, 80.5 (2Calkyne), 174.4 (CO) 
MS (ESI, m/z): 309.3 [M+H]+ 
Methyl icos-9-ynoate, 28 
Following the general procedure 4.2.1.10., alkyne 28 was obtained from 1-
dodecyne (0.32 mL, 1.64 mmol) and methyl 8-bromooctanoate 25 (300 mg, 1.26 
mmol) in 44% yield. Chromatography: hexane. 
 
Rf: 0.48 (hexane/ethyl acetate, 20:1) 
IR (ATR): 1740 (C=O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.26-1.40 (m, 20H, 10CH2); 
1.42-1.49 (m, 4H, 2CH2); 1.57-1.67 (m, 2H, CH2CH2CO); 2.13 (t, J = 6.9, 4H, 
2CH2Calkyne); 2.30 (t, J = 7.5, 2H, CH2CO); 3.66 (s, 3H, OCH3) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 18.88, 18.9 (2CH2Calkyne); 22.8, 25.1, 28.8, 
28.9, 29.0, 29.2, 29.22 (7CH2); 29.3 (2CH2); 29.5, 29.7, 29.74, 32.1 (4CH2); 34.2 
(CH2CO); 51.6 (OCH3); 80.2, 80.5 (2Calkyne); 174.4 (CO) 
Methyl (9Z)-heptadec-9-enoate, 29 
Following the general procedure 4.2.1.11., alkene 29 was obtained from alkyne 
26 (126 mg, 0.45 mmol) in 91% yield.  
 
Rf: 0.32 (hexane/ethyl acetate, 20:1) 
1H-NMR (CDCl3, 300 MHz):  0.87 (t, J = 6.6, 3H, CH3); 1.27-1.29 (m, 18H, 9CH2); 
1.59-1.63 (m, 2H, CH2CH2CO); 1.97-2.06 (m, 4H, 2CH2CHalkene); 2.30 (t, J = 7.5, 2H, 
CH2CO); 3.66 (s, 3H, OCH3); 5.28-5.39 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8, 25.1 (2CH2); 27.3, 27.4 (2CH2CHalkene); 
29.2, 29.26, 29.29, 29.3, 29.4, 29.8, 29.9, 32.0 (8CH2); 34.2 (CH2CO); 51.6 (OCH3); 
129.9, 130.1 (2CHalkene); 174.5 (CO) 
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Methyl (9Z)-nonadec-9-enoate, 30 
Following the general procedure 4.2.1.11., alkene 30 was obtained from alkyne 
27 (120 mg, 0.39 mmol) in 92% yield.  
 
Rf: 0.36 (hexane/ethyl acetate, 20:1) 
IR (ATR): 1742 (C=O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.26-1.30 (m, 22H, 11CH2); 
1.58-1.64 (m, 2H, CH2CH2CO); 1.97-2.01 (m, 4H, 2CH2CHalkene); 2.30 (t, J = 7.5, 2H, 
CH2CO); 3.66 (s, 3H, OCH3); 5.29-5.40 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8, 25.1 (2CH2); 27.3, 27.4 (2CH2CHalkene); 
29.2, 29.3, 29.31, 29.4, 29.49, 29.7, 29.8, 29.84, 29.9, 32.1 (10CH2); 34.3 (CH2CO); 
51.6 (OCH3); 129.9, 130.2 (2CHalkene); 174.5 (CO) 
MS (ESI, m/z): 311.3 [M+H]+ 
Methyl (9Z)-icos-9-enoate, 31 
Following the general procedure 4.2.1.11., alkene 31 was obtained from alkyne 
28 (128 mg, 0.40 mmol) in 89% yield.  
 
Rf: 0.48 (hexane/ethyl acetate, 20:1)  
IR (ATR): 1743 (C=O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.26-1.30 (m, 24H, 12CH2); 
1.57-1.64 (m, 2H, CH2CH2CO); 1.97-2.04 (m, 4H, 2CH2CHalkene); 2.30 (t, J = 7.5, 2H, 
CH2CO); 3.66 (s, 3H, OCH3); 5.29-5.40 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8, 25.1 (2CH2); 27.3, 27.4 (2CH2CHalkene); 
29.2, 29.28, 29.3, 29.4, 29.5, 29.7, 29.8, 29.81, 29.84, 29.9, 32.1 (11CH2); 34.3 
(CH2CO); 51.6 (OCH3); 129.9, 130.2 (2CHalkene); 174.5 (CO) 
(9Z)-Heptadec-9-enoic acid, 32 
Following the general procedure 4.2.1.12., carboxylic acid 32 was obtained from 
ester 29 (115 mg, 0.41 mmol) in quantitative yield. 
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Rf: 0.43 (hexane/ethyl acetate, 1:1) 
IR (ATR): 3252 (O-H); 1710 (C=O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.27-1.31 (m, 18H, 9CH2); 
1.58-1.66 (m, 2H, CH2CH2CO); 1.98-2.04 (m, 4H, 2CH2CHalkene); 2.35 (t, J = 7.5, 2H, 
CH2CO); 5.29-5.40 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8, 24.8 (2CH2); 27.3, 27.4 (2CH2CHalkene); 
29.2, 29.21, 29.3, 29.37, 29.4, 29.8, 29.9, 32.0 (8CH2); 34.2 (CH2CO); 129.9, 130.2 
(2CHalkene); 180.0 (CO) 
MS (ESI, m/z): 267.1 [M-H]- 
(9Z)-Nonadec-9-enoic acid, 33 
Following the general procedure 4.2.1.12., carboxylic acid 33 was obtained from 
ester 30 (111 mg, 0.36 mmol) in quantitative yield.  
 
Rf: 0.45 (hexane/ethyl acetate, 1:1) 
IR (ATR): 1710 (C=O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.26-1.31 (m, 22H, 11CH2); 
1.58-1.68 (m, 2H, CH2CH2CO); 1.98-2.04 (m, 4H, 2CH2CHalkene); 2.35 (t, J = 7.5, 2H, 
CH2CO); 5.29-5.40 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8, 24.8 (2CH2); 27.3, 27.4 (2CH2CHalkene); 
29.2, 29.22, 29.3, 29.5, 29.51, 29.7, 29.8, 29.83, 29.9, 32.1 (10CH2); 34.2 (CH2CO); 
129.9, 130.2 (2CHalkene); 180.2 (CO) 
(9Z)-Icos-9-enoic acid, 34 
Following the general procedure 4.2.1.12., carboxylic acid 34 was obtained from 
ester 31 (114 mg, 0.35 mmol) in quantitative yield.  
 
Rf: 0.46 (hexane/ethyl acetate, 1:1) 
IR (ATR): 1711 (C=O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.26-1.31 (m, 24H, 12CH2); 
1.56-1.68 (m, 2H, CH2CH2CO); 1.94-2.04 (m, 4H, 2CH2CHalkene); 2.35 (t, J = 7.5, 2H, 
CH2CO); 5.29-5.40 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.9, 24.8 (2CH2); 27.3, 27.4 (2CH2CHalkene); 
29.2, 29.22, 29.3, 29.5, 29.51, 29.7, 29.8 (7CH2); 29.82 (2CH2); 29.9, 32.1 (2CH2); 
34.1 (CH2CO); 129.9, 130.2 (2CHalkene); 180.0 (CO) 
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MS (ESI, m/z): 309.2 [M-H]- 
4.2.4.2. Synthesis of phosphorylated diol 36 
(2R)-2,3-Bis(benzyloxy)propyl di-tert-butyl phosphate, 35 
Following the general procedure 4.2.1.13., compound 35 was obtained from (S)-
2,3-bis(benzyloxy)propan-1-ol (416 mg, 1.53 mmol) and di-tert-butyl-N,N-
diisopropylphosphoramidite (0.85 mL, 3.06 mmol) in 38% yield. Chromatography: 
hexane to hexane/ethyl acetate, 1:1. 
 
Rf: 0.36 (hexane/ethyl acetate, 1:1) 
IR (ATR): 1265 (P=O); 996 (P-O) 
1H-NMR (CDCl3, 300 MHz):  1.46 (s, 18H, 6CH3); 3.56-3.66 (m, 2H, CH2OBn); 3.83 
(qt, J = 5.1, 1H, CH); 4.00-4.15 (m, 2H, CH2OP); 4.54 (s, 2H, PhCH2); 4.59-4.67 (m, 
2H, PhCH2); 7.25-7.37 (m, 10H, 10CHAr) 
13C-NMR (CDCl3, 75 MHz):  29.9 (3CH3); 30.0 (3CH3); 66.1 (d, J = 6.4, CH2OP); 69.8 
(CH2OBn); 72.4 (PhCH2); 73.5 (PhCH2); 76.9 (d, J = 8.6, CH); 82.4 (d, J = 7.5, C); 
82.5 (d, J = 7.4, C); 127.7 (4CHAr); 127.9 (2CHAr); 128.4 (2CHAr); 128.5 (2CHAr); 138.3, 
138.5 (2CAr) 
31P-NMR (CDCl3, 121 MHz):  -6.82 
[α]D20: +1.6 (c = 1.00, CHCl3) 
MS (ESI, m/z): 487.1 [M+Na]+ 
Di-tert-butyl (2R)-2,3-dihydroxypropyl phosphate, 36 
Following the general procedure 4.2.1.1., diol 36 was obtained from 35 (220 mg, 
0.47 mmol) at 60ºC in quantitative yield. 
 
Rf: 0.06 (hexane/ethyl acetate, 1:1) 
IR (ATR): 3345 (O-H); 1025 (P-O) 
1H-NMR (CDCl3, 300 MHz):  1.47 (s, 18H, 6CH3); 3.60-3.73 (m, 2H, CH2OH); 3.86-
3.92 (m, 3H, CH, 2OH); 4.02 (dd, J = 9.1, 5.3, 2H, CH2OP) 
13C-NMR (methanol-d4, 75 MHz):  30.1 (3CH3); 30.2 (3CH3); 63.7 (CH2OH); 69.2 (d, 
J = 6.8, CH2OP); 71.9 (d, J = 10.1, CH); 84.5 (d, J = 7.7, 2C) 
31P-NMR (CDCl3, 121 MHz):  -6.03 
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[α]D20: -1.5 (c = 1.70, methanol) 
MS (ESI, m/z): 307.1 [M+Na]+ 
4.2.4.3. Synthesis of esters 37-41 
(2R)-3-[(Di-tert-butoxyphosphoryl)oxy]-2-hydroxypropyl (9Z)-tetradec-9-
enoate, 37 
Following the general procedure 4.2.1.14., ester 37 was obtained from myristoleic 
acid (24 µL, 95 µmol) and diol 36 (54 mg, 0.19 mmol) in 28% yield. Chromatography: 
dichloromethane to dichloromethane/methanol, 95:5. 
 
Rf: 0.88 (dichloromethane/methanol, 95:5) 
IR (ATR): 3365 (O-H); 1739 (C=O); 1257 (P=O); 1000 (P-O) 
1H-NMR (CDCl3, 300 MHz):  0.89 (t, J = 7.0, 3H, CH3); 1.24-1.34 (m, 12H, 6CH2); 
1.49 (s, 18H, 6CH3); 1.57-1.64 (m, 2H, CH2CH2CO); 1.94-2.02 (m, 4H, 2CH2CHalkene); 
2.33 (t, J = 7.6, 2H, CH2CO); 3.95-4.13 (m, 3H, CH, CH2OP); 4.15 (app d, J = 4.7, 2H, 
CO2CH2); 5.27-5.40 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.1 (CH3); 22.5, 25.0 (2CH2); 27.1, 27.3 (2CH2CHalkene); 
29.2, 29.23, 29.3, 29.8 (4CH2); 29.9 (3CH3); 30.0 (3CH3); 32.1 (CH2); 34.3 (CH2CO); 
64.7 (CO2CH2); 68.3 (d, J = 5.8, CH2OP); 69.1 (d, J = 5.0, CH); 83.4 (d, J = 7.5, 2C); 
129.9, 130.1 (2CHalkene); 173.9 (CO) 
31P-NMR (methanol-d4, 121 MHz):  -5.11 
[α]D20: +2.6 (c = 0.50, methanol) 
MS (ESI, m/z): 515.2 [M+Na]+ 
(2R)-3-[(Di-tert-butoxyphosphoryl)oxy]-2-hydroxypropyl (9Z)-hexadec-9-
enoate, 38 
Following the general procedure 4.2.1.14., ester 38 was obtained from palmitoleic 
acid (66 µL, 0.23 mmol) and diol 36 (133 mg, 0.47 mmol) in 49% yield. 
Chromatography: hexane/ethyl acetate, 40:1 to 1:1. 
 
Rf: 0.38 (hexane/ethyl acetate, 1:1) 
IR (ATR): 3363 (O-H); 1739 (C=O); 1251 (P=O); 1000 (P-O) 
1H-NMR (CDCl3, 300 MHz):  0.87 (t, J = 6.7, 3H, CH3); 1.28 (m, 16H, 8CH2); 1.48 (s, 
18H, 6CH3); 1.56-1.69 (m, 2H, CH2CH2CO); 1.96-2.00 (m, 4H, 2CH2CHalkene); 2.32 (t, 
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J = 7.6, 2H, CH2CO); 3.85 (br s, 1H, OH); 3.95-4.09 (m, 3H, CH, CH2OP); 4.14 (app 
d, J = 4.6, 2H, CO2CH2); 5.27-5.38 (m, 2H, 2CHalkene)  
13C-NMR (CDCl3, 75 MHz):  14.2 (CH3); 22.8, 25.0 (2CH2); 27.3, 27.33 
(2CH2CHalkene); 29.1 (CH2); 29.2 (2CH2); 29.3, 29.8, 29.84 (3CH2); 29.9 (3CH3); 30.0 
(3CH3); 31.9 (CH2); 34.2 (CH2CO); 64.7 (CO2CH2); 68.3 (d, J = 6.0, CH2OP); 69.0 (d, 
J = 5.2, CH); 83.4 (d, J = 7.5, 2C); 129.9, 130.1 (2CHalkene); 173.9 (CO) 
31P-NMR (CDCl3, 121 MHz):  -5.23 
[α]D20: -1.9 (c = 1.21, CHCl3) 
MS (ESI, m/z): 543.3 [M+Na]+ 
(2R)-3-[(Di-tert-butoxyphosphoryl)oxy]-2-hydroxypropyl (9Z)-heptadec-9-
enoate, 39 
Following the general procedure 4.2.1.14., ester 39 was obtained from carboxylic 
acid 32 (92 mg, 0.34 mmol) and diol 36 (195 mg, 0.69 mmol) in 40% yield. 
Chromatography: hexane/ethyl acetate, 20:1 to 2:1. 
 
Rf: 0.36 (hexane/ethyl acetate, 1:1) 
IR (ATR): 3366 (O-H); 1739 (C=O); 1647 (C=C); 1259 (P=O); 1007 (P-O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.21-1.30 (m, 18H, 9CH2); 
1.50 (s, 18H, 6CH3); 1.60-1.64 (m, 2H, CH2CH2CO); 1.97-2.01 (m, 4H, 2CH2CHalkene); 
2.34 (t, J = 7.6, 2H, CH2CO); 3.71 (br s, 1H, OH); 3.98-4.11 (m, 3H, CH, CH2OP); 
4.16 (app d, J = 4.9, 2H, CO2CH2); 5.28-5.39 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.1 (CH3); 22.7, 24.9 (2CH2); 27.2, 27.24 
(2CH2CHalkene); 29.1 (2CH2); 29.2, 29.25, 29.3 (3CH2); 29.7 (2CH2); 29.8 (3CH3); 29.9 
(3CH3); 31.9 (CH2); 34.1 (CH2CO); 64.5 (CO2CH2); 68.3 (d, J = 5.4, CH2OP); 69.1 (d, 
J = 4.8, CH); 83.3 (d, J = 7.8, 2C); 129.8, 130.0 (2CHalkene); 173.8 (CO) 
31P-NMR (CDCl3, 121 MHz):  -5.01 
[α]D20: +3.5 (c = 0.77, methanol) 
MS (ESI, m/z): 557.3 [M+Na]+ 
(2R)-3-[(di-tert-butoxyphosphoryl)oxy]-2-hydroxypropyl (9Z)-nonadec-9-
enoate, 40 
Following the general procedure 4.2.1.14., ester 40 was obtained from carboxylic 
acid 33 (73 mg, 0.25 mmol) and diol 36 (140 mg, 0.49 mmol) in 17% yield. 
Chromatography: hexane/ethyl acetate, 20:1 to 2:1. 
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Rf: 0.37 (hexane/ethyl acetate, 1:1) 
IR (ATR): 3359 (O-H); 1738 (C=O); 1650 (C=C); 1252 (P=O); 1010 (P-O) 
1H-NMR (CDCl3, 300 MHz):  0.87 (t, J = 6.7, 3H, CH3); 1.26-1.29 (m, 22H, 11CH2); 
1.49 (s, 18H, 6CH3); 1.59-1.64 (m, 2H, CH2CH2CO); 1.97-2.01 (m, 4H, 2CH2CHalkene); 
2.33 (t, J = 7.6, 2H, CH2CO); 3.76 (br s, 1H, OH); 3.95-4.10 (m, 3H, CH, CH2OP); 
4.15 (app d, J = 4.9, 2H, CO2CH2); 5.28-5.39 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8, 25.1 (2CH2); 27.3, 27.4 (2CH2CHalkene); 
29.2 (2CH2); 29.3, 29.4, 29.5, 29.7, 29.74, 29.8, 29.9 (7CH2); 29.93 (3CH3); 30.0 
(3CH3); 32.0 (CH2); 34.1 (CH2CO); 64.7 (CO2CH2); 68.3 (d, J = 6.0, CH2OP); 69.1 (d, 
J = 5.0, CH); 83.4 (d, J = 7.5, 2C); 129.9, 130.1 (2CHalkene); 173.9 (CO) 
31P-NMR (CDCl3, 121 MHz):  -5.15 
[α]D20: -1.7 (c = 1.18, CHCl3) 
MS (ESI, m/z): 449.4 [M-2tBu+H]+; 450.4 [M-2tBu+2H] +  
(2R)-3-[(Di-tert-butoxyphosphoryl)oxy]-2-hydroxypropyl (9Z)-icos-9-enoate, 41 
Following the general procedure 4.2.1.14., ester 41 was obtained from carboxylic 
acid 34 (65 mg, 0.21 mmol) and diol 36 (121 mg, 0.42 mmol) in 12% yield. 
Chromatography: hexane/ethyl acetate, 20:1 to 2:1. 
 
Rf: 0.43 (hexane/ethyl acetate, 1:1) 
IR (ATR): 3370 (O-H); 1740 (C=O); 1258 (P=O); 1000 (P-O) 
1H-NMR (CDCl3, 300 MHz):  0.87 (t, J = 6.7, 3H, CH3); 1.26-1.30 (m, 24H, 12CH2); 
1.50 (s, 18H, 6CH3); 1.60-1.65 (m, 2H, CH2CH2CO), 1.97-2.01 (m, 4H, 2CH2CHalkene); 
2.33 (t, J = 7.6, 2H, CH2CO); 3.72 (d, J = 4.1, 1H, OH); 3.98-4.11 (m, 3H, CH, CH2OP); 
4.16 (app d, J = 4.9, 2H, CO2CH2); 5.28-5.39 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8, 25.0 (2CH2); 27.3, 27.4 (2CH2CHalkene); 
29.2 (2CH2); 29.3, 29.4, 29.5, 29.7, 29.78, 29.8, 29.84, 29.9 (8CH2); 30.0 (6CH3); 32.1 
(CH2); 34.3 (CH2CO); 64.7 (CO2CH2); 68.4 (d, J = 5.5, CH2OP); 69.2 (d, J = 4.6, CH); 
83.4 (d, J = 7.2, 2C); 129.9, 130.2 (2CHalkene); 173.9 (CO) 
31P-NMR (CDCl3, 121 MHz):  -5.01 
[α]D20: +3.4 (c = 0.92, methanol) 
MS (MALDI, m/z): 599.4 [M+Na]+ 
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4.2.4.4. Synthesis of final compounds 2a-e 
(2R)-2-Hydroxy-3-(phosphonooxy)propyl (9Z)-tetradec-9-enoate, 2a 
Following the general procedure 4.2.1.8., compound 2a was obtained from di-
tert-butyl phosphate 37 (7 mg, 14 µmol) and TFA (27 µL, 0.35 mmol) without further 
purification in 99% yield.  
 
IR (ATR): 3375 (O-H); 1737 (C=O); 1182 (P=O); 1058 (P-OH) 
1H-NMR (methanol-d4, 500 MHz):  0.91 (t, J = 7.0, 3H, CH3); 1.29-1.30 (m, 12H, 
6CH2); 1.60-1.63 (m, 2H, CH2CH2CO); 2.02-2.04 (m, 4H, 2CH2CHalkene); 2.36 (t, J = 
7.4, 2H, CH2CO); 3.96-3.98 (m, 3H, CH, CH2OP); 4.07-4.17 (m, 2H, CO2CH2); 5.29-
5.40 (m, 2H, 2CHalkene) 
13C-NMR (methanol-d4, 125 MHz):  14.3 (CH3); 23.4, 26.0 (2CH2); 27.9, 28.1 
(2CH2CHalkene); 30.1, 30.2, 30.3, 30.8, 33.1 (5CH2); 34.9 (CH2CO); 66.2 (CO2CH2); 
67.6 (d, J = 5.2, CH2OP); 69.8 (d, J = 6.9, CH); 130.8, 130.83 (2CHalkene); 175.4 (CO) 
31P-NMR (methanol-d4, 121 MHz):  3.23 
[α]D20: limited solubility 
HRMS (ESI, m/z): calculated for C17H32O7P ([M-H]-): 379.2891, found: 379.2848 
HPLC (method A, tR, min): 9.81 min 
(2R)-2-Hydroxy-3-(phosphonooxy)propyl (9Z)-hexadec-9-enoate, 2b 
Following the general procedure 4.2.1.8., compound 2b was obtained from di-
tert-butyl phosphate 38 (24 mg, 46 µmol) and TFA (88 µL, 1.15 mmol) without further 
purification in 90% yield.  
 
IR (ATR): 3392 (O-H); 1737 (C=O); 1176 (P=O); 1057 (P-OH) 
1H-NMR (methanol-d4, 300 MHz):  0.90 (t, J = 6.7, 3H, CH3); 1.29-1.33 (m, 16H, 
8CH2); 1.60-1.64 (m, 2H, CH2CH2CO); 2.00-2.04 (m, 4H, 2CH2CHalkene); 2.36 (t, J = 
7.5, 2H, CH2CO); 3.92-4.04 (m, 3H, CH, CH2OP); 4.15 (ABX system, J = 11.4, 5.5, 
4.2, 2H, CO2CH2); 5.29-5.40 (m, 2H, 2CHalkene) 
13C-NMR (methanol-d4, 75 MHz):  14.5 (CH3); 23.7, 26.0 (2CH2); 28.1, 28.2 
(2CH2CHalkene); 30.1 (CH2); 30.2 (2CH2); 30.3, 30.8, 30.84, 32.9 (4CH2); 34.9 
(CH2CO); 66.2 (CO2CH2); 67.6 (d, J = 5.3, CH2OP); 69.8 (d, J = 8.0, CH); 130.8, 130.9 
(2CHalkene); 175.4 (CO) 
31P-NMR (methanol-d4, 121 MHz):  3.79 
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[α]D20: limited solubility 
HRMS (MALDI, m/z): calculated for C19H37NaO7P ([M+Na]+): 431.2175, found: 
431.2169 
HPLC (method A, tR, min): 10.06  
(2R)-2-Hydroxy-3-(phosphonooxy)propyl (9Z)-heptadec-9-enoate, 2c 
Following the general procedure 4.2.1.8., compound 2c was obtained from di-
tert-butyl phosphate 39 (6 mg, 12 µmol) and TFA (22 µL, 0.30 mmol) without further 
purification in 99% yield.  
 
IR (ATR): 3347 (O-H); 1737 (C=O); 1652 (C=C); 1186 (P=O); 1082 (P-OH) 
1H-NMR (methanol-d4, 700 MHz):  0.90 (t, J = 6.7, 3H, CH3); 1.29-1.33 (m, 18H, 
9CH2); 1.60-1.64 (m, 2H, CH2CH2CO); 2.01-2.04 (m, 4H, 2CH2CHalkene), 2.36 (t, J = 
7.4, 2H, CH2CO); 3.89-3.91 (m, 2H, CH2OP); 3.95-3.98 (m, 1H, CH); 4.11 (dd, J = 
11.4, 6.2, 1H, ½CO2CH2); 4.18 (dd, J = 11.4, 4.3, 1H, ½CO2CH2); 5.29-5.40 (m, 2H, 
2CHalkene) 
13C-NMR (methanol-d4, 175 MHz):  14.5 (CH3); 23.7, 26.0 (2CH2); 28.1 
(2CH2CHalkene); 30.2, 30.22, 30.3, 30.34, 30.8, 30.82, 30.9, 33.1 (8CH2); 34.9 
(CH2CO); 66.4 (CO2CH2); 67.2 (d, J = 5.2, CH2OP); 70.1 (d, J = 7.9, CH); 130.8, 130.9 
(2CHalkene); 175.4 (CO) 
31P-NMR (methanol-d4, 121 MHz):  4.34 
[α]D20: limited solubility 
HRMS (MALDI, m/z): calculated for C20H39NaO7P ([M+Na]+): 445.2331, found: 
445.2311 
HPLC (method A, tR, min): 10.42 
(2R)-2-Hydroxy-3-(phosphonooxy)propyl (9Z)-nonadec-9-enoate, 2d 
Following the general procedure 4.2.1.8., compound 2d was obtained from di-
tert-butyl phosphate 40 (24 mg, 43 µmol) and TFA (82 µL, 1.08 mmol) without further 
purification in 99% yield.  
 
IR (ATR): 3360 (O-H); 1738 (C=O); 1181 (P=O); 1060 (P-OH) 
1H-NMR (methanol-d4, 300 MHz):  0.90 (t, J = 6.6, 3H, CH3); 1.29-1.33 (m, 22H, 
11CH2); 1.59-1.64 (m, 2H, CH2CH2CO); 2.02-2.04 (m, 4H, 2CH2CHalkene); 2.35 (t, J = 
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7.5, 2H, CH2CO); 3.91-4.05 (m, 3H, CH, CH2OP); 4.15 (ABX system, J = 11.4, 5.6, 
4.3, 2H, CO2CH2); 5.29-5.40 (m, 2H, 2CHalkene) 
13C-NMR (methanol-d4, 75 MHz):  14.4 (CH3); 23.7, 26.0 (2CH2); 28.1 (2CH2CHalkene); 
30.2 (2CH2); 30.3 (2CH2); 30.5, 30.6, 30.7 (3CH2); 30.8 (2CH2); 33.1 (CH2); 34.9 
(CH2CO); 66.3 (CO2CH2); 67.5 (d, J = 4.8, CH2OP); 69.9 (d, J = 7.7, CH); 130.8, 130.9 
(2CHalkene); 175.4 (CO) 
31P-NMR (methanol-d4, 121 MHz):  3.88 
[α]D20: limited solubility 
HRMS (MALDI, m/z): calculated for C22H43NaO7P ([M+Na]+): 473.2644, found: 
473.2642 
HPLC (method A, tR, min): 11.30 
(2R)-2-Hydroxy-3-(phosphonooxy)propyl (9Z)-icos-9-enoate, 2e 
Following the general procedure 4.2.1.8., compound 2e was obtained from di-
tert-butyl phosphate 41 (9 mg, 16 µmol) and TFA (30 µL, 0.40 mmol) without further 
purification in 92% yield.  
 
IR (ATR): 3350 (O-H); 1738 (C=O); 1179 (P=O); 1059 (P-OH) 
1H-NMR (methanol-d4, 700 MHz):  0.90 (t, J = 7.0, 3H, CH3); 1.29-1.33 (m, 24H, 
12CH2); 1.60-1.63 (m, 2H, CH2CH2CO); 2.02-2.05 (m, 4H, 2CH2CHalkene); 2.35 (t, J = 
7.5, 2H, CH2CO); 3.94 (app t, J = 5.7, 2H, CH2OP); 3.97-4.00 (m, 1H, CH); 4.11 (dd, 
J = 11.4, 6.0, 1H, ½CO2CH2); 4.18 (dd, J = 11.4, 4.3, 1H, ½CO2CH2); 5.32-5.37 (m, 
2H, 2CHalkene) 
13C-NMR (methanol-d4, 175 MHz):  14.5 (CH3); 23.8, 26.0 (2CH2); 28.1, 28.14 
(2CH2CHalkene); 30.2, 30.3, 30.5, 30.6 (4CH2); 30.7 (2CH2); 30.77 (2CH2); 30.8 (2CH2); 
33.1 (CH2); 34.9 (CH2CO); 66.1 (CO2CH2); 67.6 (d, J = 5.3, CH2OP); 69.7 (d, J = 7.6, 
CH); 130.8, 130.9 (2CHalkene); 175.4 (CO) 
31P-NMR (methanol-d4, 121 MHz):  3.16 
[α]D20: limited solubility 
HRMS (MALDI, m/z): calculated for C23H45NaO7P ([M+Na]+): 487.2801, found: 
487.2798 
HPLC (method A, tR, min): 12.35 
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4.2.5. Synthesis of final compounds 3a and 2f-j 
4.2.5.1. Synthesis of carboxylic acids 44, 45, and 46 
(7E,Z)-8-Phenyloct-7-enoic acid, 42 
Following the general procedure 4.2.1.15., alkene 42 was obtained from 7-
bromoheptanoic acid (441 mg, 2.11 mmol) and benzaldehyde (103 µL, 1.00 mmol) in 
61% yield. Chromatography: hexane to hexane/ethyl acetate, 1:1. 
 
Rf: 0.61 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3024 (O-H); 1707 (C=O) 
1H-NMR (CDCl3, 300 MHz): Mixture E:Z (2.3:1):  1.36-1.53 (m, 4H, 2CH2); 1.59-1.73 
(m, 2H, CH2); 2.23 (q, J = 6.8, 2H, CH2CHalkene(E)); 2.30-2.40 (m, 4H, CH2CHalkene(Z), 
CH2CO); 5.65 (dt, J = 11.7, 7.2, 1H, CH2CHalkene(Z)); 6.21 (dt, J = 15.8, 6.8, 1H, 
CH2CHalkene(E)); 6.39 (d, J = 15.6, 1H, PhCHalkene(E)); 6.43 (d, J = 11.7, 1H, 
PhCHalkene(Z)); 7.16-7.36 (m, 5H, 5CHAr) 
13C-NMR (CDCl3, 75 MHz): Mixture E:Z (2.3:1):  24.7 (CH2); 28.5 (CH2 Z); 28.7 (CH2 
E); 28.9 (CH2 Z); 29.1 (CH2 E); 32.9 (CH2CHalkene); 34.1 (CH2CO); 126.1 (2CHAr E); 126.6 
(CHAr Z); 127.0 (CHAr E); 128.3 (2CHAr Z); 128.6 (2CHAr E); 128.9 (2CHAr Z); 129.2 (CH 
alkene(Z)); 130.2 (CHalkene(E)); 130.8 (CHalkene(E)); 132.8 (CHalkene(Z)); 137.9 (CAr Z); 138.0 
(CAr E); 179.9 (CO) 
MS (ESI, m/z): 217.1 [M-H]- 
(8E,Z)-9-Phenylnon-8-enoic acid, 43 
Following the general procedure 4.2.1.15., alkene 43 was obtained from 8-
bromooctanoic acid (1g, 4.48 mmol) and benzaldehyde (0.36 mL, 3.58 mmol) in 70% 
yield. Chromatography: hexane to hexane/ethyl acetate, 1:1. 
 
Rf: 0.52 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3024 (O-H); 1706 (C=O) 
1H-NMR (CDCl3, 300 MHz): Mixture E:Z (1.5:1):  1.33-1.41 (m, 4H, 2CH2); 1.45-1.52 
(m, 2H, CH2); 1.59-1.72 (m, 2H, CH2); 2.22 (q, J = 6.9, 2H, CH2CHalkene(E)); 2.37 (app 
q, J = 7.6, 4H, CH2CHalkene(Z), CH2CO); 5.66 (dt, J = 11.7, 7.3, 1H, CH2CHalkene(Z)); 6.23 
(dt, J = 15.8, 6.8, 1H, CH2CHalkene(E)); 6.39 (d, J = 15.5, 1H, PhCHalkene(E)); 6.44 (d, J = 
11.5, 1H, PhCHalkene(Z)); 7.17-7.37 (m, 5H, 5CHAr) 
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13C-NMR (CDCl3, 75 MHz): Mixture E:Z (1.5:1):  24.7 and 24.75 (CH2 E, Z); 28.6, 28.9, 
29.0, 29.3 and 29.9 (3CH2 Z,E); 33.1 (CH2CHalkene); 34.1 and 34.14 (CH2CO E, Z); 126.0 
(2CHAr E); 126.6 (CHAr Z); 126.9 (CHAr E); 128.2 (2CHAr Z); 128.6 (2CHAr E); 128.9 (2CHAr 
Z); 129.0 (CHalkene(Z)); 130.0 (CHalkene(E)); 131.06 (CHalkene(E)); 133.10 (CHalkene(Z)); 137.9 
(CAr Z); 138.0 (CAr E); 180.1 (CO) 
MS (ESI, m/z): 231.1 [M-H]- 
8-Phenyloctanoic acid, 44 
Following the general procedure 4.2.1.1., carboxylic acid 44 was obtained from 
alkene 42 (60 mg, 0.27 mmol) at room temperature in 97% yield. The spectroscopic 
data correspond with those previously reported.106  
 
Rf: 0.60 (hexane/ethyl acetate, 8:2) 
1H-NMR (CDCl3, 300 MHz):  1.41 (app s, 6H, 3CH2); 1.70 (br s, 4H, 2CH2); 2.42 (t, 
J = 7.5, 2H, CH2CO); 2.67 (t, J = 7.7, 2H, PhCH2); 7.23-7.26 (m, 3H, 3CHAr); 7.32-
7.37 (m, 2H, 2CHAr) 
9-Phenylnonanoic acid, 45 
Following the general procedure 4.2.1.1., carboxylic acid 45 was obtained from 
alkene 43 (300 mg, 1.29 mmol) at room temperature in 81% yield.  
 
Rf: 0.61 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3063 (O-H); 1707 (C=O) 
1H-NMR (CDCl3, 300 MHz):  1.32 (app s, 8H, 4CH2); 1.56-1.65 (m, 4H, 2CH2); 2.35 
(t, J = 7.5, 2H, CH2CO); 2.60 (t, J = 7.7, 2H, PhCH2); 7.16-7.19 (m, 3H, 3CHAr); 7.25-
7.30 (m, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  24.8, 29.2, 29.3, 29.35, 29.4, 31.6 (6CH2); 34.2 
(CH2CO); 36.1 (PhCH2); 125.7 (CHAr); 128.4 (2CHAr); 128.5 (2CHAr); 143.0 (CAr); 
180.5 (CO)  
MS (ESI, m/z): 233.1 [M-H]- 
10-Phenyldecanoic acid, 46 
To a stirred solution of 10-phenyldecanol (500 mg, 2.10 mmol, 1 equiv) in dry 
DMF (2 mL), pyridinium dichromate (2.92 g, 3.89 mmol, 3.7 equiv) was added and 
the reaction was stirred at room temperature overnight. Then, solvent was evaporated 
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under reduced pressure and the crude was purified by flash chromatography 
(dichloromethane to dichloromethane/methanol, 10:1) affording carboxylic acid 46 in 
52% yield.  
 
Rf: 0.6 (dichloromethane/methanol, 9:1) 
1H-NMR (CDCl3, 300 MHz):  1.32 (m, 10H, 5CH2); 1.63-1.65 (m, 4H, 2CH2); 2.34 (t, 
J = 7.4, 2H, CH2CO); 2.60 (t, J = 7.5, 2H, PhCH2); 7.18-7.22 (m, 3H, 3CHAr); 7.27-
7.33 (m, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  24.8, 29.2, 29.4, 29.41, 29.5, 29.6, 31.6 (7CH2); 34.2 
(CH2CO); 36.1 (PhCH2); 125.7 (CHAr); 128.4 (2CHAr); 128.5 (2CHAr); 143.0 (CAr); 
180.3 (CO) 
4.2.5.2. Synthesis of the phosphorylated diols 48 and 51 
[(4R)-2,2-Dimethyl-1,3-dioxolan-4-yl]methyl diethyl phosphate, 47 
To a solution of (S)-(2,2-dimethyl-1,3-dioxolan-4-yl)methanol (0.3 mL, 2.43 mmol, 
1 equiv) in anhydrous dichloromethane (8 mL), diethyl chlorophosphate (0.44 mL, 
3.04 mmol, 1.25 equiv) and potassium tert-butoxide (408 mg, 3.64 mmol, 1.5 equiv) 
were added and the mixture was stirred at room temperature for 48 h. Then, the 
reaction was quenched with a saturated aqueous solution of NH4Cl (12 mL) and 
stirred for 10 additional min. The mixture was extracted with dichloromethane and the 
organic phase was dried over Na2SO4, filtered and concentrated under reduced 
pressure. The residue was purified by flash chromatography (dichloromethane/ethyl 
acetate, 10:1 to 1:1), to afford pure product 47 in 92% yield. 
 
Rf: 0.26 (dichloromethane/ethyl acetate, 8:2) 
IR (ATR): 1021 (P-O) 
1H-NMR (CDCl3, 300 MHz):  1.31 (td, J = 7.1, 0.9, 6H, 2CH2CH3); 1.33 (s, 3H, CH3 
acetal); 1.39 (s, 3H, CH3 acetal); 3.81 (dd, J = 8.6, 5.5, 1H, ½CH2O); 3.92-4.05 (m, 3H, 
½CH2O, CH2OP); 4.07-4.16 (m, 4H, 2CH2CH3): 4.24-4.33 (m, 1H, CH) 
13C-NMR (CDCl3, 75 MHz):  16.2 (d, J = 6.7, 2CH2CH3); 25.4 (CH3 acetal); 26.8 (CH3 
acetal); 64.1 (d, J = 5.7, 2CH2CH3); 66.3 (CH2O); 67.4 (d, J = 5.8, CH2OP); 74.2 (d, J = 
8.2, CH); 109.9 (C) 
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(2R)-2,3-Dihydroxypropyl diethyl phosphate, 48 
Following the general procedure 4.2.1.6., diol 48 was obtained from 47 (600 mg, 
2.24 mmol) in 50% yield. Chromatography: dichloromethane/methanol, 50:1 to 10:1. 
 
Rf: 0.11 (dichloromethane/methanol, 10:1) 
IR (ATR): 3405 (O-H); 1256 (P=O); 1027 (P-O) 
1H-NMR (CDCl3, 300 MHz):  1.34 (t, J = 7.1, 6H, 2CH3); 3.21 (br s, 2H, 2OH); 3.60-
3.73 (m, 2H, CH2OH); 3.75-3.83 (m, 1H, ½CH2OP); 3.86-3.94 (m, 1H, CH); 4.06-4.18 
(m, 5H, ½CH2OP, 2CH2CH3) 
13C-NMR (CDCl3, 75 MHz):  16.2 (d, J = 6.7, 2CH3); 62.9 (CH2OH); 64.5 (d, J = 6.0, 
2CH2CH3); 68.5 (d, J = 5.8, CH2OP); 70.8 (d, J = 5.5, CH) 
[α]D20: -6.5 (c = 1.11, methanol) 
Dibenzyl [(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl phosphate, 50 
Following the general procedure 4.2.1.13., compound 50 was obtained from (S)-
(2,2-dimethyl-1,3-dioxolan-4-yl)methanol (0.2 mL, 1.62 mmol) and dibenzyl-N,N-
diisopropylphosphoramidite (0.97 mL, 2.91 mmol) in 76% yield. Chromatography: 
hexane to hexane/ethyl acetate, 1:1. 
 
Rf: 0.4 (hexane/ethyl acetate, 1:1) 
IR (ATR): 1255 (P=O); 991 (P-O) 
1H-NMR (CDCl3, 300 MHz):  1.32 (s, 3H, CH3); 1.38 (s, 3H, CH3); 3.72 (dd, J = 8.6, 
5.5, 1H, ½CH2O); 3.87-4.04 (m, 3H, ½CH2O, CH2OP); 4.20 (qt, J = 5.7, 1H, CH); 4.97-
5.13 (m, 4H, 2PhCH2); 7.34 (app s, 10H, 10CHAr) 
13C-NMR (CDCl3, 75 MHz):  25.3, 26.8 (2CH3); 66.2 (CH2O); 67.5 (d, J = 5.9, 
CH2OP); 69.5 (d, J = 5.6, 2PhCH2); 74.0 (d, J = 8.3, CH); 109.9 (C); 128.1 (4CHAr); 
128.7 (6CHAr); 135.8 (d, J = 6.6, 2CAr) 
31P-NMR (CDCl3, 121 MHz):  2.03 
[α]D20: +1.6 (c = 1.00, methanol) 
MS (ESI, m/z): 393.1 [M+H]+ 
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Dibenzyl (2R)-2,3-dihydroxypropyl phosphate, 51 
Following the general procedure 4.2.1.6., diol 51 was obtained from 50 (390 mg, 
0.99 mmol) in 65% yield. Chromatography: ethyl acetate to ethyl acetate/ethanol, 7:3. 
 
Rf: 0.56 (ethyl acetate) 
IR (ATR): 3368 (O-H); 1255 (P=O); 1013 (P-O) 
1H-NMR (CDCl3, 300 MHz):  2.53 (br s, 2H, OH); 3.52-3.65 (m, 2H, CH2OH); 3.78-
3.85 (m, 1H, CH); 4.03 (dd, J = 9.5, 5.0, 2H, CH2OP); 4.98-5.11 (m, 4H, 2PhCH2); 
7.35 (app s, 10H, 10CHAr) 
13C-NMR (CDCl3, 75 MHz):  62.7 (CH2OH); 68.8 (d, J = 5.9, CH2OP); 69.9 (d, J = 
5.8, 2PhCH2); 70.7 (d, J = 5.2, CH); 128.2 (4CHAr); 128.8 (4CHAr); 128.9 (2CHAr); 
135.60 (d, J = 6.6, 2CAr) 
31P-NMR (CDCl3, 121 MHz):  3.19 
[α]D20: -4.6 (c = 0.99, methanol) 
MS (ESI, m/z): 353.0 [M+H]+ 
4.2.5.3. Synthesis of esters 49 and 52-56 
(2R)-3-[(Diethoxyphosphoryl)oxy]-2-hydroxypropyl 10-phenyldecanoate, 49 
Following the general procedure 4.2.1.14., ester 49 was obtained from carboxylic 
acid 46 (136 mg, 0.55 mmol) and diol 48 (250 mg, 1.10 mmol) in 30% yield. 
Chromatography: dichloromethane/methanol, 200:1 to 50:1. 
 
Rf: 0.45 (dichloromethane/methanol, 10:1) 
1H-NMR (CDCl3, 300 MHz):  1.28 (app s, 10H, 5CH2); 1.35 (td, J = 7.1, 0.9, 6H, 
2CH3); 1.55-1.62 (m, 4H, 2CH2); 2.33 (t, J = 7.6, 2H, CH2CO); 2.59 (t, J = 7.7, 2H, 
PhCH2); 4.02-4.26 (m, 9H, CH, 2CH2CH3, CH2OP, CO2CH2); 7.14-7.18 (m, 3H, 
3CHAr); 7.24-7.30 (m, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  16.2 (d, J = 6.6, 2CH3); 25.0, 29.2, 29.4, 29.41, 29.5, 
29.6, 31.6 (7CH2); 34.2 (CH2CO); 36.1 (PhCH2); 64.44 (d, J = 5.4, CH2CH3); 64.45 (d, 
J = 5.4, CH2CH3); 64.5 (CO2CH2); 68.8 (d, J = 5.7, CH2OP); 69.0 (d, J = 5.5, CH); 
125.7 (CHAr); 128.3 (2CHAr); 128.5 (2CHAr); 143.0 (CAr); 174.0 (CO) 
MS (ESI, m/z): 459.2 [M+H]+ 
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(2R)-3-{[Bis(benzyloxy)phosphoryl]oxy}-2-hydroxypropyl 8-phenyloctanoate, 
52 
Following the general procedure 4.2.1.14., ester 52 was obtained from carboxylic 
acid 44 (37 mg, 0.17 mmol) and diol 51 (120 mg, 0.34 mmol) in 53% yield. 
Chromatography: dichloromethane to dichloromethane/methanol, 95:5. 
 
Rf: 0.44 (dichloromethane/methanol, 95:5) 
IR (ATR): 3382 (O-H); 1738 (C=O); 1265 (P=O); 1016 (P-O) 
1H-NMR (methanol-d4, 300 MHz):  1.22-1.35 (m, 6H, 3CH2); 1.48-1.64 (m, 4H, 
2CH2); 2.19-2.32 (m, 2H, CH2CO); 2.52-2.59 (m, 2H, PhCH2); 3.42-4.70 (m, 1H, 
½CH2OP); 3.91-4.36 (m, 4H, CH, ½CH2OP, CO2CH2); 5.01-5.10 (m, 4H, 2OCH2Ph); 
7.09-7.14 (m, 3H, 3CHAr); 7.20-7.25 (m, 2H, 2CHAr); 7.30-7.39 (m, 10H, 10CHAr)  
13C-NMR (methanol-d4, 75 MHz):  26.0, 30.07, 30.1, 30.2, 32.6 (5CH2); 34.7 
(CH2CO); 36.9 (PhCH2); 65.4 (CO2CH2); 68.9 (d, J = 7.9, CH); 69.5 (d, J = 6.1, 
CH2OP); 70.9 (d, J = 5.9, 2OCH2Ph); 126.6 (CHAr); 129.2 (2CHAr); 129.24 (2CHAr); 
129.4 (4CHAr); 129.7 (4CHAr); 129.8 (2CHAr); 137.1 (d, J = 6.4, 2CAr); 143.9 (CAr); 
175.1 (CO) 
31P-NMR (methanol-d4, 121 MHz):  1.54 
[α]D20: +1.6 (c = 1.19, methanol) 
MS (ESI, m/z): 537.2 [M-H2O+H]+; 555.2 [M+H]+ 
(2R)-3-{[Bis(benzyloxy)phosphoryl]oxy}-2-hydroxypropyl 9-phenylnonanoate, 
53 
Following the general procedure 4.2.1.14., ester 53 was obtained from carboxylic 
acid 45 (90 mg, 0.38 mmol) and diol 51 (271 mg, 0.76 mmol) in 58% yield. 
Chromatography: dichloromethane to dichloromethane/methanol, 95:5. 
 
Rf: 0.44 (dichloromethane/methanol, 95:5) 
IR (ATR): 3325 (O-H); 1736 (C=O); 1245 (P=O); 1013 (P-O) 
1H-NMR (methanol-d4, 300 MHz):  1.25-1.35 (m, 8H, 4CH2); 1.55-1.64 (m, 4H, 
2CH2); 2.30 (t, J = 7.4, 2H, CH2CO); 2.58 (t, J = 7.7, 2H, PhCH2); 3.91-3.98 (m, 1H, 
CH); 3.98-4.03 (m, 2H, CH2OP); 4.07 (dd, J = 5.1, 1.5, 2H, CO2CH2); 5.05 (s, 2H, 
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OCH2Ph); 5.08 (s, 2H, OCH2Ph); 7.10-7.16 (m, 3H, 3CHAr); 7.21-7.26 (m, 2H, 2CHAr); 
7.36 (app s, 10H, 10CHAr) 
13C-NMR (methanol-d4, 75 MHz):  26.8, 30.1, 30.2, 30.3, 30.4, 32.7 (6CH2); 34.9 
(CH2CO); 36.9 (PhCH2); 65.4 (CO2CH2); 68.9 (d, J = 8.0, CH); 69.6 (d, J = 6.4, 
CH2OP); 70.9 (d, J = 5.8, 2OCH2Ph); 126.6 (CHAr); 129.20 (4CHAr); 129.24 (2CHAr); 
129.4 (2CHAr); 129.7 (4CHAr); 129.8 (2CHAr); 137.2 (d, J = 6.5, 2CAr); 144.0 (CAr); 
175.2 (CO) 
31P-NMR (methanol-d4, 121 MHz):  1.61 
[α]D20: +0.02 (c = 0.65, methanol) 
MS (ESI, m/z): 551.2 [M-H2O+H]+; 569.3 [M+H] + 
(2R)-3-{[Bis(benzyloxy)phosphoryl]oxy}-2-hydroxypropyl 10-phenyl decanoate, 
54 
Following the general procedure 4.2.1.14., ester 54 was obtained from carboxylic 
acid 46 (82 mg, 0.33 mmol) and diol 51 (233 mg, 0.66 mmol) in 16% yield. 
Chromatography: dichloromethane/ethyl acetate, 100:1 to 1:1. 
 
Rf: 0.43 (dichloromethane/ethyl acetate, 8:2) 
IR (ATR): 1738 (C=O); 1022 (P-O) 
1H-NMR (C6D6, 300 MHz):  1.15-1.20 (m, 10H, 5CH2); 1.49-1.58 (m, 4H, 2CH2); 2.11 
(t, J = 7.5, 2H, CH2CO); 2.51 (t, J = 7.5, 2H, PhCH2); 3.95-4.06 (m, 3H, CH, CH2OP); 
4.12-4.24 (m, 2H, CO2CH2); 4.86-5.00 (m, 4H, 2OCH2Ph); 7.03-7.12 (m, 9H, 9CHAr); 
7.16-7.22 (m, 6H, 6CHAr) 
13C-NMR (C6D6, 75 MHz):  25.2, 29.4, 29.6, 29.7, 29.8, 29.9, 31.9 (7CH2); 34.2 
(CH2CO); 36.4 (PhCH2); 64.6 (CO2CH2); 69.0 (d, J = 5.4, CH); 69.4 (d, J = 5.9, 
CH2OP); 69.7 (d, J = 5.0, OCH2Ph); 69.8 (d, J = 5.1, OCH2Ph); 126.0 (CHAr); 128.5 
(2CHAr); 128.6 (2CHAr); 128.8 (2CHAr); 128.83 (2CHAr); 128.9 (6CHAr); 136.4 (d, J = 
6.7, 2CAr), 143.0 (CAr); 173.2 (CO) 
31P-NMR (C6D6, 121 MHz):  3.92 
MS (ESI, m/z): 565.2 [M-H2O+H]+; 583.3 [M+H]+ 
(2R)-3-{[Bis(benzyloxy)phosphoryl]oxy}-2-hydroxypropyl 11-phenyl 
undecanoate, 55 
Following the general procedure 4.2.1.14., ester 55 was obtained from 11-
phenylundecanoic acid (37 mg, 0.14 mmol) and diol 51 (99 mg, 0.28 mmol) in 18% 
yield. Chromatography: hexane to hexane/ethyl acetate, 7:3. 
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Rf: 0.28 (hexane/ethyl acetate, 6:4) 
1H-NMR (methanol-d4, 300 MHz):  1.19-1.36 (m, 12H, 6CH2); 1.49-1.65 (m, 4H, 
2CH2); 2.19-2.37 (m, 2H, CH2CO); 2.58 (t, J = 7.6, 2H, PhCH2); 3.62-4.18 (m, 5H, CH, 
CH2OP, CO2CH2); 4.97-5.12 (m, 4H, 2OCH2Ph); 7.10-7.16 (m, 3H, 3CHAr); 7.21-7.26 
(m, H, 2CHAr); 7.28-7.41 (app s, 10H, 10 CHAr) 
13C-NMR (methanol-d4, 75 MHz):  25.9, 30.2, 30.28, 30.34 (4CH2); 30.5 (2CH2); 30.6, 
32.8 (2CH2); 34.8 (CH2CO); 36.9 (PhCH2); 65.4 (CO2CH2); 68.9 (d, J = 8.0, CH); 69.5 
(d, J = 6.0, CH2OP); 70.9 (d, J = 5.9, 2OCH2Ph); 126.6 (CHAr); 129.2 (2CHAr); 129.23 
(4CHAr); 129.4 (4CHAr); 129.7 (2CHAr); 129.8 (2CHAr); 137.1 (d, J = 6.1, 2CAr), 144.0 
(CAr); 175.1 (CO) 
31P-NMR (methanol-d4, 121 MHz):  1.61 
(2R)-3-{[Bis(benzyloxy)phosphoryl]oxy}-2-hydroxypropyl 15-phenyl 
pentadecanoate, 56 
Following the general procedure 4.2.1.14., ester 56 was obtained from 15-
phenylpentadecanoic acid (80 mg, 0.25 mmol) and diol 51 (177 mg, 0.50 mmol) in 
18% yield. Chromatography: dichloromethane/ethyl acetate, 100:1 to 1:1. 
 
Rf: 0.55 (dichloromethane/ethyl acetate, 8:2) 
IR (ATR): 3334 (O-H); 1740 (C=O); 1259 (P=O); 1017 (P-O) 
1H-NMR (C6D6, 500 MHz):  1.20-1.36 (m, 20H, 10CH2); 1.54-1.58 (m, 4H, 2CH2); 
2.10 (t, J = 7.5, 2H, CH2CO); 2.52 (t, J = 7.5, 2H, PhCH2); 3.84-3.89 (m, 1H, CH); 
3.91-3.99 (m, 2H, CH2OP); 4.07 (dd, J = 11.4, 5.3, 1H, ½CO2CH2); 4.11 (dd, J = 11.4, 
5.7, 1H, ½CO2CH2); 4.85-4.96 (m, 4H, 2OCH2Ph); 7.04-7.12 (m, 8H, 8CHAr); 7.15-
7.22 (m, 7H, 7CHAr) 
13C-NMR (C6D6, 125 MHz):  25.3, 29.5, 29.7, 29.72, 29.9, 30.0, 30.08, 30.1, 30.14 
(9CH2); 30.2 (2CH2); 32.0 (CH2); 34.2 (CH2CO); 36.4 (PhCH2); 64.5 (CO2CH2); 69.2 
(d, J = 4.8, CH); 69.4 (d, J = 5.6, CH2OP); 69.7 (d, J = 5.5, OCH2Ph); 69.74 (d, J = 
5.5, OCH2Ph); 126.2 (CHAr); 128.5 (4CHAr); 128.54 (2CHAr); 128.8 (2CHAr); 128.84 
(2CHAr); 128.9 (4CHAr); 136.4 (d, J = 6.5, 2CAr); 143.1 (CAr); 173.1 (CO) 
31P-NMR (C6D6, 121 MHz):  4.60 
MS (ESI, m/z): 653.4 [M+H]+ 
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4.2.5.4. Synthesis of final compounds 3a and 2f-j 
(1S)-2-Bromo-1-[(phosphonooxy)methyl]ethyl 10-phenyldecanoate, 3a 
Thoroughly dried diethyl phosphate 49 (76 mg, 0.17 mmol, 1 equiv) was dissolved 
in anhydrous dichloromethane (2 mL) and TMSBr (0.22 mL, 1.66 mmol, 10 equiv) was 
added dropwise at room temperature. The reaction mixture was stirred for 4 h at room 
temperature, after which the solvent was evaporated at reduced pressure and the 
crude was dissolved in 95% methanol in water (5 mL) and stirred for an additional 
hour. Evaporation of the solvent afforded compound 3a in 90% yield.  
The specific rotation value agrees with that obtained for compound (S)-3a, 
confirming the S configuration of the chiral center. 
 
IR (ATR): 3360 (O-H); 1738 (C=O), 1199 (P=O); 1025 (P-OH) 
1H-NMR (methanol-d4, 500 MHz):  1.32 (m, 10H, 5CH2); 1.60-1.65 (m, 4H, 2CH2); 
2.37 (t, J = 7.3, 2H, CH2CO); 2.59 (t, J = 7.6, 2H, PhCH2); 3.58 (dd, J = 10.9, 5.9, 1H, 
½CH2Br); 3.66 (dd, J = 10.9, 4.9, 1H, ½CH2Br); 4.12-4.18 (m, 2H, CH2OP); 5.14-5.19 
(m, 1H, CH); 7.11-7.17 (m, 3H, 3CHAr); 7.23 (t, J = 7.5, 2H, 2CHAr) 
13C-NMR (methanol-d4, 125 MHz):  26.0, 30.1, 30.3, 30.31 (4CH2); 30.5 (2CH2); 30.8 
(CH2Br); 32.7 (CH2); 34.9 (CH2CO); 36.9 (PhCH2); 66.3 (d, J = 5.0, CH2OP); 72.5 (d, 
J = 8.3, CH); 126.6 (CHAr); 129.2 (2CHAr); 129.4 (2CHAr); 144.0 (CAr); 174.3 (CO) 
31P-NMR (methanol-d4, 121 MHz):  3.10 
[α]D20: +4.9 (c = 0.50, methanol) 
HRMS (ESI, m/z): calculated for C19H2979BrO6P ([M(79Br)-H]-: 463.0891, found: 
463.0902; calculated for C19H2981BrO6P ([M(81Br)-H]-: 465.0870, found: 465.0880 
HPLC (method B, tR, min): 26.05 
(2R)-2-Hydroxy-3-(phosphonooxy)propyl 8-phenyloctanoate, 2f 
Following the general procedure 4.2.1.1., compound 2f was obtained from 
dibenzyl phosphate 52 (63 mg, 0.11 mmol) at room temperature in 80% yield.  
 
IR (ATR): 1737 (C=O); 1027 (P-O) 
1H-NMR (methanol-d4, 300 MHz):  1.33 (app s, 6H, 3CH2); 1.58-1.60 (m, 4H, 2CH2); 
2.27-2.37 (m, 2H, CH2CO); 2.59 (t, J = 7.5, 2H, PhCH2); 3.59-3.61 (m, 3H, CH, 
CH2OP); 3.99-4.41 (m, 2H, CO2CH2); 7.10-7.16 (m, 3H, 3CHAr); 7.21-7.26 (m, 2H, 
2CHAr) 
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13C-NMR (methanol-d4, 75 MHz):  25.9, 30.07, 30.1, 30.2, 32.6 (5CH2); 34.8 
(CH2CO); 36.9 (PhCH2); 65.8 (CO2CH2); 68.1 (d, J = 5.0, CH2OP); 69.3 (br s, CH); 
126.6 (CHAr); 129.2 (2CHAr); 129.4 (2CHAr); 143.9 (CAr); 175.3 (CO) 
31P-NMR (methanol-d4, 121 MHz):  3.04 
[α]D20: +2.8 (c = 1.58, methanol) 
HRMS (ESI, m/z): calculated for C17H26O7P ([M-H]-): 373.1422, found: 373.1432 
HPLC (method A, tR, min): 8.07  
(2R)-2-Hydroxy-3-(phosphonooxy)propyl 9-phenylnonanoate, 2g 
Following the general procedure 4.2.1.1., compound 2g was obtained from 
dibenzyl phosphate 53 (90 mg, 0.16 mmol) at room temperature in 99% yield.  
 
IR (ATR): 3355 (O-H); 1737 (C=O); 1259 (P=O); 1029 (P-O) 
1H-NMR (methanol-d4, 300 MHz):  1.32 (app s, 8H, 4CH2); 1.60 (br s, 4H, 2CH2); 
2.34 (t, J = 7.4, 2H, CH2CO); 2.59 (t, J = 7.8, 2H, PhCH2); 3.67-3.79 (m, 1H, CH); 
3.98-4.00 (m, 2H, CH2OP); 4.07-4.21 (m, 2H, CO2CH2); 7.09-7.17 (m, 3H, 3CHAr); 
7.21-7.26 (m, 2H, 2CHAr) 
13C-NMR (methanol-d4, 75 MHz):  25.9, 30.1, 30.2, 30.3, 30.4, 32.7 (6CH2); 34.8 
(CH2CO); 36.9 (PhCH2); 65.8 (CO2CH2); 68.1 (d, J = 6.0, CH2OP); 69.3 (d, J = 8.3, 
CH); 126.6 (CHAr); 129.2 (2CHAr); 129.4 (2CHAr); 143.9 (CAr); 175.3 (CO) 
31P-NMR (methanol-d4, 121 MHz):  3.05 
[α]D20: +2.5 (c = 1.13, methanol) 
HRMS (ESI, m/z): calculated for C18H28O7P ([M-H]-): 387.1578, found: 387.1591 
HPLC (method A, tR, min): 8.34 
(2R)-2-Hydroxy-3-(phosphonooxy)propyl 10-phenyldecanoate, 2h 
Following the general procedure 4.2.1.1., compound 2h was obtained from 
dibenzyl phosphate 54 (20 mg, 34 µmol) at room temperature in 80% yield.  
 
IR (ATR): 1739 (C=O); 1051 (P-OH) 
1H-NMR (methanol-d4, 500 MHz):  1.29-1.32 (m, 10H, 5CH2); 1.61 (m, 4H, 2CH2); 
2.35 (t, J = 7.5, 2H, CH2CO); 2.59 (t, J = 7.6, 2H, PhCH2); 3.96-4.01 (m, 3H, CH, 
CH2OP); 4.11 (dd, J = 11.3, 5.3, 1H, ½CO2CH2); 4.17 (dd, J = 11.3, 4.1, 1H, 
½CO2CH2); 7.11-7.16 (m, 3H, 3CHAr); 7.23 (t, J = 7.5, 2H, 2CHAr) 
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13C-NMR (methanol-d4, 125 MHz):  26.0, 30.2, 30.3, 30.34 (4CH2); 30.5 (2CH2); 32.7 
(CH2); 34.9 (CH2CO); 36.9 (PhCH2); 65.9 (CO2CH2); 68.1 (d, J = 5.7, CH2OP); 69.4 
(d, J = 8.1, CH); 126.6 (CHAr); 129.2 (2CHAr); 129.4 (2CHAr); 144.0 (CAr); 175.4 (CO) 
31P-NMR (methanol-d4, 202 MHz):  3.14 
[α]D20: +2.3 (c = 0.40, methanol) 
HRMS (ESI, m/z): calculated for C19H30O7P ([M-H]-): 401.1735, found: 401.1734 
HPLC (method B, tR, min): 24.37 
(2R)-2-Hydroxy-3-(phosphonooxy)propyl 11-phenylundecanoate, 2i 
Following the general procedure 4.2.1.1., compound 2i was obtained from 
dibenzyl phosphate 55 (5 mg, 8 µmol) at room temperature in 82% yield.  
 
IR (ATR): 3387 (O-H); 1739 (C=O); 1262 (P=O); 1014 (P-OH) 
1H-NMR (methanol-d4, 300 MHz):  1.26-1.32 (m, 12H, 6CH2); 1.53-1.68 (m, 4H, 
2CH2); 2.35 (t, J = 7.5, 2H, CH2CO); 2.59 (t, J = 7.7, 2H, PhCH2); 3.69-3.74 (m, 1H, 
CH); 3.98-4.02 (m, 2H, CH2OP); 4.08-4.16 (m, 2H, CO2CH2); 7.10-7.16 (m, 3H, 
3CHAr); 7.21-7.26 (m, 2H, 2CHAr) 
13C-NMR (methanol-d4, 75 MHz):  25.8, 30.2, 30.3, 30.4, 30.55, 30.56, 30.7, 32.8 
(8CH2); 34.9 (CH2CO); 36.9 (PhCH2); 65.8 (CO2CH2); 68.1 (d, J = 5.6, CH2OP); 69.3 
(d, J = 8.9, CH); 126.6 (CHAr); 129.2 (2CHAr); 129.4 (2CHAr); 144.0 (CAr); 175.3 (CO) 
31P-NMR (methanol-d4, 121 MHz):  3.07 
[α]D20: +0.2 (c = 0.32, methanol) 
HRMS (ESI, m/z): calculated for C20H32O7P ([M-H]-): 415.1891, found: 415.1906 
(2R)-2-Hydroxy-3-(phosphonooxy)propyl 15-phenylpentadecanoate, 2j 
Following the general procedure 4.2.1.1., compound 2j was obtained from 
dibenzyl phosphate 56 (20 mg, 31 µmol) at room temperature in 90% yield.  
 
IR (ATR): 1738 (C=O); 1259 (P=O); 1083 (P-OH) 
1H-NMR (methanol-d4, 300 MHz):  1.28-1.32 (m, 20H, 10CH2); 1.57-1.64 (m, 4H, 
2CH2); 2.35 (t, J = 7.4, 2H, CH2CO); 2.59 (t, J = 7.5, 2H, PhCH2); 3.97-4.35 (m, 5H, 
CO2CH2, CH, CH2OP); 7.08-7.16 (m, 3H, 3CHAr); 7.21-7.26 (m, 2H, 2CHAr) 
13C-NMR (methanol-d4, 75 MHz):  26.0, 30.2, 30.3, 30.4, 30.59, 30.6, 30.7 (7CH2); 
30.73 (2CH2); 30.75 (2CH2); 32.8 (CH2); 34.9 (CH2CO); 36.9 (PhCH2); 64.9 (CO2CH2); 
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67.1 (d, J = 5.3, CH2OP); 68.3 (d, J = 8.3, CH); 126.6 (CHAr); 129.2 (2CHAr); 129.4 
(2CHAr); 144.0 (CAr); 175.4 (CO) 
31P-NMR (methanol-d4, 121 MHz):  3.11 
[α]D20: +4.2 (c = 0.40, methanol) 
HRMS (ESI, m/z): calculated for C24H40O7P ([M-H]-): 471.2517, found: 471.2520 
HPLC (method B, tR, min): 33.42 
4.2.6. Synthesis of final compounds (S)- and (R)-3a 
4.2.6.1. Synthesis of bromoalcohols (S)- and (R)-58 
Dibenzyl (2R)-oxiran-2-ylmethyl phosphate, (R)-57  
Following the general procedure 4.2.1.13., compound (R)-57 was obtained from 
(2S)-oxiran-2-ylmethanol (0.3 mL, 4.52 mmol) and dibenzyl-N,N-
diisopropylphosphoramidite (3.04 mL, 9.04 mmol) in 76% yield. Chromatography: 
dichloromethane to dichloromethane/ethyl acetate, 20:1. 
 
Rf: 0.35 (hexane/ethyl acetate, 1:1) 
IR (ATR): 1275 (P=O); 1013 (P-O) 
1H-NMR (CDCl3, 300 MHz):  2.59 (dd, J = 4.8, 2.6, 1H, ½CH2 epox); 2.78 (t, J = 4.7, 
1H, ½CH2 epox); 3.04-3.25 (m, 1H, CH); 3.89 (ddd, J = 11.7, 8.5, 5.9, 1H, ½CH2OP); 
4.12-4.27 (m, 1H, ½CH2OP); 4.97-5.15 (m, 4H, 2PhCH2); 7.35 (app s, 10H, 10CHAr) 
13C-NMR (CDCl3, 75 MHz):  44.7 (CH2 epox); 50.0 (d, J = 8.0, CH); 68.1 (d, J = 5.5, 
CH2OP); 69.6 (d, J = 5.3, PhCH2); 69.61 (d, J = 5.5, PhCH2); 128.1 (4CHAr); 128.7 
(6CHAr); 135.8 (d, J = 6.8, 2CAr) 
31P-NMR (CDCl3, 121 MHz):  2.03 
[α]D20: -8.8 (c = 1.00, methanol) 
MS (ESI, m/z): 335.9 [M+H]+ 
Dibenzyl (2S)-oxiran-2-ylmethyl phosphate, (S)-57 
Following the general procedure 4.2.1.13., compound (S)-57 was obtained from 
(2R)-oxiran-2-ylmethanol (250 mg, 3.37 mmol) and dibenzyl-N,N-
diisopropylphosphoramidite (2.33 g, 6.75 mmol) in 95% yield. Chromatography: 
dichloromethane to dichloromethane/ethyl acetate, 9:1. The spectroscopic data are 
in agreement with those reported for (R)-57. 
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[α]D20: +1.2 (c = 1.20, methanol) 
Dibenzyl (2S)-3-bromo-2-hydroxypropyl phosphate, (S)-58 
Following the general procedure 4.2.1.16., bromoalcohol (S)-58 was obtained 
from oxirane (R)-57 (990 mg, 2.96 mmol) in 89% yield.  
 
Rf: 0.41 (dichloromethane/ethyl acetate, 10:1) 
IR (ATR): 3371 (O-H); 1009 (P=O) 
1H-NMR (CDCl3, 300 MHz):  2.96 (br s, 1H, OH); 3.36 (d, J = 5.7, 2H, CH2Br); 3.88-
3.95 (m, 1H, CH); 4.06-4.12 (m, 2H, CH2OP); 5.00-5.12 (m, 4H, 2PhCH2); 7.36 (app 
s, 10H, 10CHAr) 
13C-NMR (CDCl3, 75 MHz):  33.3 (CH2Br); 69.2 (d, J = 6.0, CH2OP); 69.7 (d, J = 6.6, 
CH); 70.3 (d, J = 5.8, PhCH2); 70.4 (d, J = 5.6, PhCH2); 128.3 (4CHAr); 128.9 (4CHAr); 
129.1 (2CHAr); 135.3 (d, J = 6.3, 2CAr) 
31P-NMR (CDCl3, 121 MHz):  2.48 
[α]D20: -2.1 (c = 1.44, methanol) 
MS (ESI, m/z): 414.8 [M(79Br)+H]+; 416.8 [M(81Br)+H]+ 
Dibenzyl (2R)-3-bromo-2-hydroxypropyl phosphate, (R)-58 
Following the general procedure 4.2.1.16., bromoalcohol (R)-58 was obtained 
from oxirane (S)-57 (1 g, 2.99 mmol) in 99% yield. The spectroscopic data are in 
agreement with those reported for (S)-58. 
 
[α]D20: +2.2 (c = 0.69, methanol) 
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4.2.6.2. Synthesis of esters (S)- and (R)-59 
(1S)-2-{[Bis(benzyloxy)phosphoryl]oxy}-1-(bromomethyl)ethyl 10-phenyl 
decanoate, (S)-59 
Following the general procedure 4.2.1.17., ester (S)-59 was obtained from carboxylic 
acid 46 (65 mg, 0.26 mmol) and bromoalcohol (S)-58 (109 mg, 0.26 mmol) in 68% 
yield. Chromatography: hexane to hexane/ethyl acetate, 6:4. 
 
Rf: 0.66 (hexane/ethyl acetate, 7:3) 
IR (ATR): 1741 (C=O); 1274 (P=O); 1012 (P-O) 
1H-NMR (methanol-d4, )(300 MHz):  1.22-1.34 (m, 10H, 5CH2); 1.52-1.63 (m, 4H, 
2CH2); 2.28 (dt, J = 7.4, 2.0, 2H, CH2CO); 2.58 (t, J = 7.6, 2H, CH2Ph); 3.48 (ABX 
system, J = 11.0, 6.0, 5.4, 2H, CH2Br); 4.17 (m, 2H, CH2OP); 5.00-5.09 (m, 4H, 
2OCH2Ph); 5.10-5.17 (m, 1H, CH); 7.10-7.16 (m, 3H, 3CHAr); 7.21-7.26 (m, 2H, 
2CHAr); 7.33-7.39 (m, 10H, 10CHAr) 
13C-NMR (methanol-d4, )(75 MHz):  25.9, 30.0, 30.1, 30.25, 30.29, 30.46, 30.49 
(7CH2); 32.7 (CH2Br); 34.9 (CH2CO); 36.9 (PhCH2); 67.9 (d, J = 5.5, CH2OP); 71.0 (d, 
J = 5.9, 2OCH2Ph); 72.1 (d, J = 7.3, CH); 126.6 (CHAr); 129.2 (6CHAr); 129.4 (2CHAr); 
129.7 (4CHAr); 129.8 (2CHAr); 137.0 (d, J = 6.8, 2CAr); 143.8 (CAr); 174.1 (CO) 
31P-NMR (methanol-d4, 121 MHz):  1.45 
[α]D20: +0.6 (c = 0.92, methanol) 
MS (ESI, m/z): 432.0 [M(79Br)-2OCH2Ph]+; 434.0 [M(81Br)-2OCH2Ph]+ 
(1R)-2-{[Bis(benzyloxy)phosphoryl]oxy}-1-(bromomethyl)ethyl 10-phenyl 
decanoate, (R)-59 
Following the general procedure 4.2.1.17., ester (R)-59 was obtained from 
carboxylic acid 46 (65 mg, 0.26 mmol) and bromoalcohol (R)-58 (109 mg, 0.26 mmol) 
in 73% yield. Chromatography: hexane to hexane/ethyl acetate, 6:4. The 
spectroscopic data are in agreement with those reported for (S)-59. 
 
[α]D20: -0.1 (c = 1.40, methanol) 
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4.2.6.3. Synthesis of final compounds (S)- and (R)-3a 
 (1S)-2-Bromo-1-[(phosphonooxy)methyl]ethyl 10-phenyldecanoate, (S)-3a 
Following the general procedure 4.2.1.1., compound (S)-3a was obtained from 
dibenzyl phosphate (S)-59 (50 mg, 0.08 mmol) at room temperature in 99% yield. The 
spectroscopic data are in agreement with those reported for 3a. 
 
[α]D20: +4.8 (c = 0.50, methanol) 
(1R)-2-Bromo-1-[(phosphonooxy)methyl]ethyl 10-phenyldecanoate, (R)-3a 
Following the general procedure 4.2.1.1., compound (R)-3a was obtained from 
dibenzyl phosphate (R)-59 (69 mg, 0.11 mmol) at room temperature in 97% yield. The 
spectroscopic data are in agreement with those reported for its enantiomer (S)-3a. 
 
[α]D20: -4.6 (c = 0.50, methanol) 
4.2.7. Synthesis of final compounds 3b-d 
4.2.7.1. Synthesis of bromoalcohol 63 
Di-tert-butyl (2R)-oxiran-2-ylmethyl phosphate, 62 
Following the general procedure 4.2.1.13., compound 62 was obtained from (2S)-
oxiran-2-ylmethanol (0.18 mL, 2.69 mmol) and di-tert-butyl N,N-
diisopropylphosphoramidite (1.7 mL, 5.39 mmol) in 52% yield. Chromatography: 
hexane to ethyl acetate.  
 
Rf: 0.5 (hexane/ethyl acetate, 1:1) 
IR (ATR): 1263 (P=O); 999 (P-O) 
1H-NMR (CDCl3, 300 MHz):  1.48 (s, 9H, 3CH3); 1.49 (s, 9H, 3CH3); 2.66 (dd, J = 
4.7, 2.6, 1H, ½CH2 epox); 2.83 (t, J = 4.7, 1H, ½CH2 epox); 3.21-3.27 (m, 1H, CH); 3.85-
3.94 (m, 1H, ½CH2OP); 4.10-4.18 (m, 1H, ½CH2OP) 
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13C-NMR (CDCl3, 75 MHz):  29.9 (3CH3); 30.0 (3CH3); 44.9 (CH2 epox); 50.3 (d, J = 
9.0, CH); 67.4 (d, J = 5.8, CH2OP); 82.8 (d, J = 7.4, C); 82.83 (d, J = 7.4, C) 
31P-NMR (CDCl3, 121 MHz):  -6.90 
[α]D20: -9.2 (c = 1.02, methanol) 
MS (ESI, m/z): 289.0 [M+Na]+ 
(2S)-3-Bromo-2-hydroxypropyl di-tert-butyl phosphate, 63 
Following the general procedure 4.2.1.16., bromoalcohol 63 was obtained from 
oxirane 62 (210 mg, 0.79 mmol) in 95% yield.  
 
Rf: 0.37 (hexane/ethyl acetate, 1:1) 
IR (ATR): 3342 (O-H); 1251 (P=O); 996 (P-O) 
1H-NMR (CDCl3, 300 MHz):  1.50 (s, 18H, 6CH3); 3.49 (d, J = 6.0, 2H, CH2Br); 4.00-
4.06 (m, 1H, CH); 4.12-4.17 (m, 2H, CH2OP); 6.34 (br s, 1H, OH) 
13C-NMR (CDCl3, 75 MHz):  29.9 (3CH3); 30.0 (3CH3); 33.4 (CH2Br); 68.5 (d, J = 6.3, 
CH2OP); 70.1 (d, J = 6.2, CH); 84.5 (d, J = 7.4, C); 84.53 (d, J = 7.4, C) 
31P-NMR (CDCl3, 121 MHz):  -7.05  
[α]D20: +3.2 (c = 1.11, methanol) 
MS (ESI, m/z): 369.0 [M(79Br)+Na)]+; 371.0 [M(81Br)+Na)]+ 
4.2.7.2. Synthesis of esters 60, 61, and 64 
(1S)-2-{[Bis(benzyloxy)phosphoryl]oxy}-1-(bromomethyl)ethyl 9-phenyl 
nonanoate, 60 
Following the general procedure 4.2.1.17., ester 60 was obtained from carboxylic 
acid 45 (122 mg, 0.52 mmol) and bromoalcohol (S)-58 (216 mg, 0.52 mmol) in 96% 
yield. Chromatography: dichloromethane to dichloromethane/ethyl acetate, 9:1. 
 
Rf: 0.90 (dichloromethane/ethyl acetate, 10:1) 
IR (ATR): 1741 (C=O); 1269 (P=O); 1015 (P-O) 
1H-NMR (methanol-d4, 300 MHz):  1.27-1.28 (m, 8H, 4CH2); 1.52-1.63 (m, 4H, 
2CH2); 2.28 (dt, J = 7.5, 1.8, 2H, CH2CO); 2.57 (t, J = 7.5, 2H, PhCH2); 3.47 (ABX 
system, J = 11.1, 6.0, 5.3, 2H, CH2Br); 4.17 (m, 2H, CH2OP); 5.04 (d, J = 2.8, 2H, 
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OCH2Ph); 5.07 (d, J = 2.9, 2H, OCH2Ph); 5.10-5.17 (m, 1H, CH); 7.10-7.15 (m, 3H, 
3CHAr); 7.21-7.26 (m, 2H, 2CHAr); 7.31-7.39 (app s, 10H, 10CHAr)  
13C-NMR (methanol-d4, 75 MHz):  24.9, 29.0, 29.1, 29.2, 29.3, 29.4 (6CH2); 31.7 
(CH2Br); 33.9 (CH2CO); 35.9 (PhCH2); 66.9 (d, J = 5.5, CH2OP); 70.0 (d, J = 5.9, 
2OCH2Ph); 71.1 (d, J = 7.6, CH); 125.6 (CHAr); 128.2 (4CHAr); 128.3 (2CHAr); 128.4 
(2CHAr); 128.8 (4CHAr); 128.9 (2CHAr); 135.95, 136.0, 143.0 (3CAr); 173.1 (CO) 
31P-NMR (methanol-d4, 121 MHz):  1.47 
[α]D20: +0.6 (c = 0.92, methanol) 
MS (ESI, m/z): 631.2 [M(79Br)+H]+; 633.2 [M(81Br)+H]+ 
(1S)-2-{[Bis(benzyloxy)phosphoryl]oxy}-1-(bromomethyl)ethyl 11-phenyl 
undecanoate, 61 
Following the general procedure 4.2.1.17., ester 61 was obtained from 11-
phenylundecanoic acid (79 mg, 0.30 mmol) and bromoalcohol (S)-58 (125 mg, 0.30 
mmol) in 55% yield. Chromatography: dichloromethane to dichloromethane/ethyl 
acetate, 9:1. 
 
Rf: 0.50 (dichloromethane/ethyl acetate, 10:1) 
IR (ATR): 1742 (C=O); 1282 (P=O); 1012 (P-O) 
1H-NMR (methanol-d4, )(300 MHz):  1.26-1.29 (m, 12H, 6CH2); 1.52-1.63 (m, 4H, 
2CH2); 2.29 (dt, J = 7.3, 2.0, 2H, CH2CO); 2.58 (t, J = 7.6, 2H, PhCH2); 3.48 (ABX 
system, J = 11.0, 5.9, 5.4, 2H, CH2Br); 4.17 (m, 2H, CH2OP); 5.04 (d, J = 2.8, 2H, 
OCH2Ph); 5.07 (d, J = 2.7, 2H, OCH2Ph); 5.13 (qt, J = 4.9, 1H, CH); 7.10-7.16 (m, 3H, 
3CHAr); 7.21-7.26 (m, 2H, 2CHAr); 7.35-7.39 (app s, 10H, 10CHAr) 
13C-NMR (methanol-d4, )(75 MHz):  25.9 (CH2); 30.1 (2CH2); 30.29, 30.31, 30.5, 
30.54, 30.6 (5CH2); 32.8 (CH2Br); 34.9 (CH2CO); 36.9 (PhCH2); 67.9 (d, J = 6.0, 
CH2OP); 71.06 (d, J = 5.9, OCH2Ph); 71.07 (d, J = 6.0, OCH2Ph); 72.1 (d, J = 7.6, 
CH); 126.6 (CHAr); 129.2 (6CHAr); 129.4 (2CHAr); 129.7 (4CHAr); 129.9 (2CHAr); 137.0, 
137.1, 144.0 (3CAr); 174.2 (CO) 
31P-NMR (methanol-d4, 121 MHz):  1.44 
[α]D20: -2.3 (c = 0.59, methanol) 
MS (ESI, m/z): 659.2 [M(79Br)+H]+; 661.2 [M(81Br)+H]+ 
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(1S)-2-Bromo-1-{[(di-tert-butoxyphosphoryl)oxy]methyl}ethyl (9Z)-octadec-9-
enoate, 64 
To a stirred solution of bromoalcohol 63 (80 mg, 0.23 mmol, 1.1 equiv) in 1.5 mL 
of anhydrous dichloromethane at room temperature, pyridine (34 µL, 0.42 mmol, 2 
equiv) was added, followed by oleoyl chloride (69 µL, 0.21 mmol, 1 equiv). The 
reaction mixture was stirred overnight at room temperature. Afterward, the reaction 
mixture was concentrated under reduced pressure and purified by flash 
chromatography (alumina, hexane to hexane/ethyl acetate, 10:1) to afford pure ester 
64 in 15% yield. 
 
Rf: 0.64 (dichloromethane/ethyl acetate, 20:1) 
IR (ATR): 1744 (C=O); 1002 (P-O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.5, 3H, CH3); 1.18-1.39 (m, 20H, 10CH2); 
1.49 (s, 18H, 6CH3); 1.57-1.71 (m, 2H, CH2); 1.95-2.06 (m, 4H, 2CH2CHalkene); 2.35 (t, 
J = 7.7, 2H, CH2CO); 3.52 (dd, J = 10.9, 5.2, 1H, ½CH2Br); 3.61 (dd, J = 10.9, 5.4, 
1H, ½CH2Br); 4.05-4.20 (m, 2H, CH2OP); 5.15 (qt, J = 5.2, 1H, CH); 5.27-5.43 (m, 
2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8, 25.0 (2CH2); 27.3, 27.4 (2CH2CHalkene); 
29.2, 29.24, 29.3 (3CH2); 29.5 (2CH2); 29.7, 29.8, 29.9 (3CH2); 29.95 (3CH3); 30.0 
(3CH3); 30.1 (CH2Br); 32.1 (CH2); 34.3 (CH2CO); 65.1 (d, J = 5.9, CH2OP); 70.7 (d, J 
= 9.3, CH); 83.0 (d, J = 7.4, C); 83.05 (d, J = 7.4, C); 129.9, 130.2 (2CHalkene); 172.9 
(CO) 
31P-NMR (CDCl3, 121 MHz):  -7.14 
[α]D20: +4.9 (c = 0.66, methanol) 
MS (ESI, m/z): 633.3 [M(79Br)+Na]+; 635.3 [M(81Br)+Na]+ 
4.2.7.3. Synthesis of final compounds 3b-d 
(1S)-2-Bromo-1-[(phosphonooxy)methyl]ethyl 9-phenylnonanoate, 3b 
Following the general procedure 4.2.1.1., compound 3b was obtained from 
dibenzyl phosphate 60 (249 mg, 0.39 mmol) at room temperature in 80% yield.  
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Rf: 0.51 (dichloromethane/ethyl acetate, 10:1) 
IR (ATR): 3320 (O-H); 1021 (P-OH) 
1H-NMR (methanol-d4, 300 MHz):  1.33 (app s, 8H, 4CH2); 1.59-1.66 (m, 4H, 2CH2); 
2.38 (t, J = 7.4, 2H, CH2CO); 2.60 (t, J = 7.7, 2H, PhCH2); 3.63 (ABX system, J = 11.0, 
6.0, 4.9, 2H, CH2Br); 4.14 (app t, J = 5.9, 2H, CH2OP); 5.17 (qt, J = 5.2, 1H, CH); 
7.10-7.17 (m, 3H, 3CHAr); 7.22-7.27 (m, 2H, 2CHAr) 
13C-NMR (methanol-d4, 75 MHz):  24.9, 29.1, 29.2, 29.3, 29.4, 29.7 (6CH2); 31.7 
(CH2Br); 33.9 (CH2CO); 35.9 (PhCH2); 65.3 (d, J = 5.1, CH2OP); 71.5 (d, J = 8.3, CH); 
125.6 (CHAr); 128.2 (2CHAr); 128.4 (2CHAr); 143.0 (CAr); 173.3 (CO) 
31P-NMR (methanol-d4, 121 MHz):  2.76 
[α]D20: +0.95 (c = 0.57, methanol) 
HRMS (ESI, m/z): calculated for C18H2779BrO6P ([M(79Br)-H]-): 449.0807, found: 
449.0465; calculated for C18H2781BrO6P ([M(81Br)-H]-): 451.0786, found: 451.0611 
HPLC (method A, tR, min): 9.42 
(1S)-2-Bromo-1-[(phosphonooxy)methyl]ethyl 11-phenylundecanoate, 3c 
Following the general procedure 4.2.1.1., compound 3c was obtained from 
dibenzyl phosphate 61 (48 mg, 73 µmol) at room temperature in 72% yield. 
 
Rf: 0.46 (dichloromethane/ethyl acetate, 10:1) 
IR (ATR): 3336 (O-H); 1689 (C=O); 1251 (P=O); 1171 (P-OH) 
1H-NMR (methanol-d4, 300 MHz):  1.26-1.36 (m, 12H, 6CH2); 1.56-1.68 (m, 4H, 
2CH2); 2.37 (t, J = 7.3, 2H, CH2CO); 2.59 (t, J = 7.6, 2H, PhCH2); 3.62 (ABX system, 
J = 10.9, 6.0, 4.8, 2H, CH2Br); 4.13 (app t, J = 5.0, 2H, CH2OP); 5.16 (qt, J = 5.1, 1H, 
CH); 7.10-7.16 (m, 3H, 3CHAr); 7.21-7.26 (m, 2H, 2CHAr) 
13C-NMR (methanol-d4, 75 MHz):  26.0, 30.1, 30.3, 30.4, 30.5, 30.55, 30.62, 30.8 
(8CH2); 32.8 (CH2Br); 34.9 (CH2CO); 36.9 (PhCH2); 66.3 (d, J = 4.9, CH2OP); 72.5 (d, 
J = 8.8, CH); 126.6 (CHAr); 129.2 (2CHAr); 129.4 (2CHAr); 144.0 (CAr); 174.3 (CO) 
31P-NMR (methanol-d4, 121 MHz):  2.82 
[α]D20: -7.8 (c = 0.81, methanol) 
HRMS (MALDI, m/z): calculated for C20H32Na79BrO6P ([M(79Br)+Na]+): 501.1018, 
found: 501.1002; calculated for C20H32Na81BrO6P ([M(81Br)+Na]+): 503.0997, found: 
503.1019 
HPLC (method A, tR, min): 10.06 
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(1S)-2-Bromo-1-[(phosphonooxy)methyl]ethyl (9Z)-octadec-9-enoate, 3d 
Following the general procedure 4.2.1.8., compound 3d was obtained from di-
tert-butyl phosphate 64 (5 mg, 8.17 µmol) and TFA (15 µL, 204 µmol) without further 
purification in 81% yield.  
 
IR (ATR): 1739 (C=O); 1666 (C=C); 1071 (P-O) 
1H-NMR (methanol-d4, 700 MHz):  0.90 (t, J = 7.0, 3H, CH3); 1.28-1.35 (m, 20H, 
10CH2); 1.62-1.65 (m, 2H, CH2CH2CO); 2.02-2.05 (m, 4H, 2CH2CHalkene); 2.37 (td, J 
= 7.4, 3.2, 2H, CH2CO); 3.60 (dd, J = 11.0, 6.1, 1H, ½CH2Br); 3.68 (dd, J = 11.0, 4.6, 
1H, ½CH2Br); 4.07-4.12 (m, 2H, CH2OP); 5.14-5.18 (m, 1H, CH); 5.32-5.37 (m, 2H, 
2CHalkene) 
13C-NMR (methanol-d4, 175 MHz):  14.5 (CH3); 23.8, 26.0 (2CH2); 28.1 
(2CH2CHalkene); 30.1, 30.2, 30.3, 30.4, 30.5, 30.6, 30.8, 30.9, 31.1, 33.1 (10CH2); 35.0 
(CH2CO); 66.0 (d, J = 3.1, CH2OP); 72.8 (d, J = 5.5, CH); 130.8, 130.9 (2CHalkene); 
174.4 (CO) 
31P-NMR (methanol-d4, 202 MHz):  3.36 
[α]D20: +3.3 (c = 0.33, methanol) 
HRMS (ESI, m/z): calculated for C21H3979BrO6P ([M(79Br)-H]-): 497.1673, found: 
497.1664; calculated for C21H3981BrO6P ([M(81Br)-H]-): 499.1653, found: 499.1642 
HPLC (method B, tR, min): 25.58 
4.2.8. Synthesis of final compounds 4a-e 
4.2.8.1. Synthesis of alcohol 68 
(2S)-2-[(Benzyloxy)methyl]oxirane, 65 
To a suspension of NaH (65 mg, 1.62 mmol, 1.2 equiv, 60% dispersion in oil) in 
anhydrous DMF (3 mL) at 0ºC under an argon atmosphere, (2R)-oxiran-2-ylmethanol 
(100 mg, 1.35 mmol, 1 equiv) was added, followed by benzyl bromide (0.21 mL, 1.76 
mmol, 1.3 equiv). The reaction was allowed to warm up to room temperature and 
stirred overnight. Afterward, water was added and the mixture was extracted with 
dichloromethane. The organic layer was washed with water and brine, dried over 
Na2SO4, filtered and concentrated under reduced pressure to afford product 65 in 
quantitative yield, which was used in the next step without further purification. 
Spectroscopic data correspond with those previously reported.107  
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1H-NMR (CDCl3, 300 MHz):  2.62 (dd, J = 5.0, 2.7, 1H, ½CH2 epox); 2.81 (dd, J = 4.9, 
4.1, 1H, ½CH2 epox); 3.17-3.22 (m, 1H, CH); 3.45 (dd, J = 11.4, 5.8, 1H, ½CH2O); 3.77 
(dd, J = 11.4, 3.0, 1H, ½CH2O); 4.56 (d, J = 11.9, 1H, ½OCH2Ph); 4.62 (d, J = 11.9, 
1H, ½OCH2Ph); 7.27-7.39 (m, 5H, 5CHAr) 
tert-Butyl (5S)-5-((benzyloxy)methyl)-2-oxotetrahydrofuran-3-carboxylate, 66 
Di-tert-butyl malonate (0.97 mL, 1.58 mmol, 2 equiv) was added dropwise to a 
stirred suspension of NaH (63 mg, 1.58 mmol, 2 equiv, 60% dispersion in oil) in a 2:1 
mixture of anhydrous DMF:THF (6 mL) at 0°C, and the mixture was stirred at room 
temperature for 30 min under an argon atmosphere. A solution of 65 (130 mg, 0.79 
mmol, 1 equiv) in dry THF (2 mL) was then added, and the resulting mixture was 
stirred at 80°C for 6 h. After cooling to room temperature, the reaction was quenched 
by addition of a saturated aqueous solution of NH4Cl, diluted with water, and extracted 
with ethyl acetate. The organic phase was washed with brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. The residue was purified by flash 
chromatography (dichloromethane) to afford lactone 66 in 62% yield.  
 
Rf: 0.36 (hexane/ethyl acetate, 9:1) 
IR (ATR): 1777 (C=O); 1729 (C=O); 1147 (C-O) 
1H-NMR (CDCl3, 300 MHz): Mixture of diastereoisomers A:B (3:2):  1.48 (s, 9H, 3CH3 
B); 1.49 (s, 9H, 3CH3 A); 2.36 (ABX system, J = 13.0, 9.7, 4.7, 2H, CH2CHCO2tBu B); 
2.42-2.49 (m, 1H, ½CH2CHCO2tBu A); 2.60-2.70 (m, 1H, ½CH2CHCO2tBu A); 3.47-
3.71 (m, 3H, CHCO2tBu, OCH2CH); 4.50-4.65 (m, 3H, PhCH2, OCH2CH B); 4.71-4.78 
(m, 1H, OCH2CH A); 7.26-7.38 (m, 5H, 5CHAr) 
13C-NMR (CDCl3, 75 MHz): Mixture of diastereoisomers A:B (3:2):  28.0 (3CH3); 28.3 
(CH2CHCO2tBu B); 28.5 (CH2CHCO2tBu A); 47.6 (CHCO2tBu B); 47.8 (CHCO2tBu A); 
71.2 (PhCH2); 73.6 (OCH2CH B); 73.7 (OCH2CH A); 77.7 (OCH2CH B); 77.8 (OCH2CH 
A); 82.8 (CA); 82.9 (CB); 127.7 (2CHAr A); 127.8 (2CHAr B); 127.9 (CHAr B); 128.0 (CHAr 
A); 128.6 (2CHAr B); 128.62 (2CHAr A); 137.6 (CAr A); 137.7 (CAr B); 166.8 (CO2tBu B); 
167.3 (CO2tBu A); 171.9 (COlactone B); 172.6 (COlactone A) 
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tert-Butyl (5S)-5-[(benzyloxy)methyl]-3-fluoro-2-oxotetrahydrofuran-3-
carboxylate, 67 
Following the general procedure 4.2.1.5., compound 67 was obtained from 
lactone 66 (1.70 g, 5.54 mmol) in 99% yield, and it was used in the next step without 
further purification.  
 
Rf: 0.80 (dichloromethane) 
IR (ATR): 1794 (C=O); 1756 (C=O); 1157 (C-F) 
1H-NMR (CDCl3, 300 MHz): Mixture of diastereoisomers A:B (2.3:1):  1.48 (s, 9H, 
3CH3 B); 1.50 (s, 9H, 3CH3 A); 2.48-2.81 (m, 2H, CH2CF); 3.60-3.76 (m, 2H, OCH2CH); 
4.59 (s, 2H, PhCH2); 4.69-4.78 (m, 1H, CH A); 4.81-4.89 (m, 1H, CH B); 7.29-7.38 (m, 
5H, 5CHAr) 
13C-NMR (CDCl3, 75 MHz): Mixture of diastereoisomers A:B (2.3:1):  27.8 (3CH3 B); 
27.9 (3CH3 A); 35.1 (d, J = 21.9, CH2CF B); 35.2 (d, J = 22.4, CH2CF A); 69.8 (PhCH2); 
73.7 (OCH2CH B); 73.8 (OCH2CH A); 76.5 (d, J = 4.9, CH A); 76.6 (CH B); 85.3 (C(CH3)3 
B); 85.6 (C(CH3)3 A); 127.7 (2CHAr B); 127.8 (2CHAr A); 128.0 (CHAr B); 128.1 (CHAr A); 
128.56 (2CHAr B); 128.59 (2CHAr A); 137.2 (CAr A); 137.5 (CAr B); 168.5 (d, J = 24.8, 
COlactone); CF and CO2tBu not observed 
MS (ESI, m/z): 342.1 [M+NH4]+ 
tert-Butyl (5S)-3-fluoro-5-(hydroxymethyl)-2-oxotetrahydrofuran-3-carboxylate, 
68 
Following the general procedure 4.2.1.1., alcohol 68 was obtained from 67 (480 
mg, 1.48 mmol) at 60ºC in quantitative yield. 
 
Rf: 0.25 (dichloromethane) 
IR (ATR): 3318 (O-H); 1689 (C=O) 
1H-NMR (CDCl3, 300 MHz): Mixture of diastereoisomers A:B (1.2:1):  1.52 (s, 9H, 
3CH3); 2.51-2.95 (m, 2H, CH2CF); 3.66-3.75 (m, 1H, ½CH2OH); 3.96-4.03 (m, 1H, 
½CH2OH); 4.67-4.75 (m, 1H, CH B); 4.78-4.86 (m, 1H, CH A) 
13C-NMR (CDCl3, 75 MHz): Mixture of diastereoisomers A:B (1.2:1):  27.9 (3CH3); 
34.2 (d, J = 22.4) and 34.3 (d, J = 21.9, CH2CF); 62.5 and 62.8 (CH2OH); 78.2 (d, J = 
4.7) and 78.9 (CH); 85.5 and 85.7 (C(CH3)3); 92.2 (d, J = 198.0) and 92.4 (d, J = 
199.0, CF); 164.5 (d, J = 26.9, CO2tBu); 168.7 (d, J = 25.0, COlactone) 
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MS (ESI, m/z): 177.9 [M-tBu]+; 159.9 [M-F-tBu]+ 
4.2.8.2. Synthesis of esters (3R, 5S)- and (3S, 5S)-69, 70, 72, 74 and 75 
tert-Butyl (3R,5S)-3-fluoro-5-{[(9Z)-hexadec-9-enoyloxy]methyl}-2-
oxotetrahydrofuran-3-carboxylate, (3R,5S)-69 and tert-butyl (3S,5S)-3-fluoro-5-
{[(9Z)-hexadec-9-enoyloxy]methyl}-2-oxotetrahydrofuran-3-carboxylate, 
(3S,5S)-69 
Following the general procedure 4.2.1.17., (3R,5S)- and (3S,5S)-69 were 
obtained from palmitoleic acid (120 mg, 0.47 mmol) and alcohol 68 (105 mg, 0.45 
mmol) in 25% and 21% yield, respectively. Chromatography: hexane to hexane/ethyl 
acetate, 4:1.  
 
Rf: 0.47 (hexane/ethyl acetate, 4:1) 
IR (ATR): 1746 (C=O); 1016 (C-F) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.9, 3H, CH3); 1.23-1.37 (m, 16H, 8CH2); 
1.53 (s, 9H, 3CH3); 1.59-1.67 (m, 2H, CH2CH2CO); 1.99-2.03 (m, 4H, 2CH2CHalkene); 
2.37 (t, J = 7.6, 2H, CH2CO); 2.44 (ddd, J = 22.9, 13.9, 8.5, 1H, ½CH2CF); 2.86 (dt, J 
= 13.9, 7.0, 1H, ½CH2CF); 4.21 (dd, J = 12.6, 5.1, 1H, ½COCH2); 4.42 (dd, J = 12.6, 
2.9, 1H, ½CO2CH2); 4.79-4.86 (m, 1H, CH); 5.30-5.39 (m, 2H, 2CHalkene)  
The following NOE effects were observed when the peak at  4.79-4.86 (m, CH) was 
irradiated: 1.53 (s, 3CH3); 2.44 (ddd, ½CH2CF); 4.42 (dd, ½CO2CH2). 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8, 24.9, 27.3, 27.4 (4CH2); 28.0 (3CH3); 
29.1, 29.21, 29.22, 29.3, 29.8, 29.9, 31.9, 34.1 (8CH2); 35.2 (d, J = 22.1, CH2CF); 
63.6 (CO2CH2); 75.1 (d, J = 4.6, 1H, CH); 85.9 (C(CH3)3); 91.4 (d, J = 206.7, CF); 
129.9, 130.2 (2CHalkene); 164.3 (d, J = 28.4, CO2tBu); 168.1 (d, J = 25.1, COlactone); 
173.4 (CO) 
19F-NMR (CDCl3, 300 MHz):  -160.4 (dd, J = 23.2, 6.7) 
 [α]D20: +4.4 (c = 0.13, methanol) 
HRMS (ESI, m/z): calculated for C26H42FO6 ([M-H]-): 469.2960, found: 469.2939 
 
Rf: 0.53 (hexane/ethyl acetate, 4:1) 
IR (ATR): 1745 (C=O); 1119 (C-F) 
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1H-NMR (CDCl3, 300 MHz):  0.87 (t, J = 6.7, 3H, CH3); 1.23-1.36 (m, 16H, 8CH2); 
1.53 (s, 9H, 3CH3); 1.57-1.71 (m, 2H, CH2CH2CO); 1.97-2.03 (m, 4H, 2CH2CHalkene); 
2.33-2.38 (m, 2H, CH2CO); 2.61 (app dd, J = 7.5, 4.0, 1H, ½CH2CF); 2.70 (app dd, J 
= 7.5, 1.1, 1H, ½CH2CF); 4.24 (dd, J = 12.4, 6.2, 1H, ½COCH2); 4.40 (dd, J = 12.4, 
3.6, 1H, ½CO2CH2); 4.91 (ddd, J = 15.1, 7.2, 3.5, 1H, CH); 5.26-5.42 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.2 (CH3); 22.8, 24.9, 27.3, 27.34 (4CH2); 28.0 (3CH3); 
29.1 (CH2); 29.2 (2CH2); 29.3, 29.8, 29.9, 31.9, 34.1 (5CH2); 35.1 (d, J = 22.8, CH2CF); 
63.9 (CO2CH2); 75.7 (CH); 85.7 (C(CH3)3); 91.7 (d, J = 199.3, CF); 129.8, 130.2 
(2CHalkene); 164.4 (d, J = 26.7, CO2tBu); 168.1 (d, J = 23.7, COlactone); 179.1 (CO) 
19F-NMR (CDCl3, 300 MHz):  -160.6 (dd, J = 27.0, 25.4) 
[α]D20: +62.4 (c = 0.03, methanol) 
HRMS (ESI, m/z): calculated for C26H42FO6 ([M-H]-): 469.3000, found: 469.2939 
tert-Butyl (5S)-3-fluoro-2-oxo-5-{[(10-phenyldecanoyl)oxy]methyl} 
tetrahydrofuran-3-carboxylate, 70 
Following the general procedure 4.2.1.17., ester 70 was obtained from carboxylic 
acid 46 (64 mg, 0.26 mmol) and alcohol 68 (60 mg, 0.26 mmol) in 35% yield. 
Chromatography: dichloromethane.  
 
Rf: 0.85 (dichloromethane) 
IR (ATR): 1743 (C=O); 1156 (C-F) 
1H-NMR (CDCl3, 300 MHz): Mixture of diastereoisomers A:B (1.7:1):  1.28-1.29 (m, 
10H, 5CH2); 1.53 (s, 9H, 3CH3 B); 1.54 (s, 9H, 3CH3 A); 1.58-1.63 (m, 4H, 2CH2); 2.36 
(t, J = 7.6, 2H, CH2CO); 2.41-2.91 (m, 2H, CH2CF); 2.59 (t, J = 7.8, 2H, PhCH2); 4.19 
(dd, J = 10.5, 5.1, 1H, ½CO2CH2 B); 4.24 (dd, J = 11.4, 5.4, 1H, ½CO2CH2 A); 4.38-
4.44 (m, 1H, ½CO2CH2); 4.79-4.86 (m, 1H, CH B); 4.87-4.96 (m, 1H, CH A); 7.16-7.18 
(m, 3H, 3CHAr); 7.24-7.30 (m, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz): Mixture of diastereoisomers A:B (1.7:1):  24.9 (CH2); 28.0 
(3CH3); 29.2, 29.3, 29.4, 29.5, 29.6, 31.6 (6CH2); 34.1 (CH2CO); 35.1 (d, J = 22.8) 
and 35.14 (d, J = 21.8, CH2CF); 36.1 (PhCH2); 63.6 and 63.9 (CO2CH2); 75.1 (d, J = 
4.6) and 75.7 (CH); 85.7 and 85.9 (C(CH3)3); 125.7 (CHAr); 128.4 (2CHAr); 128.5 
(2CHAr); 143.02 and 143.04 (CAr); 164.3 (CO2tBu); 167.8 (d, J = 23.8, COlactone); 173.4 
and 173.45 (CO); CF not observed 
MS (ESI, m/z): 482.3 [M+NH4]+ 
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Di-tert-butyl fluoro{(2S)-3-[(9Z)-hexadec-9-enoyloxy]-2-hydroxypropyl} 
propanedioate, 71 
Following the general procedure 4.2.1.14., ester 71 was obtained from palmitoleic 
acid (106 µL, 0.37 mmol) and alcohol 7 (230 mg, 0.75 mmol) in 44% yield. 
Chromatography: dichloromethane to dichloromethane/methanol, 8:2.  
 
Rf: 0.61 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3401 (O-H); 1744 (C=O); 1150 (C-F) 
1H-NMR (CDCl3, 300 MHz):  0.86 (t, J = 6.6, 3H, CH3); 1.28 (m, 16H, 8CH2); 1.48 (s, 
18H, 6CH3); 1.58-1.63 (m, 2H, CH2CH2CO); 1.96-2.02 (m, 4H, 2CH2CHalkene); 2.16-
2.49 (m, 2H, CH2CF); 2.32 (t, J = 7.5, 2H, CH2CO); 3.97-4.18 (m, 3H, CH, CO2CH2); 
5.27-5.38 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.2 (CH3); 22.8, 25.0 (2CH2); 27.2, 27.3 (2CH2CHalkene); 
27.8 (3CH3); 27.9 (3CH3); 29.1, 29.19, 29.2, 29.3, 29.8, 29.83, 31.9 (7CH2); 34.2 
(CH2CO); 37.5 (d, J = 20.7, CH2CF); 65.3 (d, J = 3.5, CH); 68.0 (CO2CH2); 83.9, 84.0 
(2C(CH3)3); 93.1 (d, J = 198.2, CF); 129.8, 130.1 (2CHalkene); 165.3 (d, J = 24.6, 
CO2tBu); 165.7 (d, J = 25.8, CO2tBu); 173.9 (CO) 
[α]D20: +6.7 (c = 1.04, methanol) 
MS (ESI, m/z): 562.4 [M+NH4]+; 567 [M+Na]+ 
Di-tert-butyl fluoro{(2S)-3-[(9Z)-hexadec-9-enoyloxy]-2-methoxypropyl} 
propanedioate, 72 
Following the general procedure 4.2.1.9., compound 72 was obtained from 71 
(86 mg, 0.16 mmol) in 27% yield. Chromatography: hexane to hexane/ethyl acetate, 
8:2.  
 
Rf: 0.81 (hexane/ethyl acetate, 8:2) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.29 (m, 16H, 8CH2); 1.48 (s, 
9H, 3CH3); 1.49 (s, 9H, 3CH3); 1.60-1.64 (m, 2H, CH2CH2CO); 1.97-2.01 (m, 4H, 
2CH2CHalkene); 2.17-2.50 (m, 2H, CH2CF); 2.33 (t, J = 7.6, 2H, CH2CO); 3.30 (s, 3H, 
OCH3); 3.57-3.64 (m, 1H, CH); 4.05 (dd, J = 11.6, 4.9, 1H, ½CO2CH2); 4.17 (dd, J = 
11.6, 4.7, 1H, ½CO2CH2); 5.28-5.39 (m, 2H, 2CHalkene) 
Experimental section 
- 129 - 
13C-NMR (CDCl3, 75 MHz):  14.2 (CH3); 22.8, 25.0 (2CH2); 27.3, 27.4 (2CH2CHalkene); 
27.9 (3CH3); 27.91 (3CH3); 29.1 (CH2); 29.2 (2CH2); 29.3, 29.8, 29.9, 31.9 (4CH2); 
34.3 (CH2CO); 36.7 (d, J = 21.2, CH2CF); 57.8 (OCH3); 64.9 (CO2CH2); 74.0 (d, J = 
3.4, CH); 83.2, 83.6 (2C(CH3)3); 92.6 (d, J = 195.3, CF); 129.9, 130.1 (2CHalkene); 
165.2 (d, J = 27.3, CO2tBu); 165.2 (d, J = 24.0, CO2tBu); 173.7 (CO) 
Di-tert-butyl fluoro{(2S)-2-hydroxy-3-[(10-phenyldecanoyl)oxy]propyl} 
propanedioate, 73 
Following the general procedure 4.2.1.14., ester 73 was obtained from carboxylic 
acid 46 (65 mg, 0.26 mmol) and alcohol 7 (161 mg, 0.52 mmol) in 75% yield. 
Chromatography: dichloromethane to dichloromethane/methanol, 99:1.  
 
Rf: 0.43 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3387 (O-H); 1743 (C=O); 1154 (C-F) 
1H-NMR (CDCl3, 300 MHz):  1.29 (m, 10H, 5CH2); 1.50 (s, 18H, 6CH3); 1.56-1.62 
(m, 4H, 2CH2); 2.17-2.44 (m, 2H, CH2CF); 2.33 (t, J = 7.5, 2H, CH2CO); 2.59 (t, J = 
7.8, 2H, PhCH2); 4.00-4.20 (m, 3H, CH, CO2CH2); 7.17 (d, J = 6.5, 3H, 3CHAr); 7.24-
7.27 (m, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  25.0 (CH2); 27.9 (3CH3); 28.0 (3CH3); 29.2, 29.4, 29.41, 
29.5, 29.6, 31.6 (6CH2); 34.3 (CH2CO); 36.1 (PhCH2); 37.5 (d, J = 20.8, CH2CF); 65.4 
(d, J = 3.5, CH); 68.0 (CO2CH2); 83.9, 84.0 (2C(CH3)3); 93.2 (d, J = 196.7, CF); 125.7 
(CHAr); 128.3 (2CHAr); 128.5 (2CHAr); 143.0 (CAr); 165.2 (d, J = 24.6, CO2tBu); 165.6 
(d, J = 25.9, CO2tBu); 173.9 (CO) 
Di-tert-butyl fluoro{(2S)-2-methoxy-3-[(10-phenyldecanoyl)oxy]propyl} 
propanedioate, 74 
Following the general procedure 4.2.1.9., compound 74 was obtained from 73 
(100 mg, 0.19 mmol) in 30% yield. Chromatography: hexane to hexane/ethyl acetate, 
8:2. 
 
Rf: 0.73 (hexane/ethyl acetate, 8:2) 
IR (ATR): 1707 (C=O); 1163 (C-F) 
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1H-NMR (CDCl3, 300 MHz):  1.25-1.29 (m, 10H, 5CH2); 1.48 (s, 9H, 3CH3); 1.49 (s, 
9H, 3CH3); 1.58-1.62 (m, 4H, 2CH2); 2.16-2.50 (m, 2H, CH2CF); 2.32 (t, J = 7.5, 2H, 
CH2CO); 2.59 (t, J = 7.7, 2H, PhCH2); 3.30 (s, 3H, OCH3); 3.57-3.65 (m, 1H, CH); 
4.05 (dd, J = 11.7, 4.8, 1H, ½CO2CH2); 4.17 (dd, J = 11.7, 4.6, 1H, ½CO2CH2); 7.14-
7.19 (m, 3H, 3CHAr); 7.24-7.29 (m, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  25.0 (CH2); 27.9 (3CH3); 27.92 (3CH3); 29.3, 29.4, 29.42, 
29.5, 29.6, 31.6 (6CH2); 34.3 (CH2CO); 36.1 (PhCH2); 36.7 (d, J = 21.4, CH2CF); 57.8 
(OCH3); 64.9 (CO2CH2); 74.0 (d, J = 3.4, CH); 83.4, 83.6 (2C(CH3)3); 92.6 (d, J = 
195.4, CF); 125.7 (CHAr); 128.4 (2CHAr); 128.5 (2CHAr); 143.0 (CAr); 165.2 (d, J = 27.5 
CO2tBu); 165.24 (d, J = 23.9, CO2tBu); 173.7 (CO) 
[α]D20: +3.0 (c = 1.69, methanol) 
MS (MALDI, m/z): 570.9 [M+NH4]+ 
(2S)-1-Bromo-3-[(di-tert-butoxyphosphoryl)oxy]propan-2-yl (9Z)-hexadec-9-
enoate, 75 
Following the general procedure 4.2.1.17., ester 75 was obtained from palmitoleic 
acid (0.25 mL, 0.85 mmol) and alcohol 63 (300 mg, 0.85 mmol) in 55% yield. 
Chromatography: hexane to hexane/ethyl acetate, 6:1.  
 
Rf: 0.38 (hexane/ethyl acetate, 8:2) 
IR (ATR): 1703 (C=O); 1003 (P-O) 
1H-NMR (CDCl3, 300 MHz):  0.81 (t, J = 6.7, 3H, CH3); 1.17-1.28 (m, 16H, 8CH2); 
1.42 (s, 18H, 6CH3); 1.52-1.61 (m, 2H, CH2CH2CO); 1.90-1.96 (m, 4H, 2CH2CHalkene); 
2.28 (t, J = 7.5, 2H, CH2CO); 3.45 (dd, J = 10.9, 5.2, 1H, ½CH2Br); 3.54 (dd, J = 10.9, 
5.5, 1H, ½CH2Br); 4.02-4.09 (m, 2H, CH2OP); 5.08 (qt, J = 5.2, 1H, CH); 5.22-5.33 
(m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8, 25.0 (2CH2); 27.3, 27.37 
(2CH2CHalkene); 29.1, 29.21, 29.23, 29.3, 29.7, 29.8, 29.9 (7CH2); 29.94 (C(CH3)3); 
30.0 (C(CH3)3); 31.9 (CH2Br); 34.9 (CH2CO); 65.1 (d, J = 5.9, CH2OP); 70.7 (d, J = 
9.2, CH); 83.0 (d, J = 7.2, C); 83.1 (d, J = 7.6, C); 129.9, 130.2 (2CHalkene); 172.9 (CO) 
HRMS (ESI, m/z): calculated for C27H52Na79BrO6P ([M(79Br)+Na]+): 605.2585, found: 
605.2602; calculated for C27H52Na81BrO6P ([M(81Br)+Na]+): 607.2581, found: 
607.2582 
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4.2.8.3. Synthesis of final compounds 4a-e 
(3S,5S)-3-Fluoro-5-{[(9Z)-hexadec-9-enoyloxy]methyl}-2-oxotetrahydrofuran-3-
carboxylic acid, (3S,5S)-4a 
Following the general procedure 4.2.1.8., compound (3S,5S)-4a was obtained 
from tert-butyl ester (3R,5S)-69 (5 mg, 10.5 µmol) and TFA (60.9 µL, 0.79 mmol) in 
85% yield.  
 
Rf: 0.10 (hexane/ethyl acetate, 1:1) 
IR (ATR): 3451 (O-H); 1787 (C=O); 1740 (C=O); 1648 (C=O) 
1H-NMR (CDCl3, 700 MHz):  0.91 (t, J = 6.9, 3H, CH3); 1.29-1.38 (m, 16H, 8CH2); 
1.59-1.72 (m, 2H, CH2CH2CO); 2.02-2.06 (m, 4H, 2CH2CHalkene); 2.39 (t, J = 7.5, 2H, 
CH2CO); 2.47-2.60 (m, 1H, ½CH2CF); 2.97-3.09 (m, 1H, ½CH2CF); 4.26 (dd, J = 12.8, 
5.1, 1H, ½COCH2); 4.46 (d, J = 12.3, 1H, ½CO2CH2); 4.92-5.02 (m, 1H, CH); 5.29-
5.43 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 175 MHz):  14.3 (CH3); 22.8, 24.9, 27.3, 27.4, 29.2, 29.22, 29.3, 
29.8, 31.9, 34.1 (11CH2); 34.9 (CH2CF); 63.5 (CO2CH2); 75.5 (CH); 130.1, 130.4 
(2CHalkene); 167.9 (br s, CO); 173.7 (CO); CF and CO not observed 
[α]D20: +12.4 (c = 0.07, methanol) 
HRMS (ESI, m/z): calculated for C22H34FO6 ([M-H]-): 413.2345, found: 413.2354 
(3R,5S)-3-Fluoro-5-{[(9Z)-hexadec-9-enoyloxy]methyl}-2-oxotetrahydrofuran-3-
carboxylic acid, (3R,5S)-4a 
Following the general procedure 4.2.1.8., compound (3R,5S)-4a was obtained 
from tert-butyl ester (3S,5S)-69 (20 mg, 42 µmol) and TFA (250 µL, 3.19 mmol) in 
69% yield.  
 
Rf: 0.10 (hexane/ethyl acetate, 1:1) 
IR (ATR): 3492 (O-H); 1788 (C=O); 1740 (C=O); 1647 (C=O) 
1H-NMR (CDCl3, 500 MHz):  0.88 (t, J = 6.9, 3H, CH3); 1.15-1.40 (m, 16H, 8CH2); 
1.57-1.72 (m, 2H, CH2CH2CO); 1.92-2.08 (m, 4H, 2CH2CHalkene); 2.35-2.39 (m, 2H, 
CH2CO); 2.73 (app d, J = 7.5, 1H, ½CH2CF); 2.79 (app dd, J = 7.5, 2.1, 1H, ½CH2CF); 
4.28 (dd, J = 12.5, 6.0, 1H, ½COCH2); 4.44 (dd, J = 12.5, 3.4, 1H, ½CO2CH2); 4.94-
4.99 (m 1H, CH); 5.28-5.41 (m, 2H, 2CHalkene) 
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13C-NMR (CDCl3, 125 MHz):  14.3 (CH3); 22.8, 24.9, 27.3, 27.4, 29.1, 29.2, 29.22, 
29.3, 29.8, 29.9, 31.9 (11CH2); 34.1 (CH2CO); 35.1 (d, J = 22.4, CH2CF); 63.7 
(CO2CH2); 76.1 (CH); 92.0 (d, J = 199.8, CF); 129.9, 130.2 (2CHalkene); 167.3 (d, J = 
23.4, CO); 168.6 (d, J = 27.2, CO); 173.6 (CO) 
[α]D20: +3.0 (c = 0.15, methanol) 
HRMS (ESI, m/z): calculated for C22H34FO6 ([M-H]-): 413.2345, found: 413.2340 
(5S)-3-Fluoro-2-oxo-5-{[(10-phenyldecanoyl)oxy]methyl}tetrahydrofuran-3-
carboxylic acid, 4b 
Following the general procedure 4.2.1.8., compound 4b was obtained from tert-
butyl ester 70 (30 mg, 65 µmol) and TFA (0.37 mL, 4.84 mmol) in 90% yield.  
 
IR (ATR): 3506 (O-H); 1795 (C=O); 1795 (C=O); 1741 (C=O) 
1H-NMR (CDCl3, 500 MHz): Mixture of diastereoisomers (1:1):  1.26-1.30 (m, 10H, 
5CH2); 1.59-1.62 (m, 4H, 2CH2); 2.36 (t, J = 7.3, 2H, CH2CO); 2.49-3.06 (m, 2H, 
CH2CF); 2.59 (t, J = 7.7, 2H, PhCH2); 4.17-4.30 (m, 1H, ½CO2CH2); 4.42-4.49 (m, 1H, 
½CO2CH2); 4.95-5.03 (m, 1H, CH); 7.16-7.18 (m, 3H, 3CHAr); 7.25-7.28 (m, 2H, 
2CHAr) 
13C-NMR (CDCl3, 125 MHz): Mixture of diastereoisomers (1:1):  24.9, 29.2, 29.3, 
29.4, 29.5, 29.6, 31.6 (7CH2); 34.0 and 34.1 (CH2CO); 35.1 (br d, J = 25.0, CH2CF); 
36.1 (PhCH2); 63.5 and 63.9 (CO2CH2); 75.6 (br s) and 76.3 (CH); 125.6 and 125.7 
(CHAr); 128.4 (2CHAr); 128.5 (2CHAr); 143.0 and 143.1 (CAr); 168.0 (br s, CO2H, 
COlactone); 173.6 and 173.8 (CO); CF not observed 
HRMS (ESI, m/z): calculated for C22H28FO6 ([M-H]-): 407.1875, found: 407.1875 
HPLC (method A, tR, min): 10.31 
Fluoro{(2S)-3-[(9Z)-hexadec-9-enoyloxy]-2-methoxypropyl}propanedioic acid, 
4c  
Following the general procedure 4.2.1.8., compound 4c was obtained from tert-
butyl ester 72 (20 mg, 36 µmol) and TFA (0.21 mL, 2.68 mmol) in 93% yield.  
 
1H-NMR (methanol-d4, 300 MHz):  0.90 (t, J = 6.3, 3H, CH3); 1.29-1.32 (m, 16H, 
8CH2); 1.57-1.64 (m, 2H, CH2CH2CO); 2.02-2.04 (m, 4H, 2CH2CHalkene); 2.10-2.59 (m, 
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2H, CH2CF); 2.35 (t, J = 7.4, 2H, CH2CO); 3.32 (s, 3H, OCH3); 3.60-3.67 (m, 1H, CH); 
4.04 (dd, J = 11.8, 4.8, 1H, ½CO2CH2); 4.25 (dd, J = 11.7, 4.1, 1H, ½CO2CH2); 5.29-
5.39 (m, 2H, 2CHalkene) 
13C-NMR (methanol-d4, 75 MHz):  14.4 (CH3); 23.7, 26.0 (2CH2); 28.1, 28.2 
(2CH2CHalkene); 30.0 (CH2); 30.1 (2CH2); 30.2, 30.8, 30.82, 32.9 (4CH2); 34.9 
(CH2CO); 38.3 (d, J = 21.3, CH2CF); 58.1 (OCH3); 65.9 (CO2CH2); 75.9 (br s CH); 
130.8, 130.9 (2CHalkene); 175.2 (CO); 2CO2H and CF not observed 
[α]D20: +14.1 (c = 0.79, methanol) 
HRMS (ESI, m/z): calculated for C23H38FO7 ([M-H]-): 445.2607, found: 445.2618 
HPLC (method A, tR, min): 11.89 
Fluoro{(2S)-2-methoxy-3-[(10-phenyldecanoyl)oxy]propyl}propanedioic acid, 
4d 
Following the general procedure 4.2.1.8., compound 4d was obtained from tert-
butyl ester 74 (44 mg, 80 µmol) and TFA (0.46 mL, 5.97 mmol) in 68% yield.  
 
IR (ATR): 3342 (O-H); 1736 (C=O)) 
1H-NMR (methanol-d4, 300 MHz):  1.28-1.31 (m, 10H, 5CH2); 1.58-1.62 (m, 4H, 
2CH2); 2.22-2.54 (m, 2H, CH2CF); 2.34 (t, J = 7.4, 2H, CH2CO); 2.59 (t, J = 7.7, 2H, 
PhCH2); 3.32 (s, 3H, OCH3); 3.60-3.65 (m, 1H, CH); 4.04 (dd, J = 11.8, 4.8, 1H, 
½CO2CH2); 4.25 (dd, J = 11.7, 4.1, 1H, ½CO2CH2); 7.09-7.16 (m, 3H, 3CHAr); 7.21-
7.26 (m, 2H, 2CHAr) 
13C-NMR (methanol-d4, 75 MHz):  26.0, 30.1, 30.2, 30.3 (4CH2); 30.5 (2CH2); 32.7 
(CH2); 34.9 (CH2CO); 36.9 (PhCH2); 38.1 (d, J = 21.3, CH2CF); 58.1 (OCH3); 65.8 
(CO2CH2); 75.8 (d, J = 3.4, CH); 126.6 (CHAr); 129.2 (2CHAr); 129.4 (2CHAr); 144.0 
(CAr); 175.2 (CO); 2CO2H and CF not observed 
[α]D20: limited solubility 
HRMS (ESI, m/z): calculated for C23H32FO6 ([M-H]-): 439.2138, found: 439.2119 
HPLC (method A, tR, min): 10.25 
(2S,9Z)-1-Bromo-3-(phosphonooxy)propan-2-yl hexadec-9-enoate, 4e  
Following the general procedure 4.2.1.8., compound 4e was obtained from tert-
butyl ester 75 (4 mg, 6.9 µmol) and TFA (40 µL, 0.51 mmol) in 93% yield.  
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IR (ATR): 1741 (C=O); 1457 (C=C); 1015 (P-O) 
1H-NMR (methanol-d4, 500 MHz):  0.93 (t, J = 6.8, 3H, CH3); 1.29-1.42 (m, 16H, 
8CH2); 1.56-1.70 (m, 2H, CH2CH2CO); 2.03-2.06 (m, 4H, 2CH2CHalkene); 2.40 (t, J = 
7.4, 2H, CH2CO); 3.62 (dd, J = 10.9, 6.1, 1H, ½CH2Br); 3.70 (dd, J = 10.7, 4.5, 1H, 
½CH2Br); 4.05-4.17 (m, 2H, CH2OP); 5.13-5.24 (m, 1H, CH); 5.31-5.44 (m, 2H, 
2CHalkene) 
13C-NMR (methanol-d4, 125 MHz):  13.4 (CH3); 22.7 (CH2); 25.0, 25.1 (2CH2CHalkene); 
27.1, 27.13, 27.14, 29.0, 29.2, 29.77, 29.78, 29.8, 31.9 (9CH2); 33.9 (CH2CO); 60.5 
(d, J = 7.2, CH2OP); 64.9 (d, J = 5.3, CH); 129.8, 129.9 (2CHalkene); 173.4 (CO) 
31P-NMR (methanol-d4, 202 MHz):  2.88 
[α]D20: +5.9 (c = 0.09, methanol) 
HRMS (ESI, m/z): calculated for C19H3579BrO6P ([M(79Br)-H]-): 469.1360, found: 
469.1361; calculated for C19H3581BrO6P ([M(81Br)-H]-): 471.1340, found: 471.1342 
4.2.9. Synthesis of final compounds 5a-b 
4.2.9.1. Synthesis of final compound 5a 
2-[(2R)-3-Bromo-2-hydroxypropyl]-1H-isoindole-1,3(2H)-dione, 76 
To a solution of (R)-(-)-N-(2,3-epoxypropyl)phthalimide (1 g, 4.92 mmol, 1 equiv), 
in chloroform (6 mL) cooled at 0°C, 48% HBr (7.4 mL) was added dropwise and the 
reaction was stirred for 30 min. Afterward the mixture was diluted with brine and 
extracted twice with dichloromethane. The organic phases were dried over anhydrous 
Na2SO4, filtered and concentrated under reduced pressure, obtaining 76 without 
further purification in 96% yield.  
 
Rf: 0.73 (hexane/ethyl acetate, 6:4) 
1H-NMR (CDCl3, 300 MHz):  2.82 (br s, 1H, OH); 3.52 (ABX system, J = 10.7, 5.5, 
4.6, 2H, CH2Br); 3.92 (ABX system, J = 14.2, 7.2, 4.3, 2H, NCH2); 4.09-4.20 (m, 1H, 
CH); 7.72-7.78 (m, 2H, 2CHAr); 7.85-7.91 (m, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  36.6 (CH2Br); 42.5 (NCH2); 69.5 (CH); 123.7 (2CHAr); 
132.0 (2CAr); 134.4 (2CHAr); 168.8 (2CO) 
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[α]D20: +2.8 (c = 0.28, methanol) 
2-[(2R)-3-Bromo-2-methoxypropyl]-1H-isoindole-1,3(2H)-dione, 77 
Following the general procedure 4.2.1.9., compound 77 was obtained from 76 
(1.32 g, 4.65 mmol) in 62% yield. Chromatography: hexane to hexane/ethyl acetate, 
8:2.  
 
Rf: 0.67 (hexane/ethyl acetate, 6:4) 
IR (ATR): 1713 (C=O); 1016 (C-O) 
1H-NMR (CDCl3, 300 MHz):  3.35-3.51 (m, 2H, CH2Br); 3.42 (m, 3H, CH3); 3.65-3.93 
(m, 3H, NCH2, CH); 7.68-7.74 (m, 2H, 2CHAr); 7.80-7.86 (m, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  32.3 (CH2Br); 39.9 (NCH2); 58.0 (CH3); 78.0 (CH); 123.5 
(2CHAr); 131.9 (2CAr); 134.2 (2CHAr); 168.3 (2CO) 
[α]D20: +0.96 (c = 0.42, methanol) 
MS (ESI, m/z): 298.0 [M(79Br)+H]+; 300.0 [M(81Br)+H]+ 
Di-tert-butyl [(2S)-3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-2-methoxypropyl] 
propanedioate, 78 
Di-tert-butyl malonate (0.66 mL, 2.94 mmol, 2 equiv) was added dropwise to a 
stirred suspension of NaH (178 mg, 4.44 mmol, 1.6 equiv, 60% dispersion in oil) in 
anhydrous DMF (10 mL) under an argon atmosphere. Then, 77 (439 mg, 1.47 mmol, 
1 equiv) and potassium iodide (269 mg, 1.62 mmol, 1.1 equiv) were added and the 
mixture was stirred overnight. Then, the solvent was removed under reduced 
pressure and the residue was dissolved in DCM and washed with 5% aqueous acetic 
acid, water and brine. The organic phase was dried over Na2SO4, filtered and 
evaporated under reduced pressure. The residue was purified by flash 
chromatography (hexane to hexane/ethyl acetate, 8:2) to afford 78 in 54% yield. 
 
Rf: 0.44 (hexane/ethyl acetate, 8:2) 
IR (ATR): 1720 (C=O) 
1H-NMR (CDCl3, 300 MHz):  1.44 (s, 18H, 6CH3); 1.91-2.11 (m, 2H, CH2CH); 3.37-
3.42 (m, 1H, CH2CH); 3.38 (m, 3H, OCH3); 3.51-3.59 (m, 1H, CHOCH3); 3.71-3.85 
(m, 2H, NCH2); 7.68-7.74 (m, 2H, 2CHAr); 7.82-7.88 (m, 2H, 2CHAr) 
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13C-NMR (CDCl3, 75 MHz):  28.0 (6CH3); 31.9 (CH2CH); 40.4 (NCH2); 50.6 (CH2CH); 
57.9 (OCH3); 76.9 (CHOCH3); 81.58, 81.62 (2C(CH3)3); 123.5 (2CHAr); 132.2 (2CAr); 
134.1 (2CHAr); 168.4 (2CON); 168.77, 168.80 (2COtBu) 
[α]D20: -1.1 (c = 0.26, methanol) 
MS (ESI, m/z): 456.1 [M+Na]+ 
Di-tert-butyl [(2S)-3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-2-methoxypropyl] 
(fluoro)propanedioate, 79 
Following the general procedure 4.2.1.5., compound 79 was obtained from 78 
(345 mg, 0.80 mmol) in 96% yield, which was used in the next step without further 
purification.  
 
Rf: 0.19 (hexane/ethyl acetate, 9:1) 
IR (ATR): 1744 (C=O); 1716 (C=O) 
1H-NMR (CDCl3, 500 MHz):  1.45 (s, 9H, 3CH3); 1.47 (s, 9H, 3CH3); 2.25-2.45 (m, 
2H, CH2CF); 3.33 (s, 3H, OCH3); 3.69-3.73 (m, 1H, CH); 3.79-3.80 (m, 2H, NCH2); 
7.71-7.74 (m, 2H, 2CHAr); 7.84-7.88 (m, 2H, 2CHAr) 
13C-NMR (CDCl3, 125 MHz):  27.8 (3CH3); 27.9 (3CH3); 37.8 (J = 21.2, CH2CF); 40.5 
(NCH2); 57.7 (OCH3); 74.3 (J = 3.1, CH); 83.1, 86.6 (2C(CH3)3); 92.6 (J = 195.6, CF); 
123.5 (2CHAr); 132.2 (2CAr); 134.2 (2CHAr); 165.16 (J = 25.4, CO2tBu); 165.17 (J = 
25.7, CO2tBu); 168.4 (2CON) 
[α]D20: -1.0 (c = 0.04, methanol) 
MS (ESI, m/z): 469.2 [M+NH4]+; 474.2 [M+Na]+ 
Di-tert-butyl [(2S)-3-amino-2-methoxypropyl](fluoro)propanedioate, 80 
To a solution of phthalimide 79 (378 mg, 0.84 mmol, 1 equiv) in absolute ethanol 
(8.4 mL), hydrazine monohydrate (1.0 mL, 2.1 mmol 2.5 equiv) was added and the 
reaction was refluxed for 3 h. Once at room temperature, the mixture was 
concentrated under reduced pressure, and the residue was dissolved in 
dichloromethane and washed with 0.5 N NaOH solution. The aqueous phase was 
extracted with dichloromethane and the combined organic layers were washed with 
water and brine, dried over Na2SO4, filtered and concentrated under reduced 
pressure. The residue was purified by flash chromatography (triethylamine-
neutralized silica gel, dichloromethane to dichloromethane/ethanol, 9:1) affording 80 
in 66% yield. 
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Rf: 0.38 (dichloromethane/ethanol, 9:1) 
IR (ATR): 3353 (N-H); 1746 (C=O) 
1H-NMR (CDCl3, 300 MHz):  1.46 (s, 18H, 6CH3); 2.08-2.18 (m, 1H, ½CH2CF); 2.38 
(ddd, J = 33.5, 15.2, 8.7, 1H, ½CH2CF); 2.63-2.68 (m, 1H, ½NH2CH2); 2.87-2.93 (m, 
1H, ½NH2CH2); 3.26 (m, 3H, OCH3); 3.33-3.40 (m, 1H, CH) 
13C-NMR (CDCl3, 75 MHz):  27.8 (3CH3); 27.9 (3CH3); 36.5 (J = 21.0, CH2CF); 44.4 
(NH2CH2); 57.2 (OCH3); 77.0 (CH); 83.2, 83.6 (2C(CH3)3); 93.0 (J = 194.9, CF); 165.3 
(J = 26.9, CO2tBu); 165.4 (J = 24.4, CO2tBu) 
MS (ESI, m/z): 322.2 [M+H]+ 
Di-tert-butyl fluoro{(2S)-3-[(9Z)-hexadec-9-enoylamino]-2-methoxypropyl} 
propanedioate, 81 
To a solution of palmitoleic acid (22 µL, 78 µmol, 1 equiv) and 80 (35 mg, 0.11 
mmol, 1.4 equiv) in anhydrous DMF (1.95 mL) under an argon atmosphere, HOBt 
(10.5 mg, 78 µmol, 1 equiv) and EDC (17.9 mg, 93 µmol, 1.2 equiv) were added. After 
stirring for 2 h at room temperature, additional EDC (6 mg, 0.031 mmol, 0.4 equiv) 
was added and the reaction was stirred overnight. Then, the mixture was transferred 
to a separating funnel and a 1:1 mixture of dichloromethane/hexane was added. The 
solution was washed three times with water, followed by 0.5 N NaOH solution, 0.5 N 
HCl solution, and brine. The organic phase was dried over Na2SO4, filtered and 
concentrated under reduced pressure. The residue was purified by flash 
chromatography (hexane to hexane/ethyl acetate, 7:3) affording 81 in 37% yield.  
 
Rf: 0.35 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3300 (N-H); 1747 (C=O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.6, 3H, CH3); 1.25-1.34 (m, 16H, 8CH2); 
1.45-1.49 (m, 18H, 6CH3); 1.58-1.69 (m, 2H, CH2CH2CO); 1.97-2.05 (m, 4H, 
2CH2CHalkene); 2.18 (t, J = 7.5, 2H, CH2CO); 2.10-2.21 (m, 1H, ½CH2CF); 2.34 (ddd, 
J = 13.7, 6.7, 3.5, 1H, ½CH2CF); 3.28 (s, 3H, OCH3); 3.39-3.43 (m, 2H, NHCH2); 3.51-
3.58 (m, 1H, CH); 5.28-5.39 (m, 2H, 2CHalkene); 5.63-5.75 (m, 1H, NH) 
13C-NMR (CDCl3, 75 MHz):  14.1 (CH3); 22.7, 25.8 (2CH2); 27.17, 27.22 
(2CH2CHalkene); 27.7 (3CH3); 27.8 (3CH3); 29.0, 29.1, 29.28, 29.3 (4CH2); 29.7 (2CH2); 
31.8 (CH2); 36.77 (d, J = 22.1, CH2CF); 36.8 (CH2CO); 41.1 (NH2CH2); 57.1 (OCH3); 
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74.5 (d, J = 2.7, CH); 83.1, 83.6 (2C(CH3)3); 92.7 (J = 196.4, CF); 129.8, 130.0 
(2CHalkene); 165.1 (d, J = 23.3, CO2tBu); 168.8 (d, J = 26.3, CO2tBu); 173.3 (CONH) 
HRMS (ESI, m/z): calculated for C31H56FNaNO6 ([M+Na]+): 580.3984, found: 
580.3992 
Fluoro{(2S)-3-[(9Z)-hexadec-9-enoylamino]-2-methoxypropyl}propanedioic 
acid, 5a 
Following the general procedure 4.2.1.8., compound 5a was obtained from tert-
butyl ester 81 (10 mg, 18 µmol) and TFA (104 µL, 1.34 mmol) in 99% yield.  
 
Rf: 0.17 (hexane/ethyl acetate, 6:4) 
IR (ATR): 3273 (N-H); 1646 (C=O); 1014 (C-O) 
1H-NMR (CDCl3, 700 MHz):  0.88 (t, J = 7.0, 3H, CH3); 1.25-1.34 (m, 16H, 8CH2); 
1.54-1.67 (m, 2H, CH2CH2CO); 1.95-2.04 (m, 4H, 2CH2CHalkene); 2.19-2.56 (m, 4H, 
CH2CO, CH2CF); 3.24-3.70 (m, 6H, NHCH2, CH, OCH3); 5.30-5.36 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 175 MHz):  14.3 (CH3); 22.8, 26.0 (2CH2); 27.4 (2CH2CHalkene); 
29.1, 29.4, 29.5 (3CH2); 29.88 (2CH2); 29.93, 31.9, 36.6 (3CH2); 36.7 (br s, CH2CF); 
42.2 (br s, NHCH2); 57.6 (OCH3); 74.5 (CH); 129.8, 130.1 (2CHalkene); 169.3 (br s, 
2CO2H); 175.6 (CONH); CF not observed 
[α]D20: -0.5 (c = 0.14, methanol) 
HRMS (ESI, m/z): calculated for C23H39FNO6 ([M-H]-): 444.2767, found: 444.2784 
HPLC (method A, tR, min): 29.71 
4.2.9.2. Synthesis of aziridine 87 
Methyl N-(tert-butoxycarbonyl)-D-serinate, 82 
To a solution of D-serine methyl ester hydrochloride (500 mg, 3.21 mmol, 1 equiv) 
and triethylamine (0.97 mL, 6.91 mmol, 2.15 equiv) in anhydrous THF (8 mL) under 
an argon atmosphere, di-tert-butyl dicarbonate (700 mg, 3.21 mmol, 1 equiv) was 
added at 0ºC. The reaction mixture was heated at 140ºC under MW irradiation for 20 
min. Once cooled to room temperature, the solvent was removed under reduced 
pressure and the residue was dissolved in ethyl acetate and washed with 1M HCl 
solution. The organic phase was washed with water and brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure, to afford 82 in 99% yield, which 
was used in next step without further purification. Spectroscopic data correspond with 
those previously reported.108 
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Rf: 0.23 (hexane/ethyl acetate, 7:3) 
1H-NMR (CDCl3, 300 MHz):  1.44 (s, 9H, 3CH3); 3.77 (s, 3H, CH3); 3.91 (qd, J = 11.2, 
3.7, 2H, CH2); 4.31-4.44 (m, 1H, CH); 5.53 (d, J = 7.3, 1H, NH) 
[α]D20: -0.2 (c = 0.30, methanol) 
Methyl N-(tert-butoxycarbonyl)-O-[(4-methylphenyl)sulfonyl]-D-serinate, 83 
Following the general procedure 4.2.1.3., tosylate 83 was obtained from 82 (720 
mg, 3.28 mmol) in 49% yield. Chromatography: hexane to hexane/ethyl acetate, 7:3. 
Spectroscopic data correspond with those previously reported.109 
 
Rf: 0.27 (hexane/ethyl acetate, 8:2) 
1H-NMR (CDCl3, 300 MHz):  1.41 (s, 9H, 3CH3); 2.45 (s, 3H, CH3CAr); 3.69 (s, 3H, 
OCH3); 4.28 (dd, J = 10.0, 2.9, 1H, ½CH2); 4.39 (dd, J = 10.1, 2.8, 1H, ½CH2); 4.48-
4.52 (m, 1H, CH); 5.29 (d, J = 7.6, 1H, NH); 7.35 (d, J = 8.4, 2H, 2CHAr); 7.76 (d, J = 
8.3, 2H, 2CHAr) 
[α]D20: -0.3 (c = 0.62, methanol) 
(2S)-2-[(tert-Butoxycarbonyl)amino]-3-hydroxypropyl 4-methylbenzene 
sulfonate, 84 
To a solution of 83 (500 mg, 1.34 mmol, 1 equiv) in absolute ethanol (4 mL) at -
5ºC, a suspension of NaBH4 (142 mg, 3.75 mmol, 2.8 equiv) in an ice/water mixture 
(1 mL) was added. After stirring 1 h at this temperature, the mixture was brought to 
pH 4 by dropwise addition of glacial acetic acid and ethanol was removed under 
reduced pressure. Then the residue was dissolved in ethyl acetate, washed with water 
and brine, dried over Na2SO4, filtered and concentrated under reduced pressure, 
affording 84 in 96% yield.  
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Rf: 0.71 (hexane/ethyl acetate, 6:4) 
1H-NMR (CDCl3, 300 MHz):  1.41 (s, 9H, 3CH3); 2.46 (s, 3H, CH3CAr); 3.64 (dd, J = 
11.2, 5.1, 1H, ½OCH2); 3.76-3.90 (m, 2H, ½OCH2, CH); 4.06-4.18 (m, 2H, CH2OH); 
4.88-4.98 (m, 1H, NH); 7.36 (d, J = 8.0, 2H, 2CHAr); 7.79 (d, J = 8.3, 2H, 2CHAr) 
MS (ESI, m/z): 245.9 [M-Boc+2H]+ 
HPLC (method A, tR, min): 22.68 
(2S)-3-{[Bis(benzyloxy)phosphoryl]oxy}-2-[(tert-butoxycarbonyl)amino]propyl 
4-methylbenzenesulfonate, 85 
Following the general procedure 4.2.1.13., compound 85 was obtained 84 (150 
mg, 0.43 mmol) and dibenzyl-N,N-diisopropylphosphoramidite (0.29 mL, 0.87 mmol) 
in 38% yield. Chromatography: hexane to hexane/ethyl acetate, 6:4. 
 
Rf: 0.12 (hexane/ethyl acetate, 7:3) 
IR (ATR): 1755 (C=O); 1238 (P=O); 1009 (P-O) 
1H-NMR (CDCl3, 300 MHz):  1.40 (s, 9H, 3CH3); 2.41 (s, 3H, CH3CAr); 3.81-4.10 (m, 
5H, CH2CHCH2); 4.86-4.96 (m, 1H, NH); 5.00 (s, 2H, CH2Ph); 5.03 (s, 2H, CH2Ph); 
7.29-7.39 (m, 12H, 12CHAr); 7.73-7.76 (m, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  21.8 (CH3CAr); 28.4 (3CH3); 49.1 (CH); 65.5 (d, J = 5.9, 
CH2OP); 67.4 (OCH2); 69.81 (d, J = 5.5, CH2Ph); 69.84 (d, J = 5.6, CH2Ph); 77.4 
(C(CH3)3); 128.1 (2CHAr); 128.15, 128.2, 128.77, 128.8, 128.9 (10CHAr); 130.1 
(2CHAr); 132.5 (CAr); 135.88 (d, J = 6.3, CAr); 135.91 (d, J = 6.4, CAr); 145.3 (CAr); 155.2 
(CO) 
31P-NMR (CDCl3, 202 MHz):  2.02 
[α]D20: -0.9 (c = 0.42, methanol) 
MS (ESI, m/z): 513.9 [M-CH2Ph]+ 
HPLC (method A, tR, min): 24.20 
tert-Butyl (1S)-2-{[bis(benzyloxy)phosphoryl]oxy}-1-(bromomethyl)ethyl 
carbamate, 86 
To a solution of 85 (300 mg, 0.50 mmol, 1 equiv) in acetone (3.5 mL), lithium 
bromide (86 mg, 0.99 mmol, 2 equiv) was added and the mixture was refluxed for 12 
h. Then the solvent was removed under reduced pressure, and the residue was 
dissolved in ethyl acetate and washed with a saturated aqueous solution of NaHCO3. 
The organic phase was dried over Na2SO4, filtered and concentrated under reduced 
pressure to afford 86 in 79% yield.  
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Rf: 0.59 (dichloromethane/methanol, 9:1) 
IR (ATR): 3402 (NH); 1696 (C=O); 1230 (P=O); 1015 (P-O) 
1H-NMR (CDCl3, 500 MHz):  1.43 (s, 9H, 3CH3); 3.34 (dd, J = 10.2, 6.6, 1H, ½CH2Br); 
3.44 (dd, J = 10.3, 2.8, 1H, ½CH2Br); 3.98-4.00 (m, 2H, CH, ½CH2O); 4.17-4.21 (m, 
1H, ½CH2O); 4.98-4.99 (m, 1H, NH); 5.02-5.10 (m, 4H, 2CH2Ph); 7.32-7.38 (app s, 
10H, 10CHAr) 
13C-NMR (CDCl3, 125 MHz):  28.4 (3CH3); 32.0 (CH2Br); 50.6 (CH); 66.6 (CH2O); 
69.9 (2CH2Ph); 80.4 (C); 128.2 (4CHAr); 128.8 (4CHAr); 128.9 (2CHAr); 135.7 (d, J = 
6.4, CAr); 135.71 (d, J = 6.1, CAr); 154.9 (CO) 
31P-NMR (CDCl3, 202 MHz):  2.70 
[α]D20: +0.5 (c = 0.46, methanol) 
MS (ESI, m/z): 421.9 [M(79Br)-CH2Ph]-; 423.9 [M(81Br)-CH2Ph]- 
HPLC (method A, tR, min): 21.92 
Dibenzyl [(2R)-1-(10-phenyldecanoyl)aziridin-2-yl]methyl phosphate, 87 
a) Deprotection of amine 86: to a solution of 86 (35 mg, 68 µmol, 1 equiv) in 
anhydrous dichloromethane (0.7 mL) under an argon atmosphere, TFA (0.1 mL, 1.36 
mmol, 20 equiv) was added and the reaction mixture was stirred at room temperature 
overnight. After this time, the solvent was removed by azeotropic distillation with 
toluene (2x) under reduced pressure to afford the corresponding trifluoroacetate salt 
in quantitative yield. 
b) Activation of carboxylic acid 46: to a solution of 46 (34 mg, 0.14 mmol, 1 equiv) 
in anhydrous dichloromethane (2 mL) under an argon atmosphere, N-
hydroxysuccinimide (32 mg, 0.28 mmol, 2 equiv) and EDC (39 mg, 0.21 mmol, 1.5 
equiv) were added successively. The reaction was stirred at room temperature for 12 
h. Then the mixture was washed with water, dried over Na2SO4, filtered and 
concentrated under reduced pressure to afford the corresponding N-
hydroxysuccinimidyl ester of 46 in quantitative yield, which was used in next step 
without further purification. 
c) Coupling reaction: to a solution of the trifluoroacetate salt of deprotected amine 
86 (35 mg, 66 µmol, 1 equiv) in anhydrous dichloromethane (4 mL) under an argon 
atmosphere, triethylamine (46 µL, 0.33 mmol, 5 equiv) and N-hydroxysuccinimidyl 
ester of 46 (45 mg, 0.13 mmol, 2 equiv) were added successively. The reaction was 
stirred at room temperature for 12 h. After this time, the mixture was washed with 
water, dried over Na2SO4, filtered and concentrated under reduced pressure. The 
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residue was purified by flash chromatography (hexane/ethyl acetate, 3:2 to 1:2) to 
afford 87 in 48% yield. 
 
Rf: 0.55 (ethyl acetate) 
IR (ATR): 1702 (C=O); 1261 (P=O); 1018 (P-O) 
1H-NMR (methanol-d4, 700 MHz):  1.25-1.32 (m, 10H, 5CH2); 1.56-1.61 (m, 4H, 
2CH2); 2.04 (d, J = 2.8, 1H, ½CH2N); 2.30-2.40 (m, 3H, CH2CO, ½CH2N); 2.59 (t, J = 
7.7, 2H, CH2Ph); 2.62-2.65 (m, 1H, CH); 3.96 (ddd, J = 11.2, 8.6, 6.2, 1H, ½CH2O); 
4.04 (ddd, J = 11.8, 7.2, 4.8, 1H, ½CH2O); 5.02-5.09 (m, 4H, 2OCH2Ph); 7.16-7.18 
(m, 3H, 3CHAr); 7.26-7.28 (m, 2H, 2CHAr); 7.32-7.37 (m, 10H, 10CHAr) 
13C-NMR (methanol-d4, 175 MHz):  25.1, 28.4, 29.4, 29.45, 29.50, 29.54, 29.6, 31.7 
(8CH2); 34.9 (d, J = 8.4, CH); 36.1 (CH2Ph); 36.6 (CH2); 68.1 (d, J = 5.3, CH2O); 69.6 
(d, J = 6.1, OCH2Ph); 69.7 (d, J = 5.4, OCH2Ph); 125.7, 128.15, 128.17, 128.4, 128.5, 
128.78, 128.82 (15CHAr); 135.7, 135.8, 143.1 (3CAr); 185.7 (CO) 
[α]D20: +6.1 (c = 0.36, methanol) 
MS (MALDI, m/z): 564.3 [M+H]+ 
Benzyl (2S)-3-bromo-2-[(10-phenyldecanoyl)amino]propyl hydrogen 
phosphate, 89 
To a solution of 87 (4 mg, 7 µmol, 1 equiv) in anhydrous diethyl ether (1 mL) 
under an argon atmosphere, magnesium bromide ethyl etherate (3.7 mg, 14 µmol, 2 
equiv) was added and the reaction mixture was stirred at room temperature for 4 h. 
After this time, the solvent was removed under reduced pressure to afford compound 
89 in quantitative yield. 
 
1H-NMR (methanol-d4, 300 MHz):  1.21-1.38 (m, 10H, 5CH2); 1.53-1.64 (m, 4H, 
2CH2); 2.13-2.25 (m, 2H, CH2CO); 2.58 (t, J = 7.6, 2H, CH2Ph); 3.44-3.50 (m, 1H, 
½CH2Br); 3.56-3.63 (m, 1H, ½CH2Br); 3.84-4.00 (m, 2H, CH2OP); 4.20-4.33 (m, 1H, 
CH); 4.85-4.95 (m, 2H, OCH2Ph); 7.07-7.41 (m, 10H, 10CHAr) 
31P-NMR (methanol-d4, 121 MHz):  -0.71 
MS (ESI, m/z): 552.1 [M(79Br)-H]-; 554.2 [M(81Br)-H]- 
HPLC (method A, tR, min): 9.67 
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4.3. Synthesis of new antagonists for the LPA1 and LPA2 receptors 
4.3.1. General procedures 
4.3.1.1. Friedel-Crafts acylation of resorcinol 
a) Preparation of the aryloxyacetyl chloride: to a solution of the corresponding 
aryloxyacetic acid (1 equiv) in anhydrous toluene (5.5 mL/mmol) under an argon 
atmosphere, thionyl chloride (2.8 mL/mmol) was added and the reaction mixture was 
refluxed for 6 h. After this time, the excess of thionyl chloride and toluene were 
evaporated under reduced pressure, affording the corresponding aryloxyacetyl 
chloride in quantitative yield. 
b) Friedel-Crafts acylation: to a cooled (0°C) stirred solution of the corresponding 
aryloxyacetyl chloride (1 equiv) and resorcinol (1.1 equiv) in anhydrous 
dichloromethane (1.5 mL/mmol) under an argon atmosphere, BF3·Et2O (1.3 
mL/mmol) was added. The reaction was stirred at 0ºC for 10 min and then at 90ºC for 
4 h. The reaction vessel was then cooled in an ice bath and the mixture poured into 
an excess of ice water. The aqueous phase was extracted with dichloromethane, and 
the combined organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure. The residue was purified by flash 
chromatography to yield the corresponding 2,4-dihydroxyphenyl ketone. 
4.3.1.2. Synthesis of chromones by Allan-Robinson reaction  
A mixture of the corresponding 2,4-dihydroxyphenyl ketone (1 equiv), freshly 
distilled acetic anhydride (0.6 mL/mmol), triethylamine (0.8 mL/mmol) and anhydrous 
sodium acetate (2.4 equiv) was stirred at 140°C for 2.5 h under an argon atmosphere. 
Afterward, cold water was added and the mixture was extracted with 
dichloromethane, washed with brine, dried over Na2SO4, filtered and concentrated 
under reduced pressure, affording the corresponding acetoxychromone in 
quantitative yield. 
4.3.1.3. Hydrolysis of acetoxychromone derivatives 
To a solution of the corresponding acetoxychromone (1 equiv) in the minimum 
amount of absolute ethanol, 36% HCl (0.6 mL/mmol) was added and the reaction was 
refluxed for 2 h. After cooling to room temperature, the mixture was diluted with ethyl 
acetate and washed with a saturated aqueous solution of NaHCO3 and brine, dried 
over Na2SO4, filtered and concentrated under reduced pressure, affording the 
corresponding hydroxychromone in quantitative yield. 
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4.3.1.4.  Alkylation of hydroxychromone derivatives 
To a solution of the corresponding hydroxychromone (1 equiv) in anhydrous 
acetone (15 mL/mmol) under an argon atmosphere, K2CO3 (2 equiv) was added and 
the reaction mixture was refluxed for 30 min. Then, a solution of the appropriate alkyl 
2-bromoacetate (3.5 equiv) in anhydrous acetone (1 mL/mmol) was added and the 
mixture was refluxed during 3 h. Then, cold water was added and acetone was 
removed under reduced pressure. The aqueous residue was extracted with 
dichloromethane, and the organic phase was dried with Na2SO4, filtered and 
concentrated under reduced pressure. The residue was purified by flash 
chromatography to afford the corresponding alkylated chromone. 
4.3.1.5. Synthesis of pyrazole derivatives by reaction with hydrazine 
A solution of the corresponding chromone or enaminone (1 equiv) in absolute 
ethanol (5 mL/mmol) at 40 °C under an argon atmosphere was treated with a solution 
of hydrazine monohydrate (65%, 0.18 mL/mmol) in absolute ethanol (1.3 mL/mmol). 
The reaction was refluxed for 30 min. After cooling to room temperature, the mixture 
was concentrated under vacuum, diluted with ethyl acetate and acidified with 1M HCl 
to pH 6. The aqueous phase was extracted with ethyl acetate, and the combined 
organic layers were washed with brine, dried over Na2SO4, filtered and concentrated 
under reduced pressure. The residue was purified by flash chromatography to yield 
the corresponding pyrazole. 
4.3.1.6. Williamson ether synthesis  
To a solution of 2,5-dichlorophenol (1 equiv) and DBU (1.2 equiv) in anhydrous 
DMF (2.6 mL/mmol) under an argon atmosphere, the appropriate 2-
bromoacetophenone (1.2 equiv) was added and the mixture was heated at 140°C for 
30 min under MW irradiation. After cooling to room temperature, the reaction mixture 
was diluted with ethyl acetate and washed with water and brine. The organic layer 
was dried over Na2SO4, filtered and concentrated under reduced pressure. The 
residue was purified by flash chromatography to yield the corresponding ether. 
4.3.1.7. Enaminone formation  
A solution of the appropriate 2-aryloxy-1-phenylethanone (1 equiv) in 1,1-
dimethoxy-N,N-dimethylethylamine (4.2 equiv) was stirred at 90ºC for 2-4 h under an 
argon atmosphere. After cooling to room temperature, the reaction mixture was 
concentrated under reduced pressure and the crude was purified by flash 
chromatography to afford the corresponding enaminone. 
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4.3.2. Synthesis of final compound 96 
Ethyl 2-amino-4-(3,4-dimethylphenyl)-5-methylthiophene-3-carboxylate, 90 
To a cooled (0°C) stirred solution of titanium tetrachloride (5.07 mL, 46.23 mmol, 
5 equiv) in anhydrous THF (185 mL) under an argon atmosphere, a solution of 1-(3,4-
dimethylphenyl)propan-1-one (1.5 g, 9.25 mmol, 1 equiv) and ethyl 2-cyanoacetate 
(1.97 mL, 18.49 mmol, 2 equiv) in anhydrous THF (46 mL) was added. Then, 
triethylamine (2.96 mL, 21.27 mmol, 2.3 equiv) was added and the mixture was stirred 
at room temperature overnight. Afterward, the solvent was evaporated and the 
residue was dissolved in ethyl acetate and washed with water and brine. The organic 
phase was dried over Na2SO4, filtered and concentrated under reduced pressure, 
affording ethyl 2-cyano-3-(3,4-dimethylphenyl)pent-2-enoate in quantitative yield.  
To a solution of ethyl 2-cyano-3-(3,4-dimethylphenyl)pent-2-enoate (2.1 g, 9.15 
mmol, 1 equiv) in anhydrous THF (37 mL) under an argon atmosphere, diethylamine 
(1.72 mL, 16.64 mmol, 1.8 equiv) and sulfur (593 mg, 18.53 mmol, 2 equiv) were 
added and the reaction mixture was stirred at room temperatura overnight. Afterward, 
the solvent was evaporated and the crude was dissolved in ethyl acetate and washed 
with water and brine. The organic phase was dried over Na2SO4, filtered and 
concentrated under reduced pressure. Flash chromatography of the residue 
(triethylamine-neutralized silica gel, hexane to hexane/ethyl acetate, 95:5) afforded 
pure 2-aminothiophene 90 in 32% yield.  
 
Rf: 0.53 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3394 (NH2); 1658 (C=O); 1014 (C-O-C) 
1H-NMR (CDCl3, 300 MHz):  0.84 (t, J = 7.1, 3H, CH2CH3); 2.05 (s, 3H, CH3C5); 2.26 
(s, 3H, CH3CAr); 2.28 (s, 3H, CH3CAr); 3.95 (q, J = 7.1, 2H, CH2); 5.90 (br s, 2H, NH2); 
6.88 (dd, J = 7.6, 1.8, 1H, H6’); 6.93 (s, 1H, H2’); 7.08 (d, J = 7.6, 1H, H5’) 
13C-NMR (CDCl3, 75 MHz):  13.2, 13.7 (2CH3); 19.7, 19.9 (2CH3CAr); 59.2 (CH2); 
107.2, 116.9 (2CAr); 127.2, 128.7, 131.1 (3CHAr); 134.6, 135.3, 135.4, 136.5 (4CAr); 
160.7 (C2); 165.8 (C=O) 
MS (ESI, m/z): 290.0 [M+H]+ 
HPLC (method A, tR, min): 27.16 
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Ethyl 2-[(tert-butoxycarbonyl)amino]-4-(3,4-dimethylphenyl)-5-methyl 
thiophene-3-carboxylate, 92 
To a solution of 2-aminothiophene 90 (857 mg, 2.96 mmol, 1 equiv) in anhydrous 
THF (50 mL) under an argon atmosphere, DMAP (36 mg, 0.30 mmol, 0.1 equiv) and 
di-tert-butyl dicarbonate (776 mg, 3.55 mmol, 1.2 equiv) were added and the reaction 
mixture was stirred at room temperature overnight. Afterward, the solvent was 
evaporated and the residue was dissolved in ethyl acetate and washed with brine. 
The organic phase was dried over Na2SO4, filtered and concentrated under reduced 
pressure. The crude was purified by flash chromatography (triethylamine-neutralized 
silica gel, hexane to hexane/ethyl acetate, 8:2) to afford pure compound 92 in 28% 
yield.  
 
Rf: 0.71 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3284 (NH); 1720, 1663 (C=O) 
1H-NMR (CDCl3, 300 MHz):  0.81 (t, J = 7.1, 3H, CH2CH3); 1.53 (s, 9H, 3CH3); 2.12 
(s, 3H, CH3C5); 2.26 (s, 3H, CH3CAr); 2.29 (s, 3H, CH3CAr); 3.96 (q, J = 7.1, 2H, CH2); 
6.86 (d, J = 7.7, 1H, H6’); 6.91 (s, 1H, H2’); 7.09 (d, J = 7.6, 1H, H5’); 10.26 (s, 1H, NH) 
13C-NMR (CDCl3, 75 MHz):  13.0, 13.4 (2CH3); 19.7, 19.9 (2CH3CAr); 28.4 (3CH3); 
60.0 (CH2); 82.0 (C(CH3)3); 109.7, 111.3, 124.3 (3CAr); 127.2, 128.8, 131.1 (3CHAr); 
134.8, 134.9, 135.3, 135.4 (4CAr); 149.0 (CONH); 166.0 (CO2) 
2-[(tert-Butoxycarbonyl)amino]-4-(3,4-dimethylphenyl)-5-methylthiophene-3-
carboxylic acid, 93 
To a solution of thiophene 92 (149 mg, 0.38 mmol, 1 equiv) in a 1:1 mixture of 
ethanol:water (10 mL), potassium hydroxide (43 mg, 0.77 mmol, 2 equiv) was added 
and the reaction mixture was stirred at 60ºC overnight. After cooling to room 
temperature, the mixture was acidified with 1M HCl solution and extracted with ethyl 
acetate (2x). The combined organic phases were washed with water and brine, dried 
over Na2SO4, filtered and concentrated under reduced pressure, affording acid 
derivative 93 in 89% yield.  
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Rf: 0.26 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3305 (NH, OH); 1720, 1642 (C=O); 1018 (C-O-C) 
1H-NMR (CDCl3, 300 MHz):  1.55 (s, 9H, 3CH3); 2.10 (s, 3H, CH3C5); 2.28 (s, 3H, 
CH3CAr); 2.30 (s, 3H, CH3CAr); 6.96 (d, J = 7.7, 1H, H6’); 6.99 (s, 1H, H2’); 7.17 (d, J = 
7.6, 1H, H5’); 10.22 (s, 1H, NH) 
13C-NMR (CDCl3, 75 MHz):  13.0 (CH3C5); 19.8, 20.0 (2CH3CAr); 28.4 (3CH3); 77.4 
(C(CH3)3); 109.7, 124.8 (2CAr); 127.5, 129.6, 131.2 (3CHAr); 133.5, 134.6, 136.0, 
136.5 (4CAr); 151.3, 152.4 (C2, CONH); 168.5 (CO2H) 
MS (ESI, m/z): 360.0 [M-H]- 
HPLC (method A, tR, min): 27.10 
tert-Butyl [3-carbamoyl-4-(3,4-dimethylphenyl)-5-methylthiophen-2-yl] 
carbamate, 94 
To a solution of carboxylic acid 93 (114 mg, 0.32 mmol, 1 equiv) in anhydrous 
dichloromethane (0.7 mL) under an argon atmosphere, EDC∙HCl (121 mg, 0.63 mmol, 
2 equiv) and HOBt (85 mg, 0.63 mmol, 2 equiv) were added and the reaction mixture 
was stirred at room temperature for 1 h. After this time, a solution of 0.5 M NH3 in 
dioxane (6.50 mL, 3.20 mmol, 10 equiv) and DIPEA (0.17 mL, 0.95 mmol, 3 equiv) 
were added and the mixture was stirred at room temperature overnight. Afterward, 
the mixture was washed sequentially with 1 M HCl, a saturated aqueous solution of 
NaHCO3 and brine. The organic phase was dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude was purified by flash 
chromatography (triethylamine-neutralized silica gel, hexane to 
hexane/dichloromethane, 1:1) to afford pure compound 94 in 70% yield.  
 
Rf: 0.51 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3459 (NH2); 1714, 1645 (C=O); 1157 (C-O-C) 
1H-NMR (CDCl3, 300 MHz):  1.52 (s, 9H, 3CH3); 2.05 (s, 3H, CH3C5); 2.28 (s, 3H, 
CH3CAr); 2.30 (s, 3H, CH3CAr); 5.28 (s, 1H, ½NH2); 5.48 (s, 1H, ½NH2); 6.99 (d, J = 
7.6, 1H, H6’); 7.03 (s, 1H, H2’); 7.20 (d, J = 7.6, 1H, H5’); 11.14 (s, 1H, NH) 
13C-NMR (CDCl3, 75 MHz):  12.9 (CH3C5); 19.7, 19.9 (2CH3CAr); 28.4 (3CH3); 81.6 
(C(CH3)3); 112.0, 124.6 (2CAr); 127.6, 130.4, 131.3 (3CHAr); 133.3, 133.4, 137.0, 
137.6 (4CAr); 148.3, 152.7 (C2, CONH); 167.8 (CONH2) 
MS (ESI, m/z): 361.1 [M+H]+; 261.1 [M-CO2tBu+2H]+ 
HPLC (method A, tR, min): 19.67 
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3-Carbamoyl-4-(3,4-dimethylphenyl)-5-methylthiophen-2-aminium 
trifluoroacetate, 91 
To a solution of N-Boc amine 94 (77 mg, 0.21 mmol, 1 equiv) in anhydrous 
dichloromethane (2.1 mL) under an argon atmosphere, TFA (0.2 mL) was added and 
the reaction mixture was stirred at room temperature overnight. After this time, the 
solvent was removed by azeotropic distillation with toluene (2x) under reduced 
pressure to afford trifluoroacetate salt 91 in quantitative yield. 
 
IR (ATR): 3382, 3358 (NH2); 1684 (C=O) 
1H-NMR (CDCl3, 300 MHz):  1.98 (s, 3H, CH3C5); 2.27 (s, 3H, CH3CAr); 2.29 (s, 3H, 
CH3CAr); 5.02 (br s, 1H, ½NH2); 5.25 (br s, 1H, ½NH2); 6.30 (br s, 2H, NH2); 6.99 (d, 
J = 7.7, 1H, H6’); 7.03 (s, 1H, H2’); 7.18 (d, J = 7.5, 1H, H5’) 
13C-NMR (CDCl3, 75 MHz):  13.0 (CH3C5); 19.7, 19.9 (2CH3CAr); 107.7, 116.9 (2CAr); 
127.5, 130.3, 131.2 (3CHAr); 134.1, 134.4, 136.7, 137.4 (4CAr); 160.4 (C2); 168.3 
(CONH2) 
MS (ESI, m/z): 261.1 [M+H]+ 
HPLC (method A, tR, min): 12.81 
4-(3,4-Dimethylphenyl)-2-(2,6-dioxopiperidin-1-yl)-5-methylthiophene-3-
carboxamide, 95 
To a solution of 2-aminothiophene 91 (79 mg, 0.21 mmol, 1 equiv) in anhydrous 
dichloromethane (2.3 mL) under an argon atmosphere, glutaric anhydride (48 mg, 
0.42 mmol, 2 equiv), DMAP (2.6 mg, 0.02 mmol, 0.1 equiv) and triethylamine (0.06 
mL, 0.42 mmol, 2 equiv) were added and the reaction was refluxed for 24 h. After 
cooling to room temperature, the mixture was concentrated under reduced pressure, 
diluted with ethyl acetate and washed with brine. The organic layer was dried over 
Na2SO4, filtered and evaporated under reduced pressure. The residue was purified 
by flash chromatography (triethylamine-neutralized silica gel, hexane/ethyl acetate, 
6:4 to ethyl acetate/metanol, 95:5) affording compound 95 in 33% yield. 
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Rf: 0.33 (ethyl acetate) 
IR (ATR): 3463 (NH2); 1695 (C=O) 
1H-NMR (CDCl3, 300 MHz):  2.09 (m, 2H, CH2); 2.25 (s, 3H, CH3C5); 2.27 (s, 3H, 
CH3CAr); 2.29 (s, 3H, CH3CAr); 2.81 (m, 4H; 2CH2CO); 5.19 (br s, 1H, ½NH2); 5.39 (br 
s, 1H, ½NH2); 7.06 (d, J = 7.7, 1H, H6’); 7.10 (s, 1H, H2’); 7.19 (d, J = 7.6, 1H, H5’) 
13C-NMR (CDCl3, 75 MHz):  14.1 (CH3C5); 16.9 (CH2); 19.7, 19.9 (2CH3CAr); 33.3 
(2CH2CO); 127.5, 130.3 (2CHAr); 130.8 (CAr); 131.2 (CHAr); 132.5, 135.2, 136.2, 
136.3, 137.0, 137.5 (6CAr); 164.2 (CONH2); 172.9 (2CON) 
MS (ESI, m/z): 357.1 [M+H]+ 
HPLC (method A, tR, min): 15.56 
2-[(4-Carboxybutanoyl)amino]-4-(3,4-dimethylphenyl)-5-methylthiophene-3-
carboxylic acid, 96 
To a solution of 95 (11.3 mg, 0.03 mmol, 1 equiv) in water (0.1 mL), triethylamine 
(0.01 mL, 0.10 mmol, 3.1 equiv) was added and the reaction was refluxed for 15 min. 
After cooling to room temperature, the mixture was treated with 1 M HCl and extracted 
with ethyl acetate (2x). The combined organic layers were washed with brine, dried 
over Na2SO4, filtered and concentrated under reduced pressure, affording final 
compound 96 in 72% yield.  
 
Rf: 0.31 (ethyl acetate) 
IR (ATR): 3203 (NH, OH); 1676, 1643 (C=O) 
1H-NMR (CDCl3, 700 MHz):  2.03-2.07 (m, 2H, CH2CH2CO2H); 2.07 (s, 3H, CH3C5); 
2.28 (s, 3H, CH3C3’); 2.30 (s, 3H, CH3C4’); 2.38 (t, J = 6.8, 2H, CH2CO2H); 2.56 (t, J = 
7.5, 2H, NHCOCH2); 5.43 (s, 1H, ½CONH2); 6.53 (s, 1H, ½CONH2); 6.97 (d, J = 7.5, 
1H, H6’); 7.01 (s, 1H, H2’); 7.20 (d, J = 7.6, 1H, H5’); 12.14 (s, 1H, NHCO) 
13C-NMR (CDCl3, 175 MHz):  12.9 (CH3C5); 19.7 (CH3C4’) 20.0 (CH3C3’); 21.2 
(CH2CH2CO2H); 34.29 (CH2CO2H); 36.2 (NHCOCH2);112.9 (C3); 126.3 (C5); 127.6 
(C6’); 130.6 (C5’); 131.2 (C2’); 133.0 (C1’); 133.1 (C4); 137.2 (C4’); 137.8 (C3’); 146.3 
(C2); 168.8 (CONH2); 170.0 (CONH); 177.9 (CO2H) 
HRMS (ESI, m/z): calculated for C19H21N2O4S [M-H]-: 373.1227, found: 373.1195  
HPLC (method A, tR, min): 21.07 
 
Experimental section 
- 150 - 
4.3.3. Synthesis of final compound 101 
2-(2,4-Dichlorophenoxy)-1-(2,4-dihydroxyphenyl)ethanone, 97 
Following the general procedure 4.3.1.1., compound 97 was obtained from 2,4-
dichlorophenoxyacetic acid (508 mg, 2.30 mmol) in 20% yield. Chromatography: 
hexane to dichloromethane. 
 
Rf: 0.41 (hexane/ethyl acetate, 7:3) 
m.p.: 190-192 ºC 
IR (ATR): 3352 (OH); 1628 (C=O); 1233 (C-O-C) 
1H-NMR (methanol-d4, 500 MHz):  5.45 (s, 2H, CH2); 6.31 (d, J = 2.3, 1H, H3); 6.41 
(dd, J = 8.9, 2.3, 1H, H5); 6.95 (d, J = 8.9, 1H, H6’); 7.22 (dd, J = 8.8, 2.6, 1H, H5’); 
7.43 (d, J = 2.5, 1H, H3’); 7.79 (d, J = 8.8, 1H, H6) 
13C-NMR (methanol-d4, 125 MHz):  71.8 (CH2); 103.8 (C3); 109.6 (C5); 112.4 (C1); 
116.1 (C6’); 124.7, 127.3 (C2’, C4’); 128.8, 130.8 (C3’, C5’); 132.9 (C6); 154.4 (C1’); 
166.2, 167.0 (C2, C4); 198.0 (C=O) 
MS (ESI, m/z): 311.0, 313.0, 315.0 [M-H]- 
HPLC (method C, tR, min): 26.82 
3-(2,4-Dichlorophenoxy)-2-methyl-4-oxo-4H-chromen-7-yl acetate, 98 
Following the general procedure 4.3.1.2., chromone 98 was obtained from 2,4-
dihydroxyphenyl ketone 97 (53 mg, 0.17 mmol) in 99% yield.  
 
Rf: 0.49 (hexane/ethyl acetate, 7:3)  
m.p.: 158-160 ºC 
IR (ATR): 1764, 1651 (C=O); 1206 (C-O-C) 
1H-NMR (CDCl3, 300 MHz):  2.37 (s, 3H, COCH3); 2.47 (s, 3H, C2CH3); 6.65 (d, J = 
8.8, 1H, H6’); 7.07 (dd, J = 8.8, 2.5, 1H, H5’); 7.15 (dd, J = 8.7, 2.1, 1H, H6); 7.32 (d, J 
= 2.1, 1H, H8); 7.44 (d, J = 2.5, 1H, H3’); 8.21 (d, J = 8.7, 1H, H5) 
13C-NMR (CDCl3, 75 MHz):  15.9 (C2CH3); 21.3 (COCH3); 111.1 (C8); 115.6  (C6’); 
119.6 (C6); 122.1 (C4a); 123.7 (C2’); 127.6 (C5); 127.7 (C5’); 127.9 (C4’); 130.5 (C3’); 
137.0 (C3); 151.6 (C1’); 154.7 (C7); 156.0 (C8a); 161.0 (C2); 168.7 (C=O); 171.3 (C4) 
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MS (ESI, m/z): 379.0, 381.0, 383.0 [M+H]+ 
HPLC (method C, tR, min): 27.32 
3-(2,4-Dichlorophenoxy)-7-hydroxy-2-methyl-4H-chromen-4-one, 99 
Following the general procedure 4.3.1.3., compound 99 was obtained from 
acetoxychromone 98 (61 mg, 0.16 mmol) in 99% yield. 
 
Rf: 0.29 (hexane/ethyl acetate, 7:3)  
m.p.: 190-192 ºC 
IR (ATR): 3100 (OH); 1595 (C=O); 1268 (C-O-C) 
1H-NMR (methanol-d4, 700 MHz):  2.42 (s, 3H, CH3); 6.79 (d, J = 8.8, 1H, H6’); 6.90 
(d, J = 2.2, 1H, H8); 6.94 (dd, J = 8.8, 2.2, 1H, H6); 7.16 (dd, J = 8.8, 2.5, 1H, H5’); 7.51 
(d, J = 2.5, 1H, H3’); 7.96 (d, J = 8.8, 1H, H5) 
13C-NMR (methanol-d4, 176 MHz):  15.6 (CH3); 103.4 (C8); 116.5 (C6); 116.7(C6’); 
117.7 (C4a); 124.2 (C2’/C4’); 128.1 (C5); 128.4 (C2’/C4’); 128.9 (C5´); 131.1 (C3’); 136.9 
(C3); 153.2 (C1’); 159.2 (C7/C8a); 162.6 (C2); 165.1 (C7/C8a); 173.5 (C4) 
MS (ESI, m/z): 334.9, 336.9, 338.9 [M-H]- 
HPLC (method C, tR, min): 25.95 
Methyl {[3-(2,4-dichlorophenoxy)-2-methyl-4-oxo-4H-chromen-7-yl]oxy}acetate, 
100 
Following the general procedure 4.3.1.4., compound 100 was obtained from 
hydroxychromone 99 (81 mg, 0.24 mmol) and methyl 2-bromoacetate (0.09 mL, 0.84 
mmol) in 51% yield. Chromatography: hexane to hexane/ethyl acetate, 7:3. 
 
Rf: 0.33 (hexane/ethyl acetate, 7:3)  
m.p.: 176-178 ºC 
IR (ATR): 1760 (C=O); 1640 (C=O); 1256 (C-O-C) 
1H-NMR (CDCl3, 500 MHz):  2.44 (s, 3H, CH3); 3.85 (s, 3H, OCH3); 4.75 (s, 2H, CH2); 
6.65 (d, J = 8.8, 1H, H6’); 6.86 (d, J = 2.4, 1H, H8); 7.02 (dd, J = 8.9, 2.4, 1H, H6); 7.06 
(dd, J = 8.8, 2.5, 1H, H5’); 7.43 (d, J = 2.5, 1H, H3’); 8.13 (d, J = 8.9, 1H, H5) 
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13C-NMR (CDCl3, 125 MHz):  15.8 (CH3); 52.7 (OCH3); 65.5 (CH2); 101.5 (C8); 114.6 
(C6); 115.6 ( C6’); 118.9 (C4a); 123.6 (C2’/C4’); 127.67 (C5’); 127.73 (C2’/C4’); 128.0 (C5); 
130.5 (C3’); 136.8 (C3); 151.8 (C1’); 157.1 (C8a); 160.2 (C2); 162.2 (C7); 168.4 (C=O); 
171.4 (C4) 
MS (ESI, m/z): 409.0, 411.0, 413.0 [M+H]+ 
HPLC (method C, tR, min): 26.08 
{4-[4-(2,4-Dichlorophenoxy)-5-methyl-1H-pyrazol-3-yl]-3-hydroxyphenoxy} 
acetic acid, 101 
Following the general procedure 4.3.1.5., pyrazole 101 was obtained from 
chromone 100 (45 mg, 0.11 mmol) in 99% yield. Chromatography: dichloromethane 
to dichloromethane/methanol, 8:2. 
 
Rf: 0.93 (dichloromethane/methanol/acetic acid, 7:3:0.01) 
m.p.: >196 ºC dec 
IR (ATR): 3413 (OH, NH); 1619 (C=O); 1182 (C-O-C) 
1H-NMR (methanol-d4, 500 MHz):  2.13 (s, 3H, CH3); 4.52 (s, 2H, CH2); 6.36 (dd, J 
= 8.7, 2.5, 1H, H6); 6.47 (d, J = 2.5, 1H, H2); 6.66 (d, J = 8.9, 1H, H6’’);  7.12 (dd, J = 
8.9, 2.5, 1H, H5’’); 7.48-7.51 (m, 2H, H5, H3’’) 
13C-NMR (methanol-d4, 125 MHz):  8.7 (CH3); 66.5 (CH2); 103.5 (C2); 107.1 (C6); 
110.5 (C4); 116.8 (C6’’); 124.1, 128.3 (C2’’, C4’’); 128.6 (C5); 129.1 (C5’’); 131.1 (C3’’); 
133.2, 135.2 (C4’, C5’); 140.2 (C3’); 153.9 (C1’’); 158.1 (C3); 160.4 (C1); 173.8 (C=O) 
HRMS (ESI, m/z): calculated for C18H13Cl2N2O5 (M)-: 407.0207, found: 407.0192 
HPLC (method C, tR, min): 25.45 
4.3.4. Synthesis of final compound 104 
7-Hydroxy-4H-chromen-4-one, 102 
A solution of 1-(2,4-dihydroxyphenyl)ethan-1-one (500 mg, 3.29 mmol, 1 equiv) 
in triethyl orthoformate (2.9 mL, 17.4 mmol, 5.3 equiv) was treated with 70% perchloric 
acid (0.3 mL, 3.83 mmol, 1.2 equiv). The resulting warm and thick dark solution was 
stirred until it cooled to room temperature (about 1 h). Anhydrous diethyl ether 
(12.5 mL) was added to precipitate out the brown-colored intermediate of the oxonium 
perchlorate salt. The salt was taken in water and hydrolyzed by heating to reflux for 
5 min. The reaction mixture was then allowed to cool at room temperature for 12 h. A 
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dark brown solid precipitated out, which was filtered, dried under vacuum, and purified 
by flash chromatography (hexane/ethyl acetate, 1:1 to ethyl acetate) to yield pure 
compound 102 in 47% yield.  
 
Rf: 0.56 (hexane/ethyl acetate, 2:8) 
IR (ATR): 3526 (OH); 1630 (C=O) 
1H-NMR (acetone-d6, 300 MHz):  7.27 (d, J = 5.6, 1H, H3); 7.34 (d, J = 2.2, 1H, H8); 
7.40 (dd, J = 9.0, 2.3, 1H, H6); 8.33 (d, J = 9.0, 1H, H5); 8.98 (d, J = 5.6, 1H, H2) 
13C-NMR (acetone-d6, 75 MHz):  103.6 (C8); 108.5 (C3); 120.2 (C6); 120.3 (C4a); 
128.3 (C5); 154.5 (C2); 161.6 (C8a); 164.4 (C7); 167.7 (C4) 
MS (ESI, m/z): 161.1 [M-H]- 
HPLC (method C, tR, min): 11.51 
Methyl [(4-oxo-4H-chromen-7-yl)oxy]acetate, 103 
Following the general procedure 4.3.1.4., compound 103 was obtained from 
chromone 102 (147 mg, 0.91 mmol) and methyl 2-bromoacetate (0.35 mL, 3.19 mmol) 
in 24% yield. Chromatography: hexane to hexane/ethyl acetate, 7:3. 
 
Rf: 0.21 (hexane/ethyl acetate, 7:3) 
m.p.: 146-148 ºC 
IR (ATR): 1756 (C=O); 1648 (C=O); 1214 (C-O-C) 
1H-NMR (CDCl3, 300 MHz):  3.83 (s, 3H, CH3); 4.73 (s, 2H, CH2); 6.28 (d, J = 6.0, 
1H, H3); 6.82 (d, J = 2.4, 1H, H8); 7.00 (dd, J = 8.9, 2.4, 1H, H6); 7.77 (d, J = 6.0, 1H, 
H2); 8.13 (d, J = 8.9, 1H, H5) 
13C-NMR (CDCl3, 75 MHz):  52.7 (CH3); 65.4 (CH2); 101.7 (C8); 113.2, 114.5 (C3, 
C6); 119.7 (C4a); 127.8 (C5); 155.1 (C2); 158.1 (C8a); 162.1 (C7); 168.4 (C=O); 177.0 
(C4) 
MS (ESI, m/z): 235.1 [M+H]+ 
HPLC (method C, tR, min): 12.69 
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[3-Hydroxy-4-(1H-pyrazol-3-yl)phenoxy]acetic acid, 104 
Following the general procedure 4.3.1.5., pyrazole 104 was obtained from 
chromone 103 (29 mg, 0.12 mmol) in 98% yield. Chromatography: dichloromethane 
to dichloromethane/methanol, 8:2. 
 
Rf: 0.79 (dichloromethane/methanol, 7:3) 
m.p.: 92-94 ºC 
IR (ATR): 3404 (OH, NH); 1623 (C=O) 
1H-NMR (DMSO-d6, 700 MHz):  4.35 (s, 2H, CH2); 6.41-6.42 (m, 2H, H2, H6); 6.71 
(br s, 1H, H4’); 7.56 (d, J = 8.7, 1H, H5); 7.80 (br s, 1H, H5’); 11.04 (br s, 1H, OH); 
13.16 (br s, 1H, NH) 
13C-NMR (DMSO-d6, 175 MHz):  66.6 (CH2); 101.3 (C4’); 102.0 (C2); 106.3 (C6); 110.0 
(C4); 127.4 (C5); 130.0 (C5’); 150.0 (C3’); 156.2 (C3); 159.1 (C1); 171.5 (C=O) 
HRMS (ESI, m/z): calculated for C11H9N2O4 [M-H]-: 233.0568, found: 233.0559 
HPLC (method C, tR, min): 11.02 
4.3.5. Synthesis of final compounds 105-107 
4.3.5.1. Synthesis of 2,4-dihydroxyphenyl ketones 108-110 
2-(4-Chlorophenoxy)-1-(2,4-dihydroxyphenyl)ethanone, 108 
Following the general procedure 4.3.1.1., aryl ketone 108 was obtained from 4-
chlorophenoxyacetic acid (500 mg, 2.68 mmol) in 20% yield. Chromatography: 
hexane to hexane/ethyl acetate, 7:3. 
 
Rf: 0.71 (hexane/ethyl acetate, 7:3) 
m.p.: 181-183 ºC 
IR (ATR): 3321 (OH); 1629 (C=O); 1233 (C-O-C) 
1H-NMR (methanol-d4, 300 MHz):  5.33 (s, 2H, CH2); 6.31 (d, J = 2.3, 1H, H3); 6.41 
(dd, J = 8.9, 2.4, 1H, H5); 6.93-6.97 (m, 2H, H2’, H6’); 7.23-7.28 (m, 2H, H3’ ,H5’); 7.78 
(d, J = 8.9, 1H, H6) 
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13C-NMR (methanol-d4, 75 MHz):  70.9 (CH2); 103.8 (C3); 109.6 (C5); 112.4 (C1); 
117.3 (C2’, C6’); 127.2 (C4’); 130.3 (C3’, C5’); 132.8 (C6); 158.5 (C1’); 166.2, 167.0 (C2, 
C4); 198.7 (C=O) 
MS (ESI, m/z): 277.0 [M(35Cl)-H]-, 279.0 [M(37Cl)-H]- 
HPLC (method C, tR, min): 27.20 
2-(2-Chlorophenoxy)-1-(2,4-dihydroxyphenyl)ethanone, 109 
Following the general procedure 4.3.1.1., aryl ketone 109 was obtained from 2-
chlorophenoxyacetic acid (50 mg, 2.68 mmol) in 20% yield. Chromatography: 
hexane/dichloromethane, 3:7 to dichloromethane. 
 
Rf: 0.39 (hexane/ethyl acetate, 7:3) 
m.p.: 161-163 ºC 
IR (ATR): 3343 (OH); 1630 (C=O); 1233 (C-O-C) 
1H-NMR (methanol-d4, 300 MHz):  5.37 (s, 2H, CH2); 6.30 (d, J = 2.3, 1H, H3); 6.39 
(dd, J = 8.9, 2.3, 1H, H5); 6.88-6.94 (m, 2H, H6’, H4’/H5’); 7.14-7.20 (m, 1H, H4’/H5’);  
7.35 (d, J = 8.1, 1H, H3’); 7.77 (d, J = 8.9, 1H, H6) 
13C-NMR (methanol-d4, 75 MHz):  71.5 (CH2); 103.7 (C3); 109.5 (C5); 112.4 (C1); 
115.1, 123.1 (2CHAr); 123.8 (C2’); 128.9, 131.3 (2CHAr); 132.9 (C6); 155.2 (C1’); 166.2, 
166.8 (C2, C4); 198.4 (C=O) 
MS (ESI, m/z): 277.0 [M(35Cl)-H]-, 279.0 [M(37Cl)-H]- 
HPLC (method C, tR, min): 25.00 
1-(2,4-Dihydroxyphenyl)-2-phenoxyethanone, 110 
Following the general procedure 4.3.1.1., aryl ketone 110 was obtained from 
phenoxyacetic acid (500 mg, 3.29 mmol) in 10% yield. Chromatography: 
hexane/dichloromethane, 3:7 to dichloromethane. 
 
Rf: 0.44 (hexane/ethyl acetate, 7:3) 
m.p.: 191-193 ºC 
IR (ATR): 3316 (OH); 1628 (CO); 1231 (C-O-C) 
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1H-NMR (methanol-d4, 300 MHz):  5.31 (s, 2H, CH2); 6.31 (d, J = 2.2, 1H, H3); 6.41 
(dd, J = 8.8, 2.2, 1H, H5); 6.93-7.00 (m, 3H, 3HAr); 7.25-7.30 (m, 2H, 2HAr); 7.80 (d, J 
= 8.9, 1H, H6) 
13C-NMR (methanol-d4, 75 MHz):  70.7 (CH2); 103.8 (C3); 109.6 (C5); 112.4 (C1); 
115.8 (2CHAr); 122.4 (CHAr); 130.5 (2CHAr); 132.9 (C6); 159.6 (C1’); 166.3, 166.9 (C2, 
C4); 199.3 (C=O) 
MS (ESI, m/z): 243.1 [M-H]- 
HPLC (method C, tR, min): 23.38 
4.3.5.2. Synthesis of acetoxychromenones 111-113 
3-(4-Chlorophenoxy)-2-methyl-4-oxo-4H-chromen-7-yl acetate, 111 
Following the general procedure 4.3.1.2., chromone 111 was obtained from 2,4-
dihydroxyphenyl ketone 108 (60 mg, 0.22 mmol) in 99% yield.  
 
Rf: 0.81 (hexane/ethyl acetate, 7:3) 
m.p.: 134-136 ºC 
IR (ATR): 1769 (C=O); 1617 (C=O); 1237 (C-O-C) 
1H-NMR (methanol-d4, 500 MHz):  2.34 (s, 3H, COCH3); 2.45 (s, 3H, C2CH3); 6.94-
6.97 (m, 2H, H2’, H6’); 7.26-7.29 (m, 3H, H3’, H5’, H6); 7.49 (d, J = 2.1, 1H, H8); 8.15 (d, 
J = 8.7, 1H, H5) 
13C-NMR (methanol-d4, 125 MHz):  15.8 (C2CH3); 20.9 (COCH3); 112.5 (C8); 117.5 
(C2’, C6’); 121.1 (C6); 122.8 (C4a); 127.8 (C5); 128.4 (C4’); 130.6 (C3’, C5’); 137.5 (C3); 
156.6, 157.3 (C7, C8a); 157.6 (C1’); 163.9 (C2); 170.1 (C=O); 173.9 (C4) 
MS (ESI, m/z): 345.0 [M(35Cl)+H]+, 347.1 [M(37Cl)+H]+ 
HPLC (method C, tR, min): 28.23 
3-(2-Chlorophenoxy)-2-methyl-4-oxo-4H-chromen-7-yl acetate, 112 
Following the general procedure 4.3.1.2., chromone 112 was obtained from 2,4-
dihydroxyphenyl ketone 109 (43 mg, 1.15 mmol) in 99% yield.  
 
Rf: 0.46 (hexane/ethyl acetate, 7:3) 
m.p.: 161-163 ºC 
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IR (ATR): 1647 (C=O); 1257 (C-O-C) 
1H-NMR (CDCl3, 300 MHz):  2.36 (s, 3H, COCH3); 2.46 (s, 3H, C2CH3); 6.70 (dd, J 
= 8.2, 1.3, 1H, H6’); 6.97 (dt, J = 7.7, 1.4, 1H, H4’/H5’); 7.07-7.16 (m, 2H, H4’/H5’, H6); 
7.32 (d, J = 2.0, 1H, H8); 7.43 (dd, J = 7.9, 1.5, 1H, H3’); 8.22 (d, J = 8.7, 1H, H5) 
13C-NMR (CDCl3, 75 MHz):  15.9 (C2CH3); 21.3 (COCH3); 111.1 (C8); 114.6, 119.5 (C6, 
C6’); 122.1, 122.7 (C2’, C4a); 123.4, 127.6 (2CHAr); 127.7 (C5); 130.8 (CHAr); 137.0 (C3); 
152.8, 154.6 (C7, C8a); 156.0 (C1’); 161.0 (C2); 168.7 (C=O); 171.6 (C4) 
MS (ESI, m/z): 345.1 [M(35Cl)+H]+, 347.0 [M(37Cl)+H]+ 
HPLC (method C, tR, min): 27.87 
2-Methyl-4-oxo-3-phenoxy-4H-chromen-7-yl acetate, 113 
Following the general procedure 4.3.1.2., chromone 113 was obtained from 2,4-
dihydroxyphenyl ketone 110 (35 mg, 0.14 mmol) in 81% yield.  
 
Rf: 0.58 (hexane/ethyl acetate, 7:3) 
IR (ATR): 1768 (C=O); 1618 (C=O); 1195 (C-O-C) 
1H-NMR (methanol-d4, 700 MHz):  2.35 (s, 3H, COCH3); 2.44 (s, 3H, C2CH3); 6.94-
6.96 (m, 2H, H2’, H6’); 7.02 (tt, J = 7.4, 0.9, 1H, H4’); 7.26-7.30 (m, 3H, H6, H3’, H5’); 
7.49 (d, J = 2.1, 1H, H8); 8.16 (d, J = 8.7, 1H, H5) 
13C-NMR (methanol-d4, 175 MHz):  15.8 (C2CH3); 20.9 (COCH3); 112.4 (C8); 115.8 
(C2’, C6’); 121.1 (C6); 122.8 (C4a); 123.5 (C4’); 127.8 (C5); 130.7 (C3’, C5’); 137.6 (C3); 
156.6, 157.6 (C7, C8a); 158.6 (C1’); 163.9 (C2); 170.1 (C=O); 174.2 (C4) 
MS (ESI, m/z): 311.1 [M+H]+ 
HPLC (method C, tR, min): 25.30 
4.3.5.3. Synthesis of hydroxychromones 114-116 
3-(4-Chlorophenoxy)-7-hydroxy-2-methyl-4H-chromen-4-one, 114 
Following the general procedure 4.3.1.3., hydroxychromone 114 was obtained 
from acetoxychromone 111 (61 mg, 0.18 mmol) in 99% yield. 
 
Rf: 0.43 (hexane/ethyl acetate, 7:3) 
m.p.: >260 ºC dec 
IR (ATR): 3393 (OH); 1651 (C=O) 
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1H-NMR (methanol-d4, 500 MHz):  2.33 (s, 3H, CH3); 6.52 (d, J = 2.2, 1H, H8); 6.69 
(dd, J = 8.9, 2.2, 1H, H6); 6.90-6.93 (m, 2H, H2’, H6’); 7.24-7.27 (m, 2H, H3’, H5’); 7.77 
(d, J = 8.9, 1H, H5) 
13C-NMR (methanol-d4, 125 MHz):  15.5 (CH3); 104.3 (C8); 116.0 (C4a); 117.4 (C2’, 
C6’); 121.5 (C6); 126.8 (C5); 127.9 (C4’); 130.4 (C3’, C5’), 136.2 (C3); 157.8, 160.7, 160.8, 
161.5 (C1’, C2, C7, C8a); 174.2 (C4) 
MS (ESI, m/z): 301.0 [M(35Cl)-H]-, 303.0 [M(37Cl)-H]- 
HPLC (method C, tR, min): 26.85 
3-(2-Chlorophenoxy)-7-hydroxy-2-methyl-4H-chromen-4-one, 115 
Following the general procedure 4.3.1.3., hydroxychromone 115 was obtained 
from acetoxychromone 112 (35 mg, 0.10 mmol) in 75% yield. 
 
Rf: 0.32 (hexane/ethyl acetate, 7:3) 
m.p.: 253-255 ºC 
IR (ATR): 3396 (OH); 1652 (C=O) 
1H-NMR (DMSO-d6, 500 MHz):  2.35 (s, 3H, CH3); 6.88 (dd, J = 8.3, 1.3, 1H, H6’); 
6.90 (d, J = 2.1, 1H, H8); 6.94 (dd, J = 8.7, 2.2, 1H, H6); 7.03 (dt, J = 7.7, 1.3, 1H, 
H4’/H5’); 7.17 (m, 1H, H4’/H5’); 7.51 (dd, J = 7.9, 1.5, 1H, H3’); 7.86 (d, J = 8.7, 1H, H5); 
10.9 (br s, 1H, OH) 
13C-NMR (DMSO-d6, 125 MHz):  15.3 (CH3); 102.2 (C8); 114.8 (C6’); 115.0 (C6); 
116.3, 120.9 (C2’, C4a); 123.1 (C4’/C5’); 126.9 (C5); 128.2 (C4’/C5’); 130.2 (C3’); 135.1 
(C3); 152.4, 156.9, 160.0, 162.7 (C1’, C2, C8a, C7); 170.4 (C4) 
MS (ESI, m/z): 301.0 [M(35Cl)-H]-, 303.0 [M(37Cl)-H]- 
HPLC (method C, tR, min): 25.76 
7-Hydroxy-2-methyl-3-phenoxy-4H-chromen-4-one, 116 
Following the general procedure 4.3.1.3., hydroxychromone 116 was obtained 
from acetoxychromone 113 (46 mg, 0.15 mmol) in 99% yield. 
 
Rf: 0.29 (hexane/ethyl acetate, 7:3) 
m.p.: 250-252 ºC 
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IR (ATR): 3229 (OH); 1594 (C=O); 1249 (C-O-C) 
1H-NMR (methanol-d4, 500 MHz):  2.39 (s, 3H, CH3); 6.89-6.95 (m, 4H, H6, H8, H2’, 
H6’); 7.01 (t, J = 7.4, 1H, H4’); 7.26-7.30 (m, 2H, H3’, H5’); 7.97 (d, J = 8.8, 1H, H5) 
13C-NMR (methanol-d4, 125 MHz):  15.7 (CH3); 103.3 (C8); 115.8 (C2’, C6’); 116.4 
(C6); 117.8 (C4a); 123.3 (C4’); 128.1 (C5); 130.7 (C3’, C5’); 137.0 (C3); 158.7, 159.1, 
162.6, 164.7 (C1’, C2, C7, C8a); 174.5 (C4) 
MS (ESI, m/z): 267.1 [M-H]- 
HPLC (method C, tR, min): 23.82 
4.3.5.4. Synthesis of chromones 117-119 
Methyl {[3-(4-chlorophenoxy)-2-methyl-4-oxo-4H-chromen-7-yl]oxy}acetate, 
117 
Following the general procedure 4.3.1.4., compound 117 was obtained from 
hydroxychromone 114 (82 mg, 0.27 mmol) and methyl 2-bromoacetate (0.10 mL, 0.95 
mmol) in 50% yield. Chromatography: hexane to hexane/ethyl acetate, 7:3. 
 
Rf: 0.48 (hexane/ethyl acetate, 7:3) 
m.p.: 147-149 ºC 
IR (ATR): 1761 (C=O); 1649 (C=O); 1237 (C-O-C) 
1H-NMR (methanol-d4, 500 MHz):  2.42 (s, 3H, CH3); 3.81 (s, 3H, OCH3); 4.92 (s, 
2H, CH2); 6.92-6.95 (m, 2H, H2’, H6’); 7.12-7.14 (m, 2H, H6, H8); 7.26-7.29 (m, 2H, H3’, 
H5’); 8.06 (d, J = 9.3, 1H, H5) 
13C-NMR (methanol-d4, 125 MHz):  15.7 (CH3); 52.8 (OCH3); 66.3 (CH2); 102.7 (C8); 
116.1 (C6); 117.5 (C2’, C6’); 119.4 (C4a); 128.0 (C5); 128.3 (C4’); 130.5 (C3’, C5’); 137.3 
(C3); 157.4 (C1’); 158.8 (C8a); 163.2 (C2); 164.3 (C7); 170.3 (C=O); 174.0 (C4) 
MS (ESI, m/z): 375.1 [M(35Cl)+H]+, 377.0 [M(37Cl)+H]+ 
HPLC (method C, tR, min): 27.19 
Methyl {[3-(2-chlorophenoxy)-2-methyl-4-oxo-4H-chromen-7-yl]oxy}acetate, 
118 
Following the general procedure 4.3.1.4., compound 118 was obtained from 
hydroxychromone 115 (30 mg, 0.10 mmol) and methyl 2-bromoacetate (0.04 mL, 0.35 
mmol) in 62% yield. Chromatography: hexane to hexane/ethyl acetate, 7:3. 
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Rf: 0.42 (hexane/ethyl acetate, 7:3) 
m.p.: 204-206 ºC 
IR (ATR): 1651 (C=O) 
1H-NMR (DMSO-d6, 700 MHz):  2.38 (s, 3H, CH3); 3.73 (s, 3H, OCH3); 5.03 (s, 2H, 
CH2); 6.93 (dd, J = 8.3, 1.3, 1H, H6’); 7.04 (dt, J = 7.9, 1.3, 1H, H4’); 7.12 (dd, J = 8.9, 
2.4, 1H, H6); 7.16-7.18 (m, 1H, H5’); 7.26 (d, J = 2.4, 1H, H8); 7.52 (dd, J = 8.0, 1.5, 
1H, H3’); 7.93 (d, J = 8.9, 1H, H5) 
13C-NMR (DMSO-d6, 175 MHz):  15.3 (CH3); 52.0 (OCH3); 65.0 (CH2); 101.6 (C8); 
114.87, 114.88 (C6, C6’); 117.9 (C4a); 121.0 (C2’); 123.2 (C4’); 126.6 (C5); 128.2 (C5’); 
130.3 (C3’); 135.4 (C3); 152.4 (C1’); 156.7 (C8a); 160.6 (C2); 162.1 (C7); 168.6 (C=O); 
170.4 (C4) 
MS (ESI, m/z): 375.0 [M(35Cl)+H]+, 377.0 [M(37Cl)+H]+ 
HPLC (method C, tR, min): 26.04 
Methyl [(2-methyl-4-oxo-3-phenoxy-4H-chromen-7-yl)oxy]acetate, 119 
Following the general procedure 4.3.1.4., compound 119 was obtained from 
hydroxychromone 116 (33 mg, 0.12 mmol) and methyl 2-bromoacetate (0.05 mL, 0.42 
mmol) in 60% yield. Chromatography: hexane to hexane/ethyl acetate, 7:3. 
 
Rf: 0.38 (hexane/ethyl acetate, 7:3) 
m.p.: 169-171 ºC 
IR (ATR): 1760 (C=O); 1650(C=O); 1234 (C-O-C) 
1H-NMR (methanol-d4, 700 MHz):  2.42 (s, 3H, CH3); 3.82 (s, 3H, OCH3); 4.92 (s, 
2H, CH2); 6.94 (d, J = 8.6, 2H, H2’, H6’); 7.02 (t, J = 7.4, 1H, H4’); 7.12-7.14 (m, 2H, H6, 
H8); 7.27-7.30 (m, 2H, H3’, H5’); 8.06 (d, J = 9.2, 1H, H5) 
13C-NMR (methanol-d4, 175 MHz):  15.7 (CH3); 52.8 (OCH3); 66.3 (CH2); 102.7 (C8); 
115.8 (C2’, C6’); 116.1 (C6); 119.4 (C4a); 123.4 (C4’); 128.0 (C5); 130.7 (C3’, C5’); 137.3 
(C3); 158.7 (C1’); 158.8 (C8a); 163.1 (C2); 164.2 (C7); 170.3 (C=O); 174.3 (C4) 
MS (ESI, m/z): 341.1 [M+H]+ 
HPLC (method C, tR, min): 24.50 
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4.3.5.5. Synthesis of pyrazoles 105-107 
{4-[4-(4-Chlorophenoxy)-5-methyl-1H-pyrazol-3-yl]-3-hydroxyphenoxy}acetic 
acid, 105 
Following the general procedure 4.3.1.5., pyrazole 105 was obtained from 
chromone 117 (14 mg, 0.04 mmol) in 99% yield. Chromatography: dichloromethane 
to dichloromethane/methanol, 8:2. 
 
Rf: 0.85 (dichloromethane/methanol, 7:3) 
m.p.: 121-123 ºC 
IR (ATR): 1627 (C=O) 
1H-NMR (methanol-d4, 700 MHz):  2.24 (s, 3H, CH3); 4.71 (s, 2H, CH2); 6.44 (dd, J 
= 8.9, 2.5, 1H, H6); 6.53 (d, J = 2.5, 1H, H2); 6.97-6.99 (m, 2H, H2’’, H6’’); 7.31-7.33 (m, 
2H, H3’’, H5’’); 7.64 (d, J = 8.8, 1H, H5) 
13C-NMR (methanol-d4, 175 MHz):  8.5 (CH3); 65.9 (CH2); 103.3 (C2); 107.3 (C6); 
108.2 (C4); 117.7 (C2’’, C6’’); 128.9 (C4’’); 130.3 (C5); 130.9 (C3’’, C5’’); 134.0, 137.5 (C4’, 
C5’); 138.3 (C3’/C4’); 157.5 (C3’/C4’); 157.6 (C1’’); 158.1 (C3); 161.6 (C1); 171.0 (C=O) 
HRMS (ESI, m/z): calculated for C18H1435ClN2O5 [M-H]-: 373.0597, found: 373.0577; 
calculated for C18H1437ClN2O5 [M-H]-: 375.0567, found: 375.0546 
HPLC (method C, tR, min): 23.84 
{4-[4-(2-Chlorophenoxy)-5-methyl-1H-pyrazol-3-yl]-3-hydroxyphenoxy}acetic 
acid, 106 
Following the general procedure 4.3.1.5, pyrazole 106 was obtained from 
chromone 118 (19 mg, 0.05 mmol) in 99% yield. Chromatography: dichloromethane 
to dichloromethane/methanol, 8:2. 
 
Rf: 0.95 (dichloromethane/methanol, 7:3) 
m.p.: 149-151 ºC 
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IR (ATR): 3365 (OH); 1629 (C=O) 
1H-NMR (methanol-d4, 700 MHz):  2.13 (s, 3H, CH3); 4.42 (s, 2H, CH2); 6.33 (dd, J 
= 8.8, 2.4, 1H, H6); 6.46 (d, J = 2.4, 1H, H2); 6.67 (dd, J = 8.3, 1.3, 1H, H6’’); 6.97 (dt, 
J = 7.8, 1.3, 1H, H4’’); 7.16-7.07 (m, 1H, H5’’); 7.46 (dd, J = 8.0, 1.5, 1H, H3’’); 7.54 (d, 
J = 8.8, 1H, H5) 
13C-NMR (methanol-d4, 175 MHz):  8.6 (CH3); 67.5 (CH2); 103.4 (C2); 107.0 (C6); 
110.5 (C4); 115.7 (C6’’); 123.2 (C2’’); 124.1 (C4’’); 128.5 (C5); 129.1 (C5’’); 131.6 (C3’’); 
133.2 (C5’); 154.9 (C1’’); 158.0 (C3); 160.6 (C1); 176.2 (C=O); C3’ and C4’ not observed 
HRMS (ESI, m/z): calculated for C18H1435ClN2O5 [M-H]-: 373.0597, found: 373.0574; 
calculated for C18H1437ClN2O5 [M-H]-: 375.0567, found: 375.0546 
HPLC (method C, tR, min): 22.74 
[3-Hydroxy-4-(5-methyl-4-phenoxy-1H-pyrazol-3-yl)phenoxy]acetic acid, 107 
Following the general procedure 4.3.1.5., pyrazole 107 was obtained from 
chromone 119 (10 mg, 0.03 mmol) in 99% yield. Chromatography: dichloromethane 
to dichloromethane/methanol, 8:2. 
 
Rf: 0.92 (dichloromethane/methanol, 7:3) 
m.p.: >180 ºC dec 
IR (ATR): 3440 (OH, NH); 1636 (C=O) 
1H-NMR (methanol-d4, 700 MHz):  2.11 (s, 3H, CH3); 4.38 (s, 2H, CH2); 6.32 (dd, J 
= 8.7, 2.2, 1H, H6); 6.46 (d, J = 2.2, 1H, H2); 6.88-6.91 (m, 2H, H2’’, H6’’); 6.99 (t, J = 
7.4, 1H, H4’’); 7.26-7.29 (m, 2H, H3’’, H5’’); 7.56 (d, J = 8.8, 1H, H5) 
13C-NMR (methanol-d4, 175 MHz):  14.4 (CH3); 68.2 (CH2); 103.3 (C2); 107.1 (C6); 
110.4 (C4); 115.9 (C2’’, C6’’); 123.2 (C4’’); 128.7 (C5); 130.8 (C3’’, C5’’); 133.5 (C5’); 158.7 
(C3); 159.6 (C1’’); 160.5 (C1); 177.1 (C=O); C3’ and C4’ not observed 
HRMS (ESI, m/z): calculated for C18H15N2O5 [M-H]-: 339.0986, found: 339.0975 
HPLC (method C, tR, min): 21.40 
4.3.6. Synthesis of final compound 120 
2-(2,4-Dichlorophenoxy)-1-phenylethanone, 121 
Following the general procedure 4.3.1.6., phenylethanone 121 was obtained from 
2-bromoacetophenone (366 mg, 1.84 mmol) in 70% yield. Chromatography: 
hexane/ethyl acetate, 9:1 to hexane/ethyl acetate, 8:2. 
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Rf: 0.50 (hexane/ethyl acetate, 5:1) 
m.p.: 72-74 ºC 
IR (ATR): 1700 (C=O); 1220 (C-O-C) 
1H-NMR (CDCl3, 300 MHz):  5.35 (s, 2H, CH2); 6.78 (d, J = 8.8, 1H, H6’); 7.14 (dd, J 
= 8.8, 2.5, 1H, H5’); 7.39 (d, J = 2.5, 1H, H3’); 7.49-7.54 (m, 2H, H3, H5); 7.61-7.66 (m, 
1H, H4); 7.99-8.01 (m, 2H, H2, H6) 
MS (ESI, m/z): 281.0, 283.0, 285.1 [M+H]+ 
HPLC (method A, tR, min): 17.26 
2-(2,4-Dichlorophenoxy)-3-(dimethylamino)-1-phenylbut-2-en-1-one, 122 
Following the general procedure 4.3.1.7., enaminone 122 was obtained from 
phenylethanone 121 (90 mg, 0.32 mmol) in 55% yield. Chromatography: hexane/ethyl 
acetate, 1:1 to ethyl acetate. 
 
Rf: 0.35 (ethyl acetate) 
IR (ATR): 1741 (C=O) 
1H-NMR (CDCl3, 300 MHz):  Mixture of isomers A:B (1:0.7): 2.06 (s, 3H, CH3 A); 2.45 
(s, 3H, CH3 B); 3.01 (s, 6H, N(CH3)2 B); 3.06 (s, 6H, N(CH3)2 A); 6.77 (d, J = 8.9, 1H, 
H6’ B); 6.80 (d, J = 8.9, 1H, H6’ A); 6.99 (dd, J = 8.9, 2.4, 1H, H5’ A); 7.00 (dd, J = 8.9, 
2.4, 1H, H5’ B); 7.16 (d, J = 2.4, 1H, H3’ B); 7.17 (d, J = 2.4, 1H, H3’ A); 7.21-7.30 (m, 
3H, H3, H4, H5); 7.63-7.71 (m, 2H, H2, H6) 
4-(2,4-Dichlorophenoxy)-5-methyl-3-phenyl-1H-pyrazole, 120 
Following the general procedure 4.3.1.5., pyrazole 120 was obtained from 
enaminone 122 (54 mg, 0.15 mmol) in 48% yield. Chromatography: toluene/acetone, 
6:1 to toluene/acetone, 1:1. 
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Rf: 0.41 (toluene/acetone, 1:1) 
IR (ATR): 3280 (NH) 
1H-NMR (CDCl3, 500 MHz):  2.14 (s, 3H, CH3); 6.61 (d, J = 8.9, 1H, H6’’); 7.00 (dd, J 
= 8.9, 2.5, 1H, H5’’); 7.27-7.30 (m, 1H, H4); 7.33-7.36 (m, 2H, H3, H5); 7.42 (d, J = 2.5, 
1H, H3’’); 7.69-7.71 (m, 2H, H2, H6) 
13C-NMR (CDCl3, 125 MHz):  9.7 (CH3); 115.6 (C6’’); 123.3 (C2’’/C4’’); 125.9 (C2, C6); 
127.4 (C2’’/C4’’); 127.9 (C5’’); 128.6 (C4); 129.0 (C3, C5); 129.7 (C1); 130.4 (C3’’); 133.5, 
136.8 (C4’, C5’); 138.7 (C3’); 152.7 (C1’’) 
HRMS (ESI, m/z): calculated for C16H11Cl2N2O [M-H]-: 317.0254, found: 317.0266 
HPLC (method A, tR, min): 14.24 
4.3.7. Synthesis of final compounds 123, 124 
4-[4-(2,4-Dichlorophenoxy)-5-methyl-1H-pyrazol-3-yl]benzene-1,3-diol, 123 
Following the general procedure 4.3.1.5., pyrazole 123 was obtained from 99 (82 
mg, 0.24 mmol) in 65% yield. Chromatography: dichloromethane to 
dichloromethane/methanol, 8:2. 
 
Rf: 0.23 (hexane/ethyl acetate, 6:4) 
m.p.: 206-208 ºC 
IR (ATR): 3293 (OH, NH) 
1H-NMR (methanol-d4, 300 MHz):  2.12 (s, 3H, CH3); 6.21 (dd, J = 8.5, 2.1, 1H, H6); 
6.34 (d, J = 2.0, 1H, H2); 6.66 (d, J = 8.9, 1H, H6’’); 7.11 (dd, J = 8.9, 2.4, 1H, H5’’); 
7.40 (d, J = 8.6, 1H, H5); 7.50 (d, J = 2.4, 1H, H3’’) 
13C-NMR (methanol-d4, 75 MHz):  8.6 (CH3); 103.9 (C2); 108.0 (C6); 108.9 (C4); 116.8 
(C6’’); 124.1 (C4’’); 128.3 (C2’’); 128.6 (C5); 129.1 (C5’’); 130.9 (CAr); 131.1 (C3’’); 133.0, 
153.9 (2CAr); 158.1 (C1’’); 159.55, 159.63 (C1, C3) 
HRMS (ESI, m/z): calculated for C16H13Cl2N2O3 ([M+H]+): 351.0298, found: 351.0323 
HPLC (method C, tR, min): 29.29 
2-[4-(2,4-Dichlorophenoxy)-5-methyl-1H-pyrazol-3-yl]-5-methoxyphenol, 124 
To a solution of pyrazole 123 (25 mg, 0.07 mmol, 1 equiv) in anhydrous acetone 
(0.8 mL) under an argon atmosphere, K2CO3 (21 mg, 0.15 mmol, 2.1 equiv) and 
iodomethane (18 mg, 0.13 mmol, 1.8 equiv) were added and the reaction was stirred 
at 65ºC for 6 h. After cooling to room temperature, the mixture was concentrated and 
Experimental section 
- 165 - 
the residue was dissolved in ethyl acetate and washed with water and brine. The 
organic layer was dried over Na2SO4, filtered and concentrated under reduced 
pressure. The crude was purified by flash chromatography (hexane to hexane/ethyl 
acetate, 7:3) to yield pure compound 124 in 19% yield. 
 
Rf: 0.50 (hexane/ethyl acetate, 6:4) 
m.p.: 220-222 ºC 
IR (ATR): 3352 (OH, NH) 
1H-NMR (methanol-d4, 700 MHz):  2.15 (s, 3H, CH3); 3.85 (s, 3H, OCH3); 6.18 (dd, 
J = 8.6, 2.5, 1H, H4); 6.31 (d, J = 2.4, 1H, H6); 6.68 (d, J = 8.9, 1H, H6’’); 7.14 (dd, J = 
8.9, 2.5, 1H, H5’’); 7.37 (d, J = 8.6, 1H, H3); 7.53 (d, J = 2.5, 1H, H3’’) 
13C-NMR (methanol-d4, 175 MHz):  8.1 (CH3); 37.1 (OCH3); 104.0 (C6); 107.9 (C4); 
109.1 (C2); 116.8 (C6’’); 124.0 (C4’’); 128.3 (C3); 128.4 (C2’’); 129.1 (C5’’); 131.2 (C3’’); 
132.8, 133.2, 141.6 (C3’, C4’, C5’); 153.9 (C1’’); 158.4, 159.5 (C5, C1) 
HRMS (ESI, m/z): calculated for C17H15Cl2N2O3 ([M+H]+): 365.0454, found: 365.0485 
HPLC (method C, tR, min): 21.90 
4.3.8. Synthesis of final compound 125 
2-(2,4-Dichlorophenoxy)-1-(4-methoxyphenyl)ethanone, 126 
Following the general procedure 4.3.1.6., arylethanone 126 was obtained from 2-
bromo-1-(4-methoxyphenyl)ethanone (1,69 g, 7.36 mmol) in 80% yield. 
Chromatography: hexane/ethyl acetate, 9:1 to hexane/ethyl acetate, 1:1. 
 
Rf: 0.40 (hexane/ethyl acetate, 5:1) 
m.p.: 110-112 ºC 
IR (ATR): 1691 (C=O); 1231 (C-O-C) 
1H-NMR (CDCl3, 300 MHz):  3.88 (s, 3H, CH3); 5.27 (s, 2H, CH2); 6.77 (d, J = 8.8, 
1H, H6’); 6.93-6.98 (m, 2H, H3, H5); 7.12 (dd, J = 8.8, 2.5, 1H, H5’); 7.37 (d, J = 2.5, 
1H, H3’); 7.97-8.02 (m, 2H, H2, H6) 
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13C-NMR (CDCl3, 75 MHz):  55.7 (CH3); 72.0 (CH2); 114.2 (C3, C5); 115.0 (C6’); 124.2, 
126.9, 127.4 (C1, C2’, C4’); 127.7 (C5’); 130.4 (C3’); 130.8 (C2, C6); 152.8, 164.4 (C4, 
C1’); 192.3 (C=O) 
MS (ESI, m/z): 311.1, 313.0, 315.1 [M+H]+ 
HPLC (method A, tR, min): 17.81 
2-(2,4-Dichlorophenoxy)-3-(dimethylamino)-1-(4-methoxyphenyl)but-2-en-1-
one, 127 
Following the general procedure 4.3.1.7., enaminone 127 was obtained from 
arylethanone 126 (263 mg, 0.85 mmol) in 52% yield. Chromatography: hexane/ethyl 
acetate, 1:1 to ethyl acetate. 
 
Rf: 0.30 (ethyl acetate) 
IR (ATR): 1741 (C=O) 
1H-NMR (CDCl3, 300 MHz):  Mixture of isomers A:B (1:0.8): 2.04 (s, 3H, CH3 A); 2.40 
(s, 3H, CH3 B); 2.99 (s, 6H, N(CH3)2 B); 3.02 (s, 6H, N(CH3)2 A); 3.78 (s, 3H, OCH3); 
6.74-6.82 (m, 3H, H3, H5, H6’); 6.99 (dd, J = 8.9, 2.5, 1H, H5’ A); 7.00 (dd, J = 8.9, 2.5, 
1H, H5’ B); 7.19 (d, J = 2.2, 1H, H3’ B); 7.20 (d, J = 2.2, 1H, H3’ A); 7.72-7.78 (m, 2H, H2, 
H6) 
4-(2,4-Dichlorophenoxy)-5-methyl-3-(4-methoxyphenyl)-1H-pyrazole, 128 
Following the general procedure 4.3.1.5., pyrazole 128 was obtained from 
enaminone 127 (154 mg, 0.41 mmol) in 44% yield. Chromatography: hexane/ethyl 
acetate, 4:1 to hexane/ethyl acetate, 1:1. 
 
Rf: 0.16 (hexane/ethyl acetate, 1:1) 
IR (ATR): 3133 (NH); 1251 (C-O-C) 
1H-NMR (CDCl3, 500 MHz):  2.13 (s, 3H, CH3); 3.79 (s, 3H, OCH3); 6.60 (d, J = 8.9, 
1H, H6’’); 6.85-6.87 (m, 2H, H3, H5); 7.00 (dd, J = 8.9, 2.5, 1H, H5’’); 7.42 (d, J = 2.5, 
1H, H3’’); 7.60-7.63 (m, 2H, H2, H6) 
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13C-NMR (CDCl3, 125 MHz):  9.7 (CH3); 55.4 (OCH3); 114.5 (C3, C5); 115.6 (C6’’); 
122.1 (C1); 123.3 (C2’’/C4’’); 127.26 (C2, C6); 127.32 (C2’’/C4’’); 127.9 (C5’’); 130.4 (C3’’); 
132.9, 137.0 (C4’, C5’); 138.3 (C3’); 152.7 (C1’’); 159.9 (C4) 
MS (ESI, m/z): 349.1, 351.1, 353.0 [M+H]+ 
HPLC (method A, tR, min): 20.54 
4-(2,4-Dichlorophenoxy)-3-(4-hydroxyphenyl)-5-methyl-1H-pyrazole, 129 
To a solution of pyrazole 128 (49 mg, 0.14 mmol, 1 equiv) in anhydrous 
dichloromethane (3.0 mL) at -78°C under an argon atmosphere, BBr3 (105 mg, 0.42 
mmol, 3.0 equiv) was added and the mixture was stirred at -78°C for 1 h. After this 
time the reaction was warmed up to room temperature and stirred at this temperarure 
for 20 h. Then, the mixture was washed with water and brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude was purified by flash 
chromatography (hexane/ethyl acetate, 1:1 to 3:7) to yield pure compound 129 in 70% 
yield. 
 
Rf: 0.54 (hexane/ethyl acetate, 1:3) 
IR (ATR): 3267 (OH, NH); 1251 (C-O-C) 
1H-NMR (CDCl3, 500 MHz):  2.14 (s, 3H, CH3); 6.61 (d, J = 8.9, 1H, H6’’); 6.80 (d, J 
= 8.7, 2H, H2, H6); 7.02 (dd, J = 8.8, 2.5, 1H, H5’’); 7.42 (d, J = 2.4, 1H, H3’’); 7.54 (d, J 
= 8.6, 2H, H3, H5) 
13C-NMR (CDCl3, 125 MHz):  9.7 (CH3); 115.6 (C6’’); 116.0 (C2, C6); 122.2 (C4); 123.3, 
127.4 (C2’’, C4’’); 127.5 (C3, C5); 127.9 (C5’’); 130.4 (C3’’); 133.0, 136.9 (C4’, C5’); 138.6 
(C3’); 152.7 (C1’’); 156.1 (C1) 
MS (ESI, m/z): 333.0.1, 335.0, 336.9 [M-H]- 
HPLC (method A, tR, min): 17.81 
4-(2,4-Dichlorophenoxy)-3-(4-(methoxycarbonyl)methoxyphenyl)-5-methyl-1H-
pyrazole, 130 
To a solution of pyrazole 129 (31 mg, 0.09 mmol, 1 equiv) in anhydrous DMF (2.0 
mL) under an argon atmosphere, K2CO3 (26 mg, 0.19 mmol, 2 equiv) and methyl 2-
bromoacetate (0.009 mL, 0.09 mmol, 1 equiv) were added at -20°C. After 4 h at this 
temperature, the reaction was stirred overnight at room temperature. Then, another 
portion of methyl 2-bromoacetate (0.002 mL, 0.02 mmol, 0.2 equiv) was added and 
the mixture was stirred for 4 h. The reaction mixture was diluted with ethyl acetate, 
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washed with water and brine, dried over Na2SO4, filtered and concentrated under 
reduced pressure. The crude was purified by flash chromatography (toluene/acetone, 
10:1 to toluene/acetone, 3:1) to yield pure compound 130 in 32% yield. 
 
Rf: 0.49 (toluene/acetone, 1:1) 
IR (ATR): 3133 (NH); 1761 (C=O) 
1H-NMR (CDCl3, 500 MHz):  2.14 (s, 3H, CH3); 3.79 (s, 3H, OCH3); 4.62 (s, 2H, CH2); 
6.61 (d, J = 8.9, 1H, H6’’); 6.88 (d, J = 9.0, 2H, H2, H6); 7.02 (dd, J = 8.9, 2.5, 1H, H5’’); 
7.42 (d, J = 2.5, 1H, H3’’); 7.63 (d, J = 9.0, 2H, H3, H5) 
13C-NMR (CDCl3, 125 MHz):  9.7 (CH3); 52.5 (OCH3); 65.4 (CH2); 115.2 (C2, C6); 
115.6 (C6’’); 123.3 (C2’’/C4’’); 123.5 (C4); 127.35 (C3, C5); 127.40 (C2’’/C4’’); 127.9 (C5’’); 
130.4 (C3’’); 133.1, 136.5 (C4’, C5’); 138.6 (C3’); 152.7 (C1’’); 158.0 (C1); 169.3 (C=O) 
MS (ESI, m/z): 407.1, 409.1, 411.0 [M+H]+ 
HPLC (method A, tR, min): 12.86 
4-(2,4-Dichlorophenoxy)-3-(4-carboxymethoxyphenyl)-5-methyl-1H-pyrazole, 
125 
A mixture of pyrazole 130 (10 mg, 0.02 mmol, 1 equiv) and 1M NaOH (0.03 mL, 
0.02 mmol, 1.2 equiv) in 1,4-dioxane (1 mL) was stirred at 60°C for 4 h under an argon 
atmosphere. After cooling to room temperature, the mixture was neutralized with 1M 
HCl, and extracted with ethyl acetate (2x). The combined organic phases were 
washed with brine, dried over Na2SO4, filtered and concentrated under reduced 
pressure. The crude was purified by flash chromatography (ethyl acetate/methanol, 
8:2 to ethyl acetate/methanol, 7:3) to yield pure compound 125 in 99% yield.  
 
Rf: 0.13 (ethyl acetate/methanol, 7:3) 
m.p.: 158-160 ºC 
IR (ATR): 3321 (NH, OH) 
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1H-NMR (methanol-d4, 700 MHz):  2.11 (s, 3H, CH3); 4.63 (s, 2H, CH2); 6.66 (d, J = 
8.9, 1H, H6’’); 6.91-6.94 (m, 2H, H2, H6); 7.12 (dd, J = 8.9, 2.5, 1H, H5’’); 7.50 (d, J = 
2.5, 1H, H3’’); 7.61-7.63 (m, 2H, H3, H5) 
13C-NMR (methanol-d4, 175 MHz):  9.2 (CH3); 66.1 (CH2); 115.9 (C2, C6); 116.7 (C6’’); 
124.1 (C2’’/C4’’); 124.4 (C4); 128.2 (C3, C5); 128.3 (C2’’/C4’’); 129.1 (C5’’); 131.1 (C3’’); 
133.7, 137.7 (C4’, C5’); 139.2 (C3’); 154.1 (C1’’); 159.5 (C1); 172.9 (C=O) 
HRMS (ESI, m/z): calculated for C18H13Cl2N2O4 ([M-H]-): 391.0258, found: 391.0247 
HPLC (method A, tR, min): 17.53 
4.3.9. Synthesis of final compound 133 
3-(2,4-Dichlorophenoxy)-7-hydroxy-4H-chromen-4-one, 131 
A mixture of 2,4-dihydroxyphenyl ketone 97 (40 mg, 0.13 mmol, 1 equiv) and 
BF3·Et2O (0.02 mL, 0.19 mmol, 1.5 equiv) in anhydrous DMF (1 mL), was stirred at 
room temperature for 1 h under an argon atmosphere. Then, the reaction was heated 
at 50°C, methanesulphonyl chloride (0.02 mL, 0.23 mmol, 1.8 equiv) was added and 
the mixture was stirred at 100°C for 90 min. After cooling to room temperature, the 
mixture was diluted with ethyl acetate and washed with a 1:1 mixture of water and 
brine. The organic phase was dried over Na2SO4, filtered and concentrated under 
reduced pressure. The crude was purified by flash chromatography (hexane/ethyl 
acetate, 8:2 to hexane/ethyl acetate, 4:6) to yield pure compound 131 in 97% yield.  
 
Rf: 0.60 (hexane/ethyl acetate, 1:2) 
IR (ATR): 3091 (OH); 1629 (C=O); 1263 (C-O-C) 
1H-NMR (methanol-d4, 300 MHz):  6.91 (d, J = 8.8, 1H, H6’); 6.91 (d, J = 2.2, 1H, H8); 
6.97 (dd, J = 8.8, 2.2, 1H, H6); 7.19 (dd, J = 8.9, 2.5, 1H, H5’); 7.50 (d, J = 2.5, 1H, 
H3’); 8.01 (d, J = 8.8, 1H, H5); 8.36 (s, 1H, H2) 
13C-NMR (methanol-d4, 75 MHz):  103.6 (C8); 116.8 (C6); 118.0 (C6’); 118.3 (C4a); 
124.8 (C2’/C4’); 128.2 (C5); 128.9 (C5’); 129.0 (C2’/C4'); 131.1 (C3’); 140.8 (C3); 150.8 
(C2); 153.6 (C1’); 159.8 (C8a); 165.1 (C7); 173.6 (C4) 
MS (ESI, m/z): 321.0, 323.0, 324.9 [M-H]- 
HPLC (method C, tR, min): 28.80 
Ethyl {[3-(2,4-dichlorophenoxy)-4-oxo-4H-chromen-7-yl]oxyacetate, 132 
Following the general procedure 4.3.1.4., compound 132 was obtained from 
hydroxychromone 131 (35 mg, 0.11 mmol) and ethyl 2-bromoacetate (0.04 mL, 0.39 
mmol) in 91% yield.  
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Rf: 0.50 (hexane/ethyl acetate, 2:1) 
IR (ATR): 1752 (C=O); 1653 (C=O); 1196 (C-O-C) 
1H-NMR (CDCl3, 300 MHz):  1.32 (t, J = 7.1, 3H, CH3); 4.30 (q, J = 7.1, 2H, CH2CH3); 
4.73 (s, 2H, CH2); 6.82 (d, J = 8.8, 1H, H6’); 6.88 (d, J = 2.4, 1H, H8); 7.05 (dd, J = 9.0, 
2.4, 1H, H6); 7.11 (dd, J = 8.8, 2.5, 1H, H5’); 7.44 (d, J = 2.5, 1H, H3’); 8.03 (s, 1H, H2); 
8.17 (d, J = 9.0, 1H, H5) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 62.0 (CH2CH3); 65.6 (CH2), 101.7 (C8); 115.0 
(C6); 117.4 (C6’); 119.4 (C4a); 124.4 (C2’/C4’); 127.8 (C5’); 128.0 (C5); 128.6 (C2’/C4’); 
130.5 (C3’); 140.6 (C3); 147.9 (C2); 151.8 (C1’); 157.6 (C8a); 162.5 (C7); 167.8 (C=O), 
171.6 (C4) 
MS (ESI, m/z): 408.9, 410.9, 412.9 [M+H]+ 
HPLC (method A, tR, min): 17.52 
{4-[4-(2,4-Dichlorophenoxy)-1H-pyrazol-3-yl]-3-hydroxyphenoxy}acetic acid, 
133 
Following the general procedure 4.3.1.5., pyrazole 133 was obtained from 
chromone 132 (27 mg, 0.07 mmol) in 58% yield. Chromatography: ethyl 
acetate/methanol, 9:1 to ethyl acetate/methanol, 8:2. 
 
Rf: 0.08 (ethyl acetate/methanol, 7:3) 
IR (ATR): 3187 (OH, NH); 1627 (C=O) 
1H-NMR (methanol-d4, 500 MHz):  4.42 (s, 2H, CH2); 6.39 (dd, J = 8.8, 2.5, 1H, H6); 
6.49 (d, J = 2.5, 1H, H2); 6.84 (d, J = 8.9, 1H, H6’’); 7.16 (dd, J = 8.9, 2.5, 1H, H5’’); 
7.50 (d, J = 2.5, 1H, H3’’); 7.57 (d, J = 8.7, 1H, H5); 7.61 (br s, 1H, H5’) 
13C-NMR (methanol-d4, 125 MHz):  67.8 (CH2); 103.5 (C2); 107.2 (C6); 110.1 (C4); 
117.8 (C6’’); 124.6 (C2’’/4’’); 128.7 (C5); 128.9 (C2’’/4’’); 129.1 (C5’’); 131.1 (C3’’); 136.6 
(C4’); 154.4 (C1’’); 157.9 (C3); 160.8 (C1); 176.4 (C=O); C3’ and C5’ not observed 
HRMS (ESI, m/z): calculated for C17H11Cl2N2O5 ([M-H]–): 393.0050, found: 393.0017  
HPLC (method A, tR, min): 21.92 
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4.4. Biological assays 
4.4.1. General reagents 
Collagen, poly-D-lysine, poly-L-lysine and LPA were purchased from Aldrich. 
Ionomycin was purchased from Cayman. RH7777 hepatoma cells stably expressing 
the LPA1 receptor and their corresponding non-transfected controls were kindly 
provided by Prof. Gabor Tigyi (University of Tennessee Health Science Center, 
Memphis, Tennessee, USA). B103 neuroblastoma cells stably expressing the LPA2 
or LPA3 receptors were provided by Prof. Jerold Chun (The Scripps Research 
Institute, La Jolla, California, USA). Retrovirus expression vector (LZRS-EGFP) and 
Phoenix retrovirus producer cell lines were provided by Prof. Garry P. Nolan (Stanford 
University, California, USA).  
4.4.2. Cell culture  
All reagents were from Gibco. All cells were grown in Dulbecco’s modified Eagle 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% non-essential 
amino acids, 1% sodium pyruvate, 100 U/mL penicillin, and 100 µg/mL streptomycin 
in a 5% CO2 humidified atmosphere at 37ºC. For passage, cells were rinsed with 
phosphate buffered saline (PBS) and incubated with 0.125% trypsin, 0.02% EDTA 
solution for 2 min at 37ºC. Detached cells were resuspended in growth medium, 
counted if necessary, and splitted onto dishes containing fresh media.  
4.4.3. Evaluation of receptor activation by Ca2+ mobilization assay  
Changes in intracellular calcium levels were measured by using the fluorescent 
calcium sensitive dye Fluo-4NW (Invitrogen). RH7777 cells or B103 cells were plated 
on poly-D-lysine or collagen-coated, respectively, black-wall clear-bottom 96-well 
plates (Corning) at a density of 50000 cells/well and cultured overnight. The culture 
medium was then replaced with Fluo-4 NW dye loading solution containing 2.5 μM of 
probenecid and incubated for 30 min at 37ºC followed by an additional 30 min at room 
temperature. Fluorescence changes were registered in a FluoStar Optima instrument 
(BMG Labtech) at 525 nm using an excitation wavelength of 494 nm. Each well was 
monitored for 240 s. 20 μL of the test compound from a 6x stock solution in assay 
buffer were added after 120 s of starting the measurement. Ca2+ transient increase 
was quantified by calculating the difference between maximum and baseline values 
for each well. As positive controls, 10 μM LPA and 10 μM ionomycin were included in 
every experiment. At this concentration, LPA induced a response about 30-33% of 
the one shown by ionomycin, which is in agreement with previously described 
results.87 
The data presented are from two to four independent experiments carried out in 
triplicate or quadruplicate. Dose-response curves were generated and EC50 and IC50 
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values calculated by nonlinear regression analysis using PRISM software version 5 
(GraphPad Software Inc, San Diego, CA, USA).  
4.4.4. BSI experiments 
BSI utilizes a red helium-neon (HeNe) laser (λ = 632.8 nm) to illuminate the 
microfluidic channel in a simple optical train. The laser is coupled to a collimating lens 
through a single-mode fiber, producing a 100 μm diameter beam and yielding probe 
volumes in the 300 picoliter range. When the laser beam intersects the fluid contained 
in the channel, a set of high-contrast interference fringes is produced, the spatial 
position of which depends on the RI of the fluid within the channel. The fringes were 
monitored in the direct backscatter region at relatively shallow angles (typically <7°) 
using a Garry 3000 linear array CCD camera (Ames Photonics). The camera was 
positioned so that the centroid of the interference pattern was located just above the 
lens on the end of the single-mode optical fiber to ensure that the alignment was along 
a central plane. Under these conditions the fringe pattern contains a dominant Fourier 
frequency; the phase of this dominant frequency is the BSI fringe shift signal, in 
radians. 
BSI chips were isotropically etched in borosilicate glass to give a cross-section 
described by two quarter-circles of 40 μm radius connected by a 10 μm flat region, 
manufactured by Micronit. For BSI measurements, the chip was maintained in the 
instrument at 25°C using a feedback-controlled peltier system. 
A cell pellet containing approximately 106 cells was re-suspended in 1 mL of ice-
cold protease inhibitor cocktail in Dulbecco’s PBS (Gibco) and sonicated during 1 min 
and 30 s at 4°C. This solution was then centrifuged for 10 min at 10000g and at 4°C, 
and the resulting supernatant was centrifuged for another 50 min at 10000g and at 
4°C. Protein concentration was determined, and 50 µL aliquots (protein concentration 
= 0.16 mg/mL) were mixed with 50 µL of a solution that contained the appropriate 
ligand concentration (0 to 0.5 µM) in buffer (Dulbecco’s PBS). 1 μL of each sample 
was introduced into the microfluidic channel for each measurement, of which 290 
picoliters are interrogated by the laser. Five aliquots containing different 
concentrations of ligand were used to generate a complete binding curve and to 
determine the KD value, using GraphPad Prism software. 
4.4.5. Receptor internalization assay  
B103 neuroblastoma cells overexpressing LPA1 receptor were plated on poly-L-
lysine-coated glass coverslips in 24-well plates (5·104 cells per well) and serum-
starved overnight. For the experiment, media was replaced with 1 mL fresh serum-
free DMEM, supplemented with 0.1% FAF BSA, 1 μM LPA, or compound. After 15 
min, cells were fixed with 4% paraformaldehyde and permeabilized with 0.025% 
Triton X-100/PBS for 15 min. F-actin was detected with rhodamine-phalloidin (Sigma) 
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in PBS and nuclei with DAPI (Sigma). For receptor internalization, cells were analysed 
using confocal fluorescence microscopy (Carl Zeiss). 
4.4.6. Receptor desensitization assay  
4.4.6.1. Primary culture of sensory neurons 
DRG were harvested from neonatal Wistar rats (3-5 days old). Ganglia were 
digested with 0.25% (w/v) collagenase (type IA) in DMEM-glutamax (Invitrogen) with 
1% P/S (5000 U/mL, Invitrogen) for 1 h (37ºC, 5% CO2). After digestion, rat DRG was 
mechanically dissociated using a glass Pasteur pipette. Single cell suspension was 
passed through a 100 μm cell strainer, and washed with DMEM glutamax plus 10% 
FBS (Invitrogen) and 1% P/S. Cells were seeded at the 30 µL of medium containing 
cells on microelectrode array chambers previously coated with poly-L-lysine (8.33 
μg/mL) and laminin (5 μg/mL). After 2 h, medium was replaced with DMEM glutamax, 
10% FBS and 1% P/S, supplemented with 50 ng/mL mouse nerve growth factor 2.5s 
(Promega), and 1.25 μg/mL cytosine arabinoside when required (37ºC, 5% CO2). All 
experiments were made 48 h after cell seeding. 
4.4.6.2. Microelectrode Array (MEA) 
Extracellular recordings were made using multiple electrode planar arrays of 60-
electrode thin MEA chips, with 30 µm diameter electrodes and 200 µm inter-electrode 
spacing with an integrated reference electrode (Multichannel Systems GmbH). The 
electrical activity of primary sensory neuron was recorded by the MEA1060 System 
(Multi Channel Systems GmbH), and MC_Rack software version 4.3.0 at a sampling 
rate of 25 kHz. LPA and (S)-3a were perfused at 10 µM for 15 s to identify evoked 
neuronal spikes on cultured rat DRG neurons, using continuous perfusion system (2 
mL/min flux). Capsaicin (500 nM) was applied at the end of the protocol to measure 
TRPV1 sensitivity of the neurons which were exposed to LPA or (S)-3a. Data were 
analyzed using MC_RACK spike sorter and Neuroexplorer Software (Nex 
Technologies). An evoked spike was defined when the amplitude of the neuronal 
electrical activity overcame a threshold set at -20 µV. The recorded signals were then 
processed to extract mean spike frequency. 
4.4.6.3. Calcium microfluorography 
DRG on coverslips loaded with 5 μM fluo-4-acetoxymethyl ester (Fluo-4AM) plus 
0.02% pluronic acid (Molecular Probes, Invitrogen) in HBSS extracellular solution 
(140 NaCl, 4 KCl, 1 MgCl2, 1.8 CaCl2, 5 D-glucose), and 10 HEPES, pH 7.4 for 1 h 
(37°C, 5% CO2) were mounted in a RC-25 chamber (Harvard Apparatus), and 
continuously perfused with test solutions at room temperature. Fluorescence from 
individual neurons monitored through a 10x air objective (Aixiovert 200 inverted 
microscope, Carl Zeiss) with an ORCA-ER CCD camera (Hamamatsu Photonics). 
Pre-programed protocols applied via computer-controlled pinch valves (Bioscience 
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Tools, 5 mL/min flux). Fluo-4AM excited at 500 nm and emitted fluorescence filtered 
at 535 nm (Lambda-10-2-filter wheel, Sutter Instruments). Images processed with 
AquaCosmos package software (Hamamatsu Photonics). LPA and (S)-3a were 
perfused at 10 μM for 10 s. TRPV1 channel activity was evoked with 10 s-application 
of Caps at 1 μM. 10 s pulse of 40 mM KCl was applied to distinguish neuronal viability. 
Ionomycin was used at 5 μM. Intracellular Ca2+ increase calculated as fluorescence 
difference between baseline and the peak reached. An evoked response defined 
when intensity overcame 20% of baseline. 
4.4.7. PAMPA assay 
The assessment of the membrane permeability of ligand 103 and reference 
compounds propranolol and metoprolol was performed in a commercially available 
96-well Corning Gentest pre-coated PAMPA plate system (Cultek S.L.U., Spain). 
Prior to use, the pre-coated PAMPA plate system was warmed to room temperature 
for 30 min and 300 μL of 200 μM solution of tested compound in 2% DMSO in PBS 
(pH 7.4) were added into wells in the receiver (donor) plate. Then 200 μL of PBS were 
added into wells in the filter (acceptor) plate. The filter plate was placed on the receiver 
plate by slowly lowering the pre-coated PAMPA plate until it sits on the receiver plate. 
The assembly was incubated at room temperature for 5 h, and then buffer samples 
were collected carefully from each plate. The final concentrations of compound in both 
donor and acceptor wells were analyzed by HPLC-MS and quantification was 
estimated by using the peak area integration normalized with an internal standard. 
Permeability value of the compounds was calculated using the following formula: P 
(cm/s) = {-ln[1-CA(t)/Ceq]}/[A*(1/VD+1/VA)*t], where A = filter area (0.3 cm2), VD = donor 
well volume (0.3 mL), VA = acceptor well volume (0.2 mL), t = incubation time (s), CA(t) 
= compound concentration (μM) in acceptor well at time t, CD(t) = compound 
concentration (μM) in donor well at time t, and Ceq = [CD(t)*VD+CA(t)*VA]/(VD+VA). 
Assays were performed in duplicate and the compound was tested in two different 
plates on different days.
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5. SUMMARY 
5.1. Introduction and Objectives 
Lysophospholipids (LPs) are cell membrane lipid derivatives that also act as 
extracellular signals and play important roles in humans and other mammals. Analysis 
of LPs in human body fluids from subjects with different pathophysiological conditions 
reveal not only the relevance of LPs and their receptors in human diseases, but also 
their potential application as biomarkers and/or therapeutic targets.1,2 Among them, 
lysophosphatidic acid (LPA) stands out as a molecule that elicits a plethora of 
biological effects by binding to specific G protein-coupled receptors: LPA1–6 
receptors.3-5  
LPA regulates a wide variety of biological activities, notably within the developing 
and adult nervous system.6,7 Considering the pleiotropic effects of LPA on many 
nervous system cell types, together with data showing localized up-regulation of LPA 
receptors after injury in mice and humans, it is likely that LPA regulates essential 
aspects of the cellular reorganization after neural trauma.8 Among all 
neuropathologies where LPA plays an important role, neurophatic pain (NP)9-13 and 
spinal cord injury (SCI)14-16 are high incidence and seriously disabling conditions which 
currently lack specific pharmacological therapies. In this context, LPA1 and LPA2 
receptor subtypes have been functionally linked to many neural processes associated 
to these pathologies,17,18 but the lack of potent and selective agonists and antagonists 
has impaired the delineation of their specific role. Hence, we have focused our efforts 
on the development of such agents to clarify the biological role of LPA1 and LPA2 
receptors in NP and SCI.  
This overall objective involves the following steps:  
1. Design and synthesis of new ligands with agonist or antagonist activity at LPA1 
and LPA2 receptors.  
2. Determination of the activity and selectivity at LPA receptors.  
3. Biological validation of the selected compounds.  
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5.2. Results and Discussion 
5.2.1. Development of new agonists for the LPA1 receptor 
In the case of NP, we proposed a stategy based on targeting LPA1 receptor with 
a selective agonist, which, after activation, should promote receptor desensitization 
and internalization, and hence, could produce long-lasting antinociceptive effects.19-21 
In order to find new molecular entities with agonist activity at LPA1, we used the 
structure of the endogenous ligand, LPA, as starting point. Initially, two series of 
compounds were designed: series I, which comprised changes in the acid group 
attached to the glycerol backbone of LPA, and series II, which included modifications 
in the hydrophobic chain (Figure 1). 
 
Figure 1. Design of new LPA1 ligands. 
Regarding series I, it has been shown that changes in the polar head of LPA are 
poorly tolerated, so phosphate mimetics, specifically carboxylic and boronic acids, 
and tetrazole were chosen as acidic replacements.22 Compounds belonging to series 
I were synthesized according to Schemes 1-3. It must be noted that the reaction 
conditions employed for the obtention of these derivatives led to the formation of 
lactones 1b and 1c instead of the expected malonic acid derivatives (Scheme 1). 
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Scheme 1. Reagents and conditions: (a) tert-Butyl bromoacetate, NaH, TBAI, THF, 0ºC to 
50ºC, 16 h, 22%; (b) H2, 10% Pd(C), EtOH, 60ºC, 89-95%; (c) mesyl chloride, Et3N, DCM, 0ºC 
to rt, 1 h, 80%; (d) di-tert-butyl malonate, NaH, NaI, DMF:THF, 0ºC to 80ºC, 17 h, 76%; (e) 
Selectfluor®, NaH, THF:DMF, 48 h, 0ºC to rt, 99%; (f) oleoyl chloride, 2,4,6-collidine, DCM, -
78ºC to rt, 24 h, 36-99%; (g) TFA, DCM, rt, 17-18 h, 52-99%. 
 
Scheme 2. Reagents and conditions: (a) Tosyl chloride, pyridine, DCM, 0ºC to rt, 16 h, 86%; 
(b) 4-hydroxyphenylboronic acid pinacol ester, Cs2CO3, DMF, 90ºC, 16 h, 84%; (c) PS-pTsOH, 
CH3OH, rt, 18 h, 88%; (d) oleoyl chloride, 2,4,6-collidine, DCM, -78ºC to rt, 24 h, 40%; (e) 
KHF2, CH3OH:H2O, rt, 30 min; 99%; (f) TMSCl, CH3CN:H2O, rt, 1 h, 60%. 
Scheme 3. Reagents and conditions: (a) i) Pyridine, triflic anhydride, DCM, -20ºC, 30 min; ii) 
KCN, CH3CN:H2O, rt, 12 h, 99%; (b) TFA, CH3OH, rt, 1.5 h, 61%; (c) oleoyl chloride, 2,4,6-
collidine, DCM, -78ºC to rt, 12 h, 88%; (d) NaN3, NH4Cl, DMF, MW, 160ºC, 45 min, 5%. 
In order to determine the agonist capacity of the synthesized compounds, 
calcium mobilization assays in RH7777 cells stably transfected with LPA1 were carried 
out. Activation of LPA1 receptor induces a transient increase in the intracellular 
calcium levels which can be detected by fluorescence. 
From this initial set of compounds only compound 1c activated the receptor, with 
a maximal receptor activation (Emax) at 10 µM of 33% and an half maximal effective 
concentration (EC50) value of 1.7 µM. Accordingly, it was necessary to confirm if the 
non-cyclic α-fluoromalonic derivative originally proposed, with two free carboxylic 
acids, would exhibit better activity at LPA1 receptor. Therefore, compounds 1f and 
1g were synthesized (Scheme 4). Only compound 1g showed agonist activity with 
an EC50 value of 6 µM.  
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Scheme 4. Reagents and conditions: (a) Mesyl chloride, Et3N, DCM, 0ºC to rt, 1 
h, 99%; (b) di-tert butyl malonate, NaH, NaI, DMF:THF, 0ºC to 80ºC, 17 h, 66%; 
(c) Selectfluor®, NaH, THF:DMF, 48 h, 0ºC to rt, 99%; (d) H2, 10% Pd(C), EtOH, 
60ºC, 95%; (e) oleoyl chloride, 2,4,6-collidine, DCM, -78ºC to rt, 24 h, 70%; (f) 
TFA, DCM, rt, 16-17 h, 90-95%; (g) trimethylsilyldiazomethane, HBF4, DCM, 0ºC, 
90 min, 38%. 
Regarding series II, a comprehensive study of the influence of the hydrophobic 
moiety was carried out, including modifications on the overall length of the fatty acid 
chain as well as the incorporation of an aromatic ring. Compounds belonging to series 
II were synthesized according to Scheme 5.  
Scheme 5. Reagents and conditions: (a) Carboxylic acid, DCC, DMAP, DCM, -20ºC to rt, 16 
h, 12-58%; (b) TFA, DCM, rt, 4-5 h, 90-99%; (c) i) TMSBr, DCM, rt, 4 h; ii) MeOH/H2O, rt, 1h, 
90%; (d) H2, 10% Pd(C), EtOH, rt, 80-99%. 
Compounds 2a-j and the unexpectedly obtained (S)-3a were tested for their 
agonist activity at the LPA1 receptor. The most remarkable conclusion that can be 
drawn from these data is the great influence on activity exerted by the length of the 
hydrophobic chain. From all the tested compounds, derivatives 2b (m = 5), 2h (n = 9) 
and (S)-3a, with Emax > 100% and EC50 values of 0.45, 0.5 and 0.24 µM respectively, 
stand out. Considering the excellent activity of compound (S)-3a, additional structural 
exploration was extended around this scaffold (Scheme 6). The obtained results 
showed that only 3d was able to activate the receptor (Emax = 39%, EC50 = 3.2 µM), 
although it did not reach the values of compound (S)-3a.  
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Scheme 6. Reagents and conditions: (a) i) (iPr)2NP(OX)2, 1H-tetrazole, DCM, rt, 2 h; ii) 
mCPBA, -30ºC, 90 min, 52-76%; (b) TBABr, TFA, CHCl3, rt, 10 min, 89-95%; (c) 
Ph(CH2)nCOOH (n = 8, 10), DCC, DMAP, DCM, rt, 16-18 h, 55-96%; (d) H2, 10% Pd(C), EtOH, 
rt, 72-86%; (e) oleoyl chloride, pyridine, rt, 18 h, 15%; (f) TFA, DCM, rt, 5 h, 81%. 
Selectivity of the identified LPA1 agonists over LPA2 and LPA3 receptors  
Taking into account the high sequence homology among the LPA1-3 receptors, 
we determined the selectivity of the best agonists of each series [1c, 1g, 2b, 2h and 
(S)-3a]. Lack of activity at LPA3 receptor is especially important, given that the 
activation of this receptor is implicated in the production of high LPA levels after 
peripheral nerve damage, responsible for initiation and maintenance of NP. Among 
the identified agonists, compounds 1c, 1g, 2b and (S)-3a resulted selective for LPA1 
versus LPA2 and LPA3 receptors (Figure 2).  
 
Figure 2. LPA1 receptor agonists with selectivity versus LPA2 and LPA3 receptors. 
Combination of the acid and hydrophobic subunits  
Next, we combined the best hydrophobic subunits and the acid moieties that 
seem to be able to mimic the phosphate group, and have yielded the most potent 
agonists [1c, 1g, 2b and (S)-3a, Figure 2]. 
Hence, the lactone, the malonic acid, and the bromo-phosphate moieties present 
in derivatives 1c, 1g, and (S)-3a, respectively, were selected as acid groups. 
Regarding the hydrophobic subunit, oleoyl (present in 1c and 1g), palmitoleoyl 
(present in 2b) and 10- phenyldecanoyl chains [present in (S)-3a] were chosen. The 
combination of these fragments led to products 1c, 1g, (S)-3a, and 3d (which were 
previously synthesized) and new derivatives 4a-e (Figure 3) which were synthesized 
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and tested as agonists of the LPA1 receptor. From this new series, only derivative 4c 
presented activity for LPA1 receptor (Emax = 43%, EC50 = 1.4 μM). 
 
Figure 3. Combination of the optimal acid and hydrophobic subunits. 
Among all the synthesized compounds, derivative (S)-3a stands out as the first 
agonist structurally different from the endogenous ligand LPA, with an excellent 
activity value and selectivity for LPA1 versus LPA2 and LPA3 receptors (Table 1). 
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Table 1. Agonist activity of compound (S)-3a and endogenous ligand LPA at LPA1-3 
receptors  
Compound 
EC50 (µM)a [Emax (%)]b 
LPA1 receptor LPA2 receptor LPA3 receptor 
 
0.24 ± 0.09 [118 ± 24] N. E.c N. E. 
 
0.83 ± 0.02 [100] 1.27 ± 0.5 [100] 3.36 ± 0.8 [100] 
aFor Emax > 30%, EC50 values are expressed as mean ± s.e.m, from a minimum of two independent experiments, 
performed in triplicate. bEmax = maximal efficacy of the drug/maximal efficacy of LPA, expressed as the 
percentage. cNo effect was observed at the highest concentration of compound tested (10 µM). 
Biological characterization of compound (S)-3a  
A set of additional experiments aimed at confirming that (S)-3a bound directly 
LPA1 receptor and at studying whether the compound induced desensitization and 
internalization, were carried out. 
The affinity of (S)-3a for the LPA1 receptor was determined by backscattering 
interferometry. The obtained result (KD = 19.9 nM) indicated that (S)-3a is a high 
affinity ligand with a KD comparable to that obtained of the endogenous ligand LPA 
(KD = 5.6 nM). 
Then, it was demonstrated the capacity of compound (S)-3a to induce 
internalization of LPA1 receptor. Representative images at 1 μM concentration of (S)-
3a are shown in Figure 4. 
 
 
Figure 4. Receptor internalization of LPA1 receptor by agonist stimulation. Cells were treated 
with compound (S)-3a, 1 μM (A) or LPA, 1 μM (B). Cells were stained with 4',6-diamidino-2-
phenylindole (DAPI) and phalloydin for cell morphology. Samples were imaged under the 
same conditions by using a Zeiss fluorescence confocal microscope (bars 10 μm). 
Finally, the capacity of (S)-3a to induce desensitization in sensory neurons was 
determined by measuring calcium influx and action potential. These experiments were 
B A 
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done in collaboration with Prof. Antonio Vicente Ferrer Montiel, at Universidad Miguel 
Hernández de Elche (Alicante, Spain). Our data show that after a first administration, 
compound (S)-3a activates the LPA1 receptor in dorsal root ganglion (DRG) sensory 
neurons in primary culture in a similar manner to LPA (Figure 5). However, a second 
administration of the agonist 4 minutes later is not able to trigger activation, reflecting 
the desensitization of the receptor (Figure 5A). A similar behavior was observed for 
(S)-3a under the same conditions (Figure 5B). Furthermore, the action potential of 
DRG neurons was affected when treated either with 10 μM LPA (Figure 5C) or (S)-3a 
(Figure 5D), confirming the action of this agonist in sensory neurons in primary culture. 
 
Figure 5. Measurement of calcium-influx peak intensity upon two repetitive applications of 10 
μM LPA (A) or (S)-3a (B). Data represent fluorescence expressed as mean ± s.e.m. Effect of 
10 μM LPA (C) or (S)-3a (D) on the neuronal firing activity on DRG neurons. LPA and (S)-3a 
were applied in two consecutive pulses (1st and 2nd pulse). Data represent mean spike 
frequency (Hz) and are expressed as mean ± s.e.m. Number of cultures ≥ 2. First pulse (1st) 
was compared to the second (2nd) by t-test paired values, ***p<0.001; *p<0.05. Number above 
columns represent percentage of responding cells to that stimulus, n= total registered neurons. 
All in sum, the data obtained up to this moment have prompted us to consider 
(S)-3a a promising candidate for the treatment of NP and to study its in vivo efficacy 
in a mouse model of NP, experiments that are currently ongoing in collaboration with 
Prof. Fernando Rodríguez de Fonseca, at Instituto de Investigación Biomédica de 
Málaga (Spain). 
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5.2.2. Development of new antagonists for the LPA1 and LPA2 receptors 
It has been recently described that activation of LPA1 and LPA2 receptors is 
detrimental for secondary damage after SCI, suggesting that LPA1 and LPA2 
antagonists might be useful tools not only to elucidate the specific mechanisms 
implicated in this pathology, but also for its therapeutic treatment. In order to discover 
new antagonists at these receptors we performed a virtual screening (VS) of the ZINC 
library of compounds against the LPA1 receptor, which 3D structure has just been 
described in complex with the selective antagonist ONO-9780307.23  
This VS yielded 18 potential hits, which were purchased and screened for 
antagonist activity at LPA1, LPA2 and LPA3 receptors given their sequence similarity. 
Among all analyzed compounds, we were able to identify one compound selective for 
each receptor of interest, VS6 (IC50 = 10.1 ± 0.9 µM) as LPA1 receptor antagonist and 
VS11 (IC50 = 1.9 ± 0.6 µM) as LPA2 receptor antagonist.  
Once the synthetic routes that allow to obtain both antagonists were set up 
(Schemes 7 and 8), their antagonist activity at LPA1-3 receptors was determined, 
confirming the half-maximum inhibitory concentration (IC50) values obtained for the 
commercially supplied compounds VS6 and VS11. 
 
Scheme 7. Reagents and conditions: (a) Ethyl 2-cyanoacetate, TiCl4, 
Et3N, THF, 0ºC to rt, 12 h; (b) S8, Et2NH, THF, rt, 12 h, 32%; (c) Boc2O, 
DMAP, THF, rt, 12 h, 28%; (d) KOH, EtOH:H2O, 60°C, 12 h, 89%; (e) 
0.5 M NH3 in dioxane, EDC, HOBt, DIPEA, DCM, rt, 13 h, 70%; (f) TFA, 
DCM, rt, 12 h, 99%; (g) glutaric anhydride, Et3N, DMAP, DCM, reflux, 
12 h, 33%; (h) Et3N, H2O, reflux, 15 min, 72%. 
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Scheme 8. Reagents and conditions: (a) i) SOCl2, toluene, 110°C, 12 h, 99%; ii) 
resorcinol, BF3.Et2O, DCM, reflux, 4 h, 20%; (b) acetic anhydride, Et3N, NaOAc, 
140°C, 2.5 h, 99%; (c) HCl, EtOH, reflux, 2 h, 99%; (d) methyl 2-bromoacetate, 
K2CO3, acetone, reflux, 3 h, 51%; (e) 65% N2H4.H2O, EtOH, reflux, 30 min, 99%. 
Derivative 101 (VS11) has been selected in order to establish whether an LPA2 
selective antagonist is able to induce a beneficial effect in SCI, which would be very 
interesting, considering the limited knowledge about the role of LPA2 receptor in this 
pathology. Towards this aim, we have started determining which structural 
characteristics are important for the antagonist activity of compound 101. Hence, we 
studied whether the 2,4-dichlorophenoxy system, the 3-hydroxyphenoxyacetic 
fragment or the methyl group in position 5 of the pyrazole ring are essential for the 
antagonism (Figure 6). 
  
Figure 6. Study of the influence of the 2,4-dichlorophenoxy system, the 3-hydroxy 
phenoxyacetic fragment or the methyl group in the antagonist activity of compound 101. 
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Once compounds 104-107, 120, 123-125, and 133 were synthesized, they were 
tested for their antagonist activity at LPA2 receptor. The obtained results indicated that 
the 2,4-dichlorophenoxy system and the 3-hydroxyphenoxyacetic fragment are 
essential for the antagonist activity, while the methyl group in position 5 of the pyrazole 
ring can be removed.  
Before to start with a Medicinal Chemistry program with hit 101, we have 
considered interesting, as proof of concept, demonstrate the interest of an LPA2 
selective antagonist in treatment of SCI. Towards this aim, we have started the first 
experiments needed to assess the suitability of antagonist 101 for these in vivo 
studies. Hence, this compound showed high binding affinity for LPA2 receptor (KD = 
19.8 nM) and an acceptable cell permeability value (P = 1.2x10-6 cm/s), important 
features for subsequent in vivo studies, which are currently ongoing in collaboration 
with Prof. Rubèn Lopez Valés, at Universidad Autónoma de Barcelona (Spain). 
Whether hit 101 is considered interesting, in a further work and as a continuation 
of this PhD thesis, an extended Medicinal Chemistry program with derivative 101 will 
be carried out, in order to obtain a second generation of antagonists at LPA2 receptor. 
5.3. Conclusions 
In the present work we have addressed the development of new potent and 
selective LPA1 receptor agonists, as antinociceptive agents, and of new selective 
antagonists of LPA1 and LPA2 receptors, as research tools to elucidate the specific 
involvement of these receptors in the pathophysiology of SCI.  
With respect to the first goal, an exhaustive SAR study of several series of 
compounds, initially based on the endogenous ligand LPA, was performed and 
compound (S)-3a stood out for its high activity and affinity at LPA1 receptor, and 
selectivity towards LPA2 and LPA3 receptors. In addition, this derivative promotes the 
internalization of LPA1 receptor and its desensitization in sensory neurons, which 
should lead to the blockade of the signal trasduction involved in pain transmission. 
Hence, we are currently validating this approach as a possible therapeutic alternative 
to treat chronic pain in an in vivo model. 
Regarding the second part of this work, a VS has allowed us to identify two potent 
and selective antagonists of LPA1 and LPA2 receptors. Once their synthetic routes 
were set up and their antagonist activities were confirmed, structural modifications of 
the LPA2 receptor antagonist 101 (VS11) were carried out to determine which parts of 
the molecule are essential for its antagonist activity. Then, derivative 101 has been 
selected, as proof of concept, to start the study of the implication of this receptor in 
SCI.  
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6. RESUMEN 
6.1. Introducción y Objetivos 
Los lisofosfolípidos son derivados lípidicos con funciones tanto estructurales 
como de señalización, por lo que juegan un papel fundamental en humanos y otros 
mamíferos. El análisis de lisofosfolípidos en fluidos humanos de pacientes con 
diferentes condiciones patológicas revela no sólo la importancia de los 
lisofosfolípidos y de sus receptores en enfermedades humanas, sino también sus 
potenciales aplicaciones como biomarcadores y/o dianas terapéuticas.1,2 Entre ellos, 
destaca el ácido lisofosfatídico (LPA) debido a su implicación en la regulación de 
procesos fisiológicos y patológicos de importancia a través de la activación de sus 
receptores correspondientes LPA1–6,3-5 todos ellos pertenecientes a la superfamilia 
de los receptores acoplados a proteínas G (GPCRs). 
El LPA regula una amplia variedad de actividades biológicas, especialmente en 
el desarrollo y el funcionamiento del sistema nervioso.6,7 Considerando los 
numerosos efectos producidos por el LPA en diferentes tipos celulares del sistema 
nervioso y la sobreexpresión de los receptores de LPA como consecuencia de un 
daño neuronal observado tanto en ratones como en humanos, es probable que el 
LPA regule aspectos esenciales en la reorganización celular después de un trauma 
neuronal.8 Entre todas las neuropatologías donde el LPA juega un papel importante, 
el dolor neuropático9-13 y el daño medular14-16 son condiciones con una elevada 
incidencia y altamente incapacitantes, que actualmente carecen de terapias 
específicas. En este contexto, los receptores LPA1 y LPA2 se han relacionado con 
estas patologías,17,18 pero la falta de agonistas y antagonistas potentes y selectivos 
ha dificultado el estudio de sus funciones específicas. Por tanto, en este trabajo, 
hemos abordado el desarrollo de ambos tipos de compuestos para así tratar de 
esclarecer la función de los receptores LPA1 y LPA2 en el dolor neuropático y en el 
daño medular.  
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Este objetivo general implica las siguientes etapas:  
1. Diseño y síntesis de nuevos ligandos con actividad agonista o antagonista en 
los receptores LPA1 y LPA2.  
2. Determinación de la actividad y selectividad por los receptores de LPA.  
3. Validación biológica de los compuestos seleccionados.  
6.2. Resultados y Discusión 
6.2.1. Desarrollo de nuevos agonistas del receptor LPA1  
Con respecto al dolor neuropático, hemos propuesto una estrategia basada en 
la unión de un agonista selectivo al receptor LPA1 de tal modo que tras la activación 
receptorial se produce la desensibilización e internalización de éste, provocando así 
un efecto antinociceptivo de larga duración.19-21  
La búsqueda de nuevas moléculas con actividad agonista por el receptor LPA1 
se basó en la modificación de la estructura del ligando endógeno, LPA. Para ello, se 
diseñaron inicialmente dos series de compuestos: la serie I, en la que se modifica el 
grupo ácido, y la serie II, que incluye modificaciones en la subunidad hidrofóbica 
(Figura 1). 
 
Figura 1. Diseño de nuevos ligandos agonistas del receptor LPA1. 
Con respecto a la serie I, se ha demostrado que modificaciones en el fragmento 
polar del LPA conllevan pérdida de actividad, por lo tanto, se eligió sustituir el grupo 
fosfato por otros fragmentos miméticos de éste, tales como ácidos carboxílicos y 
borónicos, o un anillo de tetrazol.22 Los compuestos de la serie I fueron sintetizados 
como se indica en los Esquemas 1-3. En el caso de los ésteres malónicos, las 
condiciones de reacción empleadas condujeron a la formación de las lactonas 1b y 
1c (Esquema 1). 
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Esquema 1. Reactivos y condiciones: (a) Bromoacetato de tert-butilo, NaH, TBAI, THF, 0ºC 
a 50ºC, 16 h, 22%; (b) H2, Pd(C) 10%, EtOH, 60ºC, 89-95%; (c) cloruro de mesilo, Et3N, DCM, 
0ºC a ta, 1 h, 80%; (d) malonato de di-tert-butilo, NaH, NaI, DMF:THF, 0ºC a 80ºC, 17 h, 76%; 
(e) Selectfluor®, NaH, THF:DMF, 0ºC a ta, 48 h, 99%; (f) cloruro de oleoilo, 2,4,6-colidina, 
DCM, -78ºC a ta, 24 h, 36-99%; (g) TFA, DCM, ta, 17-18 h, 52-99%. 
 
Esquema 2. Reactivos y condiciones: (a) Cloruro de tosilo, piridina, DCM, 0ºC a ta, 16 h, 
86%; (b) 4-hidroxifenilpinacolborano, Cs2CO3, DMF, 90ºC, 16 h, 84%; (c) PS-pTsOH, CH3OH, 
ta, 18 h, 88%; (d) cloruro de oleoilo, 2,4,6-colidina, DCM, -78ºC a ta, 24 h, 40%; (e) KHF2, 
CH3OH:H2O, ta, 30 min; 99%; (f) TMSCl, CH3CN:H2O, ta, 1 h, 60%. 
Esquema 3. Reactivos y condiciones: (a) i) Piridina, anhídrido tríflico, DCM, -20ºC, 30 min; ii) 
KCN, CH3CN:H2O, ta, 12 h, 99%; (b) TFA, CH3OH, ta, 1.5 h, 61%; (c) cloruro de oleoilo, 2,4,6-
colidina, DCM, -78ºC a ta, 12 h, 88%; (d) NaN3, NH4Cl, DMF, MW, 160ºC, 45 min, 5%. 
La capacidad de los compuestos sintetizados para activar el receptor LPA1 se 
determinó mediante experimentos de movilización de calcio en células RH7777 
transfectadas de forma estable con este receptor, puesto que su activación tanto por 
el LPA como por los ligandos agonistas produce un aumento en los niveles de calcio 
intracelular, el cual puede ser cuantificado mediante fluorescencia. 
Así, el compuesto 1c fue identificado como agonista del receptor LPA1, con un 
valor de activación máxima del receptor (Emax) del 33% y un valor de concentración 
efectiva 50 (CE50) de 1.7 µM. Por tanto, con objeto de obtener los derivados del ácido 
malónico propuestos inicialmente y evitar el proceso de ciclación intramolecular, se 
sintetizaron los compuestos 1f y 1g (Esquema 4). Entre ellos, únicamente el 
compuesto 1g resultó activo, con un valor de CE50 de 6 µM.  
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Esquema 4. Reactivos y condiciones: (a) Cloruro de mesilo, Et3N, DCM, 0ºC a 
ta, 1 h, 99%; (b) malonato de di-tert-butilo, NaH, NaI, DMF:THF, 0ºC a 80ºC, 17 
h, 66%; (c) Selectfluor®, NaH, THF:DMF, 0ºC a ta, 48 h, 99%; (d) H2, Pd(C) 10%, 
EtOH, 60ºC, 95%; (e) cloruro de oleoilo, 2,4,6-colidina, DCM, -78ºC a ta, 24 h, 
70%; (f) TFA, DCM, ta, 16-17 h, 90-95%; (g) trimetilsilildiazometano, HBF4, DCM, 
0ºC, 90 min, 38%. 
En el caso de la serie II, se estudió exhaustivamente la influencia de la subunidad 
hidrofóbica, incluyendo cambios en la longitud total de la cadena de ácido graso, así 
como la incorporación de anillos aromáticos. La síntesis de los compuestos se 
representa en el Esquema 5. 
Esquema 5. Reactivos y condiciones: (a) Ácido carboxílico, DCC, DMAP, DCM, -20ºC a ta, 
16 h, 12-58%; (b) TFA, DCM, ta, 4-5 h, 90-99%; (c) i) TMSBr, DCM, ta, 4 h; ii) MeOH/H2O, ta, 
1h, 90%; (d) H2, Pd(C) 10%, EtOH, ta, 80-99%. 
Los compuestos 2a-j y el producto inesperado (S)-3a fueron ensayados como 
agonistas del receptor LPA1. Los datos obtenidos muestran la gran influencia que 
ejerce la longitud de la cadena hidrofóbica en la actividad. Entre todos los 
compuestos analizados, destacan los derivados 2b (m = 5), 2h (n = 9) y (S)-3a, con 
Emax > 100% y valores de CE50 de 0.45, 0.5 y 0.24 µM, respectivamente. 
Considerando la excelente actividad mostrada por el derivado (S)-3a, se decidió 
extender su estudio estructural (Esquema 6). Los resultados obtenidos indicaron que 
únicamente el derivado 3d era capaz de activar el receptor (Emax = 39%; CE50 = 3.2 
µM), aunque sin alcanzar los valores del compuesto (S)-3a.  
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Esquema 6. Reactivos y condiciones: (a) i) (iPr)2NP(OX)2, 1H-tetrazol, DCM, ta, 2 h; ii) 
mCPBA, -30ºC, 90 min, 52-76%; (b) TBABr, TFA, CHCl3, ta, 10 min, 89-95%; (c) 
Ph(CH2)nCOOH (n = 8, 10), DCC, DMAP, DCM, ta, 16-18 h, 55-96%; (d) H2, Pd(C) 10%, EtOH, 
ta, 72-86%; (e) cloruro de oleoilo, piridina, ta, 18 h, 15%; (f) TFA, DCM, ta, 5 h, 81%. 
 
Selectividad de los agonistas del receptor LPA1 frente a los receptores LPA2 y LPA3 
Considerando la elevada similitud de secuencia entre los receptores LPA1-3, 
hemos determinado la selectividad de los mejores agonistas de cada serie [1c, 1g, 
2b, 2h y (S)-3a]. La falta de actividad al receptor LPA3 es especialmente importante, 
dado que su activación está implicada en la elevada producción de LPA que sigue a 
una lesión nerviosa periférica y que es responsable de la iniciación y el 
mantenimiento del dolor neuropático. Entre los agonistas analizados, los compuestos 
1c, 1g, 2b y (S)-3a resultaron selectivos por el receptor LPA1 frente a los receptores 
LPA2 y LPA3 (Figura 2).  
 
Figura 2. Agonistas del receptor LPA1 con selectividad frente a los receptores LPA2 y LPA3. 
Combinación de las subunidades ácidas e hidrofóbicas 
A continuación, se combinaron las mejores subunidades hidrofóbicas y los 
grupos ácidos que resultaron ser capaces de mimetizar el grupo fosfato del LPA, 
manteniendo una potente actividad agonista y selectividad [compuestos 1c, 1g, 2b y 
(S)-3a, Figura 2]. 
Por tanto, la lactona, el ácido malónico y el bromofosfato presentes en los 
derivados 1c, 1g y (S)-3a, respectivamente, fueron selecionados como grupos 
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ácidos. Como subunidades hidrofóbicas se eligieron las cadenas de oleoilo (presente 
en 1c y 1g), de palmitoleoilo (presente en 2b) y de 10-fenildecanoilo [presente en (S)-
3a]. La combinación de estos fragmentos condujo a los compuestos ya obtenidos con 
anterioridad [1c, 1g, (S)-3a y 3d] y a los nuevos productos 4a-e (Figura 3) que fueron 
sintetizados y analizados como agonistas del receptor LPA1. Entre los nuevos 
compuestos, únicamente el derivado 4c presentó actividad por el receptor LPA1 (Emax 
= 43 %, CE50 = 1.4 µM). 
 
Figura 3. Combinación de las subunidades ácidas e hidrofóbicas de los compuestos óptimos. 
Entre todos los compuestos sintetizados destaca el derivado (S)-3a como el 
primer agonista estructuralmente diferente al ligando endógeno LPA con excelentes 
valores de actividad y selectividad (Tabla 1). 
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Tabla 1. Actividad agonista del compuesto (S)-3a y del ligando endógeno LPA en los 
receptores LPA1-3 
Compuesto 
CE50 (µM)a [Emax (%)]b 
Receptor LPA1 Receptor LPA2 Receptor LPA3 
 
0.24 ± 0.09 [118 ± 24] N. E.c N. E. 
 
0.83 ± 0.02 [100] 1.27 ± 0.5 [100] 3.36 ± 0.8 [100] 
aPara Emax > 30%, los valores de CE50 corresponden al valor medio ± E.E. obtenido en un mínimo de dos 
experimentos independientes realizados por triplicado.  bEmax = eficacia máxima del compuesto/eficacia máxima 
del LPA, expresado como porcentaje. cNo se observa efecto a la máxima concentración ensayada (10 µM). 
 
Caracterización biológica del compuesto (S)-3a  
Se realizaron diversos experimentos con el fin de confirmar la unión directa de 
(S)-3a al receptor LPA1 así como su capacidad de inducir desensibilización e 
internalización del receptor LPA1. 
La afinidad de (S)-3a por el receptor LPA1 fue determinada utilizando la técnica 
de backscattering interferometry. El resultado obtenido (KD = 19.9 nM) indica que (S)-
3a es un ligando de alta afinidad con un valor de KD comparable al obtenido para el 
ligando endógeno LPA (KD = 5.6 nM). 
Asimismo, se ha demostrado la capacidad del compuesto (S)-3a para inducir la 
internalización del receptor LPA1 (Figura 4). 
 
 
Figura 4. Internalización del receptor LPA1 tras estimulación con un agonista. Las células 
fueron tratadas con el compuesto (S)-3a (1 µM) (A) o con LPA, 1 µM (B), y posteriormente 
teñidas con 4',6-diamino-2-fenilindol (DAPI) y faloidina para observar su morfología y 
visualizadas con un microscopio confocal Zeiss (barras 10 µm). 
B A 
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Por último, la capacidad del compuesto (S)-3a para inducir desensibilización en 
neuronas sensoriales fue determinada midiendo el flujo de calcio y el potencial de 
acción. Estos ensayos se han llevado a cabo en colaboración con el Prof. Antonio 
Vicente Ferrer Montiel, de la Universidad Miguel Hernández de Elche (Alicante). Los 
datos obtenidos muestran que una primera administración del compuesto (S)-3a 
conlleva la activación del receptor LPA1 en neuronas sensoriales en cultivo primario 
de una forma parecida al LPA (Figura 5). Sin embargo, una segunda administración 
del agonista no es capaz de provocar activación, hecho que refleja la 
desensibilización del receptor (Figura 5A). Un comportamiento parecido se observó 
con el compuesto (S)-3a bajo las mismas condiciones (Figura 5B). Además, la 
activación de las neuronas también disminuye tras la segunda administración de LPA 
(Figura 5C) o de (S)-3a (Figura 5D), confirmando la actividad de estos agonistas en 
neuronas sensoriales. 
 
Figura 5. Aumento de los niveles de calcio tras dos aplicaciones repetidas de LPA (A) o (S)-
3a (B). Los datos de fluorescencia corresponden al valor medio ± E.E. Efecto de LPA (C) o 
(S)-3a (D) en la actividad neuronal de neuronas de la raíz del ganglio dorsal. LPA y (S)-3a 
(ambos a una concentración de 10 µM) fueron aplicados en dos pulsos consecutivos. Los 
datos representan el valor de frecuencia (Hz) y corresponden al valor medio ± E.E. El número 
de cultivos es ≥ 2. El primer pulso fue comparado con el segundo utilizando la prueba t de 
Student, ***p<0.001; *p<0.05. Los números sobre las columnas representan el porcentaje de 
células que responden a este estímulo, donde n corresponde al número total de neuronas 
registradas. 
 
DC
DC
LPA (S)-3a
LPA 10 µM (S)-3a 10 µM
1er
pulso
2o
pulso
Capsaicina 1er
pulso
2o
pulso
Capsaicina
1er pulso 2o pulso Capsaicina
500 nM
1er pulso 2o pulso Capsaicina
500 nM
Fl
u
o
re
sc
e
n
ci
a 
(u
.a
.)
Fl
u
o
re
sc
e
n
ci
a 
(u
.a
.)
Fr
e
cu
e
n
ci
a 
Im
p
u
ls
o
 (
H
z)
Fr
e
cu
e
n
ci
a 
Im
p
u
ls
o
 (
H
z)
Resumen 
- 199 - 
En resumen, los resultados obtenidos hasta el momento indican que el 
compuesto (S)-3a puede ser considerado como un candidato prometedor para el 
tratamiento del dolor neuropático y para estudiar su eficacia in vivo en un modelo de 
ratón de dolor neuropático, experimentos que se están actualmente llevando a cabo 
en colaboración con el Prof. Fernando Rodríguez de Fonseca, del Instituto de 
Investigación Biomédica de Málaga. 
6.2.2. Desarrollo de nuevos antagonistas de los receptores LPA1 y LPA2 
Recientemente se ha demostrado que la activación de los receptores LPA1 y 
LPA2 es perjudicial para el daño secundario que sigue a una lesión medular, 
sugiriendo que los antagonistas de los receptores de LPA1 y LPA2 podrían ser 
herramientas útiles no solo para esclarecer los mecanismos implicados en esta 
patología, sino también para su tratamiento. Para obtener nuevos antagonistas de 
estos receptores hemos llevado a cabo un cribado virtual de la librería ZINC de 
compuestos sobre el receptor LPA1, cuya estructura cristalográfica ha sido descrita 
unida al antagonista selectivo ONO-9780307.23  
En el cribado virtual se identificaron 18 hits, los cuales fueron comprados y 
ensayados como antagonistas de los receptores LPA1, LPA2 y LPA3. Entre todos los 
compuestos analizados, dos de ellos resultaron selectivos por los receptores de 
interés, VS6 (CI50 = 10.1 ± 0.9 µM) como antagonista del receptor LPA1 y VS11 (CI50 
= 1.9 ± 0.6 µM) como antagonista del receptor LPA2.  
Tras poner a punto las rutas sintéticas para obtener ambos antagonistas 
(Esquemas 7 y 8), se determinó su actividad en los receptores LPA1-3, confirmando 
los valores de concentración inhibitoria 50 (CI50) obtenidos para los compuestos 
comerciales VS6 y VS11. 
 
Esquema 7. Reactivos y condiciones: (a) Cianoacetato de etilo, TiCl4, 
Et3N, THF, 0ºC a ta, 12 h; (b) S8, Et2NH, THF, ta, 12 h, 32%; (c) Boc2O, 
DMAP, THF, ta, 12 h, 28%; (d) KOH, EtOH:H2O, 60°C, 12 h, 89%; (e) 
0.5 M NH3 en dioxano, EDC, HOBt, DIPEA, DCM, ta, 13 h, 70%; (f) 
TFA, DCM, ta, 12 h, 99%; (g) anhídrido glutárico, Et3N, DMAP, DCM, 
reflujo, 12 h, 33%; (h) Et3N, H2O, reflujo, 15 min, 72%. 
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Esquema 8. Reactivos y condiciones: (a) i) SOCl2, tolueno, 110°C, 12 h 99%; ii) 
resorcinol, BF3.Et2O, DCM, reflujo, 4 h, 20%; (b) anhídrido acético, Et3N, NaOAc, 
140°C, 2.5 h, 99%; (c) HCl, EtOH, reflujo, 2 h, 99%; (d) 2-bromoacetato de metilo, 
K2CO3, acetone, reflujo, 3 h, 51%; (e) N2H4.H2O 65%, EtOH, reflujo, 30 min, 99%. 
El derivado 101 (VS11) fue seleccionado para establecer si un antagonista 
selectivo del receptor LPA2 es capaz de inducir un efecto beneficioso en el daño 
medular, resultado que sería de gran interés considerando la escasa información 
acerca del papel del receptor LPA2 en esta patología. Con este objetivo, hemos 
comenzado determinando las características estructurales responsables de la 
actividad antagonista del compuesto 101. Por tanto, hemos estudiado si el sistema 
de 2,4-diclorofenoxilo, el fragmento 3-hidroxifenoxiacético o el grupo metilo en 
posición 5 del anillo de pirazol son esenciales para la actividad antagonista (Figura 
6). 
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Figura 6. Estudio de la influencia del sistema de 2,4-diclorofenoxilo, del fragmento de 3-
hidroxifenoxiacético o del grupo metilo en la actividad antagonista del compuesto 101. 
Una vez que los compuestos 104-107, 120, 123-125, y 133 fueron sintetizados, 
se determinó su actividad antagonista en el receptor LPA2. Los resultados obtenidos 
indicaron que los sistemas de 2,4-diclorofenoxilo y de 3-hidroxifenoxiacético son 
esenciales para la actividad antagonista, mientras que el grupo metilo en posición 5 
del anillo de pirazol parece admitir modificaciones.  
Antes de comenzar con un programa más extenso de Química Médica en el hit 
101, nos ha parecido interesante, como prueba de concepto, demostrar el interés de 
un antagonista del receptor LPA2 en el tratamiento del daño medular. Con este 
objetivo, hemos iniciado los primeros experimentos previos a la evaluación in vivo. El 
compuesto 101 ha mostrado una elevada afinidad por el receptor LPA2 (KD = 19.8 
nM) y un valor de permeabilidad celular aceptable (P = 1.2x10-6 cm/s), características 
necesarias para poder iniciar estudios in vivo, los cuales se están actualmente 
llevando a cabo en colaboración con el Prof. Rubèn Lopez Valés, de la Universidad 
Autónoma de Barcelona. 
Si se confirma el interés del hit 101, en un trabajo posterior y como continuación 
a esta Tesis Doctoral, se llevará a cabo un amplio programa de Química Médica a 
partir del compuesto 101, con el objetivo de obtener antagonistas de segunda 
generación selectivos del receptor LPA2. 
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6.3. Conclusiones 
Durante el presente trabajo de investigación se han identificado nuevos 
agonistas potentes y selectivos del receptor LPA1, y nuevos antagonistas selectivos 
de los receptores LPA1 y LPA2. 
Dentro del primer objetivo, se ha llevado a cabo un estudio completo de relación 
estructura-actividad de diferentes series de compuestos, basados inicialmente en el 
ligando endógeno LPA. Entre los compuestos sintetizados, el derivado (S)-3a 
destacó por su alta actividad y afinidad por el receptor LPA1, y selectividad frente a 
los receptores LPA2 y LPA3. Además, este agonista promueve la internalización del 
receptor LPA1 y su desensibilización en neuronas sensoriales, lo que podría llevar a 
un bloqueo de la trasducción de la señal implicada en la transmisión del dolor. Por 
tanto, actualmente estamos validando esta estrategia como una posible alternativa 
terapéutica para el tratamineto del dolor crónico en un modelo in vivo. 
Con respecto al segundo objetivo de este trabajo, un cribado virtual nos ha 
permitido identificar dos antagonistas potentes y selectivos de los receptores LPA1 y 
LPA2. Tras poner a punto las rutas sintéticas para su obtención y confirmar su 
actividad antagonista, se realizaron modificaciones estructurales del antagonista del 
receptor LPA2 101 (VS11) para determinar qué partes de la molecula son esenciales 
para su actividad antagonista. Por otro lado, el derivado 101 ha sido seleccionado 
para estudiar, como prueba de concepto, la implicación de este receptor en el daño 
medular.  
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